Difference between revisions of "Staging page"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 1: Line 1:
−
<span id="BackToTop"></span>
+
{| class="wikitable sortable" style="width: 100%; text-align:center;"
−
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
+
!Surname
−
[[#top|Back to Top]]
+
!Forename
−
</div>
+
!Gender
−
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Diffuse_large_B-cell_lymphoma|main DLBCL page]] for current regimens.
+
!Site
−
{| class="wikitable" style="float:right; margin-right: 5px;"
+
!City
 +
!Region
 +
!Country
 +
!First active year
 +
!Last active year
 +
!Study group(s)
 +
!Sponsor(s)
 +
!Conditions
 +
!Total publications
 +
!Senior publications
 +
!Phase 3 RCTs
 +
!FDA pivotal studies
 +
!Co-authorships
 +
!Co-authors
 +
!Vital status
 +
|-
 +
|A'Hern
 +
|Roger P
 +
|MALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|1987
 +
|2015
 +
|London Gynaecological Oncology Group; TOPIC Trial Group
 +
|
 +
|Breast cancer; Ovarian cancer; Prostate cancer
 +
|5
 +
|0
 +
|4
 +
|0
 +
|100
 +
|83
 +
|1
 +
|-
 +
|Aamdal
 +
|Steinar
 +
|MALE
 +
|
 +
|
 +
|
 +
|Norway
 +
|1989
 +
|2015
 +
|EORTC; Nordic Melanoma Cooperative Group
 +
|
 +
|Melanoma; Small cell lung cancer
 +
|7
 +
|2
 +
|6
 +
|0
 +
|87
 +
|84
 +
|1
 +
|-
 +
|Aanur
 +
|Praveen
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2016
 +
|2021
 +
|
 +
|
 +
|Malignant pleural mesothelioma
 +
|1
 +
|0
 +
|1
 +
|1
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Aapro
 +
|Matti S
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Belgium; Switzerland
 +
|1984
 +
|2018
 +
|EORTC; International Collaborative Cancer Group
 +
|
 +
|Breast cancer; Endometrial cancer
 +
|5
 +
|3
 +
|5
 +
|1
 +
|109
 +
|108
 +
|1
 +
|-
 +
|Aaron
 +
|Lorne
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2006
 +
|2012
 +
|
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|7
 +
|7
 +
|1
 +
|-
 +
|Aaronson
 +
|Neil K
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1992
 +
|2001
 +
|EORTC
 +
|
 +
|Melanoma; Prostate cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|26
 +
|26
 +
|1
 +
|-
 +
|Aarts
 +
|Maureen J B
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Netherlands
 +
|2006
 +
|2017
 +
|BOOG; Dutch WIN-O Consortium
 +
|
 +
|Breast cancer; Renal cell carcinoma
 +
|3
 +
|0
 +
|2
 +
|0
 +
|38
 +
|30
 +
|1
 +
|-
 +
|Aasebo
 +
|Ulf
 +
|MALE
 +
|
 +
|
 +
|
 +
|Norway
 +
|1989
 +
|2013
 +
|
 +
|
 +
|Non-small cell lung cancer; Small cell lung cancer
 +
|7
 +
|1
 +
|7
 +
|0
 +
|65
 +
|44
 +
|1
 +
|-
 +
|Aass
 +
|Nina
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Norway
 +
|1996
 +
|2012
 +
|EORTC; MRC
 +
|
 +
|Renal cell carcinoma; Testicular cancer
 +
|5
 +
|1
 +
|4
 +
|0
 +
|48
 +
|34
 +
|1
 +
|-
 +
|Aastroem
 +
|Lennart
 +
|MALE
 +
|
 +
|
 +
|
 +
|Sweden
 +
|2014
 +
|2022
 +
|SPCG
 +
|
 +
|Prostate cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|21
 +
|21
 +
|1
 +
|-
 +
|Aavall Lundqvist
 +
|Elisabeth
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Sweden
 +
|1999
 +
|2017
 +
|AGO; Gynecologic Cancer Intergroup
 +
|
 +
|Ovarian cancer
 +
|4
 +
|0
 +
|4
 +
|0
 +
|64
 +
|52
 +
|1
 +
|-
 +
|Abacioglu
 +
|Ufuk
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2000
 +
|2012
 +
|
 +
|
 +
|Glioblastoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|11
 +
|11
 +
|1
 +
|-
 +
|Abad
 +
|Alberto
 +
|MALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|1989
 +
|2012
 +
|TTD
 +
|
 +
|Colorectal cancer; Non-small cell lung cancer
 +
|3
 +
|1
 +
|3
 +
|0
 +
|53
 +
|44
 +
|1
 +
|-
 +
|Abada
 +
|Paolo B
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2010
 +
|2019
 +
|
 +
|
 +
|Hepatocellular carcinoma
 +
|2
 +
|0
 +
|2
 +
|1
 +
|42
 +
|38
 +
|1
 +
|-
 +
|Abadie Lacourtoisie
 +
|Sophie
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|France
 +
|2006
 +
|2019
 +
|GINECO
 +
|
 +
|Breast cancer
 +
|3
 +
|0
 +
|1
 +
|0
 +
|55
 +
|36
 +
|1
 +
|-
 +
|Abaskharoun
 +
|Mena
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2018
 +
|2022
 +
|
 +
|
 +
|Melanoma
 +
|1
 +
|0
 +
|0
 +
|1
 +
|21
 +
|21
 +
|1
 +
|-
 +
|Abaza
 +
|Yasmin
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2002
 +
|2017
 +
|
 +
|
 +
|Acute promyelocytic leukemia
 +
|1
 +
|1
 +
|0
 +
|0
 +
|26
 +
|26
 +
|1
 +
|-
 +
|Abbadessa
 +
|A
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|2007
 +
|2007
 +
|
 +
|
 +
|CNS lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|17
 +
|17
 +
|1
 +
|-
 +
|Abbadessa
 +
|Giovanni
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2012
 +
|2018
 +
|
 +
|
 +
|Hepatocellular carcinoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|29
 +
|29
 +
|1
 +
|-
 +
|Abbal
 +
|Claire
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Switzerland
 +
|2006
 +
|2015
 +
|GRAALL
 +
|
 +
|B-cell acute lymphoblastic leukemia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Abbas
 +
|Abbas
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2002
 +
|2010
 +
|
 +
|
 +
|Esophageal adenocarcinoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|8
 +
|8
 +
|1
 +
|-
 +
|Abbas
 +
|Haider
 +
|MALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2009
 +
|2014
 +
|COG
 +
|
 +
|Esophageal cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Abbas
 +
|Mohammad
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2008
 +
|2012
 +
|
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Abbas
 +
|Moncef
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2002
 +
|2011
 +
|FFCD
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Abbas
 +
|Richat
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2006
 +
|2011
 +
|
 +
|
 +
|B-cell acute lymphoblastic leukemia; Chronic myeloid leukemia
 +
|1
 +
|0
 +
|0
 +
|1
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Abbas
 +
|Tahir
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Canada
 +
|2016
 +
|2020
 +
|NCIC-CTG
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Abbattista
 +
|Antonello
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2014
 +
|2019
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|3
 +
|0
 +
|0
 +
|1
 +
|50
 +
|28
 +
|1
 +
|-
 +
|Abbink
 +
|Floor
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Netherlands
 +
|2011
 +
|2019
 +
|
 +
|
 +
|Chronic myeloid leukemia pediatric
 +
|1
 +
|0
 +
|0
 +
|1
 +
|15
 +
|15
 +
|1
 +
|-
 +
|Abbott
 +
|Amanda
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2012
 +
|2019
 +
|
 +
|
 +
|Gastrointestinal stromal tumor
 +
|1
 +
|0
 +
|0
 +
|0
 +
|15
 +
|15
 +
|1
 +
|-
 +
|Abbott
 +
|R L
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|1982
 +
|1989
 +
|
 +
|
 +
|Bladder cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Abbott
 +
|Thomas M
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1979
 +
|1989
 +
|SWOG
 +
|
 +
|Ovarian cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|8
 +
|8
 +
|1
 +
|-
 +
|Abbou
 +
|Clement Claude
 +
|MALE
 +
|
 +
|
 +
|
 +
|France
 +
|1986
 +
|1993
 +
|
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|1
 +
|1
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Abboud
 +
|Camille N
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1993
 +
|2016
 +
|ECOG
 +
|
 +
|Acute myeloid leukemia
 +
|2
 +
|0
 +
|1
 +
|0
 +
|49
 +
|49
 +
|1
 +
|-
 +
|Abboud
 +
|Miguel R
 +
|MALE
 +
|
 +
|
 +
|
 +
|Lebanon
 +
|2017
 +
|2019
 +
|
 +
|
 +
|Sickle cell anemia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|21
 +
|21
 +
|1
 +
|-
 +
|Abbrederis
 +
|Klaus
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1994
 +
|2003
 +
|
 +
|
 +
|Chronic myeloid leukemia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|25
 +
|25
 +
|1
 +
|-
 +
|Abbruzzese
 +
|Alberto
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2003
 +
|2009
 +
|
 +
|
 +
|Bladder cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|11
 +
|11
 +
|1
 +
|-
 +
|Abbruzzese
 +
|James L
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1988
 +
|2010
 +
|SWOG
 +
|
 +
|Colorectal cancer; Esophageal adenocarcinoma; Hepatocellular carcinoma; Pancreatic cancer
 +
|5
 +
|3
 +
|2
 +
|0
 +
|47
 +
|44
 +
|1
 +
|-
 +
|Abdalla
 +
|K
 +
|CBD
 +
|
 +
|
 +
|
 +
|Brazil
 +
|2011
 +
|2017
 +
|
 +
|
 +
|Gastric cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Abdallah
 +
|Al Ola
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2018
 +
|2021
 +
|
 +
|
 +
|Multiple myeloma
 +
|2
 +
|0
 +
|0
 +
|1
 +
|55
 +
|38
 +
|1
 +
|-
 +
|Abdallah
 +
|Rehab
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|USA
 +
|2015
 +
|2021
 +
|
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|27
 +
|27
 +
|1
 +
|-
 +
|Abdeddaim
 +
|Cyril
 +
|MALE
 +
|
 +
|
 +
|
 +
|France
 +
|2017
 +
|2020
 +
|
 +
|
 +
|Endometrial cancer
 +
|1
 +
|0
 +
|0
 +
|1
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Abdel Hamid
 +
|Abdel
 +
|MALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2007
 +
|2012
 +
|
 +
|
 +
|Thyroid cancer differentiated
 +
|1
 +
|0
 +
|1
 +
|0
 +
|27
 +
|27
 +
|1
 +
|-
 +
|Abdel Rahman
 +
|Omar
 +
|MALE
 +
|
 +
|
 +
|
 +
|Egypt
 +
|2010
 +
|2013
 +
|
 +
|
 +
|Hepatocellular carcinoma
 +
|1
 +
|1
 +
|0
 +
|0
 +
|5
 +
|5
 +
|1
 +
|-
 +
|Abdel Rahman
 +
|Sultan
 +
|MALE
 +
|
 +
|
 +
|
 +
|Germany
 +
|1997
 +
|2018
 +
|EORTC; European Society for Hyperthermic Oncology
 +
|
 +
|Soft tissue sarcoma
 +
|2
 +
|0
 +
|1
 +
|0
 +
|40
 +
|26
 +
|1
 +
|-
 +
|Abdel Wahab
 +
|Manal
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2010
 +
|2013
 +
|
 +
|
 +
|Hepatocellular carcinoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|5
 +
|5
 +
|1
 +
|-
 +
|Abdel Wahab
 +
|Omar
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2002
 +
|2019
 +
|ECOG
 +
|
 +
|Acute myeloid leukemia; Chronic myelomonocytic leukemia; Erdheim-Chester disease; Essential thrombocythemia; Hairy cell leukemia; Langerhans cell histiocytosis; Polycythemia vera; Rosai-Dorfman-Destombes disease
 +
|6
 +
|1
 +
|1
 +
|1
 +
|124
 +
|114
 +
|1
 +
|-
 +
|Abdel Wahab
 +
|Sherif
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2010
 +
|2013
 +
|
 +
|
 +
|Hepatocellular carcinoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|5
 +
|5
 +
|1
 +
|-
 +
|Abdelfattah
 +
|Murad
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2001
 +
|2009
 +
|
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|12
 +
|12
 +
|1
 +
|-
 +
|Abdelghany
 +
|Osama
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2011
 +
|2020
 +
|
 +
|
 +
|Endometrial cancer
 +
|2
 +
|0
 +
|0
 +
|0
 +
|46
 +
|24
 +
|1
 +
|-
 +
|Abdi
 +
|Ehtesham A
 +
|MALE
 +
|
 +
|
 +
|
 +
|Australia
 +
|1994
 +
|2021
 +
|ALLG; IBCSG
 +
|
 +
|Breast cancer; Diffuse large B-cell lymphoma
 +
|4
 +
|0
 +
|3
 +
|0
 +
|95
 +
|72
 +
|1
 +
|-
 +
|Abdiche
 +
|Menouar Samir
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|France
 +
|2008
 +
|2020
 +
|GETUG
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|17
 +
|17
 +
|1
 +
|-
 +
|Abdo
 +
|Andre
 +
|MALE
 +
|
 +
|
 +
|
 +
|Brazil
 +
|2017
 +
|2021
 +
|
 +
|
 +
|Chronic myeloid leukemia
 +
|1
 +
|0
 +
|1
 +
|1
 +
|25
 +
|25
 +
|1
 +
|-
 +
|Abdul Razak
 +
|Albiruni R
 +
|MALE
 +
|
 +
|
 +
|
 +
|Canada
 +
|2015
 +
|2020
 +
|
 +
|
 +
|Soft tissue sarcoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Abdulkadyrov
 +
|Kudrat M
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Russian Federation
 +
|2004
 +
|2019
 +
|
 +
|
 +
|Chronic lymphocytic leukemia; Chronic myeloid leukemia; Essential thrombocythemia; Multiple myeloma
 +
|6
 +
|0
 +
|4
 +
|2
 +
|117
 +
|76
 +
|1
 +
|-
 +
|Abdullaev
 +
|S
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|USA
 +
|2014
 +
|2022
 +
|
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|0
 +
|1
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Abdullah
 +
|Shaad E
 +
|MALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2017
 +
|2021
 +
|
 +
|
 +
|Uveal melanoma
 +
|1
 +
|0
 +
|1
 +
|1
 +
|27
 +
|27
 +
|1
 +
|-
 +
|Abe
 +
|Hajime
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2002
 +
|2010
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Abe
 +
|Osahiko
 +
|UNMATCHED
 +
|
 +
|
 +
|
 +
|
 +
|1981
 +
|1994
 +
|
 +
|
 +
|Breast cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|23
 +
|17
 +
|1
 +
|-
 +
|Abe
 +
|Rikiya
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1996
 +
|2009
 +
|Adjuvant CEF Research Group for Breast Cancer
 +
|
 +
|Breast cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|27
 +
|24
 +
|1
 +
|-
 +
|Abe
 +
|Tetsuya
 +
|MALE
 +
|
 +
|
 +
|
 +
|Japan
 +
|2008
 +
|2015
 +
|JCOG
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|1
 +
|1
 +
|0
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Abe
 +
|Yasunobu
 +
|MALE
 +
|
 +
|
 +
|
 +
|Japan
 +
|2012
 +
|2016
 +
|
 +
|
 +
|Adult T-cell leukemia-lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|17
 +
|17
 +
|1
 +
|-
 +
|Abedi
 +
|Mehrdad
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2010
 +
|2021
 +
|
 +
|
 +
|B-cell acute lymphoblastic leukemia; Follicular lymphoma
 +
|2
 +
|0
 +
|0
 +
|1
 +
|37
 +
|37
 +
|1
 +
|-
 +
|Abel
 +
|Edvard
 +
|MALE
 +
|
 +
|
 +
|
 +
|Sweden
 +
|2013
 +
|2020
 +
|
 +
|
 +
|Head and neck cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Abel
 +
|Ulrich
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1990
 +
|2012
 +
|
 +
|
 +
|Diffuse large B-cell lymphoma; Pancreatic cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|40
 +
|40
 +
|1
 +
|-
 +
|Abella
 +
|Eugenia
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2001
 +
|2013
 +
|GELCAB; GELTAMO; GESIDA; PETHEMA
 +
|
 +
|Chronic lymphocytic leukemia; HIV-associated lymphoma
 +
|4
 +
|0
 +
|0
 +
|0
 +
|68
 +
|42
 +
|1
 +
|-
 +
|Abellan
 +
|Pascual Fernandez
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1999
 +
|2008
 +
|GEM; PETHEMA
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|16
 +
|16
 +
|1
 +
|-
 +
|Abeloff
 +
|Martin D
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1979
 +
|2009
 +
|Breast Cancer Intergroup of North America; CALGB; ECOG; SWOG
 +
|
 +
|Breast cancer; Small cell lung cancer
 +
|10
 +
|4
 +
|10
 +
|0
 +
|89
 +
|59
 +
|1
 +
|-
 +
|Abels
 +
|J
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|1983
 +
|1989
 +
|EORTC
 +
|
 +
|Acute myeloid leukemia
 +
|2
 +
|0
 +
|2
 +
|0
 +
|22
 +
|15
 +
|1
 +
|-
 +
|Abelson
 +
|Herbert T
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1982
 +
|1986
 +
|
 +
|
 +
|Osteosarcoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Abenhardt
 +
|Wolfgang
 +
|MALE
 +
|
 +
|
 +
|
 +
|Germany
 +
|1997
 +
|2017
 +
|GCLLSG
 +
|
 +
|Breast cancer; Chronic lymphocytic leukemia
 +
|4
 +
|0
 +
|4
 +
|0
 +
|52
 +
|37
 +
|1
 +
|-
 +
|Abergel
 +
|Armand
 +
|MALE
 +
|
 +
|
 +
|
 +
|France
 +
|1995
 +
|2019
 +
|FFCD
 +
|
 +
|Hepatocellular carcinoma
 +
|3
 +
|0
 +
|3
 +
|0
 +
|48
 +
|42
 +
|1
 +
|-
 +
|Abernethy
 +
|Amy
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2013
 +
|2017
 +
|
 +
|
 +
|Melanoma
 +
|1
 +
|0
 +
|1
 +
|1
 +
|22
 +
|22
 +
|1
 +
|-
 +
|Abeyakoon
 +
|Sarath
 +
|UNMATCHED
 +
|
 +
|
 +
|
 +
|
 +
|1996
 +
|2003
 +
|
 +
|
 +
|Head and neck cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|10
 +
|10
 +
|1
 +
|-
 +
|Abgrall
 +
|Jean Francois
 +
|MALE
 +
|
 +
|
 +
|
 +
|France
 +
|1991
 +
|1997
 +
|Intergroupe Francais des Leucemies Myeloides Chroniques
 +
|
 +
|Chronic myeloid leukemia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|11
 +
|11
 +
|1
 +
|-
 +
|Abhyankar
 +
|Sunil
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2018
 +
|2018
 +
|BMT CTN
 +
|
 +
|Graft versus host disease
 +
|1
 +
|0
 +
|0
 +
|0
 +
|21
 +
|21
 +
|1
 +
|-
 +
|Abi Gerges
 +
|Dany
 +
|MALE
 +
|
 +
|
 +
|
 +
|Lebanon
 +
|2008
 +
|2014
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Abianui
 +
|Abongnwen
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Canada
 +
|2018
 +
|2018
 +
|
 +
|
 +
|Venous thromboembolism
 +
|1
 +
|0
 +
|1
 +
|0
 +
|26
 +
|26
 +
|1
 +
|-
 +
|Abidi
 +
|Muneer H
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2004
 +
|2020
 +
|SWOG
 +
|
 +
|Hodgkin lymphoma; Multiple myeloma
 +
|6
 +
|0
 +
|3
 +
|1
 +
|82
 +
|48
 +
|1
 +
|-
 +
|Abidoye
 +
|Oyewale O
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2014
 +
|2016
 +
|
 +
|
 +
|Bladder cancer
 +
|2
 +
|0
 +
|0
 +
|2
 +
|64
 +
|43
 +
|1
 +
|-
 +
|Abildgaard
 +
|Niels
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2002
 +
|2013
 +
|
 +
|
 +
|Multiple myeloma
 +
|2
 +
|0
 +
|2
 +
|0
 +
|48
 +
|37
 +
|1
 +
|-
 +
|Abir
 +
|Esshagh
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|
 +
|1965
 +
|1965
 +
|
 +
|
 +
|B-cell acute lymphoblastic leukemia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Ablin
 +
|Arthur R
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1988
 +
|1988
 +
|CCG
 +
|
 +
|T-cell acute lymphoblastic leukemia pediatric
 +
|1
 +
|0
 +
|0
 +
|0
 +
|11
 +
|11
 +
|1
 +
|-
 +
|Aboelhassan
 +
|Rasha
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Egypt
 +
|2013
 +
|2019
 +
|
 +
|
 +
|Malignant pleural mesothelioma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|25
 +
|25
 +
|1
 +
|-
 +
|Abonour
 +
|Rafat
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2004
 +
|2018
 +
|ECOG
 +
|
 +
|Multiple myeloma
 +
|3
 +
|0
 +
|1
 +
|1
 +
|53
 +
|50
 +
|1
 +
|-
 +
|Abou Alfa
 +
|Ghassan K
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2001
 +
|2021
 +
|CALGB
 +
|
 +
|Cholangiocarcinoma; Hepatocellular carcinoma; Pancreatic cancer
 +
|13
 +
|11
 +
|7
 +
|4
 +
|267
 +
|191
 +
|1
 +
|-
 +
|Abou Nassar
 +
|Karim
 +
|MALE
 +
|
 +
|
 +
|
 +
|Canada
 +
|2013
 +
|2019
 +
|
 +
|
 +
|Follicular lymphoma; Venous thromboembolism
 +
|2
 +
|0
 +
|1
 +
|1
 +
|44
 +
|44
 +
|1
 +
|-
 +
|Abou Rached
 +
|Antoine
 +
|MALE
 +
|
 +
|
 +
|
 +
|France
 +
|1990
 +
|1995
 +
|Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire
 +
|
 +
|Hepatocellular carcinoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|5
 +
|5
 +
|1
 +
|-
 +
|Aboulafia
 +
|David
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1993
 +
|2009
 +
|AIDS Malignancy Consortium
 +
|
 +
|HIV-associated lymphoma; Kaposi sarcoma
 +
|3
 +
|0
 +
|2
 +
|0
 +
|33
 +
|29
 +
|1
 +
|-
 +
|Abraham
 +
|Aby
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1998
 +
|2010
 +
|
 +
|
 +
|Acute promyelocytic leukemia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|11
 +
|11
 +
|1
 +
|-
 +
|Abraham
 +
|Christine
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|France
 +
|2003
 +
|2019
 +
|
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|27
 +
|27
 +
|1
 +
|-
 +
|Abraham
 +
|George
 +
|MALE
 +
|
 +
|
 +
|
 +
|India
 +
|2012
 +
|2019
 +
|
 +
|
 +
|Head and neck cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|50
 +
|50
 +
|1
 +
|-
 +
|Abraham
 +
|Jacinta
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2008
 +
|2018
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|37
 +
|37
 +
|1
 +
|-
 +
|Abraham
 +
|Jean E
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2001
 +
|2019
 +
|tAnGo trial collaborators
 +
|
 +
|Breast cancer
 +
|4
 +
|0
 +
|4
 +
|0
 +
|102
 +
|66
 +
|1
 +
|-
 +
|Abraham
 +
|Julie
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|France
 +
|2014
 +
|2021
 +
|
 +
|
 +
|Diffuse large B-cell lymphoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|24
 +
|24
 +
|1
 +
|-
 +
|Abraham
 +
|Mirta
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1996
 +
|2013
 +
|Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|37
 +
|37
 +
|1
 +
|-
 +
|Abrahamse Testroote
 +
|Martine C J
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Netherlands
 +
|2006
 +
|2014
 +
|HOVON
 +
|
 +
|Chronic lymphocytic leukemia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Abrahamsson
 +
|Jonas
 +
|MALE
 +
|
 +
|
 +
|
 +
|Sweden
 +
|2004
 +
|2019
 +
|Nordic Society of Paediatric Haematology and Oncology (NOPHO)
 +
|
 +
|Acute myeloid leukemia; B-cell acute lymphoblastic leukemia pediatric
 +
|2
 +
|0
 +
|2
 +
|0
 +
|18
 +
|17
 +
|1
 +
|-
 +
|Abrahamsson
 +
|Per Anders
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2001
 +
|2007
 +
|Atrasentan Phase III Study Group Institutions
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|8
 +
|8
 +
|1
 +
|-
 +
|Abram
 +
|Paul
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1998
 +
|2004
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|10
 +
|10
 +
|1
 +
|-
 +
|Abram
 +
|Steven R
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2007
 +
|2018
 +
|
 +
|
 +
|Glioblastoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|68
 +
|68
 +
|1
 +
|-
 +
|Abramov
 +
|M
 +
|CBD
 +
|
 +
|
 +
|
 +
|Russian Federation
 +
|2011
 +
|2017
 +
|
 +
|
 +
|Gastric cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Abrams
 +
|Jeffrey S
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1982
 +
|2018
 +
|CALGB; NCIC-CTG
 +
|
 +
|Breast cancer; Melanoma
 +
|9
 +
|1
 +
|6
 +
|2
 +
|145
 +
|85
 +
|1
 +
|-
 +
|Abrams
 +
|K
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|
 +
|1988
 +
|1994
 +
|
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|4
 +
|4
 +
|1
 +
|-
 +
|Abrams
 +
|Paul G
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1984
 +
|1984
 +
|
 +
|
 +
|Follicular lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|11
 +
|11
 +
|1
 +
|-
 +
|Abrams
 +
|Ross A
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1987
 +
|2011
 +
|Radiation Therapy Oncology Group; RTOG
 +
|
 +
|Cholangiocarcinoma; Pancreatic cancer; Prostate cancer
 +
|3
 +
|0
 +
|2
 +
|1
 +
|36
 +
|27
 +
|1
 +
|-
 +
|Abrams
 +
|Thomas A
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2006
 +
|2018
 +
|
 +
|
 +
|Cholangiocarcinoma; Gallbladder cancer; Hepatocellular carcinoma
 +
|3
 +
|0
 +
|0
 +
|0
 +
|59
 +
|40
 +
|1
 +
|-
 +
|Abramson
 +
|David H
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2010
 +
|2014
 +
|
 +
|
 +
|Uveal melanoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|27
 +
|27
 +
|1
 +
|-
 +
|Abramson
 +
|Jeremy S
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2005
 +
|2022
 +
|Alliance; Blood Cancer Research Partnership of the Leukemia and Lymphoma Society; CALGB
 +
|
 +
|Chronic lymphocytic leukemia; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Primary mediastinal B-cell lymphoma; Transformed lymphoma
 +
|8
 +
|3
 +
|5
 +
|3
 +
|156
 +
|140
 +
|1
 +
|-
 +
|Abramson
 +
|Neil
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1979
 +
|2001
 +
|ECOG; NSABP
 +
|
 +
|Breast cancer; Multiple myeloma
 +
|5
 +
|0
 +
|6
 +
|0
 +
|63
 +
|40
 +
|1
 +
|-
 +
|Abramson
 +
|Vandana G
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2010
 +
|2022
 +
|NCIC-CTG
 +
|
 +
|Breast cancer; CNS carcinoma; Thyroid cancer
 +
|6
 +
|1
 +
|2
 +
|2
 +
|131
 +
|98
 +
|1
 +
|-
 +
|Abrao Miziara
 +
|Jose Elias
 +
|MALE
 +
|
 +
|
 +
|
 +
|Brazil
 +
|2006
 +
|2015
 +
|
 +
|
 +
|Non-small cell lung cancer; Non-small cell lung cancer nonsquamous
 +
|3
 +
|0
 +
|3
 +
|0
 +
|62
 +
|52
 +
|1
 +
|-
 +
|Abratt
 +
|Raymond Pierre
 +
|MALE
 +
|
 +
|
 +
|
 +
|South Africa
 +
|1995
 +
|2011
 +
|GLOB 2 group
 +
|
 +
|Non-small cell lung cancer; Prostate cancer
 +
|6
 +
|3
 +
|6
 +
|0
 +
|58
 +
|53
 +
|1
 +
|-
 +
|Abrey
 +
|Lauren E
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Switzerland; USA
 +
|1992
 +
|2018
 +
|
 +
|
 +
|Autologous HSCT; CNS lymphoma; Glioblastoma; High-grade glioma pediatric; Stem cell mobilization
 +
|9
 +
|4
 +
|1
 +
|1
 +
|101
 +
|76
 +
|1
 +
|-
 +
|Abrisqueta
 +
|Pau
 +
|MALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|2005
 +
|2021
 +
|
 +
|
 +
|Chronic lymphocytic leukemia; Diffuse large B-cell lymphoma
 +
|5
 +
|1
 +
|2
 +
|1
 +
|111
 +
|87
 +
|1
 +
|-
 +
|Abromowitch
 +
|Minnie
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1979
 +
|2012
 +
|COG
 +
|
 +
|B-cell acute lymphoblastic leukemia; B-cell acute lymphoblastic leukemia pediatric
 +
|3
 +
|1
 +
|3
 +
|0
 +
|30
 +
|27
 +
|1
 +
|-
 +
|Abruzzese
 +
|Elisabetta
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2004
 +
|2018
 +
|EORTC; FIL; GIMEMA; LYSA
 +
|
 +
|B-cell acute lymphoblastic leukemia; Chronic myeloid leukemia; Hodgkin lymphoma
 +
|7
 +
|0
 +
|5
 +
|1
 +
|174
 +
|122
 +
|1
 +
|-
 +
|Abruzzo
 +
|Lynne V
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2015
 +
|2020
 +
|
 +
|
 +
|Chronic lymphocytic leukemia; Hodgkin lymphoma
 +
|2
 +
|0
 +
|0
 +
|0
 +
|29
 +
|29
 +
|1
 +
|-
 +
|Abshire
 +
|T C
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|USA
 +
|2000
 +
|2000
 +
|POG
 +
|
 +
|B-cell acute lymphoblastic leukemia pediatric
 +
|1
 +
|1
 +
|0
 +
|0
 +
|4
 +
|4
 +
|1
 +
|-
 +
|Abt
 +
|Markus
 +
|MALE
 +
|
 +
|
 +
|
 +
|Switzerland
 +
|1998
 +
|2005
 +
|
 +
|
 +
|Colon cancer
 +
|1
 +
|0
 +
|1
 +
|1
 +
|25
 +
|25
 +
|1
 +
|-
 +
|Abu Samra
 +
|Maisun
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Germany
 +
|2010
 +
|2019
 +
|
 +
|
 +
|Acute myeloid leukemia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|32
 +
|32
 +
|1
 +
|-
 +
|Abu Zahra
 +
|Hakam
 +
|MALE
 +
|
 +
|
 +
|
 +
|Canada
 +
|1984
 +
|1998
 +
|NCIC-CTG
 +
|
 +
|Breast cancer
 +
|2
 +
|0
 +
|2
 +
|2
 +
|38
 +
|31
 +
|1
 +
|-
 +
|Abuav
 +
|Rachel
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2009
 +
|2009
 +
|
 +
|
 +
|Cutaneous T-cell lymphoma
 +
|1
 +
|0
 +
|0
 +
|1
 +
|13
 +
|13
 +
|1
 +
|-
 +
|Abubakr
 +
|Yousif A
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2002
 +
|2008
 +
|
 +
|
 +
|Colorectal cancer
 +
|2
 +
|0
 +
|3
 +
|0
 +
|30
 +
|29
 +
|1
 +
|-
 +
|Abulizi
 +
|G
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|China
 +
|2017
 +
|2021
 +
|
 +
|
 +
|Ovarian cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|33
 +
|33
 +
|1
 +
|-
 +
|Accario Winslow
 +
|Chrisann
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2001
 +
|2009
 +
|Gynecologic Cancer Intergroup
 +
|
 +
|Ovarian cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|15
 +
|15
 +
|1
 +
|-
 +
|Accomando
 +
|Emilio
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|1987
 +
|1992
 +
|
 +
|
 +
|Head and neck cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|24
 +
|24
 +
|1
 +
|-
 +
|Accortanzo
 +
|Valeria
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|1996
 +
|2016
 +
|GONO
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Acha
 +
|Tomas
 +
|MALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|2001
 +
|2015
 +
|
 +
|
 +
|Wilms tumor
 +
|1
 +
|0
 +
|1
 +
|0
 +
|13
 +
|13
 +
|1
 +
|-
 +
|Acharya
 +
|Sandip
 +
|MALE
 +
|
 +
|
 +
|
 +
|India
 +
|2009
 +
|2018
 +
|
 +
|
 +
|Chronic myeloid leukemia
 +
|2
 +
|0
 +
|1
 +
|1
 +
|36
 +
|32
 +
|1
 +
|-
 +
|Acharyya
 +
|Suddhasatta
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|USA
 +
|2018
 +
|2021
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Achebe
 +
|Maureen M
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2017
 +
|2021
 +
|
 +
|
 +
|Sickle cell anemia
 +
|2
 +
|0
 +
|1
 +
|0
 +
|32
 +
|23
 +
|1
 +
|-
 +
|Achille
 +
|Emmanuel
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1996
 +
|2007
 +
|GERCOR
 +
|
 +
|Colon cancer; Colorectal cancer
 +
|3
 +
|0
 +
|2
 +
|0
 +
|41
 +
|22
 +
|1
 +
|-
 +
|Acholonu
 +
|Sandra
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2008
 +
|2008
 +
|
 +
|
 +
|Allogeneic HSCT; Hodgkin lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|17
 +
|17
 +
|1
 +
|-
 +
|Achour
 +
|Eddine
 +
|UNMATCHED
 +
|
 +
|
 +
|
 +
|
 +
|2001
 +
|2001
 +
|
 +
|
 +
|CNS lymphoma; Stem cell mobilization
 +
|1
 +
|0
 +
|0
 +
|0
 +
|11
 +
|11
 +
|1
 +
|-
 +
|Achtelik
 +
|W
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|1994
 +
|2001
 +
|DeCOG
 +
|
 +
|Melanoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|15
 +
|15
 +
|1
 +
|-
 +
|Achtnicht
 +
|U
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|1985
 +
|1992
 +
|
 +
|
 +
|Renal cell carcinoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|8
 +
|8
 +
|1
 +
|-
 +
|Acin
 +
|Yolene
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|France
 +
|2009
 +
|2015
 +
|
 +
|
 +
|Gastrointestinal stromal tumor; Pancreatic cancer
 +
|2
 +
|0
 +
|1
 +
|0
 +
|33
 +
|29
 +
|1
 +
|-
 +
|Acker
 +
|Thomas
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2002
 +
|2012
 +
|“Aktion Bronchialkarzinom” (ABC Study Group)
 +
|
 +
|Small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|15
 +
|15
 +
|1
 +
|-
 +
|Ackerman
 +
|Charlotte
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2007
 +
|2016
 +
|
 +
|
 +
|Bladder cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Ackerman
 +
|Ilana
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Australia
 +
|2022
 +
|2022
 +
|
 +
|
 +
|Venous thromboembolism
 +
|1
 +
|0
 +
|1
 +
|0
 +
|45
 +
|45
 +
|1
 +
|-
 +
|Ackerman
 +
|Judie
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2001
 +
|2006
 +
|
 +
|
 +
|Pancreatic cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|10
 +
|10
 +
|1
 +
|-
 +
|Ackerstaff
 +
|Annemiek H
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2000
 +
|2010
 +
|
 +
|
 +
|Head and neck cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|12
 +
|12
 +
|1
 +
|-
 +
|Ackerstein
 +
|Aliza
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1998
 +
|1998
 +
|
 +
|
 +
|Allogeneic HSCT; Chronic lymphocytic leukemia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Ackland
 +
|Stephen P
 +
|MALE
 +
|
 +
|
 +
|
 +
|Australia
 +
|1990
 +
|2012
 +
|AGITG; ANZ BCTG; Australasian Gastro-Intestinal Trials Group; Trans-Tasman Radiation Oncology Group; TROG
 +
|
 +
|Breast cancer; Colorectal cancer; Esophageal cancer; Rectal cancer
 +
|8
 +
|1
 +
|8
 +
|1
 +
|109
 +
|97
 +
|1
 +
|-
 +
|Acosta Rivera
 +
|Mirelis
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2012
 +
|2020
 +
|
 +
|
 +
|Hepatocellular carcinoma
 +
|1
 +
|0
 +
|0
 +
|1
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Acosta
 +
|Mark
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2010
 +
|2010
 +
|
 +
|
 +
|Cutaneous T-cell lymphoma
 +
|1
 +
|0
 +
|1
 +
|1
 +
|8
 +
|8
 +
|1
 +
|-
 +
|Acosta
 +
|Soraida C
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Cuba
 +
|2006
 +
|2016
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|33
 +
|33
 +
|1
 +
|-
 +
|Acquino Parsons
 +
|C
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|1995
 +
|2001
 +
|
 +
|
 +
|Endometrial cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|6
 +
|6
 +
|1
 +
|-
 +
|Acs
 +
|Peter I
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2008
 +
|2013
 +
|
 +
|
 +
|Diffuse large B-cell lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|5
 +
|5
 +
|1
 +
|-
 +
|Acton
 +
|Gary
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2010
 +
|2015
 +
|
 +
|
 +
|Acute myeloid leukemia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|35
 +
|35
 +
|1
 +
|-
 +
|Adab
 +
|Fawzi
 +
|MALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2002
 +
|2017
 +
|CRUK
 +
|
 +
|Pancreatic cancer; Prostate cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|65
 +
|65
 +
|1
 +
|-
 +
|Adachi
 +
|Hisanobu
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|
 +
|2005
 +
|2013
 +
|
 +
|
 +
|Bladder cancer; Upper tract urothelial carcinoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|22
 +
|22
 +
|1
 +
|-
 +
|Adachi
 +
|Isamu
 +
|MALE
 +
|
 +
|
 +
|
 +
|Japan
 +
|1993
 +
|1996
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|1
 +
|0
 +
|0
 +
|6
 +
|6
 +
|1
 +
|-
 +
|Adachi
 +
|Susumu
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2001
 +
|2008
 +
|
 +
|
 +
|Malignant pleural mesothelioma
 +
|2
 +
|0
 +
|1
 +
|0
 +
|23
 +
|21
 +
|1
 +
|-
 +
|Adak
 +
|Sudeshna
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1991
 +
|2001
 +
|ECOG
 +
|
 +
|Non-small cell lung cancer; Small cell lung cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|12
 +
|11
 +
|1
 +
|-
 +
|Adam
 +
|H
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|1982
 +
|1994
 +
|SAKK
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|17
 +
|17
 +
|1
 +
|-
 +
|Adam
 +
|Rene
 +
|MALE
 +
|
 +
|
 +
|
 +
|France
 +
|1994
 +
|2017
 +
|SARAH Trial Group
 +
|
 +
|Colorectal cancer; Hepatocellular carcinoma
 +
|2
 +
|0
 +
|2
 +
|0
 +
|52
 +
|52
 +
|1
 +
|-
 +
|Adam
 +
|Zdenek
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2001
 +
|2013
 +
|
 +
|
 +
|Multiple myeloma
 +
|4
 +
|1
 +
|1
 +
|0
 +
|45
 +
|24
 +
|1
 +
|-
 +
|Adamchuk
 +
|Hryhoriy
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Ukraine
 +
|2008
 +
|2019
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|24
 +
|24
 +
|1
 +
|-
 +
|Adami
 +
|Bernd
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2001
 +
|2009
 +
|
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|12
 +
|12
 +
|1
 +
|-
 +
|Adami
 +
|Fausto
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|1999
 +
|2017
 +
|
 +
|
 +
|Light-chain (AL) amyloidosis; POEMS syndrome
 +
|2
 +
|0
 +
|0
 +
|0
 +
|17
 +
|16
 +
|1
 +
|-
 +
|Adami
 +
|Francesca
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|1996
 +
|2016
 +
|GONO
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Adami
 +
|Hans Olov
 +
|MALE
 +
|
 +
|
 +
|
 +
|Sweden; USA
 +
|1989
 +
|2018
 +
|SPCG
 +
|
 +
|Prostate cancer
 +
|6
 +
|0
 +
|1
 +
|0
 +
|78
 +
|22
 +
|1
 +
|-
 +
|Adamkewicz
 +
|Joanne I
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2018
 +
|2018
 +
|
 +
|
 +
|Inherited coagulopathy
 +
|1
 +
|0
 +
|1
 +
|0
 +
|16
 +
|16
 +
|1
 +
|-
 +
|Adamo
 +
|Francesco
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1995
 +
|2006
 +
|EORTC; FIL; GIMEMA
 +
|
 +
|Acute myeloid leukemia; Hodgkin lymphoma
 +
|2
 +
|0
 +
|1
 +
|0
 +
|37
 +
|36
 +
|1
 +
|-
 +
|Adamo
 +
|Vincenzo
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1983
 +
|2005
 +
|Italian Lung Cancer Project; Italian Multicentre Breast Study with Epirubicin
 +
|
 +
|Breast cancer; Colon cancer; Non-small cell lung cancer; Ovarian cancer
 +
|5
 +
|0
 +
|4
 +
|0
 +
|138
 +
|121
 +
|1
 +
|-
 +
|Adamou
 +
|Adamos
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1992
 +
|2009
 +
|HeCOG; HORG
 +
|
 +
|Breast cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|35
 +
|34
 +
|1
 +
|-
 +
|Adams
 +
|Bonne
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|USA
 +
|2017
 +
|2022
 +
|
 +
|
 +
|Vascular sarcoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|15
 +
|15
 +
|1
 +
|-
 +
|Adams
 +
|George L
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1989
 +
|2003
 +
|
 +
|
 +
|Head and neck cancer; Nasopharyngeal carcinoma
 +
|2
 +
|0
 +
|3
 +
|0
 +
|17
 +
|14
 +
|1
 +
|-
 +
|Adams
 +
|Grenfell
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1984
 +
|2004
 +
|NCIC-CTG
 +
|
 +
|Diffuse large B-cell lymphoma; Hodgkin lymphoma
 +
|2
 +
|0
 +
|1
 +
|0
 +
|28
 +
|27
 +
|1
 +
|-
 +
|Adams
 +
|Hans Peter
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1995
 +
|2003
 +
|AGO
 +
|
 +
|Ovarian cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|16
 +
|16
 +
|1
 +
|-
 +
|Adams
 +
|Julian
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2001
 +
|2004
 +
|
 +
|
 +
|Follicular lymphoma; Mantle cell lymphoma; Multiple myeloma
 +
|3
 +
|0
 +
|0
 +
|1
 +
|49
 +
|34
 +
|1
 +
|-
 +
|Adams
 +
|M
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|1995
 +
|2002
 +
|ICON
 +
|
 +
|Ovarian cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Adams
 +
|Paul T
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2007
 +
|2015
 +
|NSABP
 +
|
 +
|Breast cancer
 +
|2
 +
|0
 +
|1
 +
|0
 +
|39
 +
|21
 +
|1
 +
|-
 +
|Adams
 +
|Richard A
 +
|MALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2005
 +
|2021
 +
|MRC
 +
|
 +
|Anal cancer; Colorectal cancer
 +
|5
 +
|2
 +
|5
 +
|0
 +
|99
 +
|79
 +
|1
 +
|-
 +
|Adams
 +
|Sylvia
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2015
 +
|2021
 +
|
 +
|
 +
|Breast cancer
 +
|3
 +
|0
 +
|1
 +
|1
 +
|47
 +
|22
 +
|1
 +
|-
 +
|Adamska
 +
|Krystyna
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Poland
 +
|2008
 +
|2014
 +
|Canadian Brain Tumor Consortium; CENTRIC study team; EORTC
 +
|
 +
|Glioblastoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|36
 +
|36
 +
|1
 +
|-
 +
|Adamski
 +
|Henri
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2011
 +
|2011
 +
|
 +
|
 +
|Cutaneous squamous cell carcinoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Adamson
 +
|Peter C
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2008
 +
|2020
 +
|Children's Oncology Group; COG; European Intergroup for Childhood Non-Hodgkin Lymphoma
 +
|
 +
|Anaplastic large cell lymphoma pediatric; B-cell acute lymphoblastic leukemia pediatric; Non-Hodgkin lymphoma pediatric
 +
|3
 +
|0
 +
|2
 +
|3
 +
|50
 +
|50
 +
|1
 +
|-
 +
|Adamus
 +
|Jerzy
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1974
 +
|1982
 +
|
 +
|
 +
|Melanoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|25
 +
|25
 +
|1
 +
|-
 +
|Addamo
 +
|B
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|1998
 +
|2004
 +
|AML Study Group Ulm
 +
|
 +
|Acute myeloid leukemia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|24
 +
|24
 +
|1
 +
|-
 +
|Adde
 +
|Magdalena
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Sweden
 +
|2001
 +
|2006
 +
|
 +
|
 +
|Burkitt lymphoma; Diffuse large B-cell lymphoma; HIV-associated lymphoma
 +
|2
 +
|1
 +
|0
 +
|0
 +
|15
 +
|15
 +
|1
 +
|-
 +
|Addeo
 +
|Raffaele
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2003
 +
|2009
 +
|
 +
|
 +
|Bladder cancer
 +
|1
 +
|1
 +
|1
 +
|0
 +
|11
 +
|11
 +
|1
 +
|-
 +
|Addison
 +
|Alicia
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2013
 +
|2015
 +
|
 +
|
 +
|Mantle cell lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|24
 +
|24
 +
|1
 +
|-
 +
|Adebamowo
 +
|Clement
 +
|MALE
 +
|
 +
|
 +
|
 +
|Nigeria
 +
|2004
 +
|2016
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|29
 +
|29
 +
|1
 +
|-
 +
|Adelman
 +
|Carrie A
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2020
 +
|2020
 +
|
 +
|
 +
|Prostate cancer
 +
|2
 +
|0
 +
|0
 +
|0
 +
|38
 +
|23
 +
|1
 +
|-
 +
|Adelson
 +
|Mark D
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1985
 +
|1999
 +
|GOG
 +
|
 +
|Endometrial cancer; Ovarian cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Adelstein
 +
|David J
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1988
 +
|2018
 +
|RTOG; SWOG
 +
|
 +
|Diffuse large B-cell lymphoma; Head and neck cancer; Oropharyngeal cancer
 +
|6
 +
|4
 +
|4
 +
|0
 +
|62
 +
|56
 +
|1
 +
|-
 +
|Ademokun
 +
|Debo
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2008
 +
|2019
 +
|National Cancer Research Institute Haemato-oncology Clinical Studies Group
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|2
 +
|0
 +
|21
 +
|21
 +
|1
 +
|-
 +
|Ademuyiwa
 +
|Foluso
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|USA
 +
|2013
 +
|2017
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|33
 +
|33
 +
|1
 +
|-
 +
|Adeniran
 +
|Adebowale
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|USA
 +
|2016
 +
|2021
 +
|SWOG
 +
|
 +
|Papillary renal cell carcinoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Adenis
 +
|Antoine
 +
|MALE
 +
|
 +
|
 +
|
 +
|France
 +
|1992
 +
|2022
 +
|EORTC; FFCD; FNCLCC; French Sarcoma Group; GI Group of the French Anti-Cancer Centers; PAZOGIST study group of the French Sarcoma Groupe-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO); UNICANCER
 +
|
 +
|Anal cancer; Colorectal cancer; Esophageal cancer; Esophageal squamous cell carcinoma; Gastrointestinal stromal tumor; Pancreatic cancer
 +
|18
 +
|2
 +
|12
 +
|5
 +
|322
 +
|225
 +
|1
 +
|-
 +
|Ades
 +
|Lionel
 +
|MALE
 +
|
 +
|
 +
|
 +
|France
 +
|1993
 +
|2022
 +
|EAPLG; European APL Group; French Belgian Swiss APL group; Groupe Francophone des Myelodysplasies; PETHEMA
 +
|
 +
|Acute myeloid leukemia; Acute promyelocytic leukemia; Chronic myelomonocytic leukemia; Myelodysplastic syndrome
 +
|8
 +
|7
 +
|6
 +
|1
 +
|182
 +
|121
 +
|1
 +
|-
 +
|Adeva
 +
|Jorge
 +
|MALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|2017
 +
|2021
 +
|
 +
|
 +
|Cholangiocarcinoma
 +
|2
 +
|0
 +
|1
 +
|1
 +
|51
 +
|28
 +
|1
 +
|-
 +
|Adewoye
 +
|Adeboye H
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2012
 +
|2017
 +
|
 +
|
 +
|Chronic lymphocytic leukemia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|22
 +
|22
 +
|1
 +
|-
 +
|Adhoute
 +
|X
 +
|CBD
 +
|
 +
|
 +
|
 +
|France
 +
|2003
 +
|2015
 +
|FFCD
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|23
 +
|23
 +
|1
 +
|-
 +
|Adib
 +
|Deyaa
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2015
 +
|2020
 +
|
 +
|
 +
|Follicular lymphoma
 +
|1
 +
|0
 +
|0
 +
|1
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Adibi
 +
|Mehrad
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|USA
 +
|2017
 +
|2020
 +
|
 +
|
 +
|Upper tract urothelial carcinoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|35
 +
|35
 +
|1
 +
|-
 +
|Adie
 +
|Sam
 +
|MALE
 +
|
 +
|
 +
|
 +
|Australia
 +
|2022
 +
|2022
 +
|
 +
|
 +
|Venous thromboembolism
 +
|1
 +
|0
 +
|1
 +
|0
 +
|45
 +
|45
 +
|1
 +
|-
 +
|Adiguzel
 +
|Ibrahim
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2007
 +
|2011
 +
|
 +
|
 +
|Small cell lung cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|9
 +
|9
 +
|1
 +
|-
 +
|Adinin
 +
|Rosnie B
 +
|UNMATCHED
 +
|
 +
|
 +
|
 +
|
 +
|2001
 +
|2008
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|10
 +
|10
 +
|1
 +
|-
 +
|Adjei
 +
|Alex A
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1999
 +
|2017
 +
|ECOG-ACRIN; NCCTG
 +
|
 +
|Non-small cell lung cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|38
 +
|38
 +
|1
 +
|-
 +
|Adkins
 +
|Douglas
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2004
 +
|2021
 +
|
 +
|
 +
|Head and neck cancer; Soft tissue sarcoma; Thyroid cancer
 +
|3
 +
|0
 +
|1
 +
|2
 +
|54
 +
|54
 +
|1
 +
|-
 +
|Adler Reichel
 +
|S
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Germany
 +
|2001
 +
|2016
 +
|
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|34
 +
|34
 +
|1
 +
|-
 +
|Adler
 +
|Brian
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1992
 +
|2003
 +
|
 +
|
 +
|Sickle cell anemia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|26
 +
|26
 +
|1
 +
|-
 +
|Adler
 +
|Mathias
 +
|MALE
 +
|
 +
|
 +
|
 +
|Germany
 +
|1991
 +
|2011
 +
|CONKO; GHSG
 +
|
 +
|Hodgkin lymphoma; Pancreatic cancer
 +
|3
 +
|0
 +
|2
 +
|0
 +
|66
 +
|59
 +
|1
 +
|-
 +
|Adotevi
 +
|Olivier
 +
|MALE
 +
|
 +
|
 +
|
 +
|France
 +
|2014
 +
|2018
 +
|
 +
|
 +
|Anal cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|26
 +
|26
 +
|1
 +
|-
 +
|Adrian
 +
|Nicole
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Germany
 +
|2012
 +
|2016
 +
|
 +
|
 +
|Diffuse large B-cell lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|12
 +
|12
 +
|1
 +
|-
 +
|Adrover
 +
|Encarna
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|1999
 +
|2015
 +
|GEICAM
 +
|
 +
|Breast cancer
 +
|5
 +
|0
 +
|5
 +
|0
 +
|122
 +
|74
 +
|1
 +
|-
 +
|Advani
 +
|Anjali S
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2006
 +
|2019
 +
|CALGB; SWOG
 +
|
 +
|Acute myeloid leukemia; B-cell acute lymphoblastic leukemia; B-cell acute lymphoblastic leukemia pediatric; Diffuse large B-cell lymphoma; Follicular lymphoma; Myelodysplastic syndrome
 +
|7
 +
|3
 +
|1
 +
|1
 +
|112
 +
|91
 +
|1
 +
|-
 +
|Advani
 +
|Ranjana H
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1995
 +
|2022
 +
|ECOG; WMCTG
 +
|
 +
|Acute myeloid leukemia; Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Hodgkin lymphoma nodular lymphocyte-predominant; Mantle cell lymphoma; Mediastinal gray-zone lymphoma; Peripheral T-cell lymphoma; Primary mediastinal B-cell lymphoma; Waldenstroem macroglobulinemia
 +
|38
 +
|6
 +
|5
 +
|5
 +
|607
 +
|314
 +
|1
 +
|-
 +
|Advani
 +
|Suresh H
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1996
 +
|2005
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|10
 +
|10
 +
|1
 +
|-
 +
|Aeberhard
 +
|Peter
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1981
 +
|2008
 +
|SAKK
 +
|
 +
|Colon cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|12
 +
|9
 +
|1
 +
|-
 +
|Aebersold
 +
|Daniel M
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1994
 +
|2011
 +
|SAKK
 +
|
 +
|Head and neck cancer
 +
|1
 +
|1
 +
|1
 +
|0
 +
|10
 +
|10
 +
|1
 +
|-
 +
|Aebi
 +
|Stefan
 +
|MALE
 +
|
 +
|
 +
|
 +
|Switzerland
 +
|1993
 +
|2021
 +
|BOOG Dutch Breast Cancer Trialists' Group; Breast International Group; GEICAM Spanish Breast Cancer Group; International Breast Cancer Study Group; NRG Oncology; SAKK
 +
|
 +
|Breast cancer
 +
|9
 +
|2
 +
|5
 +
|0
 +
|179
 +
|83
 +
|1
 +
|-
 +
|Aerts
 +
|Joachim G J V
 +
|MALE
 +
|
 +
|
 +
|
 +
|Netherlands
 +
|2007
 +
|2021
 +
|
 +
|
 +
|Malignant pleural mesothelioma; Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous; Small cell lung cancer
 +
|9
 +
|1
 +
|6
 +
|1
 +
|152
 +
|125
 +
|1
 +
|-
 +
|Afable
 +
|Manuel
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2012
 +
|2012
 +
|
 +
|
 +
|Myelodysplastic syndrome
 +
|1
 +
|0
 +
|0
 +
|0
 +
|16
 +
|16
 +
|1
 +
|-
 +
|Afanasyev
 +
|Boris V
 +
|MALE
 +
|
 +
|
 +
|
 +
|Russian Federation
 +
|2003
 +
|2020
 +
|SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network
 +
|
 +
|Acute myeloid leukemia; Chronic lymphocytic leukemia; Mantle cell lymphoma; Myelodysplastic syndrome
 +
|4
 +
|0
 +
|3
 +
|2
 +
|95
 +
|95
 +
|1
 +
|-
 +
|Afchain
 +
|Pauline
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2004
 +
|2009
 +
|
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|16
 +
|16
 +
|1
 +
|-
 +
|Afenjar
 +
|Karen
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|France
 +
|2008
 +
|2019
 +
|
 +
|
 +
|Breast cancer; Gastric cancer
 +
|3
 +
|0
 +
|2
 +
|0
 +
|62
 +
|47
 +
|1
 +
|-
 +
|Afflitto
 +
|Anthony J
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2013
 +
|2018
 +
|
 +
|
 +
|Hepatocellular carcinoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Affronti
 +
|M L
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|
 +
|1992
 +
|2006
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|11
 +
|11
 +
|1
 +
|-
 +
|Afra
 +
|Denes
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1988
 +
|2008
 +
|EORTC
 +
|
 +
|Anaplastic glioma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|9
 +
|9
 +
|1
 +
|-
 +
|Afrin
 +
|Lawrence B
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2009
 +
|2017
 +
|
 +
|
 +
|Systemic mastocytosis
 +
|1
 +
|0
 +
|1
 +
|0
 +
|25
 +
|25
 +
|1
 +
|-
 +
|Aft
 +
|Rebecca
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2013
 +
|2017
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|33
 +
|33
 +
|1
 +
|-
 +
|Aftab
 +
|Dana T
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2013
 +
|2016
 +
|
 +
|
 +
|Renal cell carcinoma
 +
|1
 +
|0
 +
|1
 +
|1
 +
|22
 +
|22
 +
|1
 +
|-
 +
|Aftimos
 +
|Philippe
 +
|MALE
 +
|
 +
|
 +
|
 +
|Belgium
 +
|2017
 +
|2022
 +
|
 +
|
 +
|Breast cancer
 +
|2
 +
|0
 +
|2
 +
|1
 +
|57
 +
|54
 +
|1
 +
|-
 +
|Agajanian
 +
|Richy
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2012
 +
|2016
 +
|
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|16
 +
|16
 +
|1
 +
|-
 +
|Agaram
 +
|Narasimhan P
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2014
 +
|2018
 +
|Alliance
 +
|
 +
|Desmoid tumor
 +
|1
 +
|0
 +
|1
 +
|0
 +
|24
 +
|24
 +
|1
 +
|-
 +
|Agarwal
 +
|Archi
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|India
 +
|2012
 +
|2019
 +
|
 +
|
 +
|Head and neck cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|50
 +
|50
 +
|1
 +
|-
 +
|Agarwal
 +
|Jaiprakash
 +
|MALE
 +
|
 +
|
 +
|
 +
|India
 +
|2000
 +
|2019
 +
|
 +
|
 +
|Head and neck cancer
 +
|3
 +
|1
 +
|3
 +
|0
 +
|87
 +
|54
 +
|1
 +
|-
 +
|Agarwal
 +
|Mohan B
 +
|MALE
 +
|
 +
|
 +
|
 +
|India
 +
|2007
 +
|2011
 +
|
 +
|
 +
|Chronic myeloid leukemia
 +
|1
 +
|0
 +
|1
 +
|1
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Agarwal
 +
|Neeraj
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2006
 +
|2022
 +
|SWOG
 +
|
 +
|Bladder cancer; Prostate cancer; Renal cell carcinoma
 +
|15
 +
|2
 +
|8
 +
|3
 +
|299
 +
|211
 +
|1
 +
|-
 +
|Agarwal
 +
|Prasheen
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2004
 +
|2007
 +
|
 +
|
 +
|Chronic myeloid leukemia
 +
|2
 +
|0
 +
|0
 +
|0
 +
|32
 +
|25
 +
|1
 +
|-
 +
|Agarwal
 +
|Rishu
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Australia
 +
|2015
 +
|2018
 +
|
 +
|
 +
|Mantle cell lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|16
 +
|16
 +
|1
 +
|-
 +
|Agarwal
 +
|Shefali
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2013
 +
|2020
 +
|
 +
|
 +
|Epithelioid sarcoma; Follicular lymphoma; Ovarian cancer
 +
|3
 +
|0
 +
|1
 +
|3
 +
|71
 +
|71
 +
|1
 +
|-
 +
|Agarwal
 +
|Suresh K
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2012
 +
|2019
 +
|
 +
|
 +
|Acute myeloid leukemia; Chronic lymphocytic leukemia; Multiple myeloma
 +
|4
 +
|0
 +
|0
 +
|3
 +
|71
 +
|60
 +
|1
 +
|-
 +
|Agarwala
 +
|A
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|
 +
|2002
 +
|2011
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|14
 +
|14
 +
|1
 
|-
 
|-
−
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
+
|Agarwala
−
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
+
|Sanjiv S
−
|}
+
|MALE
−
{{TOC limit|limit=3}}
+
|
−
=Untreated=
+
|
−
==ABP {{#subobject:cefeba|Regimen=1}}==
+
|
−
ABP: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>P</u>'''rednisone
+
|USA
−
<div class="toccolours" style="background-color:#eeeeee">
+
|1974
−
===Regimen {{#subobject:04855a|Variant=1}}===
+
|2017
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|ECOG; EORTC
−
!style="width: 20%"|Study
+
|
−
!style="width: 20%"|Years of enrollment
+
|Head and neck cancer; Melanoma
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
|16
−
!style="width: 20%"|Comparator
+
|5
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+
|13
 +
|3
 +
|268
 +
|198
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1002/mpo.2950030110 Monfardini et al. 1977]
+
|Agate
−
|1972-1974
+
|Laura
−
|style="background-color:#1a9851"|Phase 3 (E-switch-ic)
+
|FEMALE
−
|[[#CVP|CVP]]
+
|
−
|style="background-color:#ffffbf"|Did not meet endpoint of ORR
+
|
 +
|
 +
|
 +
|2014
 +
|2014
 +
|
 +
|
 +
|Thyroid cancer differentiated; Thyroid cancer medullary
 +
|1
 +
|0
 +
|0
 +
|0
 +
|14
 +
|14
 +
|1
 
|-
 
|-
−
|}
+
|Agathocleous
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Agathoclis
−
====Chemotherapy====
+
|MALE
−
*[[Doxorubicin (Adriamycin)]] 75 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Bleomycin (Blenoxane)]] 15 mg/m<sup>2</sup> IV once per day on days 1 & 8
+
|
−
====Glucocorticoid therapy====
+
|
−
*[[Prednisone (Sterapred)]] 100 mg/m<sup>2</sup> IM once per day on days 1 to 5
+
|United Kingdom
−
'''21-day cycle for at least 6 cycles'''
+
|2010
−
</div></div>
+
|2010
−
===References===
+
|
−
# Monfardini S, Tancini G, De Lena M, Villa E, Valagussa P, Bonadonna G. Cyclophosphamide, vincristine, and prednisone (CVP) versus adriamycin, bleomycin, and prednisone (ABP) in stage IV non-Hodgkin's lymphomas. Med Pediatr Oncol. 1977;3(1):67-74. [https://doi.org/10.1002/mpo.2950030110 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/65728 PubMed]
+
|
−
==ACE {{#subobject:e05345|Regimen=1}}==
+
|Follicular lymphoma
−
ACE: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''toposide
+
|1
−
<div class="toccolours" style="background-color:#eeeeee">
+
|1
−
===Regimen {{#subobject:5ac5a4|Variant=1}}===
+
|0
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|0
−
!style="width: 20%"|Study
+
|11
−
!style="width: 20%"|Years of enrollment
+
|11
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
|1
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1038/sj.leu.2401955 Dumontet et al. 2000]
+
|Agbalika
−
|1995-1998
+
|Felix
−
|style="background-color:#91cf61"|Phase 2
+
|MALE
−
|style="background-color:#d3d3d3"|
+
|
−
|style="background-color:#d3d3d3"|
+
|
 +
|
 +
|
 +
|2007
 +
|2007
 +
|
 +
|
 +
|Castleman disease
 +
|1
 +
|0
 +
|0
 +
|0
 +
|12
 +
|12
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1093/annonc/mdp237 Haioun et al. 2009 (LNH 98-3)]
+
|Agelaki
−
|1999-2004
+
|Sophia
−
|style="background-color:#1a9851"|Phase 3 (E-de-esc)
+
|FEMALE
−
|[[#ACVBP|ACVBP]]
+
|
−
|style="background-color:#ffffbf"|Did not meet endpoint of OS
+
|
 +
|
 +
|Greece
 +
|2001
 +
|2017
 +
|HORG
 +
|
 +
|Breast cancer; Colorectal cancer; Non-small cell lung cancer; Small cell lung cancer
 +
|5
 +
|0
 +
|4
 +
|0
 +
|65
 +
|39
 +
|1
 
|-
 
|-
−
|}
+
|Agelidou
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Athina
−
====Chemotherapy====
+
|FEMALE
−
*[[Doxorubicin (Adriamycin)]] 75 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Cyclophosphamide (Cytoxan)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 2
+
|
−
*[[Etoposide (Vepesid)]] as follows:
+
|
−
**Cycles 2 to 4: 150 mg/m<sup>2</sup> IV once per day on days 1 to 3
+
|Greece
−
====Glucocorticoid therapy====
+
|1999
−
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> (route not specified) once per day on days 1 to 5
+
|2011
−
====CNS therapy, prophylaxis====
+
|HORG
−
*[[Methotrexate (MTX)]] 15 mg IT once on day 2
+
|
−
====Supportive therapy====
+
|Non-small cell lung cancer; Small cell lung cancer
−
*[[:Category:Granulocyte colony-stimulating factors|G-CSF]] 5 mcg/kg/day SC on days 6 to 13
+
|8
−
</div></div>
+
|0
−
===References===
+
|7
−
# Dumontet C, Thieblemont C, Espinouse D, Bouafia F, Hequet O, Salles G, Coiffier B. A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors. Leukemia. 2000 Dec;14(12):2159-65. [https://doi.org/10.1038/sj.leu.2401955 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11187906 PubMed]
+
|0
−
# '''LNH 98-3:''' Haioun C, Mounier N, Emile JF, Ranta D, Coiffier B, Tilly H, Récher C, Fermé C, Gabarre J, Herbrecht R, Morchhauser F, Gisselbrecht C. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol. 2009 Dec;20(12):1985-92. Epub 2009 Jun 30. [https://doi.org/10.1093/annonc/mdp237 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/19567453 PubMed]
+
|99
−
==ACOMLA {{#subobject:6cce0e|Regimen=1}}==
+
|47
−
ACOMLA: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>M</u>'''ethotrexate, '''<u>L</u>'''eucovorin (Folinic acid), '''<u>A</u>'''ra-C (Cytarabine)
+
|1
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:e9a344|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://pubmed.ncbi.nlm.nih.gov/6177407 Newcomer et al. 1982]
+
|Agelidou
−
|NR in abstract
+
|Maria
−
|style="background-color:#91cf61"|Randomized, <20 patients
+
|FEMALE
−
|[[#CHOP-B|CHOP-B]]
+
|
−
| style="background-color:#fc8d59" |Seems to have inferior RFS
+
|
 +
|
 +
|Greece
 +
|2000
 +
|2013
 +
|HORG
 +
|
 +
|Non-small cell lung cancer; Small cell lung cancer
 +
|6
 +
|0
 +
|5
 +
|0
 +
|79
 +
|42
 +
|1
 
|-
 
|-
−
|}
+
|Ageno
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Walter
−
====Chemotherapy====
+
|MALE
−
*[[Doxorubicin (Adriamycin)]]
+
|
−
*[[Cyclophosphamide (Cytoxan)]]
+
|
−
*[[Vincristine (Oncovin)]]
+
|
−
*[[Methotrexate (MTX)]]
+
|Italy
−
*[[Cytarabine (Ara-C)]]
+
|2008
−
</div></div>
+
|2018
−
===References===
+
|
−
# Newcomer LN, Cadman EC, Nerenberg MI, Chen M, Bertino JR, Farber LR, Prosnitz LR. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma. Cancer Treat Rep. 1982 Jun;66(6):1279-84. [https://pubmed.ncbi.nlm.nih.gov/6177407 PubMed]
+
|
−
==ACVBP {{#subobject:bb17b2|Regimen=1}}==
+
|Venous thromboembolism
−
ACVBP: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''indesine, '''<u>B</u>'''leomycin, '''<u>P</u>'''rednisone
+
|3
−
<div class="toccolours" style="background-color:#eeeeee">
+
|0
−
===Protocol {{#subobject:1cd335|Variant=1}}===
+
|3
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|0
−
!style="width: 20%"|Study
+
|30
−
!style="width: 20%"|Years of enrollment
+
|30
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
|1
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.2000.18.6.1309 Tilly et al. 2000 (LNH87-1)]
+
|Ager
−
|1987-1993
+
|Phyllis Joyce
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
+
|FEMALE
−
|[[#m-BACOD|m-BACOD]]
+
|
−
|style="background-color:#ffffbf"|Did not meet primary endpoint of FFS
+
|
 +
|
 +
|
 +
|1984
 +
|1990
 +
|NSABP
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|1
 +
|19
 +
|19
 +
|1
 
|-
 
|-
−
|[http://www.bloodjournal.org/content/102/13/4284.long Tilly et al. 2003]
+
|Agerbaek
−
|1993-1998
+
|Mads
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
+
|MALE
−
|[[#CHOP|CHOP]]
+
|
−
|style="background-color:#91cf60"|Seems to have superior OS
+
|
 +
|
 +
|Denmark
 +
|2002
 +
|2021
 +
|EORTC; German Association of Urologic Oncology; Groupe d'Etude des Tumeurs Urogenitales; National Cancer Institute of Canada Clinical Trials Group; National Cancer Research Institute Bladder Cancer Study Group
 +
|
 +
|Bladder cancer
 +
|2
 +
|0
 +
|2
 +
|1
 +
|56
 +
|55
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.3109/10428194.2010.504871 Morel et al. 2010 (LNH93-2)]
+
|Aggarwal
−
|1993-1998
+
|Charu
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|FEMALE
−
|[[Stub#ECVBP|ECVBP]]
+
|
−
|style="background-color:#ffffbf"|Did not meet primary endpoint of EFS
+
|
 +
|
 +
|USA
 +
|2011
 +
|2015
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|26
 +
|26
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1056/NEJMoa042040 Reyes et al. 2005 (LNH 93-01)]
+
|Aggarwal
−
|1993-2000
+
|Sanjay
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
+
|MALE
−
|[[#CHOP|CHOP]], then [[Diffuse_large_B-cell_lymphoma#Radiation_therapy|RT]]
+
|
−
|style="background-color:#1a9850"|Superior OS<br>OS60: 90% vs 81%
+
|
 +
|
 +
|USA
 +
|2012
 +
|2016
 +
|
 +
|
 +
|Multiple myeloma
 +
|2
 +
|0
 +
|1
 +
|1
 +
|37
 +
|37
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1093/annonc/mdp237 Haioun et al. 2009 (LNH 98-3)]
+
|Aggerholm
−
|1999-2004
+
|Anni
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|FEMALE
−
|[[#ACE|ACE]]
+
|
−
|style="background-color:#ffffbf"|Did not meet endpoint of OS
+
|
 +
|
 +
|
 +
|2004
 +
|2010
 +
|
 +
|
 +
|Acute myeloid leukemia; Chronic myelomonocytic leukemia; Myelodysplastic syndrome
 +
|1
 +
|0
 +
|0
 +
|0
 +
|19
 +
|19
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1093/annonc/mds600 Ketterer et al. 2013 (LNH03-1B)]
+
|Agha
−
|2003-2008
+
|Mounzer E
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|UNMATCHED
−
|[[Diffuse_large_B-cell_lymphoma#R-ACVBP|R-ACVBP]]
+
|
−
|style="background-color:#fc8d59"|Seems to have inferior PFS
+
|
 +
|
 +
|USA
 +
|2008
 +
|2022
 +
|
 +
|
 +
|Multiple myeloma
 +
|3
 +
|0
 +
|1
 +
|1
 +
|104
 +
|100
 +
|1
 
|-
 
|-
−
|}
+
|Aghajanian
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Carol A
−
====Chemotherapy, induction====
+
|FEMALE
−
*[[Doxorubicin (Adriamycin)]] 75 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vindesine (Eldisine)]] 2 mg/m<sup>2</sup> IV once per day on days 1 & 5
+
|
−
*[[Bleomycin (Blenoxane)]] 10 units IV once per day on days 1 & 5
+
|USA
−
====Glucocorticoid therapy====
+
|2005
−
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 5
+
|2021
−
====CNS therapy, prophylaxis====
+
|GOG
−
*[[Methotrexate (MTX)]] 15 mg IT on day 2
+
|
−
====Supportive therapy====
+
|Endometrial cancer; Leiomyosarcoma; Low-grade serous ovarian cancer; Ovarian cancer
−
*[[:Category:Granulocyte_colony-stimulating_factors|G-CSF or GM-CSF]] SC once per day on days 6 to 13
+
|19
−
'''21-day cycle for 4 cycles, followed by:'''
+
|3
−
====Chemotherapy, consolidation, part 1====
+
|11
−
*[[Methotrexate (MTX)]] 3000 mg/m<sup>2</sup> IV once on day 1
+
|6
−
====Supportive therapy====
+
|375
−
*[[Folinic acid (Leucovorin)|Leucovorin]] rescue
+
|215
−
'''14-day cycle for 2 cycles, followed by:'''
+
|1
−
====Chemotherapy, consolidation, part 2====
 
−
*[[Etoposide (Vepesid)]] 300 mg/m<sup>2</sup> IV once on day 1
 
−
*[[Ifosfamide (Ifex)]] 1500 mg/m<sup>2</sup> IV once on day 1
 
−
====Supportive therapy====
 
−
*[[Mesna (Mesnex)]] "protection" (details not provided)
 
−
'''14-day cycle for 4 cycles''', beginning 2 weeks after completion of MTX, then
 
−
====Chemotherapy, consolidation, part 3====
 
−
*[[Cytarabine (Ara-C)]] 100 mg/m<sup>2</sup> SC once per day on days 1 to 4
 
−
'''14-day cycle for 2 cycles''', beginning 2 weeks after completion of EI
 
−
</div></div>
 
−
===References===
 
−
# '''LNH87-1:''' Tilly H, Mounier N, Lederlin P, Brière J, Dupriez B, Sebban C, Bosly A, Biron P, Nouvel C, Herbrecht R, Bordessoule D, Coiffier B; Groupe d'Etude des Lymphomes de l'Adulte. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. J Clin Oncol. 2000 Mar;18(6):1309-15. [https://doi.org/10.1200/jco.2000.18.6.1309 link to original article] [https://pubmed.ncbi.nlm.nih.gov/10715302 PubMed]
 
−
# Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molina TJ, Gisselbrecht C, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003 Dec 15;102(13):4284-9. Epub 2003 Aug 14. [http://www.bloodjournal.org/content/102/13/4284.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/12920037 PubMed]
 
−
# '''LNH 93-01:''' Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, Morel P, Ferme C, Bosly A, Lederlin P, Laurent G, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005 Mar 24;352(12):1197-205. [https://doi.org/10.1056/NEJMoa042040 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15788496 PubMed]
 
−
# '''LNH 98-3:''' Haioun C, Mounier N, Emile JF, Ranta D, Coiffier B, Tilly H, Récher C, Fermé C, Gabarre J, Herbrecht R, Morchhauser F, Gisselbrecht C. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol. 2009 Dec;20(12):1985-92. Epub 2009 Jun 30. [https://doi.org/10.1093/annonc/mdp237 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19567453 PubMed]
 
−
# '''LNH93-2:''' Morel P, Munck JN, Coiffier B, Gisselbrecht C, Ranta D, Bosly A, Tilly H, Quesnel B, Thyss A, Mounier N, Brière J, Molina T, Reyes F; GELA. Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol. Leuk Lymphoma. 2010 Sep;51(9):1668-77. [https://doi.org/10.3109/10428194.2010.504871 link to original article] [https://pubmed.ncbi.nlm.nih.gov/20807094 PubMed]
 
−
# '''LNH03-1B:''' Ketterer N, Coiffier B, Thieblemont C, Fermé C, Brière J, Casasnovas O, Bologna S, Christian B, Connerotte T, Récher C, Bordessoule D, Fruchart C, Delarue R, Bonnet C, Morschhauser F, Anglaret B, Soussain C, Fabiani B, Tilly H, Haioun C; GELA. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). Ann Oncol. 2013 Apr;24(4):1032-7. Epub 2012 Dec 12. [https://doi.org/10.1093/annonc/mds600 link to original article] [https://pubmed.ncbi.nlm.nih.gov/23235801 PubMed] NCT00140595
 
−
==ACVBP (Methylprednisolone) {{#subobject:015a69|Regimen=1}}==
 
−
ACVBP: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''indesine, '''<u>B</u>'''leomycin, Methyl'''<u>P</u>'''rednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:2tq46d|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.1986.4.2.147 Coiffier et al. 1986 (LNH-80)]
+
|Aghemo
−
|1980-1984
+
|E
−
|style="background-color:#91cf61"|Phase 2
+
|CBD
 +
|
 +
|
 +
|
 +
|Italy
 +
|2010
 +
|2016
 +
|
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|29
 +
|29
 +
|1
 
|-
 
|-
−
|}
+
|Agis
−
''Note: this regimen is referred to as "intensified CHOP-Bleo" in the original manuscript, but bears more resemblance to ACVBP induction and is therefore re-named as ACVBP.''
+
|Hermine
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|FEMALE
−
====Chemotherapy====
+
|
−
*[[Doxorubicin (Adriamycin)]] 75 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vindesine (Eldisine)]] 2 mg/m<sup>2</sup> IV once per day on days 1 & 5
+
|Austria
−
*[[Bleomycin (Blenoxane)]] 5 mg/m<sup>2</sup> IV once per day on days 1 to 5
+
|2000
−
====Glucocorticoid therapy====
+
|2006
−
*[[Methylprednisolone (Solumedrol)]] 60 mg/m<sup>2</sup> (route not specified) once per day on days 1 to 5
+
|
−
====CNS therapy, prophylaxis====
+
|
−
*[[Methotrexate (MTX)]] 15 mg IT once
+
|Chronic myeloid leukemia
−
'''15-day cycle for 3 cycles; cycles were delayed until ANC greater than 1500/uL'''
+
|1
−
</div>
+
|0
−
<div class="toccolours" style="background-color:#cbd5e7">
+
|1
−
====Subsequent treatment====
+
|1
−
*[[#Cytarabine_.26_Methotrexate_.28CYM.29_88|CYM]], then [[#CVAP-Bleo|CVAP-Bleo]]
+
|31
−
</div></div>
+
|31
−
===References===
+
|1
−
# '''LNH-80:''' Coiffier B, Bryon PA, Berger F, Archimbaud E, Ffrench M, Extra JM, Guyotat D, Fiere D, Gentilhomme O, Magaud JP, Blanc M, Peaud PY, Vuvan H, Viala JJ. Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (protocol LNH-80). J Clin Oncol. 1986 Feb;4(2):147-53. [https://doi.org/10.1200/jco.1986.4.2.147 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/2418166 PubMed]
 
−
==BCOP {{#subobject:f79d88|Regimen=1}}==
 
−
BCOP: '''<u>B</u>'''CNU (Carmustine), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine),  '''<u>P</u>'''rednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:39f753|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1200/JCO.1985.3.9.1188 Gams et al. 1985]
+
|Aglietta
−
|1977-1981
+
|Massimo
−
|style="background-color:#1a9851"|Phase 3 (E-switch-ic)
+
|MALE
−
|[[#CHOP|CHOP]]
+
|
−
|style="background-color:#fee08b"|Might have inferior OS
+
|
 +
|
 +
|Italy
 +
|1998
 +
|2022
 +
|Italian Group for the Study of Gastrointestinal Cancer
 +
|
 +
|Colorectal cancer; Multiple myeloma; Osteosarcoma; Soft tissue sarcoma
 +
|8
 +
|1
 +
|4
 +
|2
 +
|138
 +
|119
 +
|1
 
|-
 
|-
−
|}
+
|Agnelli
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Giancarlo
−
====Chemotherapy====
+
|MALE
−
*[[Carmustine (BCNU)]] 100 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 1 mg/m<sup>2</sup> IV once on day 1
+
|
−
====Glucocorticoid therapy====
+
|Italy
−
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5
+
|2010
−
'''28-day cycle for 6 cycles'''
+
|2020
−
</div></div>
+
|
−
===References===
+
|
−
# Gams RA, Rainey M, Dandy M, Bartolucci AA, Silberman H, Omura G; Southeastern Cancer Study Group. Phase III study of BCOP v CHOP in unfavorable categories of malignant lymphoma: a Southeastern Cancer Study Group trial. J Clin Oncol. 1985 Sep;3(9):1188-95. [https://doi.org/10.1200/JCO.1985.3.9.1188 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/3897470 PubMed]
+
|Venous thromboembolism
−
==CAP-BOP {{#subobject:dc0598|Regimen=1}}==
+
|6
−
CAP-BOP: '''<u>C</u>'''yclophosphamide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>P</u>'''rocarbazine, '''<u>B</u>'''leomycin, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
+
|3
−
<br>COP-BLAM: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone, '''<u>BL</u>'''eomycin, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>M</u>'''atulane (Procarbazine), 
+
|6
−
<div class="toccolours" style="background-color:#eeeeee">
+
|0
−
===Regimen {{#subobject:be42ea|Variant=1}}===
+
|81
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
+
|51
−
!style="width: 33%"|Study
+
|1
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[https://doi.org/10.7326/0003-4819-97-2-190 Laurence et al. 1982]
+
|Agnelli
−
|1977-1981
+
|L
−
|style="background-color:#91cf61"|Phase 2
+
|CBD
 +
|
 +
|
 +
|
 +
|Italy
 +
|2013
 +
|2013
 +
|
 +
|
 +
|Plasma cell leukemia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|29
 +
|29
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.1988.6.3.425 Boyd et al. 1988]
+
|Agodoa
−
|1981-1984
+
|Irene
−
|style="background-color:#91cf61"|Phase 2
+
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2017
 +
|2021
 +
|
 +
|
 +
|Sickle cell anemia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|11
 +
|11
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.1986.4.2.160 Armitage et al. 1986]
+
|Agopian
−
|1982-1984
+
|Julie
−
|style="background-color:#91cf61"|Phase 2
+
|FEMALE
 +
|
 +
|
 +
|
 +
|France
 +
|2009
 +
|2017
 +
|
 +
|
 +
|Systemic mastocytosis
 +
|1
 +
|0
 +
|1
 +
|0
 +
|25
 +
|25
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.1988.6.12.1838 Vose et al. 1988]
+
|Agostara
−
|1982-1986
+
|Biagio
−
|style="background-color:#91cf61"|Phase 2
+
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1997
 +
|2010
 +
|GOIM; Gruppo Oncologico Italia Meridionale
 +
|
 +
|Breast cancer; Colorectal cancer; Non-small cell lung cancer
 +
|3
 +
|0
 +
|3
 +
|0
 +
|53
 +
|46
 +
|1
 
|-
 
|-
−
|}
+
|Agostinelli
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Claudio
−
====Chemotherapy====
+
|MALE
−
*[[Cyclophosphamide (Cytoxan)]]
+
|
−
*[[Doxorubicin (Adriamycin)]]
+
|
−
*[[Procarbazine (Matulane)]]
+
|
−
*[[Bleomycin (Blenoxane)]]
+
|Italy
−
*[[Vincristine (Oncovin)]]
+
|2006
−
====Glucocorticoid therapy====
+
|2017
−
*[[Prednisone (Sterapred)]]
+
|
−
</div></div>
+
|
−
===References===
+
|Diffuse large B-cell lymphoma
−
# Laurence J, Coleman M, Allen SL, Silver RT, Pasmantier M. Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. Ann Intern Med. 1982 Aug;97(2):190-5. [https://doi.org/10.7326/0003-4819-97-2-190 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6179448 PubMed]
+
|1
−
# Armitage JO, Weisenburger DD, Hutchins M, Moravec DF, Dowling M, Sorensen S, Mailliard J, Okerbloom J, Johnson PS, Howe D, Bascom GK, Casey J, Linder J, Purtilo DT. Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions. J Clin Oncol. 1986 Feb;4(2):160-4. [https://doi.org/10.1200/jco.1986.4.2.160 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2418167 PubMed]
+
|0
−
# Boyd DB, Coleman M, Papish SW, Topilow A, Kopel SK, Bernhardt B, Files JC, Schwartz S, Gaynor M, McDermott D, Reisman AM, Coleman BL. COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma. J Clin Oncol. 1988 Mar;6(3):425-33. [https://doi.org/10.1200/jco.1988.6.3.425 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2450970 PubMed]
+
|1
−
# Vose JM, Armitage JO, Weisenburger DD, Bierman PJ, Sorensen S, Hutchins M, Moravec DF, Howe D, Dowling MD, Mailliard J, Johnson PS, Pevnick W, Packard WM, Okerbloom J, Thompson RF, Langdon RM Jr, Soori G, Peterson C. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1988 Dec;6(12):1838-44. [https://doi.org/10.1200/jco.1988.6.12.1838 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2462026 PubMed]
+
|0
−
==CCOP {{#subobject:9a2b69|Regimen=1}}==
+
|25
−
CCOP: '''<u>C</u>'''yclophosphamide, '''<u>C</u>'''aelyx (Pegylated liposomal doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
+
|25
−
<div class="toccolours" style="background-color:#eeeeee">
+
|1
−
===Regimen {{#subobject:4efe2a|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[http://www.haematologica.org/content/87/8/822.long Martino et al. 2002]
+
|Agostini
−
|1998-2000
+
|Cecile
−
|style="background-color:#91cf61"|Phase 2
+
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2000
 +
|2007
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|13
 +
|13
 +
|1
 
|-
 
|-
−
|}
+
|Agrawal
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Manish
−
====Chemotherapy====
+
|MALE
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV over 30 minutes once on day 1
+
|
−
*[[Pegylated liposomal doxorubicin (Doxil)]] 30 mg/m<sup>2</sup> IV over 60 minutes once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 2 mg IV over 15 minutes once on day 1
+
|
−
====Glucocorticoid therapy====
+
|USA
−
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 5
+
|2014
−
'''21-day cycle for 6 to 8 cycles'''
+
|2017
−
</div></div>
+
|
−
===References===
+
|
−
# Martino R, Perea G, Caballero MD, Mateos MV, Ribera JM, de Oteyza JP, Arranz R, Terol MJ, Sierra J, San Miguel JF. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. Haematologica. 2002 Aug;87(8):822-7. [http://www.haematologica.org/content/87/8/822.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/12161358 PubMed]
+
|Bladder cancer
−
==CEEP {{#subobject:31f2c7|Regimen=1}}==
+
|1
−
CEEP: '''<u>C</u>'''yclophosphamide,  '''<u>E</u>'''pirubicin, '''<u>E</u>'''ldesine (Vindesine), '''<u>P</u>'''rednisone
+
|0
−
<div class="toccolours" style="background-color:#eeeeee">
+
|0
−
===Regimen {{#subobject:1bbbf3|Variant=1}}===
+
|1
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|17
−
!style="width: 20%"|Study
+
|17
−
!style="width: 20%"|Years of enrollment
+
|1
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1056/NEJMoa031770 Milpied et al. 2004 (GOELAMS 072)]
+
|Agrawal
−
|1994-1999
+
|Rajiv K
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
+
|MALE
−
|[[#CHOP|CHOP]]
+
|
−
| style="background-color:#91cf60" |Seems to have superior EFS
+
|
 +
|
 +
|United Kingdom
 +
|1996
 +
|2019
 +
|NEAT Investigators and the SCTBG; tAnGo trial collaborators
 +
|
 +
|Breast cancer
 +
|5
 +
|0
 +
|5
 +
|0
 +
|120
 +
|71
 +
|1
 
|-
 
|-
−
|}
+
|Agrawal
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Samir
−
====Chemotherapy====
+
|MALE
−
*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Epirubicin (Ellence)]] 100 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vindesine (Eldisine)]] 3 mg/m<sup>2</sup> IV once on day 1
+
|
−
====Glucocorticoid therapy====
+
|
−
*[[Prednisone (Sterapred)]] 80 mg/m<sup>2</sup> PO or IV once per day on days 1 to 5
+
|2006
−
====CNS therapy, prophylaxis====
+
|2012
−
*[[Methotrexate (MTX)]] 15 mg IT once on day 2
+
|NCRI
−
*[[Methylprednisolone (Solumedrol)]] IT once on day 2
+
|
−
'''2 cycles'''
+
|Chronic lymphocytic leukemia; Multiple myeloma; Stem cell mobilization
−
</div>
+
|2
−
<div class="toccolours" style="background-color:#cbd5e7">
+
|0
−
====Subsequent treatment====
+
|0
−
*Patients with at least PR: [[#Cytarabine_.26_Methotrexate_.28CYM.29_88|CYM]], then [[#BEAM.2C_then_auto_HSCT_88|BEAM with auto HSCT]]
+
|0
−
</div></div>
+
|34
−
===References===
+
|34
−
# '''GOELAMS 072:''' Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau JL; Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004 Mar 25;350(13):1287-95. [https://doi.org/10.1056/NEJMoa031770 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15044639 PubMed]
+
|1
−
==CEOP {{#subobject:76ytfe|Regimen=1}}==
 
−
CEOP: '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''pirubicin, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:a8h895|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1034/j.1600-0609.2002.01620.x Economopoulos et al. 2002]
+
|Agrawal
−
|1993-1999
+
|Shruti
−
| style="background-color:#1a9851" |Phase 3 (C)
+
|FEMALE
−
|[[#CNOP|CNOP]]
+
|
−
| style="background-color:#ffffbf" |Did not meet efficacy endpoints
+
|
 +
|
 +
|USA
 +
|2006
 +
|2021
 +
|
 +
|
 +
|Chronic myeloid leukemia pediatric; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous
 +
|2
 +
|0
 +
|1
 +
|2
 +
|42
 +
|42
 +
|1
 
|-
 
|-
−
|[https://www.karger.com/Article/Abstract/87284 Chamorey et al. 2005]
+
|Agresta
−
|1994-1998
+
|Samuel V
−
| style="background-color:#1a9851" |Phase 3 (C)
+
|MALE
−
|[[#MEMID_99|MEMID]]
+
|
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
+
|
 +
|
 +
|USA
 +
|2013
 +
|2019
 +
|
 +
|
 +
|Acute myeloid leukemia
 +
|4
 +
|0
 +
|0
 +
|2
 +
|109
 +
|54
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1097/PPO.0b013e3181570170 Economopoulos et al. 2007 (HE22A99)]
+
|Agricola
−
|1999-2005
+
|Karen
−
| style="background-color:#1a9851" |Phase 3 (C)
+
|FEMALE
−
|[[#CEOP-14_99|CEOP-14]]
+
|
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
+
|
 +
|
 +
|USA
 +
|2007
 +
|2015
 +
|
 +
|
 +
|Subependymal giant cell astrocytoma
 +
|3
 +
|0
 +
|0
 +
|1
 +
|23
 +
|14
 +
|1
 
|-
 
|-
−
|}
+
|Aguado Fraile
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Elia
−
====Chemotherapy====
+
|FEMALE
−
*[[Cyclophosphamide (Cytoxan)]] 1000 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Epirubicin (Ellence)]] 70 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 2 mg IV once on day 1
+
|
−
====Glucocorticoid therapy====
+
|USA
−
*[[Prednisone (Sterapred)]] 60 mg PO once per day on days 1 to 7
+
|2017
−
'''21-day cycles'''
+
|2021
−
</div></div>
+
|
−
===References===
+
|
−
# Economopoulos T, Dimopoulos MA, Mellou S, Pavlidis N, Samantas E, Nicolaides C, Tsatalas C, Papadopoulos A, Papageogriou E, Papasavvas P, Fountzilas G. Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP. Eur J Haematol. 2002 Mar;68(3):135-43. [https://doi.org/10.1034/j.1600-0609.2002.01620.x link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/12068793 PubMed]
+
|Cholangiocarcinoma
−
# Chamorey E, Gressin R, Peyrade F, Rossi JF, Lepeu G, Foussard C, Harrousseau JL, Fabbro M, Richard B, Delwail V, Maisonneuve H, Vilque JP, Thyss A. Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma. Oncology. 2005;69(1):19-26. Epub 2005 Jul 28. [https://www.karger.com/Article/Abstract/87284 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16088231 PubMed]
+
|1
−
# '''HE22A99:''' Economopoulos T, Psyrri A, Dimopoulos MA, Kalogera-Fountzila A, Pavlidis N, Tsatalas C, Nikolaides C, Mellou S, Xiros N, Fountzilas G; Hellenic Cooperative Oncology Group. CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Group. Cancer J. 2007 Sep-Oct;13(5):327-34. [https://doi.org/10.1097/PPO.0b013e3181570170 link to original article] [https://pubmed.ncbi.nlm.nih.gov/17921732 PubMed]
+
|0
−
==CEOP (Prednisolone) {{#subobject:1560fe|Regimen=1}}==
+
|1
−
CEOP: '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''pirubicin, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisolone
+
|1
−
<div class="toccolours" style="background-color:#eeeeee">
+
|26
−
===Regimen {{#subobject:550895|Variant=1}}===
+
|26
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|1
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1002/ajh.23684 Hertzberg et al. 2014 (ALLG NHL07)]
+
|Aguado
−
|1994-1999
+
|M Jose
−
| style="background-color:#1a9851" |Phase 3 (C)
+
|MALE
−
|[[#Dose-intense_CEOP_99|DI-CEOP]]
+
|
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS60
+
|
 +
|
 +
|
 +
|1999
 +
|1999
 +
|
 +
|
 +
|Hodgkin lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|5
 +
|5
 +
|1
 
|-
 
|-
−
|}
+
|Aguggini
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|S
−
====Chemotherapy====
+
|CBD
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once on day 1
+
|
−
====Glucocorticoid therapy====
+
|
−
*[[Prednisolone (Millipred)]] 100 mg PO once per day on days 1 to 5
+
|1997
−
'''21-day cycle for 6 cycles'''
+
|2005
−
</div></div>
+
|
−
===References===
+
|
−
# '''ALLG NHL07:''' Hertzberg M, Matthews JP, Stone JM, Dubosq MC, Grigg A, Ellis D, Benson W, Browett P, Horvath N, Januszewicz H, Abdi E, Green M, Bonaventura A, Marlton P, Cannell P, Wolf M; ALLG. A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial. Am J Hematol. 2014 May;89(5):536-41. Epub 2014 Feb 21. [https://doi.org/10.1002/ajh.23684 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/24481640 PubMed]
+
|Breast cancer
−
==CHOEP-14 {{#subobject:c516ab|Regimen=1}}==
+
|1
−
CHOEP-14: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>E</u>'''toposide, '''<u>P</u>'''rednisone every '''<u>14</u>''' days
+
|0
−
<br>CHOPE: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''redniso(lo)ne, '''<u>E</u>'''toposide
+
|1
−
<br>VACOP: '''<u>V</u>'''epesid (Etoposide), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
+
|0
−
<div class="toccolours" style="background-color:#eeeeee">
+
|13
−
===Regimen {{#subobject:f61648|Variant=1}}===
+
|13
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|1
−
!style="width: 17%"|Study
 
−
!style="width: 15%"|Years of enrollment
 
−
!style="width: 17%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 17%"|Comparator
 
−
!style="width: 17%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
!style="width: 17%"|[[Levels_of_Evidence#Toxicity|Comparative Toxicity]]
 
 
|-
 
|-
−
|rowspan=2|[http://www.bloodjournal.org/content/104/3/626.long Pfreundschuh et al. 2004 (NHL-B1)]
+
|Aguiar
−
|rowspan=2|1993-2000
+
|Melanie
−
|rowspan=2 style="background-color:#1a9851"|Phase 3 (E-esc)
+
|Not yet determined
−
|1. [[#CHOP|CHOP-21]]<br>2. [[#CHOP-14|CHOP-14]]
+
|
−
|style="background-color:#1a9850" |Superior EFS
+
|
−
|style="background-color:#fc8d59"|Seems more toxic
+
|
 +
|United Kingdom
 +
|2012
 +
|2022
 +
|
 +
|
 +
|B-cell acute lymphoblastic leukemia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|25
 +
|25
 +
|1
 
|-
 
|-
−
|3. [[#CHOEP-21|CHOEP-21]]
+
|Aguiar
−
| style="background-color:#91cf60" |Seems to have superior OS
+
|Ricardo C T
 +
|MALE
 
|
 
|
 +
|
 +
|
 +
|USA
 +
|2014
 +
|2014
 +
|
 +
|
 +
|Hypereosinophilic syndrome
 +
|1
 +
|0
 +
|0
 +
|0
 +
|18
 +
|18
 +
|1
 
|-
 
|-
−
|[http://www.bloodjournal.org/content/104/3/634.long Pfreundschuh et al. 2004 (NHL-B2)]
+
|Aguilera
−
|1993-2000
+
|Nadia
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
+
|FEMALE
−
|1. [[#CHOEP-21|CHOEP-21]]<br>2. [[#CHOP|CHOP-21]]<br> 3. [[#CHOP-14|CHOP-14]]
+
|
−
|style="background-color:#ffffbf"|Did not meet primary endpoint of EFS
+
|
−
|style="background-color:#fc8d59"|Seems more toxic
+
|
 +
|Cuba
 +
|2006
 +
|2016
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|33
 +
|33
 +
|1
 
|-
 
|-
−
|}
+
|Aguilo
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Rafael
−
====Chemotherapy====
+
|MALE
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 2 mg IV once on day 1
+
|
−
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
+
|
−
====Glucocorticoid therapy====
+
|2000
−
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5
+
|2010
−
====Supportive therapy====
+
|Spanish Lung Cancer Group
−
*[[Filgrastim (Neupogen)]] by the following weight-based criteria:
+
|
−
**Patients less than 75 kg: 300 mcg SC once per day on days 4 to 13
+
|Non-small cell lung cancer
−
**Patients at least 75 kg: 480 mcg SC once per day on days 4 to 13
+
|1
−
'''14-day cycle for 6 cycles''', next cycle to start as long as WBC count is greater than 2.5 x 10<sup>9</sup>/L and platelets greater than 80 x 10<sup>9</sup>/L
+
|0
−
</div>
+
|1
−
<div class="toccolours" style="background-color:#cbd5e7">
+
|0
−
====Subsequent treatment====
+
|19
−
*Some protocols: Patients with initial bulky disease (mass conglomerate at least 7.5 cm) received 36 Gy [[Diffuse_large_B-cell_lymphoma#Radiation_therapy|radiation therapy]] to extranodal sites of disease when possible
+
|19
−
</div></div>
+
|1
−
===References===
 
−
# '''NHL-B1:''' Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rübe C, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004 Aug 1;104(3):626-33. Epub 2004 Feb 24. [http://www.bloodjournal.org/content/104/3/626.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/14982884 PubMed]
 
−
# '''NHL-B2:''' Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004 Aug 1;104(3):634-41. Epub 2004 Mar 11. [http://www.bloodjournal.org/content/104/3/634.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15016643 PubMed]
 
−
# Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 May;7(5):379-91. [https://doi.org/10.1016/S1470-2045%2806%2970664-7 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16648042 PubMed]
 
−
## '''Update:''' Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; MabThera International Trial Group. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial Group. Lancet Oncol. 2011 Oct;12(11):1013-22. [https://doi.org/10.1016/S1470-2045%2811%2970235-2 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/21940214 PubMed]
 
−
==CHOEP-21 {{#subobject:cad12b|Regimen=1}}==
 
−
CHOEP-21: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>E</u>'''toposide, '''<u>P</u>'''rednisone every '''<u>21</u>''' days
 
−
<br>CHOPE: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''redniso(lo)ne, '''<u>E</u>'''toposide
 
−
<br>VACOP: '''<u>V</u>'''epesid (Etoposide), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:18ddca|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 17%"|Study
 
−
!style="width: 15%"|Years of enrollment
 
−
!style="width: 17%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 17%"|Comparator
 
−
!style="width: 17%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
!style="width: 17%"|[[Levels_of_Evidence#Toxicity|Comparative Toxicity]]
 
 
|-
 
|-
−
|[https://doi.org/10.1002/hon.2900090407 Köppler et al. 1991]
+
|Agulnik
−
|NR
+
|Jason
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|MALE
−
|[[#hCHOP.2FIVEP|hCHOP/IVEP]]
+
|
−
|style="background-color:#d3d3d3"|
+
|
−
|style="background-color:#d3d3d3"|
+
|
 +
|Canada
 +
|2008
 +
|2016
 +
|
 +
|
 +
|Non-small cell lung cancer nonsquamous
 +
|1
 +
|0
 +
|1
 +
|0
 +
|14
 +
|14
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1200/JCO.2002.07.075 Kaiser et al. 2002]
+
|Agulnik
−
|1990-1997
+
|Mark B
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|MALE
−
|[[#CHOEP-21|CHOEP]], then [[#BEAM.2C_then_auto_HSCT|BEAM with auto HSCT]]
 
−
|style="background-color:#ffffbf"|Did not meet primary endpoint of OS
 
 
|
 
|
 +
|
 +
|
 +
|USA
 +
|2004
 +
|2020
 +
|
 +
|
 +
|Epithelioid sarcoma; Head and neck cancer; Osteosarcoma; Soft tissue sarcoma; Vascular sarcoma
 +
|7
 +
|1
 +
|3
 +
|2
 +
|132
 +
|100
 +
|1
 
|-
 
|-
−
|rowspan=2|[http://www.bloodjournal.org/content/104/3/626.long Pfreundschuh et al. 2004 (NHL-B1)]
+
|Agunwamba
−
|rowspan=2|1993-2000
+
|Blessing U
−
|rowspan=2 style="background-color:#1a9851"|Phase 3 (E-esc)
+
|FEMALE
−
|1. [[#CHOP|CHOP-21]]<br>2. [[#CHOP-14|CHOP-14]]
+
|
−
|style="background-color:#1a9850" |Superior EFS
+
|
−
|style="background-color:#fc8d59"|Seems more toxic
+
|
 +
|USA
 +
|2009
 +
|2013
 +
|
 +
|
 +
|Melanoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|23
 +
|23
 +
|1
 
|-
 
|-
−
|3. [[#CHOEP-14|CHOEP-14]]
+
|Agura
−
| style="background-color:#fc8d59" |Seems to have inferior OS
+
|Edward
 +
|MALE
 +
|
 +
|
 
|
 
|
 +
|USA
 +
|1997
 +
|2018
 +
|
 +
|
 +
|Acute myeloid leukemia; Allogeneic HSCT; Chronic lymphocytic leukemia; Hodgkin lymphoma
 +
|8
 +
|1
 +
|1
 +
|1
 +
|131
 +
|83
 +
|1
 
|-
 
|-
−
|[http://www.bloodjournal.org/content/104/3/634.long Pfreundschuh et al. 2004 (NHL-B2)]
+
|Agus
−
|1993-2000
+
|David B
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
+
|MALE
−
|1. [[#CHOEP-14|CHOEP-14]]<br>2. [[#CHOP|CHOP-21]]<br> 3. [[#CHOP-14|CHOP-14]]
+
|
−
|style="background-color:#ffffbf"|Did not meet primary endpoint of EFS
+
|
−
|style="background-color:#fc8d59"|Seems more toxic
+
|
 +
|USA
 +
|1993
 +
|2015
 +
|
 +
|
 +
|Diffuse large B-cell lymphoma; Prostate cancer
 +
|2
 +
|0
 +
|1
 +
|0
 +
|38
 +
|38
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1093/annonc/mdm514 Pfreundschuh et al. 2007 (DSHNHL-1999-2)]
+
|Aguzzi
−
|2000-2003
+
|Rasha
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|Not yet determined
−
|[[#MegaCHOEP_99|High CHOEP-21]]
+
|
−
|style="background-color:#ffffbf"|Did not meet primary endpoint of EFS36
+
|
−
| style="background-color:#1a9850" |Less toxic
+
|
 +
|USA
 +
|2018
 +
|2018
 +
|
 +
|
 +
|Paroxysmal nocturnal hemoglobinuria
 +
|1
 +
|0
 +
|1
 +
|1
 +
|13
 +
|13
 +
|1
 
|-
 
|-
−
|}
+
|Ah See
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Antoinne K
−
====Chemotherapy====
+
|MALE
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 2 mg IV once on day 1
+
|
−
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
+
|
−
====Glucocorticoid therapy====
+
|2002
−
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5
+
|2002
−
====Supportive therapy====
+
|
−
*[[Filgrastim (Neupogen)]] by discretion of ordering physician
+
|
−
'''21-day cycle for 4 to 6 cycles''', next cycle to start as long as WBC is >2.5 and platelets >80
+
|Breast cancer
−
</div>
+
|1
−
<div class="toccolours" style="background-color:#cbd5e7">
+
|0
−
====Subsequent treatment====
+
|1
−
*Some protocols: Patients with initial bulky disease (mass conglomerate at least 7.5 cm) received 36 Gy [[Diffuse_large_B-cell_lymphoma#Radiation_therapy|radiation therapy]] to extranodal sites of disease when possible
+
|0
−
</div></div>
+
|11
−
===References===
+
|11
−
# Köppler H, Pflüger KH, Eschenbach I, Pfab R, Birkmann J, Zeller W, Steinhauer EU, Gropp C, Oehl S, Lötzke E, Kuhn H, Drings P, Gossmann HH, Lennert K, Stein H, Havemann K. Sequential versus alternating chemotherapy for high grade non-Hodgkin's lymphomas: a randomized multicentre trial. Hematol Oncol. 1991 Jul-Oct;9(4-5):217-23. [https://doi.org/10.1002/hon.2900090407 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1743624 PubMed]
+
|1
−
# Kaiser U, Uebelacker I, Abel U, Birkmann J, Trümper L, Schmalenberg H, Karakas T, Metzner B, Hossfeld DK, Bischoff HG, Franke A, Reiser M, Müller P, Mantovani L, Grundeis M, Rothmann F, von Seydewitz CU, Mesters RM, Steinhauer EU, Krahl D, Schumacher K, Kneba M, Baudis M, Schmitz N, Pfab R, Köppler H, Parwaresch R, Pfreundschuh M, Havemann K. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol. 2002 Nov 15;20(22):4413-9. [https://doi.org/10.1200/JCO.2002.07.075 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12431962 PubMed]
 
−
# '''NHL-B1:''' Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rübe C, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004 Aug 1;104(3):626-33. Epub 2004 Feb 24. [http://www.bloodjournal.org/content/104/3/626.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/14982884 PubMed]
 
−
# '''NHL-B2:''' Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004 Aug 1;104(3):634-41. Epub 2004 Mar 11. [http://www.bloodjournal.org/content/104/3/634.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15016643 PubMed]
 
−
# Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 May;7(5):379-91. [https://doi.org/10.1016/S1470-2045%2806%2970664-7 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16648042 PubMed]
 
−
## '''Update:''' Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; MabThera International Trial Group. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011 Oct;12(11):1013-22. [https://doi.org/10.1016/S1470-2045%2811%2970235-2 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/21940214 PubMed]
 
−
# '''DSHNHL-1999-2:''' Pfreundschuh M, Zwick C, Zeynalova S, Dührsen U, Pflüger KH, Vrieling T, Mesters R, Mergenthaler HG, Einsele H, Bentz M, Lengfelder E, Trümper L, Rübe C, Schmitz N, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II - Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2008 Mar;19(3):545-52. Epub 2007 Dec 6. [https://doi.org/10.1093/annonc/mdm514 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/18065407/ PubMed] NCT00053768
 
−
==CHOP {{#subobject:4ca454|Regimen=1}}==
 
−
CHOP: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #1, 3 cycles, prednisone 40 mg/m<sup>2</sup> {{#subobject:4893da|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1056/NEJM199004263221701 Link et al. 1990]
+
|Ah See
−
|1983-1987
+
|Mei Lin
−
|style="background-color:#1a9851"|Phase 3 (E-de-esc)
+
|Not yet determined
−
|[[#CHOP_.26_RT_88|CHOP & RT]]
+
|
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of DFS
+
|
 +
|
 +
|United Kingdom
 +
|2007
 +
|2019
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|31
 +
|31
 +
|1
 
|-
 
|-
−
|}
+
|Ahern
−
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. Note some substantial differences from typical CHOP protocols.''
+
|Charlotte
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|FEMALE
−
====Chemotherapy====
+
|
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Doxorubicin (Adriamycin)]] 40 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once on day 1
+
|USA
−
====Glucocorticoid therapy====
+
|2009
−
*[[Prednisone (Sterapred)]] as follows:
+
|2013
−
**Cycle 1: 40 mg/m<sup>2</sup> PO once per day on days 1 to 21
+
|COG
−
**Cycle 2: 40 mg/m<sup>2</sup> PO once per day on days 1 to 7
+
|
−
**Cycle 3: 40 mg/m<sup>2</sup> PO once per day on days 1 to 5
+
|Anaplastic large cell lymphoma pediatric
−
'''21-day cycle for 3 cycles'''
+
|1
−
</div>
+
|0
−
<div class="toccolours" style="background-color:#cbd5e7">
+
|0
−
====Subsequent treatment====
+
|1
−
*6-MP & MTX maintenance
+
|13
−
</div></div><br>
+
|13
−
<div class="toccolours" style="background-color:#eeeeee">
+
|1
−
===Regimen variant #2, 3 cycles, prednisone 100 mg {{#subobject:503b17|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1056/NEJM199807023390104 Miller et al. 1998 (SWOG S8736)]
+
|Ahlberg
−
|1988-1995
+
|Lucia
−
|style="background-color:#1a9851"|Phase 3 (E-switch-ooc)
+
|FEMALE
−
|[[Complex_multipart_regimens#SWOG_S8736|See link]]
+
|
−
| style="background-color:#91cf60" |[[Complex_multipart_regimens#SWOG_S8736|See link]]
+
|
 +
|
 +
|
 +
|2002
 +
|2013
 +
|
 +
|
 +
|Multiple myeloma
 +
|2
 +
|0
 +
|2
 +
|0
 +
|48
 +
|37
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1056/NEJMoa042040 Reyes et al. 2005 (LNH 93-01)]
+
|Ahlborn
−
|1993-2000
+
|Miriam
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|FEMALE
−
|[[#ACVBP|ACVBP]]
+
|
−
|style="background-color:#d73027"|Inferior OS
+
|
 +
|
 +
|Germany
 +
|2012
 +
|2021
 +
|GHSG
 +
|
 +
|Hodgkin lymphoma
 +
|1
 +
|0
 +
|2
 +
|0
 +
|35
 +
|35
 +
|1
 
|-
 
|-
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287635/ Persky et al. 2014 (SWOG S0313)]
+
|Ahlgren
−
|2004-2008
+
|Goeran M
−
|style="background-color:#91cf61"|Phase 2
+
|MALE
−
| style="background-color:#d3d3d3" |
+
|
−
| style="background-color:#d3d3d3" |
+
|
 +
|
 +
|Sweden
 +
|2005
 +
|2018
 +
|SPCG
 +
|
 +
|Prostate cancer
 +
|2
 +
|1
 +
|2
 +
|0
 +
|30
 +
|29
 +
|1
 
|-
 
|-
−
|}
+
|Ahlgren
−
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
+
|James D
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|MALE
−
====Chemotherapy====
+
|
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV over 15 minutes once on day 1
+
|
−
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV over 1 to 2 minutes once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV over 1 to 2 minutes once on day 1
+
|
−
====Glucocorticoid therapy====
+
|1984
−
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5
+
|1989
−
'''21-day cycle for 3 cycles'''
+
|MAOP
−
</div>
+
|
−
<div class="toccolours" style="background-color:#cbd5e7">
+
|Colorectal cancer
−
====Subsequent treatment====
+
|1
−
*SWOG S0313: [[Diffuse_large_B-cell_lymphoma#Radiation_therapy|IFRT]], then [[#Ibritumomab_tiuxetan_protocol|ibritumomab tiuxetan]] consolidation
+
|0
−
*Others (see papers): [[Diffuse_large_B-cell_lymphoma#Radiation_therapy|Involved field radiation therapy]], 180 to 200 cGy fractions, total dose of 4000 to 5500 cGy. Total dose was often influenced by whether patients had clinical evidence of residual disease after 4000 cGy.
+
|1
−
</div></div><br>
+
|0
−
<div class="toccolours" style="background-color:#eeeeee">
+
|4
−
===Regimen variant #3, 4 cycles {{#subobject:5368c8|Variant=1}}===
+
|4
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
+
|1
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.1993.11.4.720 Tondini et al. 1993]
+
|Ahlgren
−
|1985-1990
+
|Johan
−
|style="background-color:#91cf61"|Phase 2
+
|MALE
 +
|
 +
|
 +
|
 +
|Sweden
 +
|2004
 +
|2022
 +
|
 +
|
 +
|Breast cancer
 +
|3
 +
|0
 +
|1
 +
|0
 +
|57
 +
|27
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1200/JCO.2006.07.0722 Bonnet et al. 2007]
+
|Ahlgren
−
|1993-2002
+
|Tomas
−
|style="background-color:#91cf61"|Non-randomized portion of RCT
+
|MALE
 +
|
 +
|
 +
|
 +
|Sweden
 +
|2002
 +
|2015
 +
|Nordic Lymphoma Group
 +
|
 +
|Follicular lymphoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|12
 +
|12
 +
|1
 
|-
 
|-
−
|}
+
|Ahlman
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Hakan
−
====Chemotherapy====
+
|MALE
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
+
|
−
====Glucocorticoid therapy====
+
|
−
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 5
+
|1979
−
'''21-day cycle for 4 cycles'''
+
|2010
−
</div>
+
|
−
<div class="toccolours" style="background-color:#cbd5e7">
+
|
−
====Subsequent treatment====
+
|Adrenocortical carcinoma
−
*[[Diffuse_large_B-cell_lymphoma#Radiation_therapy|IFRT]] x 40 Gy versus [[Diffuse_large_B-cell_lymphoma#Observation|no further treatment]]
+
|1
−
</div></div><br>
+
|1
−
<div class="toccolours" style="background-color:#eeeeee">
+
|0
−
===Regimen variant #4, 6 cycles, 100 mg prednisone {{#subobject:9e770b|Variant=1}}===
+
|0
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|8
−
!style="width: 20%"|Study
+
|8
−
!style="width: 20%"|Years of enrollment
+
|1
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|rowspan=2|[http://www.bloodjournal.org/content/104/3/626.long Pfreundschuh et al. 2004 (NHL-B1)]
+
|Ahlmann
−
|rowspan=2|1993-2000
+
|Martina
−
|rowspan=2 style="background-color:#1a9851"|Phase 3 (C)
+
|FEMALE
−
|1. [[#CHOEP-14|CHOEP-14]]<br>2. [[#CHOP-14|CHOP-14]]
+
|
−
|style="background-color:#fc8d59"|Seems to have inferior OS
+
|
 +
|
 +
|Germany
 +
|2020
 +
|2020
 +
|
 +
|
 +
|Hemophagocytic lymphohistiocytosis
 +
|1
 +
|0
 +
|0
 +
|1
 +
|19
 +
|19
 +
|1
 
|-
 
|-
−
|3. [[#CHOEP-21|CHOEP-21]]
+
|Ahluwalia
−
|style="background-color:#d73027"|Inferior EFS
+
|Manmeet S
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2009
 +
|2020
 +
|
 +
|
 +
|Glioblastoma
 +
|2
 +
|0
 +
|2
 +
|0
 +
|47
 +
|46
 +
|1
 
|-
 
|-
−
|rowspan=3|[http://www.bloodjournal.org/content/104/3/634.long Pfreundschuh et al. 2004 (NHL-B2)]
+
|Ahmad
−
|rowspan=3|1993-2000
+
|Chaudhary E
−
|rowspan=3 style="background-color:#1a9851"|Phase 3 (C)
+
|Not yet determined
−
|1. [[#CHOEP-14|CHOEP-14]]
+
|
−
|style="background-color:#ffffbf"|Did not meet primary endpoint of EFS
+
|
 +
|
 +
|Canada
 +
|2016
 +
|2020
 +
|NCIC-CTG
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|20
 +
|20
 +
|1
 
|-
 
|-
−
|2. [[#CHOEP-21|CHOEP-21]]
+
|Ahmad
−
|style="background-color:#ffffbf"|Did not meet primary endpoint of EFS
+
|Rizvana
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2009
 +
|2015
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|20
 +
|20
 +
|1
 
|-
 
|-
−
|3. [[#CHOP-14|CHOP-14]]
+
|Ahmad
−
|style="background-color:#d73027"|Inferior OS
+
|Shaharyar
 +
|UNMATCHED
 +
|
 +
|
 +
|
 +
|
 +
|2013
 +
|2013
 +
|
 +
|
 +
|Hodgkin lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|3
 +
|3
 +
|1
 
|-
 
|-
−
|[http://www.bloodjournal.org/content/109/7/2759.long Verdonck et al. 2007 (HOVON-26)]
+
|Ahmadi
−
|1994-2004
+
|Jamshid
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|MALE
−
|[[#CHOP-14|I-CHOP]]
+
|
−
|style="background-color:#ffffbf"|Did not meet primary endpoint of OS
+
|
 +
|
 +
|USA
 +
|1992
 +
|2015
 +
|SWOG
 +
|
 +
|Meningioma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|12
 +
|12
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1007/s00277-009-0811-x Fridrik et al. 2009 (AGMT NHL-5)]
+
|Ahmadi
−
|1995-2001
+
|Tahamtan
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|MALE
−
|[[#CEOP.2FIMVP-Dexa_88|CEOP/IMVP-Dexa]]
+
|
−
| style="background-color:#d73027" |Inferior OS
+
|
 +
|
 +
|USA
 +
|2008
 +
|2021
 +
|
 +
|
 +
|Follicular lymphoma; Light-chain (AL) amyloidosis; Mantle cell lymphoma; Multiple myeloma
 +
|16
 +
|1
 +
|6
 +
|9
 +
|409
 +
|214
 +
|1
 
|-
 
|-
−
|}
+
|Ahmann
−
<div class="toccolours" style="background-color:#cbd5e8">
+
|David L
−
====Preceding treatment====
+
|MALE
−
*NHL-B1 and NHL-B2: [[Diffuse_large_B-cell_lymphoma#Vincristine_.26_Prednisone|Pre-phase vincristine & prednisone]]
+
|
−
</div>
+
|
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|
−
====Chemotherapy====
+
|USA
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
+
|1977
−
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
+
|1995
−
*[[Vincristine (Oncovin)]] 2 mg IV once on day 1
+
|
−
====Glucocorticoid therapy====
+
|
−
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5
+
|Breast cancer; Melanoma
−
====Supportive therapy====
+
|7
−
*Per '''NHL-B1''' and '''NHL-B2''': At the discretion of ordering physician: [[Filgrastim (Neupogen)]] 300 mcg (for patients less than 75 kg) or 480 mcg (for patients at least 75 kg) SC once per day on days 4 to 13
+
|2
−
'''21-day cycle for 6 cycles'''
+
|7
−
</div>
+
|1
−
<div class="toccolours" style="background-color:#cbd5e7">
+
|54
−
====Subsequent treatment====
+
|30
−
*NHL-B2, patients with "lymphoma masses or conglomerates with a diameter ≥7.5 cm) or extranodal involvement": [[Diffuse_large_B-cell_lymphoma#Radiation_therapy|RT]] x 36 Gy to areas of initial bulky disease
+
|1
−
</div></div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #5, 6 cycles, 50 mg/m<sup>2</sup> prednisone {{#subobject:9f1357|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1200/JCO.1995.13.10.2530 Sonneveld et al. 1995]
+
|Ahmann
−
|1988-1993
+
|Frederick R
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|MALE
−
|[[#CNOP|CNOP]]
+
|
−
| style="background-color:#91cf60" |Seems to have superior OS
+
|
 +
|
 +
|
 +
|2002
 +
|2007
 +
|
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|18
 +
|18
 +
|1
 
|-
 
|-
−
|}
+
|Ahmann
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Gregory J
−
====Chemotherapy====
+
|MALE
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
+
|
−
====Glucocorticoid therapy====
+
|USA
−
*[[Prednisone (Sterapred)]] 50 mg/m<sup>2</sup> PO once per day on days 1 to 5
+
|2004
−
'''28-day cycle for 6 cycles'''
+
|2018
−
</div></div><br>
+
|ECOG
−
<div class="toccolours" style="background-color:#eeeeee">
+
|
−
===Regimen variant #6, 6 to 8 cycles {{#subobject:5b37b5|Variant=1}}===
+
|Multiple myeloma
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|2
−
!style="width: 20%"|Study
+
|0
−
!style="width: 20%"|Years of enrollment
+
|1
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
|1
−
!style="width: 20%"|Comparator
+
|42
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+
|39
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.3109/10428199509107906 Zinzani et al. 1995]
+
|Ahmed
−
|1991-1993
+
|Asra
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|FEMALE
−
|[[#CIOP_99|CIOP]]
+
|
−
| style="background-color:#ffffbf" |Did not meet efficacy endpoints
+
|
 +
|
 +
|
 +
|2005
 +
|2012
 +
|
 +
|
 +
|Multiple myeloma
 +
|2
 +
|0
 +
|0
 +
|0
 +
|28
 +
|25
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.2005.05.1003 Habermann et al. 2006 (ECOG E4494)]
+
|Ahmed
−
|1998-2001
+
|Atif A
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|Not yet determined
−
|[[Diffuse_large_B-cell_lymphoma#R-CHOP|R-CHOP]]
+
|
−
|style="background-color:#fc8d59"|Seems to have inferior FFS
+
|
 +
|
 +
|USA
 +
|2010
 +
|2021
 +
|COG
 +
|
 +
|Ewing sarcoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|23
 +
|23
 +
|1
 
|-
 
|-
−
|}
+
|Ahmed
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Ikhlaaq
−
====Chemotherapy====
+
|Not yet determined
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
+
|
−
====Glucocorticoid therapy====
+
|United Kingdom
−
*[[Prednisone (Sterapred)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 5
+
|1998
−
====Supportive therapy====
+
|2019
−
*[[Filgrastim (Neupogen)]] "recommended according to guidelines"
+
|
−
'''21-day cycle for 6 to 8 cycles'''
+
|
−
</div>
+
|Breast cancer
−
<div class="toccolours" style="background-color:#cbd5e7">
+
|1
−
====Subsequent treatment====
+
|0
−
*ECOG E4494, patients with CR/PR: [[Diffuse_large_B-cell_lymphoma#Rituximab_monotherapy|Rituximab]] maintenance versus [[Diffuse_large_B-cell_lymphoma_-_null_regimens#Observation|observation]]
+
|1
−
</div></div><br>
+
|0
−
<div class="toccolours" style="background-color:#eeeeee">
+
|19
−
===Regimen variant #7, 8 cycles, 40 mg/m<sup>2</sup> prednisone {{#subobject:9f1357|Variant=1}}===
+
|19
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|1
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[http://www.bloodjournal.org/content/102/13/4284.long Tilly et al. 2003]
+
|Ahmed
−
|1993-1998
+
|Nazma
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|FEMALE
−
|[[#ACVBP|ACVBP]]
+
|
−
|style="background-color:#fc8d59"|Seems to have inferior OS
+
|
 +
|
 +
|Switzerland
 +
|2006
 +
|2015
 +
|
 +
|
 +
|Head and neck cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|24
 +
|24
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1056/NEJMoa011795 Coiffier et al. 2002 (LNH 98-5)]
+
|Ahmed
−
|1998-2000
+
|Sairah
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|FEMALE
−
|[[Diffuse_large_B-cell_lymphoma#R-CHOP|R-CHOP]]
+
|
−
|style="background-color:#d73027"|Inferior OS
+
|
 +
|
 +
|USA
 +
|2009
 +
|2014
 +
|
 +
|
 +
|Allogeneic HSCT; Mantle cell lymphoma; Transformed lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|13
 +
|13
 +
|1
 
|-
 
|-
−
|}
+
|Ahn
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Chul
−
====Chemotherapy====
+
|MALE
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
+
|
−
====Glucocorticoid therapy====
+
|USA
−
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 5
+
|2013
−
====Supportive therapy====
+
|2014
−
*[[Filgrastim (Neupogen)]] used for later cycles if patients developed grade 4 neutropenia or febrile neutropenia
+
|
−
'''21-day cycle for 8 cycles'''
+
|
−
</div></div><br>
+
|Blastic plasmacytoid dendritic cell neoplasm
−
<div class="toccolours" style="background-color:#eeeeee">
+
|1
−
===Regimen variant #8, 8 cycles, 100 mg prednisone {{#subobject:256065|Variant=1}}===
+
|0
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|0
−
!style="width: 20%"|Study
+
|0
−
!style="width: 20%"|Years of enrollment
+
|14
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
|14
−
!style="width: 20%"|Comparator
+
|1
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1002/1097-0142(197610)38:4%3C1484::aid-cncr2820380407%3E3.0.co;2-i McKelvey et al. 1976]
+
|Ahn
−
|1972-1974
+
|Daniel H
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
+
|MALE
−
|[[#HOP|HOP]]
+
|
−
| style="background-color:#ffffbf" |Did not meet endpoint of OS
+
|
 +
|
 +
|USA
 +
|2015
 +
|2019
 +
|
 +
|
 +
|Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer
 +
|2
 +
|0
 +
|0
 +
|0
 +
|31
 +
|30
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1002/1097-0142(197810)42:4%3C1705::AID-CNCR2820420408%3E3.0.CO;2-P Elias et al. 1978]
+
|Ahn
−
|1974-1977
+
|Hanjong
−
|style="background-color:#91cf61"|Non-randomized
+
|Not yet determined
−
|style="background-color:#d3d3d3"|
+
|
−
|style="background-color:#d3d3d3"|
+
|
 +
|
 +
|South Korea
 +
|2014
 +
|2022
 +
|
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|8
 +
|8
 +
|1
 
|-
 
|-
−
|rowspan=3|[https://doi.org/10.1056/NEJM199304083281404 Fisher et al. 1993 (SWOG-8516/Intergroup 0067)]
+
|Ahn
−
|rowspan=3|1986-1991
+
|Inhye E
−
|rowspan=3 style="background-color:#1a9851"|Phase 3 (C)
+
|Not yet determined
−
|1. [[#MACOP-B|MACOP-B]]
+
|
−
|style="background-color:#ffffbf"|Did not meet endpoint of OS
+
|
 +
|
 +
|USA
 +
|2015
 +
|2020
 +
|
 +
|
 +
|Chronic lymphocytic leukemia
 +
|1
 +
|1
 +
|0
 +
|0
 +
|16
 +
|16
 +
|1
 
|-
 
|-
−
|2. [[#m-BACOD|m-BACOD]]
+
|Ahn
−
|style="background-color:#ffffbf"|Did not meet endpoint of OS
+
|Jae Sook
 +
|MALE
 +
|
 +
|
 +
|
 +
|South Korea
 +
|2009
 +
|2015
 +
|Adult Acute Lymphoblastic Leukemia Working Party of the Korean Society of Hematology
 +
|
 +
|B-cell acute lymphoblastic leukemia; CNS leukemia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|36
 +
|36
 +
|1
 
|-
 
|-
−
|3. [[#ProMACE-CytaBOM|ProMACE-CytaBOM]]
+
|Ahn
−
|style="background-color:#ffffbf"|Did not meet endpoint of OS
+
|Jin Hee
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|South Korea
 +
|2007
 +
|2022
 +
|KCSG
 +
|
 +
|Breast cancer
 +
|4
 +
|0
 +
|4
 +
|1
 +
|79
 +
|66
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1056/NEJM199504203321601 Verdonck et al. 1995]
+
|Ahn
−
|1987-1994
+
|Jin Seok
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|MALE
−
|[[#CHOP|CHOP]] x 3, then HDT with auto HSCT
+
|
−
|style="background-color:#ffffbf"|Did not meet primary endpoint of EFS
+
|
 +
|
 +
|South Korea
 +
|2002
 +
|2020
 +
|KCSG
 +
|
 +
|Breast cancer; CNS carcinoma; Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Small cell lung cancer
 +
|15
 +
|1
 +
|10
 +
|4
 +
|230
 +
|152
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1056/NEJM199807023390104 Miller et al. 1998 (SWOG S8736)]
+
|Ahn
−
|1988-1995
+
|Joong Bae
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|MALE
−
|[[#CHOP|CHOP]] x 3, then [[Diffuse_large_B-cell_lymphoma#Radiation_therapy|RT]]
+
|
−
|style="background-color:#fc8d59"|Seems to have inferior OS
+
|
 +
|
 +
|South Korea
 +
|2008
 +
|2019
 +
|
 +
|
 +
|Colorectal cancer; Rectal cancer
 +
|6
 +
|0
 +
|3
 +
|1
 +
|103
 +
|65
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1023/a:1008392528248 Jerkeman et al. 1999]
+
|Ahn
−
|1989-1994
+
|Myung Ju
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|FEMALE
−
|[[#MACOP-B|MACOP-B]]
+
|
−
|style="background-color:#ffffbf"|Did not meet primary endpoint of OS
+
|
 +
|
 +
|South Korea
 +
|2002
 +
|2021
 +
|KCSG
 +
|
 +
|CNS carcinoma; Esophageal squamous cell carcinoma; Head and neck cancer; Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous; NTRK; Small cell lung cancer
 +
|41
 +
|4
 +
|20
 +
|11
 +
|735
 +
|423
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1093/annonc/mdl153 Betticher et al. 2006 (MISTRAL)]
+
|Ahn
−
|1997-2003
+
|Sei Hyun
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|Not yet determined
−
|[[#SHiDo_99|SHiDo]]
+
|
−
|style="background-color:#ffffbf"|Did not meet primary endpoint of OS
+
|
 +
|
 +
|South Korea
 +
|2012
 +
|2020
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|1
 +
|1
 +
|0
 +
|9
 +
|8
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1093/annonc/mdq619 Ohmachi et al. 2010 (JCOG 9809)]
+
|Ahn
−
|1999-2002
+
|Sung Ja
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|Not yet determined
−
|[[#CHOP-14|CHOP-14]]
+
|
−
|style="background-color:#ffffbf"|Did not meet primary endpoint of PFS
+
|
 +
|
 +
|
 +
|2005
 +
|2013
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|1
 +
|1
 +
|0
 +
|11
 +
|11
 +
|1
 
|-
 
|-
−
|}
+
|Ahn
−
''Note: McKelvey et al. 1976 gave CHOP for 3 cycles past CR.''
+
|Yeon S
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Not yet determined
−
====Chemotherapy====
+
|
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV over 15 minutes once on day 1
+
|
−
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV over 1 to 2 minutes once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV over 1 to 2 minutes once on day 1
+
|
−
====Glucocorticoid therapy====
+
|1983
−
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5
+
|1983
−
'''21-day cycle for 8 cycles'''
+
|
−
</div></div><br>
+
|
−
<div class="toccolours" style="background-color:#eeeeee">
+
|Immune thrombocytopenia
−
===Regimen variant #9, 8 cycles, uncapped vincristine, 100 mg prednisone {{#subobject:d4f664|Variant=1}}===
+
|1
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|1
−
!style="width: 20%"|Study
+
|0
−
!style="width: 20%"|Years of enrollment
+
|0
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
|5
−
!style="width: 20%"|Comparator
+
|5
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+
|1
 
|-
 
|-
−
|[https://doi.org/10.1200/JCO.1985.3.9.1188 Gams et al. 1985]
+
|Ahn
−
|1977-1981
+
|Yong Chan
−
|style="background-color:#1a9851"|Phase 3 (E-switch-ic)
+
|MALE
−
|[[#BCOP|BCOP]]
+
|
−
|style="background-color:#d9ef8b"|Might have superior OS
+
|
 +
|
 +
|South Korea
 +
|2003
 +
|2015
 +
|Consortium for Improving Survival of Lymphoma; KCSG
 +
|
 +
|Extranodal NK- and T-cell lymphoma nasal type; Gastric cancer; Non-small cell lung cancer; Small cell lung cancer
 +
|4
 +
|1
 +
|3
 +
|0
 +
|69
 +
|60
 +
|1
 
|-
 
|-
−
|}
+
|Ahren
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Bo
−
====Chemotherapy====
+
|MALE
−
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 1 mg/m<sup>2</sup> IV once on day 1
+
|
−
====Glucocorticoid therapy====
+
|
−
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5
+
|1991
−
'''21-day cycle for 8 cycles'''
+
|2003
−
</div></div><br>
+
|
−
<div class="toccolours" style="background-color:#eeeeee">
+
|
−
===Regimen variant #10, 8 cycles, uncapped vincristine, 100 mg/m<sup>2</sup> prednisone {{#subobject:872c7f|Variant=1}}===
+
|Neuroendocrine tumor
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|1
−
!style="width: 20%"|Study
+
|1
−
!style="width: 20%"|Years of enrollment
+
|0
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
|0
−
!style="width: 20%"|Comparator
+
|3
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+
|3
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1056/NEJMoa031770 Milpied et al. 2004 (GOELAMS 072)]
+
|Ahrens
−
|1994-1999
+
|S
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|CBD
−
|[[#CEEP|CEEP]], then [[#Cytarabine_.26_Methotrexate_.28CYM.29_88|CYM]], then [[#BEAM.2C_then_auto_HSCT_88|BEAM with auto HSCT]]
+
|
−
| style="background-color:#fc8d59" |Seems to have inferior EFS
+
|
 +
|
 +
|
 +
|2001
 +
|2001
 +
|
 +
|
 +
|Ewing sarcoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|18
 +
|18
 +
|1
 
|-
 
|-
−
|}
+
|Ahsan
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|S
−
====Chemotherapy====
+
|Not yet determined
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once on day 1
+
|
−
====Glucocorticoid therapy====
+
|USA
−
*[[Prednisone (Sterapred)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 5
+
|2011
−
'''21-day cycle for 8 cycles'''
+
|2019
−
</div></div><br>
+
|
−
<div class="toccolours" style="background-color:#eeeeee">
+
|
−
===Regimen variant #11, other {{#subobject:889c7f|Variant=1}}===
+
|Melanoma
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|1
−
!style="width: 20%"|Study
+
|0
−
!style="width: 20%"|Years of enrollment
+
|0
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
|0
−
!style="width: 20%"|Comparator
+
|19
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+
|19
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.3109/02841869009091789 Andersen et al. 1990]
+
|Ahsan
−
|1983-1985
+
|Sama
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|FEMALE
−
|[[#CisEBP_99|CisEBP]]
+
|
−
| style="background-color:#1a9850" |Superior CR rate
+
|
 +
|
 +
|United Kingdom; USA
 +
|2015
 +
|2022
 +
|SWOG
 +
|
 +
|Melanoma
 +
|2
 +
|0
 +
|2
 +
|1
 +
|57
 +
|54
 +
|1
 
|-
 
|-
−
|}
+
|Ahuja
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Harish
−
====Chemotherapy====
+
|MALE
−
*[[Cyclophosphamide (Cytoxan)]]
+
|
−
*[[Doxorubicin (Adriamycin)]]
+
|
−
*[[Vincristine (Oncovin)]]
+
|
−
====Glucocorticoid therapy====
+
|
−
*[[Prednisone (Sterapred)]]
+
|2005
−
</div></div>
+
|2005
−
===References===
+
|
−
# McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, Gutterman J, Coltman C, Moon TE. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976 Oct;38(4):1484-93. [https://doi.org/10.1002/1097-0142(197610)38:4%3C1484::aid-cncr2820380407%3E3.0.co;2-i link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/791473 PubMed]
+
|
−
# Elias L, Portlock CS, Rosenberg SA. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer. 1978 Oct;42(4):1705-10. [https://doi.org/10.1002/1097-0142(197810)42:4%3C1705::AID-CNCR2820420408%3E3.0.CO;2-P link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/361209 PubMed]
+
|Esophageal cancer
−
# Gams RA, Rainey M, Dandy M, Bartolucci AA, Silberman H, Omura G; Southeastern Cancer Study Group. Phase III study of BCOP v CHOP in unfavorable categories of malignant lymphoma: a Southeastern Cancer Study Group trial. J Clin Oncol. 1985 Sep;3(9):1188-95. [https://doi.org/10.1200/JCO.1985.3.9.1188 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3897470 PubMed]
+
|1
−
# Link MP, Donaldson SS, Berard CW, Shuster JJ, Murphy SB; POG. Results of treatment of childhood localized non-Hodgkin's lymphoma with combination chemotherapy with or without radiotherapy. N Engl J Med. 1990 Apr 26;322(17):1169-74. [https://doi.org/10.1056/NEJM199004263221701 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/2183052 PubMed]
+
|0
−
# Andersen J, Thorling K, Bentzen SM, Brincker H, Christensen BE, Pedersen M; Danish Lymphoma Study Group. Phase III trial of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) versus cisplatin, etoposide, bleomycin and prednisone (CisEBP) for the treatment of advanced non-Hodgkin's lymphoma of high grade malignancy. Acta Oncol. 1990;29(8):995-9. [https://doi.org/10.3109/02841869009091789 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1703769 PubMed]
+
|0
−
# Pavlovsky S, Santarelli MT, Erazo A, Diaz Maqueo JC, Somoza N, Lluesma Goñalons M, Cervantes G, Garcia Vela EL, Corrado C, Magnasco H, Milone G. Results of a randomized study of previously-untreated intermediate and high grade lymphoma using CHOP versus CNOP. Ann Oncol. 1992 Mar;3(3):205-9. [https://doi.org/10.1093/oxfordjournals.annonc.a058153 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1586618 PubMed]
+
|0
−
# '''SWOG-8516/Intergroup 0067:''' Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993 Apr 8;328(14):1002-6. [https://doi.org/10.1056/NEJM199304083281404 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7680764 PubMed]
+
|10
−
<!-- ## '''Update:''' Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. A phase III comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol. 1994;5 Suppl 2:91-5. [https://pubmed.ncbi.nlm.nih.gov/7515652 PubMed] -->
+
|10
−
## '''Update:''' Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. J Clin Oncol. 2009 Jan 1;27(1):114-9. Epub 2008 Dec 1. [https://doi.org/10.1200/jco.2008.16.8021 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4879698/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19047289 PubMed]
+
|1
−
# Tondini C, Zanini M, Lombardi F, Bengala C, Rocca A, Giardini R, Buzzoni R, Valagussa P, Bonadonna G. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas. J Clin Oncol. 1993 Apr;11(4):720-5. [https://doi.org/10.1200/jco.1993.11.4.720 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8478665 PubMed]
 
−
# Verdonck LF, van Putten WL, Hagenbeek A, Schouten HC, Sonneveld P, van Imhoff GW, Kluin-Nelemans HC, Raemaekers JM, van Oers RH, Haak HL, Schots R, Dekker AW, de Gast GC, Löwenberg B. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med. 1995 Apr 20;332(16):1045-51. [https://doi.org/10.1056/NEJM199504203321601 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/7898521 PubMed]
 
−
# Zinzani PL, Martelli M, Storti S, Musso M, Cantonetti M, Leone G, Cajozzo A, Papa G, Iannitto E, Perrotti A, Bendandi M, Gherlinzoni F, Gentilini P, Rossi G, Aitini E, Mandelli F, Tura S. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 1995 Oct;19(3-4):329-35. [https://doi.org/10.3109/10428199509107906 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8535227 PubMed]
 
−
# Sonneveld P, de Ridder M, van der Lelie H, Nieuwenhuis K, Schouten H, Mulder A, van Reijswoud I, Hop W, Lowenberg B. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol. 1995 Oct;13(10):2530-9. [https://doi.org/10.1200/JCO.1995.13.10.2530 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/7595704 PubMed]
 
−
# '''SWOG S8736:''' Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998 Jul 2;339(1):21-6. [https://doi.org/10.1056/NEJM199807023390104 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/9647875 PubMed] NCT00005089
 
−
##'''Update:''' Stephens DM, Li H, LeBlanc ML, Puvvada SD, Persky D, Friedberg JW, Smith SM. Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: Final and long-term analysis of Southwest Oncology Group study S8736. J Clin Oncol. 2016 Sep 1;34(25):2997-3004. Epub 2016 Jul 5. [https://doi.org/10.1200/jco.2015.65.4582 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012710/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27382104 PubMed]
 
−
# Jerkeman M, Anderson H, Cavallin-Ståhl E, Dictor M, Hagberg H, Johnson A, Kaasa S, Kvaløy S, Sundström C, Akerman M; Nordic Lymphoma Group. CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial. Ann Oncol. 1999 Sep;10(9):1079-86. [https://doi.org/10.1023/a:1008392528248 link to original article] '''does not contain dosing details''' [https://pubmed.ncbi.nlm.nih.gov/10572606 PubMed]
 
−
# '''LNH 98-5:''' Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C; Groupe d'Etude des Lymphomes de l'Adulte. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235-42. [https://doi.org/10.1056/NEJMoa011795 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/11807147 PubMed]
 
−
## '''Update:''' Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005 Jun 20;23(18):4117-26. [https://doi.org/10.1200/jco.2005.09.131 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/15867204 PubMed]
 
−
## '''Update:''' Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Fermé C, Tilly H. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010 Sep 23;116(12):2040-5. [http://www.bloodjournal.org/content/116/12/2040.long link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951853/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20548096 PubMed]
 
−
## '''Update:''' Mounier N, Heutte N, Thieblemont C, Briere J, Gaulard P, Feugier P, Ghesquieres H, Van Den Neste E, Robu D, Tilly H, Bouabdallah R, Safar V, Coiffier B; Groupe d'Etude des Lymphomes de l'Adulte. Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial. Clin Lymphoma Myeloma Leuk. 2012 Jun;12(3):151-4. Epub 2012 Feb 1. [https://doi.org/10.1016/j.clml.2011.11.004 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22301063 PubMed]
 
−
# Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molina TJ, Gisselbrecht C, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003 Dec 15;102(13):4284-9. Epub 2003 Aug 14. [http://www.bloodjournal.org/content/102/13/4284.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/12920037 PubMed]
 
−
# '''NHL-B1:''' Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rübe C, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004 Aug 1;104(3):626-33. Epub 2004 Feb 24. [http://www.bloodjournal.org/content/104/3/626.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/14982884 PubMed]
 
−
# '''NHL-B2:''' Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004 Aug 1;104(3):634-41. Epub 2004 Mar 11. [http://www.bloodjournal.org/content/104/3/634.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15016643 PubMed]
 
−
# '''GOELAMS 072:''' Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau JL; Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004 Mar 25;350(13):1287-95. [https://doi.org/10.1056/NEJMoa031770 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15044639 PubMed]
 
−
# '''ECOG E1484:''' Horning SJ, Weller E, Kim K, Earle JD, O'Connell MJ, Habermann TM, Glick JH. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol. 2004 Aug 1;22(15):3032-8. Epub 2004 Jun 21. [https://doi.org/10.1200/jco.2004.06.088 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15210738 PubMed]
 
−
# '''LNH 93-01:''' Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, Morel P, Ferme C, Bosly A, Lederlin P, Laurent G, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005 Mar 24;352(12):1197-205. [https://doi.org/10.1056/NEJMoa042040 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15788496 PubMed]
 
−
# Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 May;7(5):379-91. [https://doi.org/10.1016/S1470-2045%2806%2970664-7 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16648042 PubMed]
 
−
## '''Update:''' Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; MabThera International Trial Group. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011 Oct;12(11):1013-22. [https://doi.org/10.1016/S1470-2045%2811%2970235-2 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/21940214 PubMed]
 
−
# '''ECOG E4494:''' Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006 Jul 1;24(19):3121-7. Epub 2006 Jun 5. [https://doi.org/10.1200/jco.2005.05.1003 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16754935 PubMed] NCT00003150
 
−
# '''MISTRAL:''' Betticher DC, Martinelli G, Radford JA, Kaufmann M, Dyer MJ, Kaiser U, Aulitzky WE, Beck J, von Rohr A, Kovascovics T, Cogliatti SB, Cina S, Maibach R, Cerny T, Linch DC. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol. 2006 Oct;17(10):1546-52. Epub 2006 Aug 3. [https://doi.org/10.1093/annonc/mdl153 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16888080 PubMed] NCT00003215
 
−
# Bonnet C, Fillet G, Mounier N, Ganem G, Molina TJ, Thiéblemont C, Fermé C, Quesnel B, Martin C, Gisselbrecht C, Tilly H, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007 Mar 1;25(7):787-92. Epub 2007 Jan 16. [https://doi.org/10.1200/JCO.2006.07.0722 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/17228021 PubMed]
 
−
<!-- Presented orally and in abstract form at the 47th annual meeting of the American Society of Hematology, Atlanta, Georgia, December 11, 2005. -->
 
−
# '''HOVON-26:''' Verdonck LF, Notenboom A, de Jong DD, MacKenzie MA, Verhoef GE, Kramer MH, Ossenkoppele GJ, Doorduijn JK, Sonneveld P, van Imhoff GW. Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Blood. 2007 Apr 1;109(7):2759-66. [http://www.bloodjournal.org/content/109/7/2759.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/17132720 PubMed]
 
−
# '''AGMT NHL-5:''' Fridrik MA, Hausmaninger H, Lang A, Drach J, Krieger O, Geissler D, Michlmayr G, Ulsperger E, Chott A, Oberaigner W, Greil R. Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma. Ann Hematol. 2010 Mar;89(3):273-82. Epub 2009 Aug 20. [https://doi.org/10.1007/s00277-009-0811-x link to original article] [https://pubmed.ncbi.nlm.nih.gov/19693500 PubMed]
 
−
# '''JCOG 9809:''' Ohmachi K, Tobinai K, Kobayashi Y, Itoh K, Nakata M, Shibata T, Morishima Y, Ogura M, Suzuki T, Ueda R, Aikawa K, Nakamura S, Fukuda H, Shimoyama M, Hotta T; Lymphoma Study Group of the Japan Clinical Oncology Group. Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809. Ann Oncol. 2011 Jun;22(6):1382-91. Epub 2010 Dec 31. [https://doi.org/10.1093/annonc/mdq619 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21196441 PubMed] NCT00133302
 
−
# '''SWOG S0313:''' Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, LeBlanc M, Fisher RI. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood. 2015 Jan 8;125(2):236-41. Epub 2014 Nov 13. [http://www.bloodjournal.org/content/125/2/236.long link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287635/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25395425 PubMed] NCT00070018
 
−
==CHOP-14 {{#subobject:6f7a21|Regimen=1}}==
 
−
CHOP-DI: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone, '''<u>D</u>'''ose '''<u>I</u>'''ntense
 
−
<br>I-CHOP: '''<u>I</u>'''ntensified '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
 
−
<br>CHOP-14: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone every '''<u>14</u>''' days
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #1 {{#subobject:39e6ac|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.2003.06.137 Blayney et al. 2003 (SWOG 9349)]
+
|Ai
−
|1994-1997
+
|Ping
−
|style="background-color:#91cf61"|Phase 2
+
|FEMALE
 +
|
 +
|
 +
|
 +
|China
 +
|2011
 +
|2019
 +
|
 +
|
 +
|Nasopharyngeal carcinoma
 +
|2
 +
|0
 +
|2
 +
|0
 +
|67
 +
|34
 +
|1
 
|-
 
|-
−
|}
+
|Ai
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Weiyun
−
====Chemotherapy====
+
|FEMALE
−
*[[Cyclophosphamide (Cytoxan)]] 1600 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Doxorubicin (Adriamycin)]] 65 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once on day 1
+
|
−
====Glucocorticoid therapy====
+
|USA
−
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5
+
|2018
−
====Supportive therapy====
+
|2021
−
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 2 to 11, or until ANC is greater than 10,000/uL
+
|
−
'''14-day cycle for up to 6 cycles'''
+
|
−
</div></div><br>
+
|Diffuse large B-cell lymphoma; Transformed lymphoma
−
<div class="toccolours" style="background-color:#eeeeee">
+
|1
−
===Regimen variant #2 {{#subobject:d78eb4|Variant=1}}===
+
|0
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|0
−
!style="width: 20%"|Study
+
|1
−
!style="width: 20%"|Years of enrollment
+
|17
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
|17
−
!style="width: 20%"|Comparator
+
|1
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[http://www.bloodjournal.org/content/109/7/2759.long Verdonck et al. 2007 (HOVON-26)]
+
|Ai
−
|1994-2004
+
|Xinghao
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
+
|Not yet determined
−
|[[#CHOP|CHOP-21]]
+
|
−
|style="background-color:#ffffbf"|Did not meet primary endpoint of OS
+
|
 +
|
 +
|China
 +
|2018
 +
|2021
 +
|
 +
|
 +
|Non-small cell lung cancer nonsquamous; Small cell lung cancer
 +
|2
 +
|1
 +
|2
 +
|0
 +
|57
 +
|51
 +
|1
 
|-
 
|-
−
|}
+
|Aiba
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Keisuke
−
====Chemotherapy====
+
|Not yet determined
−
*[[Cyclophosphamide (Cytoxan)]] 1000 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Doxorubicin (Adriamycin)]] 70 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 2 mg IV once on day 1
+
|
−
====Glucocorticoid therapy====
+
|Japan
−
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5
+
|2010
−
====Supportive therapy====
+
|2021
−
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 2 to 11
+
|
−
'''14-day cycle for 6 cycles'''
+
|
−
</div></div><br>
+
|Colon cancer
−
<div class="toccolours" style="background-color:#eeeeee">
+
|2
−
===Regimen variant #3 {{#subobject:22ca16|Variant=1}}===
+
|0
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|1
−
!style="width: 20%"|Study
+
|0
−
!style="width: 20%"|Years of enrollment
+
|41
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
|30
−
!style="width: 20%"|Comparator
+
|1
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|rowspan=2|[http://www.bloodjournal.org/content/104/3/626.long Pfreundschuh et al. 2004 (NHL-B1)]
+
|Aiello
−
|rowspan=2|1993-2000
+
|Maria
−
|rowspan=2 style="background-color:#1a9851"|Phase 3 (E-esc)
+
|FEMALE
−
|1. [[#CHOEP-14|CHOEP-14]]
+
|
−
|style="background-color:#d73027"|Inferior EFS
+
|
 +
|
 +
|USA
 +
|2012
 +
|2014
 +
|
 +
|
 +
|Chronic lymphocytic leukemia
 +
|1
 +
|0
 +
|1
 +
|1
 +
|26
 +
|26
 +
|1
 
|-
 
|-
−
|2. [[#CHOEP-21|CHOEP-21]]<br> 3. [[#CHOP|CHOP-21]]
+
|Aieta
−
|style="background-color:#91cf60"|Seems to have superior OS
+
|Michele
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2007
 +
|2018
 +
|Reader study level-I and level-II Groups
 +
|
 +
|Breast cancer; Testicular cancer
 +
|2
 +
|0
 +
|1
 +
|0
 +
|40
 +
|40
 +
|1
 
|-
 
|-
−
|rowspan=3|[https://doi.org/10.1016/S1470-2045%2808%2970002-0 Pfreundschuh et al. 2008 (RICOVER-60)]
+
|Aihara
−
|rowspan=3|2000-2005
+
|Satomi
−
|rowspan=3 style="background-color:#1a9851"|Phase 3 (C)
+
|Not yet determined
−
|1. [[#CHOP-14|CHOP-14]] x 8
+
|
−
|style="background-color:#fc8d59"|Seems to have inferior EFS
+
|
 +
|
 +
|Japan
 +
|2015
 +
|2021
 +
|
 +
|
 +
|Ovarian cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|41
 +
|41
 +
|1
 
|-
 
|-
−
|2. [[Diffuse_large_B-cell_lymphoma#R-CHOP-14|R-CHOP-14]] x 6
+
|Aihara
−
|style="background-color:#d73027"|Inferior OS
+
|Tomohiko
 +
|MALE
 +
|
 +
|
 +
|
 +
|Japan
 +
|2002
 +
|2010
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|1
 +
|1
 +
|0
 +
|20
 +
|20
 +
|1
 
|-
 
|-
−
|3. [[Diffuse_large_B-cell_lymphoma#R-CHOP-14|R-CHOP-14]] x 8
+
|Aikata
−
|style="background-color:#d73027"|Inferior PFS
+
|Hiroshi
 +
|MALE
 +
|
 +
|
 +
|
 +
|Japan
 +
|2008
 +
|2018
 +
|
 +
|
 +
|Hepatocellular carcinoma
 +
|2
 +
|0
 +
|2
 +
|0
 +
|35
 +
|32
 +
|1
 
|-
 
|-
−
|}
+
|Aikawa
−
<div class="toccolours" style="background-color:#cbd5e8">
+
|Keiko
−
====Preceding treatment====
+
|Not yet determined
−
*[[Diffuse_large_B-cell_lymphoma#Vincristine_.26_Prednisone|Pre-phase vincristine & prednisone]] (recommended in NHL-B1 and mandatory in RICOVER-60)
+
|
−
</div>
+
|
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|
−
====Chemotherapy====
+
|Japan
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
+
|1995
−
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
+
|2010
−
*[[Vincristine (Oncovin)]] 2 mg IV once on day 1
+
|JCOG
−
====Glucocorticoid therapy====
+
|
−
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5
+
|Adult T-cell leukemia-lymphoma; Diffuse large B-cell lymphoma
−
====Supportive therapy====
+
|2
−
*(per Pfreundschuh et al. 2004):
+
|0
−
*[[Filgrastim (Neupogen)]] 300 mcg (for patients  less than 75 kg) or 480 mcg (for patients at least 75 kg) SC once per day on days 4 to 13
+
|1
−
'''14-day cycle for 6 cycles'''
+
|0
−
</div>
+
|32
−
<div class="toccolours" style="background-color:#cbd5e7">
+
|25
−
====Subsequent treatment====
+
|1
−
*Patients with "Initial bulky disease": patients with "lymphoma masses or conglomerates with a diameter of at least 7.5 cm or extranodal involvement": [[#Radiation_therapy|RT]], 36 Gy to areas of initial bulky disease
 
−
</div></div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #4 {{#subobject:23cb16|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|rowspan=3|[https://doi.org/10.1016/S1470-2045%2808%2970002-0 Pfreundschuh et al. 2008 (RICOVER-60)]
+
|Aiken
−
|rowspan=3|2000-2005
+
|Robert
−
|rowspan=3 style="background-color:#1a9851"|Phase 3 (C)
+
|Not yet determined
−
|1. [[#CHOP-14|CHOP-14]] x 6
+
|
−
|style="background-color:#91cf60"|Seems to have superior EFS
+
|
 +
|
 +
|USA
 +
|2007
 +
|2018
 +
|
 +
|
 +
|Glioblastoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|68
 +
|68
 +
|1
 
|-
 
|-
−
|2. [[Diffuse_large_B-cell_lymphoma#R-CHOP-14|R-CHOP-14]] x 6
+
|Ailawadhi
−
|style="background-color:#d3d3d3"|Not reported
+
|Sikander
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2012
 +
|2018
 +
|
 +
|
 +
|Chronic myeloid leukemia; Multiple myeloma
 +
|3
 +
|0
 +
|0
 +
|1
 +
|70
 +
|51
 +
|1
 
|-
 
|-
−
|3. [[Diffuse_large_B-cell_lymphoma#R-CHOP-14|R-CHOP-14]] x 8
+
|Aimone
−
|style="background-color:#d3d3d3"|Not reported
+
|Paola
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Switzerland
 +
|2007
 +
|2021
 +
|
 +
|
 +
|Chronic myeloid leukemia; Chronic myeloid leukemia pediatric; Head and neck cancer; Renal cell carcinoma
 +
|7
 +
|0
 +
|3
 +
|4
 +
|146
 +
|116
 +
|1
 
|-
 
|-
−
|}
+
|Airatovich Gafanov
−
<div class="toccolours" style="background-color:#cbd5e8">
+
|Rustem
−
====Preceding treatment====
+
|MALE
−
*[[Diffuse_large_B-cell_lymphoma#Vincristine_.26_Prednisone|Pre-phase vincristine & prednisone]]
+
|
−
</div>
+
|
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|
−
====Chemotherapy====
+
|Russian Federation
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
+
|2016
−
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
+
|2021
−
*[[Vincristine (Oncovin)]] 2 mg IV once on day 1
+
|
−
====Glucocorticoid therapy====
+
|
−
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5
+
|Clear cell renal cell carcinoma; Non-clear cell renal cell carcinoma; Prostate cancer; Renal cell carcinoma
−
====Supportive therapy====
+
|5
−
*[[Filgrastim (Neupogen)]] 300 mcg (for patients less than 75 kg) or 480 mcg (for patients at least 75 kg) SC once per day on days 4 to 13
+
|0
−
'''14-day cycle for 8 cycles'''
+
|2
−
</div>
+
|1
−
<div class="toccolours" style="background-color:#cbd5e7">
+
|107
−
====Subsequent treatment====
+
|78
−
*Patients with "Initial bulky disease": patients with "lymphoma masses or conglomerates with a diameter of at least 7.5 cm or extranodal involvement": [[#Radiation_therapy|RT]], 36 Gy to areas of initial bulky disease
+
|1
−
</div></div>
 
−
===References===
 
−
# '''SWOG 9349:''' Blayney DW, LeBlanc ML, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH, Taylor SA, Bearman SI, Miller TP, Fisher RI; [[Study_Groups#SWOG|SWOG]]. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol. 2003 Jul 1;21(13):2466-73. [https://doi.org/10.1200/jco.2003.06.137 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/12829664 PubMed]
 
−
# '''NHL-B1:''' Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rübe C, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004 Aug 1;104(3):626-33. Epub 2004 Feb 24. [http://www.bloodjournal.org/content/104/3/626.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/14982884 PubMed]
 
−
# '''NHL-B2:''' Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004 Aug 1;104(3):634-41. Epub 2004 Mar 11. [http://www.bloodjournal.org/content/104/3/634.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/15016643 PubMed]
 
−
<!-- Presented orally and in abstract form at the 47th annual meeting of the American Society of Hematology, Atlanta, Georgia, December 11, 2005. -->
 
−
# '''HOVON-26:''' Verdonck LF, Notenboom A, de Jong DD, MacKenzie MA, Verhoef GE, Kramer MH, Ossenkoppele GJ, Doorduijn JK, Sonneveld P, van Imhoff GW. Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Blood. 2007 Apr 1;109(7):2759-66. [http://www.bloodjournal.org/content/109/7/2759.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/17132720 PubMed]
 
−
# '''RICOVER-60:''' Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M; German High-Grade Non-Hodgkin Lymphoma Study Group. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008 Feb;9(2):105-16. [https://doi.org/10.1016/S1470-2045%2808%2970002-0 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/18226581 PubMed] NCT00052936
 
−
==CHOP Modified {{#subobject:bb947a|Regimen=1}}==
 
−
mCHOP: '''<u>m</u>'''odified '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:7b74fc|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[https://doi.org/10.1056/NEJM199710303371802 Link et al. 1997]
+
|Aird
−
|1983-1991
+
|William
−
| style="background-color:#91cf61" |Non-randomized portion of RCT
+
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1990
 +
|2000
 +
|
 +
|
 +
|Acute myeloid leukemia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|6
 +
|6
 +
|1
 
|-
 
|-
−
|}
+
|Airewele
−
''Note: This regimen has some major differences from standard CHOP.''
+
|Gladstone
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Not yet determined
−
====Chemotherapy====
+
|
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once per day on days 1, 22, 43
+
|
−
*[[Doxorubicin (Adriamycin)]] 40 mg/m<sup>2</sup> IV once per day on days 1, 22, 43
+
|
−
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29, 36, 43
+
|USA
−
====Glucocorticoid therapy====
+
|2004
−
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup>/day on days 1 to 28, 43 to 47
+
|2014
−
'''9-week course'''
+
|
−
</div></div>
+
|
−
===References===
+
|Acute myeloid leukemia pediatric; Sickle cell anemia
−
# Link MP, Shuster JJ, Donaldson SS, Berard CW, Murphy SB. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. N Engl J Med. 1997 Oct 30;337(18):1259-66. [https://doi.org/10.1056/NEJM199710303371802 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9345074 PubMed]
+
|2
−
 
+
|0
−
==CHOP Modified (Prednisolone) {{#subobject:bb947|Regimen=1}}==
+
|1
−
mCHOP: '''<u>m</u>'''odified '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisolone
+
|0
−
<div class="toccolours" style="background-color:#eeeeee">
+
|56
−
===Regimen {{#subobject:4f9502|Variant=1}}===
+
|56
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|1
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1093/annonc/mdg067 Bessell et al. 2003 (CLG NH 3003)]
+
|Airoma
−
|1993-2000
+
|G
−
|style="background-color:#1a9851"|Phase 3 (E-switch-ic)
+
|CBD
−
|[[#CNOP_.28Prednisolone.29|MCOP]]
+
|
−
|style="background-color:#d3d3d3"|Not designed to look at efficacy
+
|
 +
|
 +
|
 +
|1990
 +
|1996
 +
|GOSCI
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|18
 +
|18
 +
|1
 
|-
 
|-
−
|}
+
|Aisa
−
''Note: This regimen is designed for elderly patients and is of lower intensity than standard CHOP.''
+
|Yoshinobu
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|MALE
−
====Chemotherapy====
+
|
−
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Doxorubicin (Adriamycin)]] 30 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 1 mg IV once on day 1
+
|
−
====Glucocorticoid therapy====
+
|2015
−
*[[Prednisolone (Millipred)]] 20 mg PO twice per day on days 1 to 5
+
|2015
−
'''21-day cycle for 6 cycles'''
+
|
−
</div></div>
+
|
−
===References===
+
|Follicular lymphoma
−
# '''CLG NH 3003:''' Bessell EM, Burton A, Haynes AP, Glaholm J, Child JA, Cullen MH, Davies JM, Smith GM, Ellis IO, Jack A, Jones EL; Central Lymphoma Group UK. A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2003 Feb;14(2):258-67. [https://doi.org/10.1093/annonc/mdg067 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/12562653 PubMed] NCT00002576
+
|1
−
 
+
|0
−
==CHOP-BCG {{#subobject:236052|Regimen=1}}==
+
|0
−
CHOP-BCG: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone, '''<u>B</u>'''acillus '''<u>C</u>'''almette-'''<u>G</u>'''uérin
+
|0
−
<div class="toccolours" style="background-color:#eeeeee">
+
|18
−
===Regimen {{#subobject:a81974|Variant=1}}===
+
|18
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|1
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|rowspan=2|[https://doi.org/10.1002/1097-0142%28197902%2943%3A2%3C417%3A%3AAID-CNCR2820430203%3E3.0.CO%3B2-I Jones et al. 1979]
+
|Aisner
−
|rowspan=2|1974-1977
+
|D L
−
|rowspan=2|style="background-color:#1a9851"|Phase 3 (E-esc)
+
|CBD
−
|1. [[#CHOP-B|CHOP-B]]
+
|
−
| style="background-color:#d3d3d3" |Not reported
+
|
 +
|
 +
|USA
 +
|2011
 +
|2015
 +
|
 +
|
 +
|Pancreatic cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|30
 +
|30
 +
|1
 
|-
 
|-
−
|2. [[#COP-Bleo|COP-Bleo]]
+
|Aisner
−
| style="background-color:#d9ef8b" |Might have superior CR rate
+
|Joseph A
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1976
 +
|2003
 +
|CALGB
 +
|
 +
|Breast cancer; Head and neck cancer; Soft tissue sarcoma; Thymoma
 +
|9
 +
|3
 +
|6
 +
|0
 +
|93
 +
|65
 +
|1
 
|-
 
|-
−
|}
+
|Aisner
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Seena C
−
====Chemotherapy====
+
|FEMALE
−
*[[Cyclophosphamide (Cytoxan)]]
+
|
−
*[[Doxorubicin (Adriamycin)]]
+
|
−
*[[Vincristine (Oncovin)]]
+
|
−
====Glucocorticoid therapy====
+
|USA
−
*[[Prednisone (Sterapred)]]
+
|1982
−
====Immunotherapy====
+
|2017
−
*[[Bacillus Calmette-Guérin (BCG)]]
+
|ECOG; ECOG-ACRIN; SECSG; SWOG
−
</div></div>
+
|
−
===References===
+
|Non-small cell lung cancer; Small cell lung cancer; Thymoma
−
# Jones SE, Grozea PN, Metz EN, Haut A, Stephens RL, Morrison FS, Butler JJ, Byrne GE Jr, Moon TE, Fisher R, Haskins CL, Coltman CA Jr; [[Study_Groups#SWOG|SWOG]]. Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma: a Southwest Oncology Group study. Cancer. 1979 Feb;43(2):417-25. [https://doi.org/10.1002/1097-0142%28197902%2943%3A2%3C417%3A%3AAID-CNCR2820430203%3E3.0.CO%3B2-I link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/84706 PubMed]
+
|8
−
## '''Update:''' Jones SE, Grozea PN, Metz EN, Haut A, Stephens RL, Morrison FS, Talley R, Butler JJ, Byrne GE Jr, Hartsock R, Dixon D, Salmon SE. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy: a Southwest Oncology Group Study. Cancer. 1983 Mar 15;51(6):1083-90. [https://doi.org/10.1002/1097-0142(19830315)51:6%3C1083::aid-cncr2820510619%3E3.0.co;2-m link to original article] [https://pubmed.ncbi.nlm.nih.gov/6185212 PubMed]
+
|0
−
==CHOP-B {{#subobject:015a69|Regimen=1}}==
+
|3
−
CHOP-B: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone, '''<u>B</u>'''leomycin
+
|0
−
<br>B-CHOP: '''<u>B</u>'''leomycin, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
+
|72
−
<br>BACOP: '''<u>B</u>'''leomycin, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
+
|56
−
<div class="toccolours" style="background-color:#eeeeee">
+
|1
−
===Regimen {{#subobject:2ae46d|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[http://www.bloodjournal.org/content/49/3/325.long Rodriguez et al. 1977]
+
|Aitchison
−
|1973-1975
+
|Michael A
−
|style="background-color:#91cf61"|Phase 2
+
|MALE
−
|style="background-color:#d3d3d3"|
+
|
−
|style="background-color:#d3d3d3"|
+
|
 +
|
 +
|United Kingdom
 +
|1998
 +
|2018
 +
|EORTC; MRC
 +
|
 +
|Renal cell carcinoma
 +
|3
 +
|1
 +
|3
 +
|0
 +
|48
 +
|47
 +
|1
 
|-
 
|-
−
|[http://www.bloodjournal.org/content/49/5/759.long Skarin et al. 1977]
+
|Aitini
−
|1973-1975
+
|Enrico
−
|style="background-color:#91cf61"|Phase 2
+
|MALE
−
|style="background-color:#d3d3d3"|
+
|
−
|style="background-color:#d3d3d3"|
+
|
 +
|
 +
|Italy
 +
|1987
 +
|2014
 +
|GERCOR; GISCAD; Italian Group for the Study of Digestive Tract Cancer; Mammella InterGruppo
 +
|
 +
|Breast cancer; Colorectal cancer; Diffuse large B-cell lymphoma; Gastric cancer; Malignant pleural mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
 +
|13
 +
|0
 +
|10
 +
|0
 +
|216
 +
|176
 +
|1
 
|-
 
|-
−
|rowspan=2|[https://doi.org/10.1002/1097-0142%28197902%2943%3A2%3C417%3A%3AAID-CNCR2820430203%3E3.0.CO%3B2-I Jones et al. 1979]
+
|Aitken
−
|rowspan=2|1974-1977
+
|Casey N
−
|rowspan=2 style="background-color:#1a9851"|Phase 3 (E-esc)
+
|UNMATCHED
−
|1. [[#CHOP-BCG|CHOP-BCG]]
+
|
−
| style="background-color:#d3d3d3" |Not reported
+
|
 +
|
 +
|USA
 +
|2017
 +
|2017
 +
|
 +
|
 +
|Transformed lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|34
 +
|34
 +
|1
 
|-
 
|-
−
|2. [[#COP-Bleo|COP-Bleo]]
+
|Aivado
−
| style="background-color:#d9ef8b" |Might have superior CR rate
+
|Manuel
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2010
 +
|2010
 +
|
 +
|
 +
|Immune thrombocytopenia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|8
 +
|8
 +
|1
 
|-
 
|-
−
|[https://pubmed.ncbi.nlm.nih.gov/6177407 Newcomer et al. 1982]
+
|Aix
−
|NR in abstract
+
|Santiago Ponce
−
|style="background-color:#91cf61"|Randomized, <20 patients (E-de-esc)
+
|Not yet determined
−
|[[#ACOMLA|ACOMLA]]
+
|
−
|style="background-color:#91cf60"|Seems to have superior RFS
+
|
 +
|
 +
|Spain
 +
|2014
 +
|2020
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|19
 +
|19
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1016/0360-3016(88)90340-9 Bajetta et al. 1988]
+
|Aizawa
−
|1976-1984
+
|Masataka
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
+
|Not yet determined
−
|[[#CVP|CVP]]
+
|
−
|style="background-color:#91cf60"|Seems to have superior FFFP
+
|
 +
|
 +
|
 +
|2005
 +
|2013
 +
|
 +
|
 +
|Bladder cancer; Upper tract urothelial carcinoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|22
 +
|22
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1056/NEJM199312093292404 Meyer et al. 1993]
+
|Ajani
−
|1982-1989
+
|Jaffer A
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|MALE
−
|[[#eBACOP_99|esc-BACOP]]
+
|
−
|style="background-color:#ffffbf"|Did not meet efficacy endpoints
+
|
 +
|
 +
|USA
 +
|1990
 +
|2022
 +
|RTOG; USA Intergroup
 +
|
 +
|Anal cancer; Esophageal adenocarcinoma; Esophageal cancer; Esophageal squamous cell carcinoma; Gastric cancer
 +
|21
 +
|11
 +
|13
 +
|5
 +
|316
 +
|237
 +
|1
 
|-
 
|-
−
|}
+
|Ajaz
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Mazhar
−
====Chemotherapy====
+
|Not yet determined
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
+
|
−
*[[Bleomycin (Blenoxane)]] 4 mg/m<sup>2</sup> IV once on day 1
+
|United Kingdom
−
====Glucocorticoid therapy====
+
|2016
−
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5
+
|2019
−
'''21-day cycle for 8 cycles'''
+
|
−
</div></div>
+
|
−
===References===
+
|Melanoma
−
# Rodriguez V, Cabanillas F, Burgess MA, McKelvey EM, Valdivieso M, Bodey GP, Freireich EJ. Combination chemotherapy ("CHOP-Bleo") in advanced (non-Hodgkin) malignant lymphoma. Blood. 1977 Mar;49(3):325-33. [http://www.bloodjournal.org/content/49/3/325.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/65189 PubMed]
+
|1
−
# Skarin AT, Rosenthal DS, Moloney WC, Frei E 3rd. Combination chemotherapy of advanced non-Hodgkin lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP). Blood. 1977 May;49(5):759-70. [http://www.bloodjournal.org/content/49/5/759.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/66957 PubMed]
+
|0
−
# Jones SE, Grozea PN, Metz EN, Haut A, Stephens RL, Morrison FS, Butler JJ, Byrne GE Jr, Moon TE, Fisher R, Haskins CL, Coltman CA Jr; [[Study_Groups#SWOG|SWOG]]. Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma: a Southwest Oncology Group study. Cancer. 1979 Feb;43(2):417-25. [https://doi.org/10.1002/1097-0142%28197902%2943%3A2%3C417%3A%3AAID-CNCR2820430203%3E3.0.CO%3B2-I link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/84706 PubMed]
+
|0
−
## '''Update:''' Jones SE, Grozea PN, Metz EN, Haut A, Stephens RL, Morrison FS, Talley R, Butler JJ, Byrne GE Jr, Hartsock R, Dixon D, Salmon SE. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy: a Southwest Oncology Group Study. Cancer. 1983 Mar 15;51(6):1083-90. [https://doi.org/10.1002/1097-0142(19830315)51:6%3C1083::aid-cncr2820510619%3E3.0.co;2-m link to original article] [https://pubmed.ncbi.nlm.nih.gov/6185212 PubMed]
+
|0
−
# Newcomer LN, Cadman EC, Nerenberg MI, Chen M, Bertino JR, Farber LR, Prosnitz LR. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma. Cancer Treat Rep. 1982 Jun;66(6):1279-84. [https://pubmed.ncbi.nlm.nih.gov/6177407 PubMed]
+
|18
−
# Bajetta E, Valagussa P, Bonadonna G, Lattuada A, Buzzoni R, Rilke F, Banfi A. Combined modality treatment for stage I-II non-Hodgkin's lymphomas: CVP versus BACOP chemotherapy. Int J Radiat Oncol Biol Phys. 1988 Jul;15(1):3-12. [https://doi.org/10.1016/0360-3016(88)90340-9 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2455701 PubMed]
+
|18
−
# Meyer RM, Quirt IC, Skillings JR, Cripps MC, Bramwell VH, Weinerman BH, Gospodarowicz MK, Burns BF, Sargeant AM, Shepherd LE, Zee B, Hryniuk WM. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N Engl J Med. 1993 Dec 9;329(24):1770-6. [https://doi.org/10.1056/NEJM199312093292404 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7694148 PubMed]
+
|1
−
==CHVP {{#subobject:15cj69|Regimen=1}}==
 
−
CHVP: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>V</u>'''umon (Teniposide), '''<u>P</u>'''rednisone
 
−
<br>CHVmP: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>Vm</u>'''26 (Teniposide), '''<u>P</u>'''rednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:2acj5d|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1016/0360-3016(83)90201-8 Burgers et al. 1983 (EORTC 20751)]
+
|Akabane
−
|1975-1980
+
|Hiromitsu
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|MALE
−
|[[#CVP|CVP]]
+
|
−
| style="background-color:#d3d3d3" |Not reported
+
|
 +
|
 +
|Japan
 +
|2006
 +
|2021
 +
|
 +
|
 +
|Breast cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|21
 +
|19
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1093/oxfordjournals.annonc.a057979 Carde et al. 1991]
+
|Akaike
−
|1980-1986
+
|Makoto
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|MALE
−
|[[#CHVmP-VB|CHVmP-VB]]
+
|
−
| style="background-color:#d73027" |Inferior OS
+
|
 +
|
 +
|Japan
 +
|2003
 +
|2014
 +
|JCOG
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|17
 +
|17
 +
|1
 
|-
 
|-
−
|}
+
|Akaike
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Tomoko
−
====Chemotherapy====
+
|FEMALE
−
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Teniposide (Vumon)]] 60 mg/m<sup>2</sup> IV over 60 minutes once on day 1
+
|
−
====Glucocorticoid therapy====
+
|USA
−
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 5
+
|2015
−
</div></div>
+
|2021
−
===References===
+
|
−
# '''EORTC 20751:''' Burgers JM, Somers R, Quasim MM, van Glabbekke M. Report on the EORTC 20751 lymphoma trial. Int J Radiat Oncol Biol Phys. 1983 Jan;9(1):11-5. [https://doi.org/10.1016/0360-3016(83)90201-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6341333 PubMed]
+
|
−
# Carde P, Meerwaldt JH, van Glabbeke M, Somers R, Monconduit M, Thomas J, de Wolf-Peeters C, de Pauw B, Tanguy A, Kluin-Nelemans JC, Noordijk EM, Regnier R, Bron D, Lustman-Marechal J, Caillou B, Bosq J, van Heerde P, van Unnik JAM, Burgers MV, Hayat M, Cosset JM, van der Schueren E, Wagener J, Hagenbeek A, Cattan A, Duez N, Tubiana M; [[Study_Groups#EORTC|EORTC]] Lymphoma Group. Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): the 1980-1985 EORTC trial. Ann Oncol. 1991 Jun;2(6):431-5. [https://doi.org/10.1093/oxfordjournals.annonc.a057979 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/1722697 PubMed]
+
|Merkel cell carcinoma
−
==CHVmP-VB {{#subobject:0a9c69|Regimen=1}}==
+
|1
−
CHVmP-VB: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>Vm</u>'''26 (Teniposide), '''<u>P</u>'''rednisone, '''<u>V</u>'''incristine, '''<u>B</u>'''leomycin
+
|0
−
<div class="toccolours" style="background-color:#eeeeee">
+
|0
−
===Regimen {{#subobject:2jb46d|Variant=1}}===
+
|1
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|28
−
!style="width: 20%"|Study
+
|28
−
!style="width: 20%"|Years of enrollment
+
|1
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1093/oxfordjournals.annonc.a057979 Carde et al. 1991]
+
|Akamaru
−
|1980-1986
+
|Yusuke
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
+
|MALE
−
|[[#CHVP|CHVP]]
+
|
−
| style="background-color:#1a9850" |Superior OS
+
|
 +
|
 +
|Japan
 +
|2007
 +
|2015
 +
|
 +
|
 +
|Gastric cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|16
 +
|16
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1093/annonc/5.suppl_2.s85 Somers et al. 1994a]
+
|Akamatsu
−
|1986-1991
+
|Hiroaki
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|MALE
−
|[[#ProMACE-MOPP|ProMACE-MOPP]]
+
|
−
| style="background-color:#d73027" |Inferior ORR
+
|
 +
|
 +
|Japan
 +
|2014
 +
|2021
 +
|
 +
|
 +
|CNS carcinoma; Non-small cell lung cancer; Non-small cell lung cancer nonsquamous
 +
|3
 +
|0
 +
|2
 +
|1
 +
|53
 +
|42
 +
|1
 
|-
 
|-
−
|}
+
|Akamatsu
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Hiroki
−
====Chemotherapy====
+
|Not yet determined
−
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Teniposide (Vumon)]] 60 mg/m<sup>2</sup> IV over 60 minutes once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 2 mg IV once on day 15
+
|Japan
−
*[[Bleomycin (Blenoxane)]] 10 mg IV once on day 15
+
|2011
−
====Glucocorticoid therapy====
+
|2017
−
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 5
+
|
−
</div></div>
+
|
−
===References===
+
|Rectal cancer
−
# Carde P, Meerwaldt JH, van Glabbeke M, Somers R, Monconduit M, Thomas J, de Wolf-Peeters C, de Pauw B, Tanguy A, Kluin-Nelemans JC, Noordijk EM, Regnier R, Bron D, Lustman-Marechal J, Caillou B, Bosq J, van Heerde P, van Unnik JAM, Burgers MV, Hayat M, Cosset JM, van der Schueren E, Wagener J, Hagenbeek A, Cattan A, Duez N, Tubiana M; [[Study_Groups#EORTC|EORTC]] Lymphoma Group. Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): the 1980-1985 EORTC trial. Ann Oncol. 1991 Jun;2(6):431-5. [https://doi.org/10.1093/oxfordjournals.annonc.a057979 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/1722697 PubMed]
+
|1
−
# Somers R, Carde P, Thomas J, Tirelli U, Keuning JJ, Bron D, Delmer A, de Bock R, De Wolf-Peeters C, van Glabbeke M, Duez N; [[Study_Groups#EORTC|EORTC]]. EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma. Ann Oncol. 1994;5 Suppl 2:85-9. Erratum in: Ann Oncol 1994 May;5(5):475. [https://doi.org/10.1093/annonc/5.suppl_2.s85 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/7515651 PubMed]
+
|0
−
==C-MOPP {{#subobject:5c18a1|Regimen=1}}==
+
|1
−
C-MOPP: '''<u>C</u>'''yclophospha'''<u>M</u>'''ide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
+
|0
−
<br>COPP: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
+
|12
−
<div class="toccolours" style="background-color:#eeeeee">
+
|12
−
===Regimen {{#subobject:a3fc4e|Variant=1}}===
+
|1
−
{| class="wikitable sortable" style="width: 80%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|Years of enrollment
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1016/s0140-6736(75)91142-3 DeVita et al. 1975]
+
|Akapame
−
|1965-1972
+
|Sydney
−
|style="background-color:#91cf61"|Phase 2
+
|MALE
−
|style="background-color:#d3d3d3"|
+
|
 +
|
 +
|
 +
|USA
 +
|2015
 +
|2022
 +
|
 +
|
 +
|Bladder cancer
 +
|1
 +
|0
 +
|0
 +
|1
 +
|18
 +
|18
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.7326/0003-4819-81-5-601 Stein et al. 1974]
+
|Akard
−
|1970-1973
+
|Luke
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
+
|MALE
−
|Vincristine & Prednisone (VP)
+
|
 +
|
 +
|
 +
|USA
 +
|2006
 +
|2015
 +
|
 +
|
 +
|Chronic myeloid leukemia; Testicular cancer
 +
|3
 +
|0
 +
|0
 +
|2
 +
|40
 +
|34
 +
|1
 
|-
 
|-
−
|}
+
|Akaza
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Hideyuki
−
====Chemotherapy====
+
|MALE
−
*[[Cyclophosphamide (Cytoxan)]]
+
|
−
*[[Vincristine (Oncovin)]]
+
|
−
*[[Procarbazine (Matulane)]]
+
|
−
====Glucocorticoid therapy====
+
|Japan
−
*[[Prednisone (Sterapred)]]
+
|2000
−
</div></div>
+
|2020
−
===References===
+
|Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer
−
# Stein RS, Moran EM, Desser RK, Miller JB, Golomb HM, Ultmann JE. Combination chemotherapy of lymphomas other than Hodgkin's disease. Ann Intern Med. 1974 Nov;81(5):601-8. [https://doi.org/10.7326/0003-4819-81-5-601 link to original article] [https://pubmed.ncbi.nlm.nih.gov/4608355 PubMed]
+
|
−
# DeVita VT Jr, Canellos GP, Chabner B, Schein P, Hubbard SP, Young RC. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet. 1975 Feb 1;1(7901):248-50. [https://doi.org/10.1016/s0140-6736(75)91142-3 link to original article] [https://pubmed.ncbi.nlm.nih.gov/46388 PubMed]
+
|Prostate cancer
−
==CNOP {{#subobject:3121b4|Regimen=1}}==
+
|6
−
CNOP: '''<u>C</u>'''yclophosphamide, '''<u>N</u>'''ovantrone (Mitoxantrone), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
+
|3
−
<br>MCOP: '''<u>M</u>'''itoxantrone, '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
+
|5
−
<div class="toccolours" style="background-color:#eeeeee">
+
|1
−
===Regimen {{#subobject:4a0ab|Variant=1}}===
+
|66
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|57
−
!style="width: 20%"|Study
+
|1
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971727/ Sonneveld & Michiels 1990]
+
|Akazawa
−
|NR
+
|Kohei
−
|style="background-color:#91cf61"|Phase 2
+
|MALE
−
|style="background-color:#d3d3d3"|
+
|
−
|style="background-color:#d3d3d3"|
+
|
 +
|
 +
|Japan
 +
|2010
 +
|2018
 +
|
 +
|
 +
|Hepatocellular carcinoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|21
 +
|21
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1093/oxfordjournals.annonc.a058153 Pavlovsky et al. 1992a]
+
|Akazawa
−
|1985-1988
+
|Rio
−
|style="background-color:#1a9851"|Phase 3 (E-switch-ic)
+
|FEMALE
−
|[[#CHOP|CHOP]]
+
|
−
|style="background-color:#ffffbf"|Did not meet endpoint of OS
+
|
 +
|
 +
|Japan
 +
|2013
 +
|2018
 +
|
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|11
 +
|11
 +
|1
 
|-
 
|-
−
|}
+
|Akbulut
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Hakan
−
====Chemotherapy====
+
|MALE
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Mitoxantrone (Novantrone)]] 10 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once on day 1
+
|
−
====Glucocorticoid therapy====
+
|
−
*[[Prednisone (Sterapred)]] 50 mg/m<sup>2</sup> PO once per day on days 1 to 5
+
|1992
−
'''28-day cycle for 6 cycles'''
+
|2005
−
</div></div>
+
|Turkish Oncology Group
−
===References===
+
|
−
# Sonneveld P, Michiels JJ. Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma: a feasibility study using a mitoxantrone containing regimen. Br J Cancer. 1990 Jul;62(1):105-8. [https://doi.org/10.1038/bjc.1990.238 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971727/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/2390469 PubMed]
+
|Breast cancer
−
# Pavlovsky S, Santarelli MT, Erazo A, Diaz Maqueo JC, Somoza N, Lluesma Goñalons M, Cervantes G, Garcia Vela EL, Corrado C, Magnasco H, Milone G. Results of a randomized study of previously-untreated intermediate and high grade lymphoma using CHOP versus CNOP. Ann Oncol. 1992 Mar;3(3):205-9. [https://doi.org/10.1093/oxfordjournals.annonc.a058153 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1586618 PubMed]
+
|2
−
## '''Update:''' Bezwoda W, Rastogi RB, Erazo Valla A, Diaz-Maqueo JC, Pavlovsky S, Morioka H, Resegotti L, Rueckle H, Somoza N, Moreno-Nogueira JA, Bernasconi C, Ho A, Burns I, Lardinois J, van der Merwe A, Richards E; Novantrone International Study Group. Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Eur J Cancer. 1995 Jun;31A(6):903-11. [https://doi.org/10.1016/0959-8049(95)00076-3 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7646919 PubMed]
+
|0
−
==CNOP (Prednisolone) {{#subobject:3525b4|Regimen=1}}==
+
|2
−
CNOP: '''<u>C</u>'''yclophosphamide, '''<u>N</u>'''ovantrone (Mitoxantrone), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisolone
+
|0
−
<br>MCOP: '''<u>M</u>'''itoxantrone, '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisolone
+
|25
−
<div class="toccolours" style="background-color:#eeeeee">
+
|21
−
===Regimen {{#subobject:85jbab|Variant=1}}===
+
|1
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1093/annonc/mdg067 Bessell et al. 2003 (CLG NH 3003)]
+
|Akdas
−
|1993-2000
+
|Atif
−
|style="background-color:#1a9851"|Phase 3 (E-switch-ic)
+
|MALE
−
|[[#CHOP_Modified_.28Prednisolone.29|Modified CHOP]]
+
|
−
|style="background-color:#d3d3d3"|Not designed to look at efficacy
+
|
 +
|
 +
|Turkey
 +
|1997
 +
|2009
 +
|EORTC
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|15
 +
|15
 +
|1
 
|-
 
|-
−
|}
+
|Aker
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Memet
−
====Chemotherapy====
+
|MALE
−
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Mitoxantrone (Novantrone)]] 10 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 1 mg IV once on day 1
+
|
−
====Glucocorticoid therapy====
+
|
−
*[[Prednisolone (Millipred)]] 20 mg PO twice per day on days 1 to 5
+
|1998
−
'''21-day cycle for 6 cycles'''
+
|1998
−
</div></div>
+
|
−
===References===
+
|
−
# '''CLG NH 3003:''' Bessell EM, Burton A, Haynes AP, Glaholm J, Child JA, Cullen MH, Davies JM, Smith GM, Ellis IO, Jack A, Jones EL; Central Lymphoma Group UK. A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2003 Feb;14(2):258-67. [https://doi.org/10.1093/annonc/mdg067 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/12562653 PubMed] NCT00002576
+
|Allogeneic HSCT; Chronic lymphocytic leukemia
−
==COMP {{#subobject:97155c|Regimen=1}}==
+
|1
−
COMP: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>M</u>'''ethotrexate, '''<u>P</u>'''rednisone
+
|0
−
<div class="toccolours" style="background-color:#eeeeee">
+
|0
−
===Regimen {{#subobject:a2c727|Variant=1}}===
+
|0
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|14
−
!style="width: 20%"|Study
+
|14
−
!style="width: 20%"|Years of enrollment
+
|1
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1056/NEJM198303103081003 Anderson et al. 1983]
+
|Akerley
−
|1977-1979
+
|Wallace
−
|style="background-color:#1a9851"|Phase 3 (E-de-esc)
+
|MALE
−
|[[#LSA2-L2_88|LSA<sub>2</sub>-L<sub>2</sub>]]
+
|
−
|style="background-color:#ffffbf"|Did not meet primary endpoint of FFS
+
|
 +
|
 +
|USA
 +
|1998
 +
|2016
 +
|CALGB
 +
|
 +
|Melanoma; Non-small cell lung cancer; Small cell lung cancer
 +
|4
 +
|0
 +
|4
 +
|1
 +
|74
 +
|72
 +
|1
 
|-
 
|-
−
|}
+
|Akerman
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Maans
−
====Chemotherapy====
+
|MALE
−
*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 2 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 3, 10, 17, 24
+
|
−
*[[Methotrexate (MTX)]] 180 mg/m<sup>2</sup> IV push, then 120 mg/m<sup>2</sup> IV over 4 hours once on day 12
+
|
−
====Glucocorticoid therapy====
+
|
−
*[[Prednisone (Sterapred)]] 15 mg/m<sup>2</sup> (maximum dose of 60 mg/day) PO four times per day on days 3 to 30, then taper off on days 31 to 37
+
|1989
−
====CNS therapy, prophylaxis====
+
|2008
−
*[[Methotrexate (MTX)]] 6.25 mg/m<sup>2</sup> IT once per day on days 5, 31, 34
+
|Nordic Lymphoma Group
−
'''One course'''
+
|
−
</div>
+
|Autologous HSCT; Diffuse large B-cell lymphoma; Mantle cell lymphoma
−
<div class="toccolours" style="background-color:#cbd5e7">
+
|2
−
====Subsequent treatment====
+
|1
−
*[[#COMP_88|COMP]] maintenance
+
|1
−
</div></div>
+
|0
−
===References===
+
|30
−
# Anderson JR, Wilson JF, Jenkin DT, Meadows AT, Kersey J, Chilcote RR, Coccia P, Exelby P, Kushner J, Siegel S, Hammond D. Childhood non-Hodgkin's lymphoma: the results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med. 1983 Mar 10;308(10):559-65. [https://doi.org/10.1056/NEJM198303103081003 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/6338381 PubMed]
+
|28
−
==COP-Bleo {{#subobject:303d31|Regimen=1}}==
+
|1
−
COP-Bleo: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone, '''<u>Bleo</u>'''mycin
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:241a27|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://pubmed.ncbi.nlm.nih.gov/71206 Coltman et al. 1977]
+
|Akewanlop
−
|1966-1974
+
|Charuwan
−
| style="background-color:#91cf61" |Non-randomized
+
|FEMALE
−
| style="background-color:#d3d3d3" |
+
|
−
| style="background-color:#d3d3d3" |
+
|
 +
|
 +
|Thailand
 +
|2015
 +
|2020
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|1
 +
|23
 +
|23
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1002/1097-0142%28197902%2943%3A2%3C417%3A%3AAID-CNCR2820430203%3E3.0.CO%3B2-I Jones et al. 1979]
+
|Akhter
−
|1974-1977
+
|Chameli
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|Not yet determined
−
|1. [[#CHOP-BCG|CHOP-BCG]]<br>2. [[#CHOP-B|CHOP-B]]
+
|
−
| style="background-color:#fee08b" |Might have inferior CR rate
+
|
 +
|
 +
|Bangladesh
 +
|2004
 +
|2016
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|29
 +
|29
 +
|1
 
|-
 
|-
−
|}
+
|Akilov
−
''Note: to our knowledge, this regimen was not tested as an experimental arm in a RCT prior to becoming a standard comparator arm.''
+
|Oleg E
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|MALE
−
====Chemotherapy====
+
|
−
*[[Cyclophosphamide (Cytoxan)]]
+
|
−
*[[Vincristine (Oncovin)]]
+
|
−
*[[Bleomycin (Blenoxane)]]
+
|USA
−
====Glucocorticoid therapy====
+
|2012
−
*[[Prednisone (Sterapred)]]
+
|2021
−
</div></div>
+
|
−
===References===
+
|
−
# Coltman CA Jr, Luce JK, McKelvey EM, Jones SE, Moon TE; [[Study_Groups#SWOG|SWOG]]. Chemotherapy of non-Hodgkin's lymphoma: 10 years' experience in the Southwest Oncology Group. Cancer Treat Rep. 1977 Sep;61(6):1067-78. [https://pubmed.ncbi.nlm.nih.gov/71206 Pubmed]
+
|Cutaneous T-cell lymphoma
−
# Jones SE, Grozea PN, Metz EN, Haut A, Stephens RL, Morrison FS, Butler JJ, Byrne GE Jr, Moon TE, Fisher R, Haskins CL, Coltman CA Jr; [[Study_Groups#SWOG|SWOG]]. Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma: a Southwest Oncology Group study. Cancer. 1979 Feb;43(2):417-25. [https://doi.org/10.1002/1097-0142%28197902%2943%3A2%3C417%3A%3AAID-CNCR2820430203%3E3.0.CO%3B2-I link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/84706 PubMed]
+
|2
−
## '''Update:''' Jones SE, Grozea PN, Metz EN, Haut A, Stephens RL, Morrison FS, Talley R, Butler JJ, Byrne GE Jr, Hartsock R, Dixon D, Salmon SE. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy: a Southwest Oncology Group Study. Cancer. 1983 Mar 15;51(6):1083-90. [https://doi.org/10.1002/1097-0142(19830315)51:6%3C1083::aid-cncr2820510619%3E3.0.co;2-m link to original article] [https://pubmed.ncbi.nlm.nih.gov/6185212 PubMed]
+
|0
−
==CVP {{#subobject:236441|Regimen=1}}==
+
|1
−
CVP: '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''incristine, '''<u>P</u>'''rednisone
+
|1
−
<br>COP:  '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
+
|57
−
<br>VCP: '''<u>V</u>'''incristine, '''<u>C</u>'''yclophosphamide, '''<u>P</u>'''rednisone
+
|37
−
<div class="toccolours" style="background-color:#eeeeee">
+
|1
−
===Regimen {{#subobject:527252|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[http://www.bloodjournal.org/content/33/2/370.short Hoogstraten et al. 1969]
+
|Akimasa
−
|NR
+
|Nakao
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
+
|UNMATCHED
−
|Cyclophosphamide
+
|
−
| style="background-color:#1a9850" |Superior CR rate
+
|
 +
|
 +
|
 +
|2003
 +
|2007
 +
|Chubu Clinical Cancer Group
 +
|
 +
|Gastric cancer
 +
|1
 +
|1
 +
|0
 +
|0
 +
|12
 +
|12
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.7326/0003-4819-76-2-227 Bagley et al. 1972]
+
|Akimov
−
|1967-1970
+
|Mikhail
−
|style="background-color:#91cf61"|Phase 2
+
|MALE
−
|style="background-color:#d3d3d3"|
+
|
−
|style="background-color:#d3d3d3"|
+
|
 +
|
 +
|Switzerland
 +
|2020
 +
|2020
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|0
 +
|0
 +
|1
 +
|31
 +
|31
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1002/1097-0142(197611)38:5%3C1896::AID-CNCR2820380505%3E3.0.CO;2-Z Benjamin et al. 1976]
+
|Akin
−
|1970-1973
+
|Cem
−
|style="background-color:#91cf61"|Randomized, <20 pts (E-de-esc)
+
|MALE
−
|[[#MOPP_88|MOPP]]
+
|
−
|style="background-color:#d3d3d3"|Not reported
+
|
 +
|
 +
|USA
 +
|2003
 +
|2016
 +
|
 +
|
 +
|Hypereosinophilic syndrome; Systemic mastocytosis
 +
|3
 +
|0
 +
|0
 +
|1
 +
|34
 +
|34
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1002/mpo.2950030110 Monfardini et al. 1977]
+
|Akinaga
−
|1972-1974
+
|Shiro
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|MALE
−
|[[#ABP|ABP]]
+
|
−
|style="background-color:#ffffbf"|Did not meet endpoint of ORR
+
|
 +
|
 +
|Japan
 +
|2010
 +
|2015
 +
|
 +
|
 +
|Adult T-cell leukemia-lymphoma; CNS leukemia; Cutaneous T-cell lymphoma; Non-small cell lung cancer; Peripheral T-cell lymphoma
 +
|3
 +
|0
 +
|1
 +
|0
 +
|54
 +
|47
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1016/0360-3016(88)90340-9 Bajetta et al. 1988]
+
|Akita
−
|1976-1984
+
|Hirotoshi
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|MALE
−
|[[#CHOP-B|BACOP]]
+
|
−
|style="background-color:#fc8d59"|Seems to have inferior FFFP
+
|
 +
|
 +
|
 +
|1992
 +
|1992
 +
|
 +
|
 +
|Small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|10
 +
|10
 +
|1
 
|-
 
|-
−
|}
+
|Akiya
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Toshikazu
−
====Chemotherapy====
+
|MALE
−
*[[Cyclophosphamide (Cytoxan)]] 1000 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
+
|
−
====Glucocorticoid therapy====
+
|
−
*[[Prednisone (Sterapred)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 5
+
|
−
'''21-day cycles'''
+
|2002
−
</div></div>
+
|2008
−
===References===
+
|
−
# Hoogstraten B, Owens AH, Lenhard RE, Glidewell OJ, Leone LA, Olson KB, Harley JB, Townsend SR, Miller S, Spurr CL. Combination chemotherapy in lymphosarcoma and reticulum cell sarcoma. Blood. 1969 Feb;33(2):370-8. [http://www.bloodjournal.org/content/33/2/370.short link to original article] [https://pubmed.ncbi.nlm.nih.gov/4886120 PubMed]
+
|
−
# Bagley CM Jr, Devita VT Jr, Berard CW, Canellos GP. Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann Intern Med. 1972 Feb;76(2):227-34. [https://doi.org/10.7326/0003-4819-76-2-227 link to original article] [https://pubmed.ncbi.nlm.nih.gov/5066691 PubMed]
+
|Gastric cancer
−
# Benjamin RS, Wiernik PH, O'Connell MJ, Chang P, Sutherland JC. A comparison of cyclophosphamide, vincristine, and prednisone (COP) with nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP) in the treatment of nodular, poorly differentiated, lymphocytic lymphoma. Cancer. 1976 Nov;38(5):1896-902. [https://doi.org/10.1002/1097-0142(197611)38:5%3C1896::AID-CNCR2820380505%3E3.0.CO;2-Z link to original article] [https://pubmed.ncbi.nlm.nih.gov/1036467 PubMed]
+
|1
−
# Monfardini S, Tancini G, De Lena M, Villa E, Valagussa P, Bonadonna G. Cyclophosphamide, vincristine, and prednisone (CVP) versus adriamycin, bleomycin, and prednisone (ABP) in stage IV non-Hodgkin's lymphomas. Med Pediatr Oncol. 1977;3(1):67-74. [https://doi.org/10.1002/mpo.2950030110 link to original article] [https://pubmed.ncbi.nlm.nih.gov/65728 PubMed]
+
|0
−
# Bajetta E, Valagussa P, Bonadonna G, Lattuada A, Buzzoni R, Rilke F, Banfi A. Combined modality treatment for stage I-II non-Hodgkin's lymphomas: CVP versus BACOP chemotherapy. Int J Radiat Oncol Biol Phys. 1988 Jul;15(1):3-12. [https://doi.org/10.1016/0360-3016(88)90340-9 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2455701 PubMed]
+
|1
−
==DA-EPOCH {{#subobject:9b4e41|Regimen=1}}==
+
|0
−
DA-EPOCH: '''<u>D</u>'''ose '''<u>A</u>'''djusted '''<u>E</u>'''toposide, '''<u>P</u>'''rednisone, '''<u>O</u>'''ncovin (Vincristine), '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin)
+
|16
−
<div class="toccolours" style="background-color:#eeeeee">
+
|16
−
===Regimen {{#subobject:263b57|Variant=1}}===
+
|1
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[http://www.bloodjournal.org/content/99/8/2685.long Wilson et al. 2002]
+
|Akiyama
−
|1993-1999
+
|Hideki
−
|style="background-color:#91cf61"|Phase 2
+
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1993
 +
|2013
 +
|JALSG
 +
|
 +
|B-cell acute lymphoblastic leukemia; Chronic myeloid leukemia
 +
|2
 +
|0
 +
|1
 +
|1
 +
|35
 +
|35
 +
|1
 
|-
 
|-
−
|}
+
|Akiyoshi
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Kohei
−
====Chemotherapy====
+
|Not yet determined
−
*[[Etoposide (Vepesid)]] 50 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 200 mg/m<sup>2</sup>)
+
|
−
*[[Vincristine (Oncovin)]] 0.4 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 1.6 mg/m<sup>2</sup>)
+
|
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV over 15 minutes once on day 5
+
|
−
*[[Doxorubicin (Adriamycin)]] 10 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 40 mg/m<sup>2</sup>)
+
|Japan
−
====Glucocorticoid therapy====
+
|2019
−
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO twice per day on days 1 to 5
+
|2019
−
====Supportive therapy====
+
|
−
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting on day 6 and continuing until ANC greater than 5000/uL past nadir
+
|
−
*PCP prophylaxis with ONE of the following:
+
|Carcinoma of unknown primary
−
**[[Trimethoprim-Sulfamethoxazole (Bactrim DS)]] 160/800 mg PO twice per day 3 days per week
+
|1
−
**[[Atovaquone (Mepron)]] 1500 mg PO once per day
+
|0
−
**[[Pentamidine (Nebupent)]] 300 mg nebulized every 28 days
+
|0
−
'''21-day cycle for 6 to 8 cycles'''
+
|0
−
====Dose modifications====
+
|20
−
*Start cycle 1 as described above.
+
|20
−
*Obtain CBCs twice per week for nadir measurements.
+
|1
−
*If nadir ANC greater than 500/uL, increase etoposide, doxorubicin, and cyclophosphamide by 20% compared to previous cycle.
 
−
*If nadir ANC less than 500/uL on 1 or 2 measurements, use same doses as last cycle.
 
−
*If nadir ANC less than 500/uL on at least 3 measurements, decrease etoposide, doxorubicin, and cyclophosphamide by 20% compared to previous cycle.
 
−
*And/or if nadir platelet count less than 25 x 10<sup>9</sup>/L on at least 1 measurement, decrease etoposide, doxorubicin, and cyclophosphamide by 20% compared to previous cycle.
 
−
*'''Dose adjustments below the cycle 1 starting dose only applies to cyclophosphamide.'''  The lowest etoposide and doxorubicin would be dosed at is the original cycle 1 dose.
 
−
*Can start new cycle every 21 days if ANC greater than 1000/uL and platelets greater than 100 x 10<sup>9</sup>/L.  If counts are below those levels, check daily CBC and continue growth factor support until counts are adequate and next cycle can start.
 
−
</div></div>
 
−
===References===
 
−
# Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002 Apr 15;99(8):2685-93. [http://www.bloodjournal.org/content/99/8/2685.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/11929754 PubMed]
 
−
==DICEP {{#subobject:b2b482|Regimen=1}}==
 
−
DICEP: '''<u>D</u>'''ose '''<u>I</u>'''ntensive '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''toposide, '''<u>P</u>'''latinol (Cisplatin)
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:aa3d2e|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[http://www.bloodjournal.org/content/107/12/4623.long Stewart et al. 2006]
+
|Akkermans Vogelaar
−
|1998-2004
+
|Janine M
−
|style="background-color:#91cf61"|Phase 2
+
|FEMALE
 +
|
 +
|
 +
|
 +
|Netherlands
 +
|2013
 +
|2022
 +
|Dutch Pancreatic Cancer Group
 +
|
 +
|Pancreatic cancer
 +
|2
 +
|0
 +
|1
 +
|0
 +
|60
 +
|31
 +
|1
 +
|-
 +
|Akopov
 +
|Audrey
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Russian Federation
 +
|2015
 +
|2021
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|1
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Akpek
 +
|Gorgun
 +
|UNMATCHED
 +
|
 +
|
 +
|
 +
|USA
 +
|2016
 +
|2016
 +
|BMT CTN
 +
|
 +
|Autologous HSCT; HIV-associated lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|21
 +
|21
 +
|1
 +
|-
 +
|Akram Hussain
 +
|Syed Md
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Bangladesh
 +
|2004
 +
|2016
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|29
 +
|29
 +
|1
 +
|-
 +
|Akram
 +
|Muhammed
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2018
 +
|2021
 +
|
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|0
 +
|1
 +
|35
 +
|35
 +
|1
 +
|-
 +
|Aksnes
 +
|Anne Kirsti
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Norway
 +
|2008
 +
|2014
 +
|
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|1
 +
|1
 +
|12
 +
|12
 +
|1
 +
|-
 +
|Aktan
 +
|Gursel
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2005
 +
|2022
 +
|NeoALTTO Study Team
 +
|
 +
|Breast cancer
 +
|6
 +
|0
 +
|5
 +
|2
 +
|123
 +
|95
 +
|1
 +
|-
 +
|Aktan
 +
|Melih
 +
|MALE
 +
|
 +
|
 +
|
 +
|Turkey
 +
|2010
 +
|2018
 +
|
 +
|
 +
|Chronic lymphocytic leukemia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|16
 +
|16
 +
|1
 +
|-
 +
|Aktas
 +
|Bahriye
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Germany
 +
|2000
 +
|2019
 +
|GBG
 +
|
 +
|Breast cancer
 +
|7
 +
|0
 +
|5
 +
|0
 +
|144
 +
|87
 +
|1
 +
|-
 +
|Akusawa
 +
|Hiroshi
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1987
 +
|1996
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|7
 +
|7
 +
|1
 +
|-
 +
|Al Akash
 +
|Samhar I
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|USA
 +
|2016
 +
|2016
 +
|
 +
|
 +
|Atypical hemolytic uremic syndrome
 +
|1
 +
|0
 +
|0
 +
|0
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Al Ali
 +
|Haifa Kathrin
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Germany
 +
|1997
 +
|2017
 +
|OSHO
 +
|
 +
|Acute myeloid leukemia; Allogeneic HSCT; Autologous HSCT; Chronic lymphocytic leukemia; CNS lymphoma; Follicular lymphoma; Myelofibrosis
 +
|10
 +
|1
 +
|5
 +
|1
 +
|165
 +
|117
 +
|1
 +
|-
 +
|Al Batran
 +
|Salah Eddin
 +
|MALE
 +
|
 +
|
 +
|
 +
|Germany
 +
|2000
 +
|2020
 +
|AIO
 +
|
 +
|Breast cancer; Colorectal cancer; Esophageal adenocarcinoma; Esophageal squamous cell carcinoma; Follicular lymphoma; Gastric cancer; Gastrointestinal stromal tumor; Mantle cell lymphoma; Marginal zone lymphoma; MSI-H or dMMR; Waldenstroem macroglobulinemia
 +
|19
 +
|6
 +
|10
 +
|2
 +
|415
 +
|280
 +
|1
 +
|-
 +
|Al Booz
 +
|Hoda
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2012
 +
|2018
 +
|De-ESCALaTE HPV Trial Group
 +
|
 +
|Oropharyngeal cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|30
 +
|30
 +
|1
 +
|-
 +
|Al Dewik
 +
|Nader
 +
|MALE
 +
|
 +
|
 +
|
 +
|Qatar
 +
|2015
 +
|2015
 +
|
 +
|
 +
|Essential thrombocythemia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|13
 +
|13
 +
|1
 +
|-
 +
|Al Fayoumi
 +
|Suliman
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2014
 +
|2018
 +
|
 +
|
 +
|Myelofibrosis
 +
|1
 +
|0
 +
|1
 +
|1
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Al Ghuzlan
 +
|Abir
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|France
 +
|2013
 +
|2022
 +
|
 +
|
 +
|Thyroid cancer differentiated
 +
|1
 +
|0
 +
|1
 +
|0
 +
|33
 +
|33
 +
|1
 +
|-
 +
|Al Kali
 +
|Aref
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2010
 +
|2016
 +
|
 +
|
 +
|Myelodysplastic syndrome
 +
|1
 +
|0
 +
|1
 +
|0
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Al Kateb
 +
|Hussam
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|USA
 +
|2013
 +
|2017
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|33
 +
|33
 +
|1
 +
|-
 +
|Al Rajabi
 +
|Raed
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2015
 +
|2020
 +
|
 +
|
 +
|Cholangiocarcinoma; Esophageal cancer; Esophageal squamous cell carcinoma
 +
|2
 +
|0
 +
|1
 +
|2
 +
|44
 +
|44
 +
|1
 +
|-
 +
|Al Sakaff
 +
|Nedal
 +
|MALE
 +
|
 +
|
 +
|
 +
|Switzerland
 +
|2001
 +
|2019
 +
|Herceptin Adjuvant (HERA) Trial Study Team
 +
|
 +
|Breast cancer
 +
|2
 +
|0
 +
|2
 +
|2
 +
|26
 +
|25
 +
|1
 +
|-
 +
|al Sarraf
 +
|Muhyi
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1977
 +
|1999
 +
|Radiation Therapy Oncology Group; RTOG; SWOG
 +
|
 +
|Esophageal cancer; Glioblastoma; Melanoma; Nasopharyngeal carcinoma; Prostate cancer
 +
|7
 +
|2
 +
|6
 +
|1
 +
|70
 +
|53
 +
|1
 +
|-
 +
|Al Sawaf
 +
|Othman
 +
|MALE
 +
|
 +
|
 +
|
 +
|Germany
 +
|2005
 +
|2022
 +
|GCLLSG
 +
|
 +
|Chronic lymphocytic leukemia
 +
|6
 +
|2
 +
|4
 +
|1
 +
|148
 +
|80
 +
|1
 +
|-
 +
|Al Shukri
 +
|Salman
 +
|MALE
 +
|
 +
|
 +
|
 +
|Russian Federation
 +
|2010
 +
|2016
 +
|
 +
|
 +
|Renal cell carcinoma
 +
|2
 +
|0
 +
|1
 +
|0
 +
|17
 +
|11
 +
|1
 +
|-
 +
|Al Toubah
 +
|Taymeyah E
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|USA
 +
|2016
 +
|2020
 +
|
 +
|
 +
|Cholangiocarcinoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|10
 +
|10
 +
|1
 +
|-
 +
|Al Tweigeri
 +
|Taher
 +
|MALE
 +
|
 +
|
 +
|
 +
|Canada
 +
|1997
 +
|2005
 +
|BCIRG
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|1
 +
|31
 +
|31
 +
|1
 +
|-
 +
|Al Zoubi
 +
|Ammar
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2005
 +
|2012
 +
|
 +
|
 +
|Multiple myeloma
 +
|2
 +
|0
 +
|0
 +
|0
 +
|28
 +
|25
 +
|1
 +
|-
 +
|Alabiso
 +
|O
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|2007
 +
|2007
 +
|
 +
|
 +
|Malignant pleural mesothelioma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Alakel
 +
|N
 +
|CBD
 +
|
 +
|
 +
|
 +
|Germany
 +
|2012
 +
|2015
 +
|
 +
|
 +
|Acute myeloid leukemia; Allogeneic HSCT
 +
|1
 +
|0
 +
|0
 +
|0
 +
|25
 +
|25
 +
|1
 +
|-
 +
|Alakl
 +
|May
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|France
 +
|1994
 +
|2010
 +
|EORTC
 +
|
 +
|Breast cancer; Colorectal cancer; Light-chain (AL) amyloidosis
 +
|5
 +
|0
 +
|3
 +
|3
 +
|82
 +
|81
 +
|1
 +
|-
 +
|Alam
 +
|A
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|2005
 +
|2005
 +
|
 +
|
 +
|Follicular lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Alam
 +
|Rafeul
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2001
 +
|2003
 +
|
 +
|
 +
|Hypereosinophilic syndrome
 +
|1
 +
|0
 +
|0
 +
|0
 +
|25
 +
|25
 +
|1
 +
|-
 +
|Alam
 +
|Yasmin
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2006
 +
|2012
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|3
 +
|0
 +
|1
 +
|0
 +
|70
 +
|47
 +
|1
 +
|-
 +
|Alama
 +
|A
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|1983
 +
|1987
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|15
 +
|15
 +
|1
 +
|-
 +
|Alamoudi
 +
|Sameer
 +
|MALE
 +
|
 +
|
 +
|
 +
|Canada
 +
|2003
 +
|2015
 +
|NCIC-CTG
 +
|
 +
|Transformed lymphoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Alamouti
 +
|Sepideh
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Canada
 +
|2010
 +
|2016
 +
|
 +
|
 +
|Diffuse large B-cell lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|23
 +
|23
 +
|1
 +
|-
 +
|Alanko
 +
|Tuomo
 +
|MALE
 +
|
 +
|
 +
|
 +
|Finland
 +
|2000
 +
|2009
 +
|
 +
|
 +
|Breast cancer
 +
|3
 +
|0
 +
|2
 +
|0
 +
|56
 +
|34
 +
|1
 +
|-
 +
|Alao
 +
|Hawwa
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|USA
 +
|2014
 +
|2019
 +
|
 +
|
 +
|Hypereosinophilic syndrome
 +
|1
 +
|0
 +
|0
 +
|0
 +
|24
 +
|24
 +
|1
 +
|-
 +
|Alapi
 +
|Krisztina Zuborne
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2012
 +
|2022
 +
|
 +
|
 +
|B-cell acute lymphoblastic leukemia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|25
 +
|25
 +
|1
 +
|-
 +
|Alarcon
 +
|Jesus
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2007
 +
|2007
 +
|
 +
|
 +
|Diffuse large B-cell lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|9
 +
|9
 +
|1
 +
|-
 +
|Alashkar
 +
|Ferras
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Germany
 +
|2021
 +
|2021
 +
|
 +
|
 +
|Paroxysmal nocturnal hemoglobinuria
 +
|1
 +
|0
 +
|0
 +
|0
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Alatorre Alexander
 +
|Jorge
 +
|MALE
 +
|
 +
|
 +
|
 +
|Mexico
 +
|2016
 +
|2021
 +
|
 +
|
 +
|Small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|1
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Alattar
 +
|Mona Lisa
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2011
 +
|2013
 +
|
 +
|
 +
|Acute myeloid leukemia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Alavi
 +
|Jane
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2003
 +
|2003
 +
|
 +
|
 +
|CNS lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|7
 +
|7
 +
|1
 +
|-
 +
|Alba
 +
|Emilio
 +
|MALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|1995
 +
|2021
 +
|GEICAM
 +
|
 +
|Breast cancer
 +
|13
 +
|3
 +
|12
 +
|1
 +
|280
 +
|186
 +
|1
 +
|-
 +
|Albain
 +
|Kathy S
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1989
 +
|2021
 +
|Breast Cancer Intergroup of North America; NCIC-CTG; NSABP; RTOG; SWOG
 +
|
 +
|Breast cancer; Non-small cell lung cancer
 +
|19
 +
|4
 +
|12
 +
|3
 +
|361
 +
|250
 +
|1
 +
|-
 +
|Albala
 +
|Maurice M
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1968
 +
|1968
 +
|
 +
|
 +
|Head and neck cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|2
 +
|2
 +
|1
 +
|-
 +
|Albanell
 +
|Juan
 +
|MALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|1987
 +
|2014
 +
|GEICAM
 +
|
 +
|Breast cancer
 +
|3
 +
|0
 +
|2
 +
|0
 +
|38
 +
|38
 +
|1
 +
|-
 +
|Albano
 +
|Edythe
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2002
 +
|2006
 +
|
 +
|
 +
|B-cell acute lymphoblastic leukemia pediatric
 +
|1
 +
|0
 +
|0
 +
|1
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Albano
 +
|Francesco
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2004
 +
|2019
 +
|GIMEMA
 +
|
 +
|Acute promyelocytic leukemia; Chronic myeloid leukemia
 +
|3
 +
|0
 +
|3
 +
|1
 +
|113
 +
|69
 +
|1
 +
|-
 +
|Alberici
 +
|Federico
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|1994
 +
|2015
 +
|GOIRC; POLAR-01 Trial Investigators
 +
|
 +
|Erdheim-Chester disease; Renal cell carcinoma
 +
|2
 +
|0
 +
|1
 +
|0
 +
|34
 +
|32
 +
|1
 +
|-
 +
|Alberola
 +
|Vincente
 +
|MALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|1989
 +
|2012
 +
|Spanish Lung Cancer Group
 +
|
 +
|Non-small cell lung cancer; Non-small cell lung cancer nonsquamous
 +
|6
 +
|1
 +
|6
 +
|2
 +
|109
 +
|85
 +
|1
 +
|-
 +
|Albers
 +
|Gregory W
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2018
 +
|2018
 +
|
 +
|
 +
|Venous thromboembolism
 +
|1
 +
|0
 +
|1
 +
|0
 +
|12
 +
|12
 +
|1
 +
|-
 +
|Albers
 +
|Mary E
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1990
 +
|1998
 +
|
 +
|
 +
|Head and neck cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|8
 +
|8
 +
|1
 +
|-
 +
|Albers
 +
|Peter
 +
|MALE
 +
|
 +
|
 +
|
 +
|Germany
 +
|1994
 +
|2021
 +
|AUO; EORTC; German Association of Urologic Oncology; Groupe d'Etude des Tumeurs Urogenitales; National Cancer Institute of Canada Clinical Trials Group; National Cancer Research Institute Bladder Cancer Study Group
 +
|
 +
|Bladder cancer; Prostate cancer; Testicular cancer
 +
|9
 +
|3
 +
|8
 +
|0
 +
|156
 +
|127
 +
|1
 +
|-
 +
|Albert
 +
|Catherine M
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2015
 +
|2020
 +
|
 +
|
 +
|NTRK
 +
|1
 +
|0
 +
|0
 +
|3
 +
|28
 +
|28
 +
|1
 +
|-
 +
|Albert
 +
|Donald
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2002
 +
|2008
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|7
 +
|7
 +
|1
 +
|-
 +
|Albert
 +
|Istvan
 +
|MALE
 +
|
 +
|
 +
|
 +
|Hungary
 +
|2006
 +
|2019
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|4
 +
|0
 +
|4
 +
|1
 +
|74
 +
|64
 +
|1
 +
|-
 +
|Albert
 +
|Michael H
 +
|MALE
 +
|
 +
|
 +
|
 +
|Germany
 +
|2003
 +
|2015
 +
|
 +
|
 +
|Allogeneic HSCT; B-cell acute lymphoblastic leukemia pediatric; T-cell acute lymphoblastic leukemia pediatric
 +
|1
 +
|0
 +
|0
 +
|0
 +
|22
 +
|22
 +
|1
 +
|-
 +
|Albert
 +
|Paul S
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2006
 +
|2008
 +
|
 +
|
 +
|Glioblastoma
 +
|1
 +
|0
 +
|0
 +
|1
 +
|12
 +
|12
 +
|1
 +
|-
 +
|Albert
 +
|Ute Susann
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1998
 +
|2009
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Alberti
 +
|Daniele
 +
|UNMATCHED
 +
|
 +
|
 +
|
 +
|
 +
|1996
 +
|2002
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|9
 +
|9
 +
|1
 +
|-
 +
|Albertini
 +
|Mark R
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1998
 +
|2019
 +
|ECOG
 +
|
 +
|Melanoma; Uveal melanoma
 +
|3
 +
|0
 +
|2
 +
|0
 +
|67
 +
|58
 +
|1
 +
|-
 +
|Alberto
 +
|Pierre
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1979
 +
|1994
 +
|SAKK
 +
|
 +
|Breast cancer
 +
|2
 +
|1
 +
|2
 +
|0
 +
|22
 +
|19
 +
|1
 +
|-
 +
|Alberts
 +
|David S
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1974
 +
|2019
 +
|GOG; GRACES Clinical Trial Consortium; Gynecologic Cancer Intergroup; SWOG
 +
|
 +
|Cervical cancer; Multiple myeloma; Ovarian cancer
 +
|16
 +
|13
 +
|11
 +
|1
 +
|144
 +
|105
 +
|1
 +
|-
 +
|Alberts
 +
|Steven R
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1997
 +
|2017
 +
|CALGB; ECOG; NCCTG; SWOG
 +
|
 +
|Cholangiocarcinoma; Colon cancer; Colorectal cancer; Gallbladder cancer; Gastric cancer; Pancreatic cancer
 +
|10
 +
|2
 +
|8
 +
|2
 +
|121
 +
|97
 +
|1
 +
|-
 +
|Albertsen
 +
|Birgitte Klug
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Denmark
 +
|2008
 +
|2019
 +
|
 +
|
 +
|B-cell acute lymphoblastic leukemia pediatric
 +
|1
 +
|1
 +
|1
 +
|0
 +
|9
 +
|9
 +
|1
 +
|-
 +
|Albertson
 +
|Tina M
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2016
 +
|2020
 +
|
 +
|
 +
|Diffuse large B-cell lymphoma; Primary mediastinal B-cell lymphoma; Transformed lymphoma
 +
|1
 +
|0
 +
|0
 +
|1
 +
|21
 +
|21
 +
|1
 +
|-
 +
|Albertsson
 +
|Maria
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Sweden
 +
|1991
 +
|2015
 +
|Nordic Gastrointestinal Tumour Adjuvant Therapy Group
 +
|
 +
|Colon cancer; Colorectal cancer; Esophageal cancer; Esophageal squamous cell carcinoma
 +
|4
 +
|1
 +
|3
 +
|0
 +
|34
 +
|30
 +
|1
 +
|-
 +
|Albiges
 +
|Laurence
 +
|MALE
 +
|
 +
|
 +
|
 +
|France; USA
 +
|2004
 +
|2022
 +
|GETUG
 +
|
 +
|Non-clear cell renal cell carcinoma; Papillary renal cell carcinoma; Prostate cancer; Renal cell carcinoma
 +
|9
 +
|3
 +
|7
 +
|2
 +
|187
 +
|143
 +
|1
 +
|-
 +
|Albitar
 +
|Maher
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1998
 +
|2009
 +
|
 +
|
 +
|Acute myeloid leukemia; B-cell acute lymphoblastic leukemia; Chronic lymphocytic leukemia; Chronic myeloid leukemia; CNS leukemia; Hypereosinophilic syndrome; Myelodysplastic syndrome; Systemic mastocytosis
 +
|7
 +
|0
 +
|2
 +
|3
 +
|98
 +
|74
 +
|1
 +
|-
 +
|Albo
 +
|Vincent C
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1988
 +
|1988
 +
|CCG
 +
|
 +
|T-cell acute lymphoblastic leukemia pediatric
 +
|1
 +
|0
 +
|0
 +
|0
 +
|11
 +
|11
 +
|1
 +
|-
 +
|Albright
 +
|A L
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|
 +
|1999
 +
|1999
 +
|CCG
 +
|
 +
|Medulloblastoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|15
 +
|15
 +
|1
 +
|-
 +
|Albright
 +
|Robert E
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1999
 +
|2000
 +
|Temodal Brain Tumor Group
 +
|
 +
|Anaplastic glioma; Glioblastoma
 +
|2
 +
|0
 +
|0
 +
|1
 +
|36
 +
|27
 +
|1
 +
|-
 +
|Albritton
 +
|Karen
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2004
 +
|2004
 +
|
 +
|
 +
|Ewing sarcoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|9
 +
|9
 +
|1
 +
|-
 +
|Albuquerque
 +
|Marco
 +
|MALE
 +
|
 +
|
 +
|
 +
|Canada
 +
|2010
 +
|2016
 +
|
 +
|
 +
|Diffuse large B-cell lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|23
 +
|23
 +
|1
 +
|-
 +
|Alcaide
 +
|Julia
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|2010
 +
|2018
 +
|TTD
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|26
 +
|26
 +
|1
 +
|-
 +
|Alcaide
 +
|Miguel
 +
|MALE
 +
|
 +
|
 +
|
 +
|Canada
 +
|2010
 +
|2016
 +
|
 +
|
 +
|Diffuse large B-cell lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|23
 +
|23
 +
|1
 +
|-
 +
|Alcaraz
 +
|Antonio
 +
|MALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|2011
 +
|2022
 +
|
 +
|
 +
|Prostate cancer
 +
|3
 +
|0
 +
|2
 +
|1
 +
|50
 +
|38
 +
|1
 +
|-
 +
|Alcedo
 +
|Juan Carlos
 +
|MALE
 +
|
 +
|
 +
|
 +
|Panama
 +
|2002
 +
|2016
 +
|
 +
|
 +
|Breast cancer; Cervical cancer
 +
|2
 +
|0
 +
|3
 +
|0
 +
|26
 +
|26
 +
|1
 +
|-
 +
|Alcindor
 +
|Thierry
 +
|MALE
 +
|
 +
|
 +
|
 +
|Canada
 +
|2003
 +
|2019
 +
|EORTC
 +
|
 +
|Gastric cancer; Liposarcoma; Soft tissue sarcoma; Tenosynovial giant cell tumor
 +
|7
 +
|0
 +
|6
 +
|2
 +
|138
 +
|107
 +
|1
 +
|-
 +
|Aldaoud
 +
|Ali
 +
|MALE
 +
|
 +
|
 +
|
 +
|Germany
 +
|1996
 +
|2017
 +
|European Mantle Cell Lymphoma Network; GCLLSG; GLSG
 +
|
 +
|Autologous HSCT; Chronic lymphocytic leukemia; Follicular lymphoma; Mantle cell lymphoma; Stem cell mobilization
 +
|6
 +
|0
 +
|6
 +
|1
 +
|111
 +
|75
 +
|1
 +
|-
 +
|Aldape
 +
|Kenneth D
 +
|MALE
 +
|
 +
|
 +
|
 +
|Canada; USA
 +
|2002
 +
|2017
 +
|Canadian Brain Tumor Consortium; CENTRIC study team; EORTC; RTOG
 +
|
 +
|Anaplastic glioma; Glioblastoma
 +
|5
 +
|0
 +
|6
 +
|0
 +
|137
 +
|102
 +
|1
 +
|-
 +
|Alderdice
 +
|M
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|1995
 +
|2002
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|16
 +
|16
 +
|1
 +
|-
 +
|Alderete
 +
|Daniel
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1987
 +
|1997
 +
|
 +
|
 +
|Hodgkin lymphoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|9
 +
|9
 +
|1
 +
|-
 +
|Alderson
 +
|Derek
 +
|MALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|1989
 +
|2017
 +
|MRC
 +
|
 +
|Colorectal cancer; Esophageal adenocarcinoma
 +
|3
 +
|1
 +
|4
 +
|0
 +
|42
 +
|33
 +
|1
 +
|-
 +
|Alderuccio
 +
|Juan Pablo
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2018
 +
|2021
 +
|
 +
|
 +
|Diffuse large B-cell lymphoma; Transformed lymphoma
 +
|1
 +
|0
 +
|0
 +
|1
 +
|17
 +
|17
 +
|1
 +
|-
 +
|Aldrighetti
 +
|Daniela
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1996
 +
|2004
 +
|GONO
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Aldrighetti
 +
|Luca
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2000
 +
|2005
 +
|
 +
|
 +
|Pancreatic cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|16
 +
|16
 +
|1
 +
|-
 +
|Aledo
 +
|Alexander
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2002
 +
|2014
 +
|COG
 +
|
 +
|B-cell acute lymphoblastic leukemia pediatric
 +
|2
 +
|0
 +
|0
 +
|1
 +
|37
 +
|20
 +
|1
 +
|-
 +
|Aledort
 +
|Louis M
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1991
 +
|2008
 +
|
 +
|
 +
|Immune thrombocytopenia
 +
|2
 +
|1
 +
|2
 +
|0
 +
|35
 +
|34
 +
|1
 +
|-
 +
|Alegakis
 +
|Athanasios
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2004
 +
|2004
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|1
 +
|1
 +
|0
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Alegre
 +
|Adrian
 +
|MALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|2004
 +
|2021
 +
|GEM; PETHEMA
 +
|
 +
|Multiple myeloma
 +
|8
 +
|0
 +
|3
 +
|2
 +
|199
 +
|112
 +
|1
 +
|-
 +
|Aleinikova
 +
|Olga
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Belarus
 +
|2001
 +
|2020
 +
|EBMT Paediatric Diseases Working Party; I-BFM SCT Study Group; IBFM Study Group; IntReALL Study Group
 +
|
 +
|Acute myeloid leukemia; Acute myeloid leukemia pediatric; Allogeneic HSCT
 +
|2
 +
|0
 +
|3
 +
|0
 +
|49
 +
|49
 +
|1
 +
|-
 +
|Alekar
 +
|Shilpa
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2014
 +
|2014
 +
|
 +
|
 +
|B-cell acute lymphoblastic leukemia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Aleksandrovic
 +
|Jasna
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1991
 +
|2000
 +
|
 +
|
 +
|Head and neck cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|7
 +
|7
 +
|1
 +
|-
 +
|Alekseev
 +
|Boris Yakovlevich
 +
|MALE
 +
|
 +
|
 +
|
 +
|Russian Federation
 +
|2010
 +
|2022
 +
|
 +
|
 +
|Bladder cancer; Non-clear cell renal cell carcinoma; Prostate cancer; Renal cell carcinoma
 +
|22
 +
|0
 +
|15
 +
|8
 +
|482
 +
|310
 +
|1
 +
|-
 +
|Alekseev
 +
|Sergey
 +
|MALE
 +
|
 +
|
 +
|
 +
|Russian Federation
 +
|2012
 +
|2021
 +
|
 +
|
 +
|Hodgkin lymphoma
 +
|3
 +
|0
 +
|1
 +
|1
 +
|79
 +
|38
 +
|1
 +
|-
 +
|Alekseeva
 +
|Yulia
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Russian Federation
 +
|2017
 +
|2022
 +
|
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|27
 +
|27
 +
|1
 +
|-
 +
|Aleman
 +
|Berthe M P
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Netherlands
 +
|1988
 +
|2017
 +
|EORTC; GELA
 +
|
 +
|Hodgkin lymphoma
 +
|3
 +
|1
 +
|5
 +
|0
 +
|75
 +
|56
 +
|1
 +
|-
 +
|Aleman
 +
|Karen
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2012
 +
|2016
 +
|
 +
|
 +
|Kaposi sarcoma
 +
|2
 +
|0
 +
|0
 +
|1
 +
|27
 +
|20
 +
|1
 
|-
 
|-
−
|}
+
|Alencar
−
<div class="toccolours" style="background-color:#cbd5e8">
+
|Alvaro
−
====Preceding treatment====
+
|Not yet determined
−
*[[#CHOP|CHOP]] x 1
+
|
−
</div>
+
|
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|
−
====Chemotherapy====
+
|USA
−
*[[Cyclophosphamide (Cytoxan)]]
+
|2014
−
*[[Etoposide (Vepesid)]]
+
|2019
−
*[[Cisplatin (Platinol)]]
+
|Blood Cancer Research Partnership of the Leukemia and Lymphoma Society
−
</div>
+
|
−
<div class="toccolours" style="background-color:#cbd5e7">
+
|Chronic lymphocytic leukemia
−
====Subsequent treatment====
+
|1
−
*[[#BEAM.2C_then_auto_HSCT_88|BEAM, then auto HSCT]]
+
|0
−
</div></div>
+
|0
−
===References===
+
|0
−
# Stewart DA, Bahlis N, Valentine K, Balogh A, Savoie L, Morris DG, Jones A, Brown C, Russell JA. Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2006 Jun 15;107(12):4623-7. Epub 2006 Feb 7. [http://www.bloodjournal.org/content/107/12/4623.long link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/16467197 PubMed] content property of [http://hemonc.org HemOnc.org]
+
|22
−
==F-MACHOP {{#subobject:425e33|Regimen=1}}==
+
|22
−
F-MACHOP: '''<u>F</u>'''luorouracil, '''<u>M</u>'''ethotrexate, '''<u>A</u>'''ra-C (Cytarabine), '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''redniso(lo)ne
+
|1
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:c378e6|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[https://pubmed.ncbi.nlm.nih.gov/4012340 Amadori et al. 1985]
+
|Alese
−
|NR in abstract
+
|Olatunji B
−
|style="background-color:#91cf61"|Non-randomized
+
|Not yet determined
 +
|
 +
|
 +
|
 +
|USA
 +
|2016
 +
|2020
 +
|
 +
|
 +
|Cholangiocarcinoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|10
 +
|10
 +
|1
 
|-
 
|-
−
|[http://www.haematologica.org/content/81/6/521.long Infanti et al. 1996]
+
|Alessandri
−
|1991-1996
+
|S
−
|style="background-color:#91cf61"|Non-randomized
+
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|1982
 +
|1986
 +
|
 +
|
 +
|Ovarian cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|33
 +
|33
 +
|1
 
|-
 
|-
−
|}
+
|Alessandrino
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Emilio Paolo
−
====Chemotherapy====
+
|MALE
−
*[[Fluorouracil (5-FU)]]
+
|
−
*[[Methotrexate (MTX)]]
+
|
−
*[[Cytarabine (Ara-C)]]
+
|
−
*[[Cyclophosphamide (Cytoxan)]]
+
|Italy
−
*[[Doxorubicin (Adriamycin)]]
+
|1996
−
*[[Vincristine (Oncovin)]]
+
|2015
−
====Glucocorticoid therapy====
+
|
−
*[[Prednisone (Sterapred)]]
+
|
−
</div></div>
+
|Acute myeloid leukemia; Allogeneic HSCT; Multiple myeloma; Stem cell mobilization
−
===References===
+
|3
−
# Amadori S, Guglielmi C, Anselmo AP, Cimino G, Ruco LP, Papa G, Biagini C, Mandelli F. Treatment of diffuse aggressive non-Hodgkin's lymphomas with an intensive multi-drug regimen including high-dose cytosine arabinoside (F-MACHOP). Semin Oncol. 1985 Jun;12(2 Suppl 3):218-22. [https://pubmed.ncbi.nlm.nih.gov/4012340 PubMed]
+
|0
−
## '''Update:''' Guglielmi C, Amadori S, Anselmo AP, Baroni CD, Biagini C, Cimino G, Papa G, Mandelli F. Sequential combination chemotherapy of high-grade non-Hodgkin's lymphoma with 5-fluorouracil, methotrexate, cytosine-arabinoside, cyclophosphamide, doxorubicin, vincristine, and prednisone (F-MACHOP). Cancer Invest. 1987;5(3):159-69. [https://doi.org/10.3109/07357908709011732 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3651863 PubMed]
+
|1
−
## '''Update:''' Guglielmi C, Amadori S, Ruco LP, Mantovani L, Martelli M, Papa G, Mandelli F. Combination chemotherapy for the treatment of diffuse aggressive lymphomas: F-MACHOP update. Semin Oncol. 1987 Jun;14(2 Suppl 1):104-9. [https://pubmed.ncbi.nlm.nih.gov/3589684 PubMed]
+
|0
−
## '''Update:''' Guglielmi C, Amadori S, Martelli M, Dragoni F, Mandelli F. The F-MACHOP sequential combination chemotherapy regimen in advanced diffuse aggressive lymphomas: long-term results. Ann Oncol. 1991 May;2(5):365-71. [https://doi.org/10.1093/oxfordjournals.annonc.a057958 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1954181 PubMed]
+
|77
−
# Infanti L, Silvestri F, Fanin R, Salmaso F, Zaja F, Barillari G, Patriarca F, Geromin A, Cerno M, Damiani D, Baccarani M. The F-MACHOP regimen in the treatment of aggressive non-Hodgkin's lymphomas: a single center experience in 72 patients. Haematologica. 1996 Nov-Dec;81(6):521-8. [http://www.haematologica.org/content/81/6/521.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/9009439 PubMed]
+
|60
−
==HOP {{#subobject:f63e46|Regimen=1}}==
+
|1
−
HOP: '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
 
−
<br>APO: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>P</u>'''rednisone, '''<u>O</u>'''ncovin (Vincristine)
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:e5509d|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1002/1097-0142(197610)38:4%3C1484::aid-cncr2820380407%3E3.0.co;2-i McKelvey et al. 1976]
+
|Alessandroni
−
|1972-1974
+
|Paolo
−
|style="background-color:#1a9851"|Phase 3 (E-de-esc)
+
|MALE
−
|[[#CHOP|CHOP]]
+
|
−
| style="background-color:#ffffbf" |Did not meet endpoint of OS
+
|
 +
|
 +
|
 +
|2006
 +
|2012
 +
|
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|10
 +
|10
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.3109/10428190109064597 Laver et al. 2001 (POG 8615)]
+
|Alexander
−
|1986-1991
+
|Eben
−
| style="background-color:#1a9851" |Phase 3 (C)
+
|MALE
−
|[[#ACOP_99|ACOP]]
+
|
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of EFS
+
|
 +
|
 +
|USA
 +
|1969
 +
|1980
 +
|BTSG
 +
|
 +
|Glioblastoma
 +
|2
 +
|0
 +
|2
 +
|0
 +
|27
 +
|18
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1200/JCO.2005.11.075 Laver et al. 2005 (POG 9315)]
+
|Alexander
−
|1994-2000
+
|Sarah
−
| style="background-color:#91cf61" |Non-randomized portion of RCT
+
|FEMALE
−
| style="background-color:#d3d3d3" |
+
|
−
| style="background-color:#d3d3d3" |
+
|
 +
|
 +
|Canada
 +
|2011
 +
|2021
 +
|Children's Oncology Group; COG; European Intergroup for Childhood Non-Hodgkin Lymphoma
 +
|
 +
|Anaplastic large cell lymphoma pediatric; Non-Hodgkin lymphoma pediatric
 +
|3
 +
|1
 +
|1
 +
|1
 +
|38
 +
|33
 +
|1
 
|-
 
|-
−
|}
+
|Alexandre
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Jerome
−
====Chemotherapy====
+
|MALE
−
*[[Doxorubicin (Adriamycin)]]
+
|
−
*[[Vincristine (Oncovin)]]
+
|
−
====Glucocorticoid therapy====
+
|
−
*[[Prednisone (Sterapred)]]
+
|Canada
−
</div></div>
+
|2006
−
===References===
+
|2016
−
# McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, Gutterman J, Coltman C, Moon TE. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976 Oct;38(4):1484-93. [https://doi.org/10.1002/1097-0142(197610)38:4%3C1484::aid-cncr2820380407%3E3.0.co;2-i link to original article] [https://pubmed.ncbi.nlm.nih.gov/791473 PubMed]
+
|JGOG
−
# '''POG 8615:''' Laver JH, Mahmoud H, Pick TE, Hutchinson RE, Weinstein HJ, Schwenn M, Weitzman S, Murphy SB, Ochoa S, Shuster JJ; Pediatric Oncology Group. Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma. 2001 Jul;42(3):399-405. [https://doi.org/10.3109/10428190109064597 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11699405 PubMed]
+
|
−
# '''POG 9315:''' Laver JH, Kraveka JM, Hutchison RE, Chang M, Kepner J, Schwenn M, Tarbell N, Desai S, Weitzman S, Weinstein HJ, Murphy SB. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005 Jan 20;23(3):541-7. [https://doi.org/10.1200/JCO.2005.11.075 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15659500 PubMed] NCT00002618
+
|Ovarian cancer
−
==LD-ACOP-B {{#subobject:72a974|Regimen=1}}==
+
|1
−
LD-ACOP-B: '''<u>L</u>'''ow-'''<u>D</u>'''ose '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone, '''<u>B</u>'''leomycin
+
|0
−
<div class="toccolours" style="background-color:#eeeeee">
+
|1
−
===Regimen {{#subobject:6eb553|Variant=1}}===
+
|0
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
+
|23
−
!style="width: 33%"|Study
+
|23
−
!style="width: 33%"|Years of enrollment
+
|1
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.1991.9.5.741 O'Reilly et al. 1991]
+
|Alexandris
−
|1983-1985
+
|Ekaterine
−
|style="background-color:#91cf61"|Non-randomized
+
|FEMALE
−
|}
+
|
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|
−
====Chemotherapy====
+
|
−
*[[Cyclophosphamide (Cytoxan)]]
+
|USA
−
*[[Doxorubicin (Adriamycin)]]
+
|2010
−
*[[Vincristine (Oncovin)]]
+
|2014
−
*[[Bleomycin (Blenoxane)]]
+
|
−
====Glucocorticoid therapy====
+
|
−
*[[Prednisone (Sterapred)]]
+
|Non-small cell lung cancer
−
</div></div>
+
|1
−
===References===
+
|0
−
# O'Reilly SE, Klimo P, Connors JM. Low-dose ACOP-B and VABE: weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma. J Clin Oncol. 1991 May;9(5):741-7. [https://doi.org/10.1200/jco.1991.9.5.741 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1707954 PubMed]
+
|1
−
==MACOP-B {{#subobject:ee1449|Regimen=1}}==
+
|1
−
MACOP-B: '''<u>M</u>'''ethotrexate, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone, '''<u>B</u>'''leomycin
+
|25
−
<div class="toccolours" style="background-color:#eeeeee">
+
|25
−
===Regimen {{#subobject:de7d83|Variant=1}}===
+
|1
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://pubmed.ncbi.nlm.nih.gov/2580468 Klimo et al. 1985a]
+
|Alexandru
−
|1981-1984
+
|Aurelia
−
|style="background-color:#91cf61"|Non-randomized
+
|FEMALE
−
|style="background-color:#d3d3d3"|
+
|
−
|style="background-color:#d3d3d3"|
+
|
 +
|
 +
|Romania
 +
|2015
 +
|2021
 +
|
 +
|
 +
|Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous
 +
|3
 +
|0
 +
|2
 +
|2
 +
|77
 +
|52
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1056/NEJM199304083281404 Fisher et al. 1993 (SWOG-8516/Intergroup 0067)]
+
|Alexanian
−
|1986-1991
+
|Raymond
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
+
|MALE
−
|1. [[#CHOP|CHOP]]<br>2. [[#m-BACOD|m-BACOD]]<br> 3. [[#ProMACE-CytaBOM|ProMACE-CytaBOM]]
+
|
−
| style="background-color:#ffffbf" |Did not meet endpoint of OS
+
|
 +
|
 +
|USA
 +
|1965
 +
|2008
 +
|SWOG
 +
|
 +
|Multiple myeloma
 +
|14
 +
|10
 +
|3
 +
|2
 +
|90
 +
|48
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.1994.12.7.1366 Sertoli et al. 1994]
+
|Alexeeva
−
|1987-1991
+
|Julia A
−
|style="background-color:#1a9851"|Phase 3 (E-switch-ic)
+
|FEMALE
−
|[[#ProMACE-MOPP|ProMACE-MOPP]]
+
|
−
| style="background-color:#ffffbf" |Did not meet endpoint of OS36
+
|
 +
|
 +
|Russian Federation
 +
|2004
 +
|2016
 +
|SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network
 +
|
 +
|Acute myeloid leukemia; Mantle cell lymphoma
 +
|3
 +
|0
 +
|2
 +
|1
 +
|65
 +
|63
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1056/NEJM199705013361804 Gianni et al. 1997]
+
|Alexis Vigier
−
|1987-NR
+
|Magda
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|FEMALE
−
|High-dose sequential therapy
+
|
−
| style="background-color:#d73027" |Inferior EFS
+
|
 +
|
 +
|France
 +
|1990
 +
|2021
 +
|France Intergroupe des Leucemies Myeloides Chroniques; GOELAMS
 +
|
 +
|Chronic myeloid leukemia; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Mantle cell lymphoma
 +
|4
 +
|0
 +
|2
 +
|0
 +
|106
 +
|96
 +
|1
 
|-
 
|-
−
|}
+
|Alexopoulos
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Athanasios
−
====Chemotherapy====
+
|MALE
−
*[[Methotrexate (MTX)]] 400 mg/m<sup>2</sup> IV once per week on weeks 2, 6, 10
+
|
−
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once per week on weeks 1, 3, 5, 7, 9, 11
+
|
−
*[[Cyclophosphamide (Cytoxan)]] 350 mg/m<sup>2</sup> IV once per week on weeks 1, 3, 5, 7, 9, 11
+
|
−
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once per week on weeks 2, 4, 6, 8, 10, 12
+
|
−
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per week on weeks 4, 8, 12
+
|1997
−
====Glucocorticoid therapy====
+
|2003
−
*[[Prednisone (Sterapred)]] 75 mg PO once per day, tapered over last 15 days (schedule not reported)
+
|Greek Oncology Cooperative Group (GOCG) for Lung Cancer; HORG
−
====CNS therapy, prophylaxis====
+
|
−
*(for patients with bone marrow involvement):
+
|Non-small cell lung cancer
−
*[[Methotrexate (MTX)]] 12 mg IV
+
|2
−
====Supportive therapy====
+
|0
−
*[[Trimethoprim-Sulfamethoxazole (Bactrim DS)]] 2 tablets (not specified if SS or DS) PO twice per day
+
|2
−
'''12-week course'''
+
|0
−
</div></div>
+
|19
−
===References===
+
|18
−
# Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med. 1985 May;102(5):596-602. [https://doi.org/10.7326/0003-4819-102-5-596 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2580468 PubMed]
+
|1
−
## '''Update:''' Klimo P, Connors JM. Updated clinical experience with MACOP-B. Semin Hematol. 1987 Apr;24(2 Suppl 1):26-34. [https://pubmed.ncbi.nlm.nih.gov/2438779 PubMed]
 
−
# '''SWOG-8516:''' Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993 Apr 8;328(14):1002-6. [https://doi.org/10.1056/NEJM199304083281404 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7680764 PubMed]
 
−
<!-- ## '''Update:''' Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. A phase III comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol. 1994;5 Suppl 2:91-5. [https://pubmed.ncbi.nlm.nih.gov/7515652 PubMed] -->
 
−
## '''Update:''' Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. J Clin Oncol. 2009 Jan 1;27(1):114-9. Epub 2008 Dec 1. [https://doi.org/10.1200/jco.2008.16.8021 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4879698/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19047289 PubMed]
 
−
# Sertoli MR, Santini G, Chisesi T, Congiu AM, Rubagotti A, Contu A, Salvagno L, Coser P, Porcellini A, Vespignani M, Capnist G, Rossi E, Mangoni L, Fabris P, Vinante O, Tedeschi L, Endrizzi L, Miglio LP, Perrotta A, Rosso R, Damasio E, Rizzoli V. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol. 1994 Jul;12(7):1366-74. [https://doi.org/10.1200/jco.1994.12.7.1366 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7517442 PubMed]
 
−
# Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, Gandola L, Tarella C, Pileri A, Ravagnani F, Valagussa P, Bonadonna G. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997 May 1;336(18):1290-7. [https://doi.org/10.1056/NEJM199705013361804 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9113932 PubMed]
 
−
# Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 May;7(5):379-91. [https://doi.org/10.1016/S1470-2045%2806%2970664-7 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16648042 PubMed]
 
−
## '''Update:''' Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; MabThera International Trial Group. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011 Oct;12(11):1013-22. [https://doi.org/10.1016/S1470-2045%2811%2970235-2 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/21940214 PubMed]
 
−
==m-BACOD {{#subobject:c52d3a|Regimen=1}}==
 
−
m-BACOD: '''<u>m</u>'''ethotrexate (moderate dose), '''<u>B</u>'''leomycin, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>D</u>'''examethasone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:7a2f2d|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.1983.1.2.91 Skarin et al. 1983]
+
|Alexopoulos
−
|1976-1981
+
|Constantinos G
−
|style="background-color:#91cf61"|Non-randomized
+
|MALE
−
|style="background-color:#d3d3d3"|
+
|
−
|style="background-color:#d3d3d3"|
+
|
 +
|
 +
|
 +
|1990
 +
|2007
 +
|ELCWP
 +
|
 +
|Non-small cell lung cancer
 +
|4
 +
|0
 +
|4
 +
|0
 +
|51
 +
|23
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.1990.8.1.84 Shipp et al. 1990]
+
|Alfaro
−
|1981-1986
+
|Elizabeth
−
|style="background-color:#91cf61"|Non-randomized
+
|FEMALE
−
|style="background-color:#d3d3d3"|
+
|
−
|style="background-color:#d3d3d3"|
+
|
 +
|
 +
|
 +
|1987
 +
|1997
 +
|
 +
|
 +
|Hodgkin lymphoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|9
 +
|9
 +
|1
 
|-
 
|-
−
|[https://pubmed.ncbi.nlm.nih.gov/1701924 Gherlinzoni et al. 1990]
+
|Alfaro
−
|1984-1986
+
|Vicente
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|MALE
−
|[[#m-BNCOD|m-BNCOD]]
+
|
−
| style="background-color:#ffffbf" |Did not meet endpoints of OS/RFS
+
|
 +
|
 +
|Spain
 +
|2008
 +
|2021
 +
|
 +
|
 +
|Multiple myeloma; Ovarian cancer; Small cell lung cancer; Soft tissue sarcoma
 +
|4
 +
|0
 +
|3
 +
|1
 +
|84
 +
|76
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1056/NEJM199211053271903 Gordon et al. 1992]
+
|Alfieri
−
|1984-1988
+
|Sergio
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
+
|MALE
−
|[[#CHOP|CHOP]]
+
|
−
| style="background-color:#ffffbf" |Did not meet endpoint of OS
+
|
 +
|
 +
|Italy
 +
|2005
 +
|2019
 +
|
 +
|
 +
|Rectal cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|27
 +
|27
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1056/NEJM199304083281404 Fisher et al. 1993 (SWOG-8516/Intergroup 0067)]
+
|Alfonsi
−
|1986-1991
+
|Marc
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
+
|MALE
−
|1. [[#CHOP|CHOP]]<br>2. [[#MACOP-B|MACOP-B]]<br> 3. [[#ProMACE-CytaBOM|ProMACE-CytaBOM]]
+
|
−
| style="background-color:#ffffbf" |Did not meet endpoint of OS
+
|
 +
|
 +
|France
 +
|1994
 +
|2020
 +
|GORTEC
 +
|
 +
|Head and neck cancer
 +
|9
 +
|0
 +
|8
 +
|0
 +
|162
 +
|84
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.2000.18.6.1309 Tilly et al. 2000 (LNH87-1)]
+
|Algarra
−
|1987-1993
+
|Lorenzo
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|MALE
−
|[[#ACVBP|ACVBP]]
+
|
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of FFS
+
|
 +
|
 +
|Spain
 +
|2014
 +
|2021
 +
|PETHEMA Group
 +
|
 +
|Acute myeloid leukemia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|32
 +
|32
 +
|1
 
|-
 
|-
−
|}
+
|Algazi
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Alain P
−
====Chemotherapy====
+
|MALE
−
*[[Methotrexate (MTX)]] 200 mg/m<sup>2</sup> IV once per day on days 8 & 15
+
|
−
*[[Bleomycin (Blenoxane)]] 4 units/m<sup>2</sup> IV once on day 1
+
|
−
*[[Doxorubicin (Adriamycin)]] 45 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
+
|USA
−
*[[Vincristine (Oncovin)]] 1 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
+
|2010
−
====Glucocorticoid therapy====
+
|2021
−
*[[Dexamethasone (Decadron)]] 6 mg/m<sup>2</sup> (no route specified) once per day on days 1 to 5
+
|
−
====Supportive therapy====
+
|
−
*[[Folinic acid (Leucovorin)]] 10 mg/m<sup>2</sup> IV or PO every 6 hours on days 9 & 10, 16 & 17, starting 24 hours after each [[Methotrexate (MTX)]]
+
|CNS melanoma; Melanoma
−
'''21-day cycle for 10 cycles'''
+
|7
−
====Dose modifications====
+
|0
−
*If nadir WBC <1,000 or nadir platelets less than 50,000: 50% of cyclophosphamide and doxorubicin
+
|0
−
*If WBC <1,000, platelets less than 50,000, or creatinine >50% of baseline on day of treatment, methotrexate was omitted
+
|1
−
</div></div>
+
|166
−
===References===
+
|91
−
# Skarin AT, Canellos GP, Rosenthal DS, Case DC Jr, MacIntyre JM, Pinkus GS, Moloney WC, Frei E 3rd. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol. 1983 Feb;1(2):91-8. [https://doi.org/10.1200/jco.1983.1.2.91 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6199472 PubMed]
+
|1
−
# Gherlinzoni F, Guglielmi C, Mazza P, Amadori S, Mandelli F, Tura S. Phase III comparative trial (m-BACOD v m-BNCOD) in the treatment of stage II to IV non-Hodgkin's lymphomas with intermediate- or high-grade histology. Semin Oncol. 1990 Dec;17(6 Suppl 10):3-8; discussion 8-9. [https://pubmed.ncbi.nlm.nih.gov/1701924 PubMed]
 
−
# Shipp MA, Yeap BY, Harrington DP, Klatt MM, Pinkus GS, Jochelson MS, Rosenthal DS, Skarin AT, Canellos GP. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol. 1990 Jan;8(1):84-93. [https://doi.org/10.1200/jco.1990.8.1.84 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/1688615 PubMed]
 
−
# Gordon LI, Harrington D, Andersen J, Colgan J, Glick J, Neiman R, Mann R, Resnick GD, Barcos M, Gottlieb A, O'Connell M. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med. 1992 Nov 5;327(19):1342-9. [https://doi.org/10.1056/NEJM199211053271903 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1383819 PubMed]
 
−
# '''SWOG 8516:''' Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993 Apr 8;328(14):1002-6. [https://doi.org/10.1056/NEJM199304083281404 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7680764 PubMed]
 
−
<!-- ## '''Update:''' Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. A phase III comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol. 1994;5 Suppl 2:91-5. [https://pubmed.ncbi.nlm.nih.gov/7515652 PubMed] -->
 
−
## '''Update:''' Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. J Clin Oncol. 2009 Jan 1;27(1):114-9. Epub 2008 Dec 1. [https://doi.org/10.1200/jco.2008.16.8021 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4879698/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19047289 PubMed]
 
−
# '''LNH87-1:''' Tilly H, Mounier N, Lederlin P, Brière J, Dupriez B, Sebban C, Bosly A, Biron P, Nouvel C, Herbrecht R, Bordessoule D, Coiffier B; Groupe d'Etude des Lymphomes de l'Adulte. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. J Clin Oncol. 2000 Mar;18(6):1309-15. [https://doi.org/10.1200/jco.2000.18.6.1309 link to original article] [https://pubmed.ncbi.nlm.nih.gov/10715302 PubMed]
 
−
==m-BNCOD {{#subobject:e28311|Regimen=1}}==
 
−
m-BNCOD: '''<u>m</u>'''ethotrexate (moderate dose), '''<u>B</u>'''leomycin, '''<u>N</u>'''ovantrone (Mitoxantrone), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>D</u>'''examethasone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:dd1012|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://pubmed.ncbi.nlm.nih.gov/1701924 Gherlinzoni et al. 1990]
+
|Algeri
−
|1984-1986
+
|Renato
−
|style="background-color:#1a9851"|Phase 3 (E-switch-ic)
+
|MALE
−
|[[#m-BACOD|m-BACOD]]
+
|
−
| style="background-color:#ffffbf" |Did not meet endpoints of OS/RFS
+
|
 +
|
 +
|
 +
|1991
 +
|2000
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|9
 +
|9
 +
|1
 
|-
 
|-
−
|}
+
|Algul
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Hana
−
====Chemotherapy====
+
|FEMALE
−
*[[Methotrexate (MTX)]]
+
|
−
*[[Bleomycin (Blenoxane)]]
+
|
−
*[[Mitoxantrone (Novantrone)]]
+
|
−
*[[Cyclophosphamide (Cytoxan)]]
+
|Germany
−
*[[Vincristine (Oncovin)]]
+
|2015
−
====Glucocorticoid therapy====
+
|2019
−
*[[Dexamethasone (Decadron)]]
+
|
−
</div></div>
+
|
−
===References===
+
|Pancreatic cancer
−
# Gherlinzoni F, Guglielmi C, Mazza P, Amadori S, Mandelli F, Tura S. Phase III comparative trial (m-BACOD v m-BNCOD) in the treatment of stage II to IV non-Hodgkin's lymphomas with intermediate- or high-grade histology. Semin Oncol. 1990 Dec;17(6 Suppl 10):3-8; discussion 8-9. [https://pubmed.ncbi.nlm.nih.gov/1701924 PubMed]
+
|1
−
==P/DOCE {{#subobject:375d4a|Regimen=1}}==
+
|0
−
P/DOCE: '''<u>P</u>'''rednisone, '''<u>D</u>'''oxorubicin, '''<u>O</u>'''ncovin (Vincristine), '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''toposide,
+
|1
−
<div class="toccolours" style="background-color:#eeeeee">
+
|1
−
===Regimen {{#subobject:6972b2|Variant=1}}===
+
|18
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
+
|18
−
!style="width: 33%"|Study
+
|1
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.1993.11.11.2250 O'Reilly et al. 1993]
+
|Ali
−
|1988-1991
+
|Adnan
−
|style="background-color:#91cf61"|Phase 2
+
|Not yet determined
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2005
 +
|2019
 +
|
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|49
 +
|49
 +
|1
 
|-
 
|-
−
|}
+
|Ali
−
''Note: although the drugs are the same as those used in CHOEP, the doses are significantly different and this is intended for elderly persons (65+ years of age).''
+
|Arif N
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|MALE
−
====Glucocorticoid therapy====
+
|
−
*[[Prednisone (Sterapred)]] 50 mg/day PO on days 1 to 10, 28 to 37, 49 to 58
+
|
−
====Chemotherapy====
+
|
−
*[[Doxorubicin (Adriamycin)]] 40 mg/m<sup>2</sup> IV once per week on weeks 1, 2, 7, 8
+
|USA
−
*[[Vincristine (Oncovin)]] 1.2 mg/m<sup>2</sup> IV once per day on days 1, 28, 49
+
|1990
−
*[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup> IV once per day on days 1, 28, 49
+
|2018
−
*[[Etoposide (Vepesid)]] 50 mg/m<sup>2</sup> IV once on day 28, then 100 mg/m<sup>2</sup> PO once per day on days 29 to 32
+
|RTOG
−
'''8-week course'''
+
|
−
</div></div>
+
|Glioblastoma
−
===References===
+
|1
−
# O'Reilly SE, Connors JM, Howdle S, Hoskins P, Klasa R, Klimo P, Stuart DS. In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: results of a phase II study of P/DOCE chemotherapy. J Clin Oncol. 1993 Nov;11(11):2250-7. [https://doi.org/10.1200/jco.1993.11.11.2250 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/8229141 PubMed]
+
|1
−
 
+
|1
−
==PACEBOM {{#subobject:b78c96|Regimen=1}}==
+
|0
−
PACEBOM: '''<u>P</u>'''rednisolone, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''toposide, '''<u>B</u>'''leomycin, '''<u>O</u>'''ncovin (Vincristine), '''<u>M</u>'''ethotrexate
+
|17
−
<div class="toccolours" style="background-color:#eeeeee">
+
|17
−
===Regimen {{#subobject:5b3956|Variant=1}}===
+
|1
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|-
−
!style="width: 20%"|Study
+
|Ali
−
!style="width: 20%"|Years of enrollment
+
|Haris
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
|MALE
−
!style="width: 20%"|Comparator
+
|
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+
|
 +
|
 +
|USA
 +
|2016
 +
|2020
 +
|
 +
|
 +
|Graft versus host disease
 +
|1
 +
|0
 +
|0
 +
|1
 +
|12
 +
|12
 +
|1
 +
|-
 +
|Ali
 +
|Haythem
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2008
 +
|2017
 +
|
 +
|
 +
|Thyroid cancer medullary
 +
|2
 +
|0
 +
|1
 +
|1
 +
|36
 +
|21
 +
|1
 +
|-
 +
|Ali
 +
|Kulsam
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2003
 +
|2009
 +
|
 +
|
 +
|Small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|10
 +
|10
 +
|1
 +
|-
 +
|Ali
 +
|Marco
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2017
 +
|2017
 +
|
 +
|
 +
|Thymoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|23
 +
|23
 +
|1
 +
|-
 +
|Ali
 +
|Nasim
 +
|MALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2010
 +
|2020
 +
|
 +
|
 +
|Gastrointestinal stromal tumor; Leiomyosarcoma; Soft tissue sarcoma
 +
|2
 +
|0
 +
|1
 +
|0
 +
|38
 +
|37
 +
|1
 +
|-
 +
|Ali
 +
|Ridvan
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2006
 +
|2010
 +
|
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Ali
 +
|Saad
 +
|MALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2015
 +
|2018
 +
|
 +
|
 +
|Endometrial cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|13
 +
|13
 +
|1
 +
|-
 +
|Ali
 +
|Sahra
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2006
 +
|2017
 +
|MRC; UK NCRI
 +
|
 +
|Acute myeloid leukemia; Essential thrombocythemia; Myelofibrosis
 +
|4
 +
|0
 +
|1
 +
|0
 +
|53
 +
|42
 +
|1
 +
|-
 +
|Ali
 +
|Shamshad
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1992
 +
|2014
 +
|GOG
 +
|
 +
|Cervical cancer; Vulvar cancer
 +
|3
 +
|0
 +
|2
 +
|0
 +
|24
 +
|24
 +
|1
 +
|-
 +
|Ali
 +
|Shyanne
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2009
 +
|2014
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|22
 +
|22
 +
|1
 +
|-
 +
|Ali
 +
|Siraj M
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2017
 +
|2022
 +
|
 +
|
 +
|Bladder cancer; Non-small cell lung cancer
 +
|4
 +
|0
 +
|1
 +
|0
 +
|121
 +
|106
 +
|1
 +
|-
 +
|Aliberti
 +
|Camillo
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2006
 +
|2012
 +
|
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|10
 +
|10
 +
|1
 +
|-
 +
|Aliberti
 +
|Sandra
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2009
 +
|2009
 +
|
 +
|
 +
|Osteosarcoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|8
 +
|8
 +
|1
 +
|-
 +
|Alietti
 +
|Alessandra
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2008
 +
|2014
 +
|
 +
|
 +
|Chronic lymphocytic leukemia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|39
 +
|39
 +
|1
 +
|-
 +
|Alimam
 +
|Samah
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2012
 +
|2017
 +
|
 +
|
 +
|Essential thrombocythemia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Alimena
 +
|Giuliana
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2001
 +
|2016
 +
|EORTC; GIMEMA; GIMEMA CML Working Party
 +
|
 +
|Acute myeloid leukemia; Chronic myeloid leukemia
 +
|8
 +
|0
 +
|3
 +
|2
 +
|171
 +
|108
 +
|1
 +
|-
 +
|Alinari
 +
|Lapo
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1996
 +
|2010
 +
|
 +
|
 +
|Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma
 +
|3
 +
|0
 +
|2
 +
|0
 +
|51
 +
|39
 +
|1
 +
|-
 +
|Aljijakli
 +
|Ahmad
 +
|MALE
 +
|
 +
|
 +
|
 +
|France
 +
|2008
 +
|2012
 +
|ALFA
 +
|
 +
|Acute myeloid leukemia
 +
|1
 +
|0
 +
|1
 +
|1
 +
|21
 +
|21
 +
|1
 +
|-
 +
|Aljitawi
 +
|Omar S
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2011
 +
|2011
 +
|BMT CTN
 +
|
 +
|Allogeneic HSCT
 +
|1
 +
|0
 +
|0
 +
|0
 +
|13
 +
|13
 +
|1
 +
|-
 +
|Aljumaily
 +
|Raid
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2014
 +
|2017
 +
|
 +
|
 +
|Bladder cancer
 +
|1
 +
|0
 +
|0
 +
|1
 +
|17
 +
|17
 +
|1
 +
|-
 +
|Alkan
 +
|Serhan
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2008
 +
|2008
 +
|
 +
|
 +
|Acute myeloid leukemia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|9
 +
|9
 +
|1
 +
|-
 +
|Alkhouri
 +
|Naim
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|USA
 +
|2013
 +
|2020
 +
|
 +
|
 +
|Thrombocytopenia in liver disease
 +
|1
 +
|1
 +
|2
 +
|0
 +
|7
 +
|7
 +
|1
 +
|-
 +
|Alkindi
 +
|Salam
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Oman
 +
|2017
 +
|2019
 +
|
 +
|
 +
|Sickle cell anemia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|21
 +
|21
 +
|1
 +
|-
 +
|Alkuzweny
 +
|Baha
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2004
 +
|2004
 +
|
 +
|
 +
|Follicular lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|4
 +
|4
 +
|1
 +
|-
 +
|Allaham
 +
|Wassim
 +
|MALE
 +
|
 +
|
 +
|
 +
|France
 +
|2011
 +
|2017
 +
|SARAH Trial Group
 +
|
 +
|Hepatocellular carcinoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|36
 +
|36
 +
|1
 +
|-
 +
|Allal
 +
|Abdelkarim S
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1994
 +
|2011
 +
|SAKK
 +
|
 +
|Head and neck cancer
 +
|2
 +
|0
 +
|1
 +
|0
 +
|28
 +
|24
 +
|1
 +
|-
 +
|Allan
 +
|John N
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2021
 +
|2021
 +
|
 +
|
 +
|Waldenstroem macroglobulinemia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|22
 +
|22
 +
|1
 +
|-
 +
|Allan
 +
|Karen
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2008
 +
|2018
 +
|
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|35
 +
|35
 +
|1
 +
|-
 +
|Allan
 +
|Norman C
 +
|MALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|1986
 +
|1995
 +
|MRC
 +
|
 +
|Chronic myeloid leukemia
 +
|1
 +
|1
 +
|1
 +
|0
 +
|2
 +
|2
 +
|1
 +
|-
 +
|Alland
 +
|Leila
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1998
 +
|2006
 +
|
 +
|
 +
|B-cell acute lymphoblastic leukemia; Breast cancer; Chronic myeloid leukemia; Hypereosinophilic syndrome; Systemic mastocytosis
 +
|3
 +
|0
 +
|2
 +
|1
 +
|43
 +
|41
 +
|1
 +
|-
 +
|Allangba
 +
|Olivier
 +
|MALE
 +
|
 +
|
 +
|
 +
|France
 +
|2013
 +
|2018
 +
|IFM
 +
|
 +
|Multiple myeloma
 +
|2
 +
|0
 +
|1
 +
|0
 +
|77
 +
|54
 +
|1
 +
|-
 +
|Allard
 +
|Christian
 +
|MALE
 +
|
 +
|
 +
|
 +
|France
 +
|2003
 +
|2010
 +
|Intergroupe Francais des Leucemies Myeloides Chroniques; SPIRIT Investigators
 +
|
 +
|Chronic myeloid leukemia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|22
 +
|22
 +
|1
 +
|-
 +
|Allegra
 +
|Carmen J
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1991
 +
|2020
 +
|NSABP; SWOG
 +
|
 +
|Colon cancer; Colorectal cancer; Rectal cancer
 +
|11
 +
|6
 +
|6
 +
|1
 +
|153
 +
|82
 +
|1
 +
|-
 +
|Allegrini
 +
|Giacomo
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2001
 +
|2015
 +
|GONO
 +
|
 +
|Colorectal cancer
 +
|4
 +
|0
 +
|3
 +
|0
 +
|75
 +
|48
 +
|1
 +
|-
 +
|Allen Mersh
 +
|T G
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|1988
 +
|1994
 +
|
 +
|
 +
|Colorectal cancer
 +
|1
 +
|1
 +
|1
 +
|0
 +
|4
 +
|4
 +
|1
 +
|-
 +
|Allen
 +
|Aaron M
 +
|MALE
 +
|
 +
|
 +
|
 +
|Israel
 +
|2008
 +
|2022
 +
|
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|21
 +
|21
 +
|1
 +
|-
 +
|Allen
 +
|Andrew R
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2013
 +
|2016
 +
|
 +
|
 +
|Ovarian cancer
 +
|1
 +
|0
 +
|0
 +
|1
 +
|30
 +
|30
 +
|1
 +
|-
 +
|Allen
 +
|Carl
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2020
 +
|2020
 +
|
 +
|
 +
|Hemophagocytic lymphohistiocytosis
 +
|1
 +
|0
 +
|0
 +
|1
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Allen
 +
|Jeffrey C
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1985
 +
|1999
 +
|CCG
 +
|
 +
|High-grade glioma pediatric; Low-grade glioma; Medulloblastoma
 +
|3
 +
|0
 +
|1
 +
|0
 +
|47
 +
|36
 +
|1
 +
|-
 +
|Allen
 +
|Jennifer L
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2015
 +
|2018
 +
|
 +
|
 +
|Endometrial cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|13
 +
|13
 +
|1
 +
|-
 +
|Allen
 +
|Jill N
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2006
 +
|2018
 +
|
 +
|
 +
|Cholangiocarcinoma; Gallbladder cancer; Hepatocellular carcinoma; Pancreatic cancer
 +
|3
 +
|0
 +
|0
 +
|0
 +
|56
 +
|44
 +
|1
 +
|-
 +
|Allen
 +
|John
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1995
 +
|2014
 +
|
 +
|
 +
|Hodgkin lymphoma; Hodgkin lymphoma nodular lymphocyte-predominant
 +
|2
 +
|0
 +
|0
 +
|0
 +
|14
 +
|10
 +
|1
 +
|-
 +
|Allen
 +
|L
 +
|CBD
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|1984
 +
|1985
 +
|
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|5
 +
|5
 +
|1
 +
|-
 +
|Allen
 +
|Lee F
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2006
 +
|2018
 +
|
 +
|
 +
|Cutaneous T-cell lymphoma; Immune thrombocytopenia; Peripheral T-cell lymphoma; Thrombocytopenia in liver disease
 +
|4
 +
|1
 +
|3
 +
|1
 +
|47
 +
|42
 +
|1
 +
|-
 +
|Allen
 +
|Mary S
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2014
 +
|2014
 +
|
 +
|
 +
|Autologous HSCT
 +
|1
 +
|0
 +
|0
 +
|0
 +
|6
 +
|6
 +
|1
 +
|-
 +
|Allen
 +
|Peter J
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2007
 +
|2016
 +
|
 +
|
 +
|Hepatocellular carcinoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Allen
 +
|Roberta S
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1998
 +
|2002
 +
|
 +
|
 +
|Follicular lymphoma
 +
|1
 +
|0
 +
|0
 +
|1
 +
|11
 +
|11
 +
|1
 +
|-
 +
|Allen
 +
|Steven L
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1977
 +
|2015
 +
|CALGB
 +
|
 +
|Acute myeloid leukemia; Acute promyelocytic leukemia; Adult T-cell leukemia-lymphoma; Breast cancer; Cutaneous T-cell lymphoma; Diffuse large B-cell lymphoma; Peripheral T-cell lymphoma
 +
|9
 +
|0
 +
|3
 +
|1
 +
|128
 +
|100
 +
|1
 +
|-
 +
|Allepuz
 +
|Alex
 +
|MALE
 +
|
 +
|
 +
|
 +
|Switzerland
 +
|2013
 +
|2021
 +
|
 +
|
 +
|Chronic myeloid leukemia; Chronic myeloid leukemia pediatric
 +
|3
 +
|0
 +
|1
 +
|2
 +
|63
 +
|45
 +
|1
 +
|-
 +
|Allerton
 +
|Rozenn
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2009
 +
|2015
 +
|
 +
|
 +
|Breast cancer; CNS carcinoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Allevi
 +
|G
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|1997
 +
|2005
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|13
 +
|13
 +
|1
 +
|-
 +
|Allewelt
 +
|Heather
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2014
 +
|2022
 +
|
 +
|
 +
|Marginal zone lymphoma
 +
|1
 +
|0
 +
|0
 +
|1
 +
|13
 +
|13
 +
|1
 +
|-
 +
|Allgeier
 +
|Anouk
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Belgium
 +
|1988
 +
|2012
 +
|EORTC; NCIC-CTG
 +
|
 +
|Anaplastic glioma; Glioblastoma
 +
|5
 +
|0
 +
|3
 +
|1
 +
|84
 +
|43
 +
|1
 +
|-
 +
|Allietta
 +
|Nathalie
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|France
 +
|2006
 +
|2013
 +
|
 +
|
 +
|Multiple myeloma
 +
|2
 +
|0
 +
|0
 +
|1
 +
|20
 +
|17
 +
|1
 +
|-
 +
|Allione
 +
|Bernardino
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|1993
 +
|2020
 +
|EORTC
 +
|
 +
|Acute myeloid leukemia; Chronic myelomonocytic leukemia; HIV-associated lymphoma; Multiple myeloma
 +
|4
 +
|0
 +
|2
 +
|0
 +
|81
 +
|80
 +
|1
 +
|-
 +
|Allis
 +
|Simona
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1992
 +
|2010
 +
|
 +
|
 +
|Head and neck cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|13
 +
|13
 +
|1
 +
|-
 +
|Allison
 +
|James
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2015
 +
|2017
 +
|
 +
|
 +
|Anal cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|28
 +
|28
 +
|1
 +
|-
 +
|Allison
 +
|Mary Ann K
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2007
 +
|2013
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Allman
 +
|David
 +
|MALE
 +
|
 +
|
 +
|
 +
|France
 +
|1996
 +
|2001
 +
|
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|1
 +
|1
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Allmark
 +
|Christine
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2014
 +
|2021
 +
|
 +
|
 +
|Gastric cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|33
 +
|33
 +
|1
 +
|-
 +
|Allmer
 +
|Christine
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2004
 +
|2008
 +
|NCCTG
 +
|
 +
|Mantle cell lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|11
 +
|11
 +
|1
 +
|-
 +
|Alloisio
 +
|M
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|1998
 +
|2002
 +
|
 +
|
 +
|Bladder cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|9
 +
|9
 +
|1
 +
|-
 +
|Allolio
 +
|Bruno
 +
|MALE
 +
|
 +
|
 +
|
 +
|Germany
 +
|2004
 +
|2012
 +
|
 +
|
 +
|Adrenocortical carcinoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|36
 +
|36
 +
|1
 +
|-
 +
|Allotey
 +
|David
 +
|MALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2011
 +
|2021
 +
|UK NCRI
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|22
 +
|22
 +
|1
 +
|-
 +
|Allouache
 +
|Djelila
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|France
 +
|1999
 +
|2022
 +
|GINECO; Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01)
 +
|
 +
|Breast cancer; Carcinoma of unknown primary
 +
|3
 +
|0
 +
|1
 +
|0
 +
|58
 +
|55
 +
|1
 +
|-
 +
|Allouache
 +
|Nedla
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|France
 +
|2006
 +
|2019
 +
|GETUG
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|21
 +
|21
 +
|1
 +
|-
 +
|Allred
 +
|Alicia J
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2010
 +
|2021
 +
|
 +
|
 +
|Melanoma; Multiple myeloma
 +
|2
 +
|0
 +
|0
 +
|1
 +
|60
 +
|59
 +
|1
 +
|-
 +
|Allred
 +
|D Craig
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1989
 +
|2011
 +
|ACOSOG
 +
|
 +
|Breast cancer
 +
|3
 +
|0
 +
|1
 +
|0
 +
|38
 +
|38
 +
|1
 +
|-
 +
|Allred
 +
|Jacob B
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2004
 +
|2012
 +
|
 +
|
 +
|Light-chain (AL) amyloidosis; Multiple myeloma; Myelofibrosis
 +
|7
 +
|0
 +
|0
 +
|0
 +
|126
 +
|40
 +
|1
 +
|-
 +
|Allsup
 +
|David J
 +
|MALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2006
 +
|2017
 +
|NCRI
 +
|
 +
|Chronic lymphocytic leukemia
 +
|2
 +
|0
 +
|0
 +
|0
 +
|38
 +
|35
 +
|1
 +
|-
 +
|Allum
 +
|William H
 +
|MALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|1976
 +
|2017
 +
|British Stomach Cancer Group; MAGIC Trial Participants; MRC
 +
|
 +
|Esophageal adenocarcinoma; Esophageal cancer; Gastric cancer
 +
|5
 +
|3
 +
|5
 +
|0
 +
|40
 +
|33
 +
|1
 +
|-
 +
|Ally
 +
|Mina S
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2009
 +
|2016
 +
|
 +
|
 +
|Cutaneous basal cell carcinoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|12
 +
|12
 +
|1
 +
|-
 +
|Alm
 +
|Gunnar
 +
|MALE
 +
|
 +
|
 +
|
 +
|Sweden
 +
|1983
 +
|1983
 +
|
 +
|
 +
|Neuroendocrine tumor
 +
|1
 +
|1
 +
|0
 +
|0
 +
|2
 +
|2
 +
|1
 +
|-
 +
|Almeida
 +
|Antonio
 +
|MALE
 +
|
 +
|
 +
|
 +
|Portugal
 +
|2010
 +
|2021
 +
|
 +
|
 +
|Myelodysplastic syndrome
 +
|2
 +
|0
 +
|2
 +
|0
 +
|48
 +
|39
 +
|1
 +
|-
 +
|Almeida
 +
|M S S
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Brazil
 +
|2006
 +
|2015
 +
|
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|11
 +
|11
 +
|1
 +
|-
 +
|Almenar
 +
|Daniel
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2000
 +
|2005
 +
|Spanish Germ Cell Cancer Cooperative Group; Spanish Lung Cancer Group
 +
|
 +
|Non-small cell lung cancer; Testicular cancer
 +
|2
 +
|0
 +
|1
 +
|0
 +
|38
 +
|38
 +
|1
 +
|-
 +
|Almenar
 +
|Sergio
 +
|MALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|1999
 +
|2010
 +
|GEICAM
 +
|
 +
|Breast cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|64
 +
|49
 +
|1
 +
|-
 +
|Almond
 +
|Jennifer P
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1994
 +
|2001
 +
|European Study Group for Pancreatic Cancer
 +
|
 +
|Pancreatic cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|16
 +
|16
 +
|1
 +
|-
 +
|Aloe
 +
|Alessandra
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|
 +
|1996
 +
|2009
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|10
 +
|10
 +
|1
 +
|-
 +
|Aloj
 +
|Luigi
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2014
 +
|2014
 +
|
 +
|
 +
|Hodgkin lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|16
 +
|16
 +
|1
 +
|-
 +
|Alonso Carrion
 +
|Lorenzo
 +
|MALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|2021
 +
|2021
 +
|
 +
|
 +
|Uveal melanoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|13
 +
|13
 +
|1
 +
|-
 +
|Alonso Garcia
 +
|Miriam
 +
|MALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|1995
 +
|2021
 +
|
 +
|
 +
|Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous
 +
|2
 +
|0
 +
|3
 +
|3
 +
|44
 +
|44
 +
|1
 +
|-
 +
|Alonso Gordoa
 +
|Teresa
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|2016
 +
|2021
 +
|
 +
|
 +
|Clear cell renal cell carcinoma; Renal cell carcinoma
 +
|2
 +
|0
 +
|1
 +
|1
 +
|56
 +
|55
 +
|1
 +
|-
 +
|Alonso Orduna
 +
|Vicente
 +
|MALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|2006
 +
|2012
 +
|TTD
 +
|
 +
|Colorectal cancer; Esophageal adenocarcinoma
 +
|2
 +
|0
 +
|1
 +
|1
 +
|33
 +
|33
 +
|1
 +
|-
 +
|Alonso
 +
|Carmen
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|1994
 +
|2004
 +
|
 +
|
 +
|Small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|16
 +
|16
 +
|1
 +
|-
 +
|Alonso
 +
|Guillermo
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2000
 +
|2010
 +
|Spanish Lung Cancer Group
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Alonso
 +
|Liuba
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Cuba
 +
|2006
 +
|2016
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|33
 +
|33
 +
|1
 +
|-
 +
|Alonso
 +
|Maria Carmen
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|1978
 +
|1995
 +
|
 +
|
 +
|Breast cancer
 +
|2
 +
|1
 +
|2
 +
|0
 +
|13
 +
|12
 +
|1
 +
|-
 +
|Alonso
 +
|Mirta Garcia
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|2009
 +
|2020
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|1
 +
|30
 +
|30
 +
|1
 +
|-
 +
|Alonso
 +
|Natalia
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2013
 +
|2013
 +
|
 +
|
 +
|Burkitt lymphoma; HIV-associated lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Alonso
 +
|Silvia
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2003
 +
|2009
 +
|
 +
|
 +
|Bladder cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|8
 +
|8
 +
|1
 +
|-
 +
|Alonzo
 +
|Todd A
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1979
 +
|2014
 +
|CCG; COG
 +
|
 +
|Acute myeloid leukemia; Acute myeloid leukemia pediatric; Chronic myeloid leukemia pediatric
 +
|4
 +
|1
 +
|4
 +
|1
 +
|46
 +
|37
 +
|1
 +
|-
 +
|Alousi
 +
|Amin M
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2009
 +
|2020
 +
|BMT CTN
 +
|
 +
|Acute myeloid leukemia; Allogeneic HSCT; Follicular lymphoma; Graft versus host disease; Mantle cell lymphoma; Transformed lymphoma
 +
|5
 +
|0
 +
|1
 +
|0
 +
|84
 +
|60
 +
|1
 +
|-
 +
|Alpen
 +
|B
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|
 +
|1997
 +
|1997
 +
|
 +
|
 +
|MALT lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|9
 +
|9
 +
|1
 +
|-
 +
|Alquati
 +
|Palmiro
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1991
 +
|2005
 +
|Epirubicin-Lonidamine Group
 +
|
 +
|Breast cancer
 +
|3
 +
|0
 +
|3
 +
|0
 +
|46
 +
|37
 +
|1
 +
|-
 +
|Alsayed
 +
|Yazan
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1998
 +
|2010
 +
|
 +
|
 +
|Multiple myeloma
 +
|4
 +
|0
 +
|0
 +
|0
 +
|59
 +
|28
 +
|1
 +
|-
 +
|Alsina Maqueda
 +
|Maria
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|2011
 +
|2021
 +
|
 +
|
 +
|Colorectal cancer; Esophageal cancer; Esophageal squamous cell carcinoma; Gastric cancer
 +
|8
 +
|0
 +
|8
 +
|2
 +
|161
 +
|129
 +
|1
 +
|-
 +
|Alsina
 +
|Melissa
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2001
 +
|2022
 +
|
 +
|
 +
|Multiple myeloma
 +
|14
 +
|0
 +
|2
 +
|4
 +
|279
 +
|159
 +
|1
 +
|-
 +
|Altavilla
 +
|Giuseppe
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|1983
 +
|2012
 +
|Associazione Italiana Oncologia Toracica; Groupe Francais de Pneumo-Cancerologie; Italian Lung Cancer Project; Italian Lung Cancer Task Force; Italian Multicentre Breast Study with Epirubicin; Spanish Lung Cancer Group
 +
|
 +
|Breast cancer; Non-small cell lung cancer
 +
|4
 +
|0
 +
|4
 +
|1
 +
|157
 +
|151
 +
|1
 +
|-
 +
|Altenhofer
 +
|Petra
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Austria
 +
|2010
 +
|2016
 +
|AGMT
 +
|
 +
|Chronic lymphocytic leukemia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|34
 +
|34
 +
|1
 +
|-
 +
|Alter
 +
|Robert S
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2015
 +
|2020
 +
|
 +
|
 +
|Bladder cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Alterio
 +
|D
 +
|CBD
 +
|
 +
|
 +
|
 +
|Italy
 +
|2008
 +
|2017
 +
|GSTTC
 +
|
 +
|Head and neck cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|36
 +
|36
 +
|1
 +
|-
 +
|Altermatt
 +
|Hans J
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1998
 +
|2007
 +
|BIG
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|1
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Altes
 +
|Albert
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2001
 +
|2008
 +
|
 +
|
 +
|Chronic lymphocytic leukemia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Althaus
 +
|Betsy L
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2009
 +
|2020
 +
|
 +
|
 +
|Breast cancer; Gastric cancer
 +
|3
 +
|0
 +
|1
 +
|0
 +
|42
 +
|42
 +
|1
 +
|-
 +
|Althausen
 +
|Alex F
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1993
 +
|1993
 +
|
 +
|
 +
|Bladder cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|5
 +
|5
 +
|1
 +
|-
 +
|Altieri
 +
|Vincenzo
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2011
 +
|2011
 +
|
 +
|
 +
|Penile cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|15
 +
|15
 +
|1
 +
|-
 +
|Altinbas
 +
|M
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|1997
 +
|2005
 +
|Turkish Oncology Group
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|16
 +
|16
 +
|1
 +
|-
 +
|Altinmakas
 +
|Emre
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2010
 +
|2015
 +
|
 +
|
 +
|Non-clear cell renal cell carcinoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|15
 +
|15
 +
|1
 +
|-
 +
|Altintas
 +
|Sevilay
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Belgium
 +
|2011
 +
|2016
 +
|
 +
|
 +
|Ovarian cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|23
 +
|23
 +
|1
 +
|-
 +
|Altman
 +
|Arnold
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2002
 +
|2006
 +
|
 +
|
 +
|B-cell acute lymphoblastic leukemia pediatric
 +
|1
 +
|0
 +
|0
 +
|1
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Altman
 +
|Jessica K
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2007
 +
|2022
 +
|ECOG
 +
|
 +
|Acute myeloid leukemia; Acute promyelocytic leukemia; Hairy cell leukemia; Myelodysplastic syndrome
 +
|10
 +
|0
 +
|4
 +
|2
 +
|248
 +
|176
 +
|1
 +
|-
 +
|Altman
 +
|Stanley J
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1979
 +
|1993
 +
|COG; SWOG
 +
|
 +
|Breast cancer; Soft tissue sarcoma; Testicular cancer
 +
|3
 +
|0
 +
|3
 +
|0
 +
|26
 +
|26
 +
|1
 +
|-
 +
|Altmann
 +
|Bettina
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Germany
 +
|2003
 +
|2021
 +
|DSHNHL; FLYER Trial Investigators; German Lymphoma Alliance
 +
|
 +
|Autologous HSCT; Diffuse large B-cell lymphoma; Peripheral T-cell lymphoma
 +
|4
 +
|1
 +
|4
 +
|0
 +
|130
 +
|90
 +
|1
 +
|-
 +
|Altorjai
 +
|Gabriela
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2004
 +
|2007
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|8
 +
|8
 +
|1
 +
|-
 +
|Altorki
 +
|Nasser K
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2007
 +
|2021
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|2
 +
|0
 +
|2
 +
|1
 +
|35
 +
|35
 +
|1
 +
|-
 +
|Altug
 +
|Sedat
 +
|MALE
 +
|
 +
|
 +
|
 +
|Turkey
 +
|2009
 +
|2014
 +
|
 +
|
 +
|Non-small cell lung cancer nonsquamous
 +
|1
 +
|0
 +
|1
 +
|0
 +
|11
 +
|11
 +
|1
 +
|-
 +
|Altwein
 +
|Jens Erik
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1986
 +
|1991
 +
|
 +
|
 +
|Prostate cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|12
 +
|12
 +
|1
 +
|-
 +
|Alu
 +
|Massimiliano
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1996
 +
|2002
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|9
 +
|9
 +
|1
 +
|-
 +
|Alumkal
 +
|Joshi J
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2007
 +
|2017
 +
|Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium
 +
|
 +
|Prostate cancer
 +
|3
 +
|0
 +
|0
 +
|0
 +
|40
 +
|35
 +
|1
 +
|-
 +
|Alva
 +
|Ajjai S
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2012
 +
|2021
 +
|SWOG
 +
|
 +
|Bladder cancer; Clear cell renal cell carcinoma; Papillary renal cell carcinoma; Renal cell carcinoma
 +
|4
 +
|1
 +
|3
 +
|2
 +
|100
 +
|92
 +
|1
 +
|-
 +
|Alvarado
 +
|Gladys
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1995
 +
|2009
 +
|
 +
|
 +
|Melanoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Alvarado
 +
|Yesid
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2011
 +
|2020
 +
|
 +
|
 +
|Acute myeloid leukemia; B-cell acute lymphoblastic leukemia; Chronic lymphocytic leukemia; Myelodysplastic syndrome
 +
|4
 +
|0
 +
|0
 +
|0
 +
|115
 +
|66
 +
|1
 +
|-
 +
|Alvarez Cabellos
 +
|Ruth
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2013
 +
|2013
 +
|GOTEL
 +
|
 +
|Follicular lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|11
 +
|11
 +
|1
 +
|-
 +
|Alvarez de Celis
 +
|Isabel
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2004
 +
|2013
 +
|
 +
|
 +
|Follicular lymphoma
 +
|1
 +
|0
 +
|2
 +
|0
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Alvarez Larran
 +
|Alberto
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2005
 +
|2005
 +
|
 +
|
 +
|Myelofibrosis
 +
|1
 +
|0
 +
|0
 +
|0
 +
|4
 +
|4
 +
|1
 +
|-
 +
|Alvarez Secord
 +
|Angeles
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1999
 +
|2022
 +
|GOG
 +
|
 +
|Endometrial cancer; Gestational trophoblastic neoplasia; Low-grade serous ovarian cancer; Ovarian cancer
 +
|8
 +
|1
 +
|7
 +
|2
 +
|149
 +
|122
 +
|1
 +
|-
 +
|Alvarez Twose
 +
|Ivan
 +
|MALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|2018
 +
|2021
 +
|
 +
|
 +
|Systemic mastocytosis
 +
|1
 +
|0
 +
|0
 +
|1
 +
|23
 +
|23
 +
|1
 +
|-
 +
|Alvarez Vicent
 +
|J J
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|1996
 +
|2002
 +
|
 +
|
 +
|Head and neck cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|10
 +
|10
 +
|1
 +
|-
 +
|Alvarez
 +
|Ana
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|2005
 +
|2015
 +
|
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Alvarez
 +
|Axxx
 +
|CBD
 +
|
 +
|
 +
|
 +
|Argentina
 +
|1991
 +
|1999
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|9
 +
|9
 +
|1
 +
|-
 +
|Alvarez
 +
|Elena
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1987
 +
|1999
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|1
 +
|1
 +
|0
 +
|9
 +
|9
 +
|1
 +
|-
 +
|Alvarez
 +
|Isabel
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|1995
 +
|2020
 +
|ANZ BCTG; GEICAM; Intergroup Exemestane Study
 +
|
 +
|Breast cancer; Diffuse large B-cell lymphoma
 +
|9
 +
|0
 +
|9
 +
|1
 +
|230
 +
|159
 +
|1
 +
|-
 +
|Alvarez
 +
|Ivan
 +
|MALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|2006
 +
|2006
 +
|
 +
|
 +
|Allogeneic HSCT; Hodgkin lymphoma
 +
|1
 +
|1
 +
|0
 +
|0
 +
|17
 +
|17
 +
|1
 +
|-
 +
|Alvarez
 +
|Jose Valero
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1999
 +
|2008
 +
|GEICAM
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|34
 +
|34
 +
|1
 +
|-
 +
|Alvarez
 +
|Ofelia A
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2013
 +
|2016
 +
|
 +
|
 +
|Sickle cell anemia
 +
|1
 +
|0
 +
|0
 +
|1
 +
|15
 +
|15
 +
|1
 +
|-
 +
|Alvarez
 +
|Pablo
 +
|MALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2007
 +
|2012
 +
|
 +
|
 +
|Thyroid cancer differentiated
 +
|1
 +
|0
 +
|1
 +
|0
 +
|27
 +
|27
 +
|1
 +
|-
 +
|Alvarez
 +
|Ronald D
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1985
 +
|2008
 +
|GOG; GRACES Clinical Trial Consortium; SWOG
 +
|
 +
|Cervical cancer; Endometrial cancer; Ovarian cancer
 +
|5
 +
|1
 +
|4
 +
|0
 +
|39
 +
|36
 +
|1
 +
|-
 +
|Alvarnas
 +
|Joseph C
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2016
 +
|2016
 +
|BMT CTN
 +
|
 +
|Autologous HSCT; HIV-associated lymphoma
 +
|1
 +
|1
 +
|0
 +
|0
 +
|21
 +
|21
 +
|1
 +
|-
 +
|Alvegaard
 +
|Thor
 +
|MALE
 +
|
 +
|
 +
|
 +
|Sweden
 +
|2004
 +
|2020
 +
|
 +
|
 +
|Gastrointestinal stromal tumor
 +
|3
 +
|0
 +
|1
 +
|1
 +
|58
 +
|29
 +
|1
 +
|-
 +
|Aly
 +
|Abdalla
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2009
 +
|2018
 +
|
 +
|
 +
|Pancreatic cancer
 +
|1
 +
|0
 +
|1
 +
|1
 +
|11
 +
|11
 +
|1
 +
|-
 +
|Alyasova
 +
|Anna
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Russian Federation
 +
|2010
 +
|2021
 +
|
 +
|
 +
|Head and neck cancer; Renal cell carcinoma
 +
|4
 +
|0
 +
|2
 +
|1
 +
|95
 +
|89
 +
|1
 +
|-
 +
|Alyea
 +
|Edwin P
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2003
 +
|2017
 +
|BMT CTN; CALGB
 +
|
 +
|Acute myeloid leukemia; Allogeneic HSCT; Multiple myeloma
 +
|3
 +
|1
 +
|2
 +
|0
 +
|60
 +
|51
 +
|1
 +
|-
 +
|Alzate
 +
|Stefanie
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2012
 +
|2017
 +
|
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Alzieu
 +
|Claude
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1984
 +
|2006
 +
|FNCLCC
 +
|
 +
|Head and neck cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|25
 +
|25
 +
|1
 +
|-
 +
|Alzouebi
 +
|Mymoona
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2005
 +
|2015
 +
|
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|46
 +
|46
 +
|1
 +
|-
 +
|Amabile
 +
|Marilina
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1994
 +
|2009
 +
|GIMEMA; GIMEMA CML Working Party; Italian Cooperative Study Group on Myeloid Leukemia
 +
|
 +
|Chronic myeloid leukemia
 +
|3
 +
|0
 +
|1
 +
|0
 +
|51
 +
|32
 +
|1
 +
|-
 +
|Amado
 +
|Rafael G
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2004
 +
|2008
 +
|
 +
|
 +
|Colorectal cancer
 +
|2
 +
|2
 +
|2
 +
|1
 +
|23
 +
|23
 +
|1
 +
|-
 +
|Amador Barciela
 +
|Maria L
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|2014
 +
|2021
 +
|PETHEMA Group
 +
|
 +
|Acute myeloid leukemia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|32
 +
|32
 +
|1
 +
|-
 +
|Amador
 +
|Rosa M
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Cuba
 +
|2006
 +
|2016
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|33
 +
|33
 +
|1
 +
|-
 +
|Amadori
 +
|Dino
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|1981
 +
|2017
 +
|GONO; International Collaborative Cancer Group
 +
|
 +
|Bladder cancer; Breast cancer; Colorectal cancer; Gastric cancer; Hepatocellular carcinoma
 +
|14
 +
|4
 +
|11
 +
|0
 +
|196
 +
|155
 +
|1
 +
|-
 +
|Amadori
 +
|Sergio
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|1984
 +
|2020
 +
|AIEOP; EORTC; German-Austrian Acute Myeloid Leukemia Study Group; GIMEMA; Study Alliance Leukemia
 +
|
 +
|Acute myeloid leukemia; Acute promyelocytic leukemia; B-cell acute lymphoblastic leukemia; Chronic myeloid leukemia; CNS leukemia; Diffuse large B-cell lymphoma; Multiple myeloma; Myelodysplastic syndrome
 +
|30
 +
|7
 +
|21
 +
|3
 +
|594
 +
|249
 +
|1
 +
|-
 +
|Amaducci
 +
|Laura
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|1997
 +
|2021
 +
|GIM; Reader study level-I and level-II Groups
 +
|
 +
|Breast cancer
 +
|3
 +
|0
 +
|3
 +
|0
 +
|77
 +
|71
 +
|1
 +
|-
 +
|Amagai
 +
|Kenji
 +
|MALE
 +
|
 +
|
 +
|
 +
|Japan
 +
|2008
 +
|2018
 +
|Tokyo Cooperative Oncology Group
 +
|
 +
|Gastric cancer
 +
|4
 +
|0
 +
|4
 +
|0
 +
|70
 +
|61
 +
|1
 +
|-
 +
|Amam
 +
|Josif
 +
|MALE
 +
|
 +
|
 +
|
 +
|Germany
 +
|2005
 +
|2019
 +
|FLYER Trial Investigators; German Lymphoma Alliance
 +
|
 +
|Diffuse large B-cell lymphoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|43
 +
|43
 +
|1
 +
|-
 +
|Amann
 +
|G
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|2001
 +
|2001
 +
|
 +
|
 +
|Ewing sarcoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Amano
 +
|Hodaka
 +
|UNMATCHED
 +
|
 +
|
 +
|
 +
|
 +
|1986
 +
|2002
 +
|Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract
 +
|
 +
|Periampullary adenocarcinoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|7
 +
|7
 +
|1
 +
|-
 +
|Amant
 +
|Frederic
 +
|MALE
 +
|
 +
|
 +
|
 +
|Belgium
 +
|1998
 +
|2010
 +
|EORTC; NCIC-CTG
 +
|
 +
|Breast cancer; Ovarian cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|32
 +
|32
 +
|1
 +
|-
 +
|Amar
 +
|Avraham
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1998
 +
|1998
 +
|
 +
|
 +
|Allogeneic HSCT; Chronic lymphocytic leukemia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Amaravadi
 +
|Ravi K
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2009
 +
|2012
 +
|
 +
|
 +
|Melanoma
 +
|1
 +
|0
 +
|0
 +
|1
 +
|24
 +
|24
 +
|1
 +
|-
 +
|Amare
 +
|Mammo
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|
 +
|1977
 +
|1983
 +
|SWOG
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|0
 +
|0
 +
|1
 +
|-
 +
|Amato
 +
|Giovanni
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2013
 +
|2021
 +
|
 +
|
 +
|CNS melanoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|16
 +
|16
 +
|1
 +
|-
 +
|Amato
 +
|Robert J
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1985
 +
|2010
 +
|
 +
|
 +
|Bladder cancer; Penile cancer; Prostate cancer; Renal cell carcinoma; Testicular cancer
 +
|5
 +
|2
 +
|3
 +
|0
 +
|39
 +
|35
 +
|1
 +
|-
 +
|Amato
 +
|S
 +
|CBD
 +
|
 +
|
 +
|
 +
|Argentina
 +
|1995
 +
|1999
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Amatruda
 +
|Thomas T
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2006
 +
|2015
 +
|NCCTG
 +
|
 +
|Melanoma
 +
|3
 +
|0
 +
|1
 +
|1
 +
|48
 +
|43
 +
|1
 +
|-
 +
|Amatu
 +
|Alessio
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2012
 +
|2017
 +
|
 +
|
 +
|Colorectal cancer; Non-small cell lung cancer; NTRK
 +
|2
 +
|0
 +
|0
 +
|2
 +
|63
 +
|57
 +
|1
 +
|-
 +
|Ambarkhane
 +
|Sumeet
 +
|MALE
 +
|
 +
|
 +
|
 +
|Germany
 +
|2016
 +
|2021
 +
|
 +
|
 +
|Diffuse large B-cell lymphoma; Transformed lymphoma
 +
|2
 +
|0
 +
|0
 +
|1
 +
|36
 +
|21
 +
|1
 +
|-
 +
|Ambinder
 +
|Richard F
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1998
 +
|2018
 +
|A5264/AMC-067 REACT-KS Team; AIDS Malignancy Consortium; BMT CTN
 +
|
 +
|Autologous HSCT; Burkitt lymphoma; Diffuse large B-cell lymphoma; Graft versus host disease; HIV-associated lymphoma; Hodgkin lymphoma; Kaposi sarcoma
 +
|9
 +
|2
 +
|4
 +
|0
 +
|136
 +
|109
 +
|1
 +
|-
 +
|Ambo
 +
|Y
 +
|CBD
 +
|
 +
|
 +
|
 +
|Japan
 +
|2007
 +
|2018
 +
|
 +
|
 +
|Cholangiocarcinoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Ambros
 +
|Peter F
 +
|MALE
 +
|
 +
|
 +
|
 +
|Austria
 +
|2002
 +
|2018
 +
|SIOP Europe Neuroblastoma Group (SIOPEN)
 +
|
 +
|Neuroblastoma
 +
|2
 +
|0
 +
|1
 +
|0
 +
|50
 +
|32
 +
|1
 +
|-
 +
|Ambrose
 +
|David
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2015
 +
|2015
 +
|
 +
|
 +
|Chronic lymphocytic leukemia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|17
 +
|17
 +
|1
 +
|-
 +
|Ambrosetti
 +
|Achille
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|1995
 +
|2017
 +
|FIL; IELSG
 +
|
 +
|Chronic lymphocytic leukemia; CNS lymphoma; Hairy cell leukemia; Hodgkin lymphoma; MALT lymphoma; Mantle cell lymphoma
 +
|7
 +
|0
 +
|1
 +
|0
 +
|211
 +
|166
 +
|1
 +
|-
 +
|Ambrosini
 +
|Giovanni
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|1983
 +
|2011
 +
|Italian Multicentre Breast Study with Epirubicin
 +
|
 +
|Breast cancer; Rectal cancer
 +
|3
 +
|2
 +
|2
 +
|0
 +
|97
 +
|96
 +
|1
 +
|-
 +
|Ambrosini
 +
|Grazia
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2010
 +
|2014
 +
|
 +
|
 +
|Uveal melanoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|27
 +
|27
 +
|1
 +
|-
 +
|Ambrosini
 +
|Maria Teresa
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2002
 +
|2007
 +
|GIMEMA--Italian Multiple Myeloma Network; Gruppo Italiano Malattie Ematologicche dell'Adulto; Italian Multiple Myeloma Network
 +
|
 +
|Multiple myeloma
 +
|3
 +
|0
 +
|1
 +
|0
 +
|52
 +
|36
 +
|1
 +
|-
 +
|Ambrosio
 +
|Francesca
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2009
 +
|2017
 +
|GOIRC
 +
|
 +
|Small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Ambrun
 +
|Alexis
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|France
 +
|2016
 +
|2016
 +
|
 +
|
 +
|Hereditary hemorrhagic telangiectasia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Amellal
 +
|Nadia
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Germany; USA
 +
|1999
 +
|2008
 +
|
 +
|
 +
|Head and neck cancer
 +
|4
 +
|0
 +
|2
 +
|3
 +
|53
 +
|40
 +
|1
 +
|-
 +
|Amendola
 +
|Angela
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2006
 +
|2006
 +
|GIMEMA
 +
|
 +
|Immune thrombocytopenia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|15
 +
|15
 +
|1
 +
|-
 +
|Amenedo Gancedo
 +
|Margarita
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|1999
 +
|2020
 +
|GEICAM
 +
|
 +
|Breast cancer; Ovarian cancer
 +
|4
 +
|0
 +
|2
 +
|1
 +
|93
 +
|48
 +
|1
 +
|-
 +
|Ames
 +
|Frederick C
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1977
 +
|2004
 +
|
 +
|
 +
|Breast cancer
 +
|5
 +
|0
 +
|5
 +
|0
 +
|65
 +
|36
 +
|1
 +
|-
 +
|Ames
 +
|Patricia
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1998
 +
|2002
 +
|
 +
|
 +
|Melanoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|11
 +
|11
 +
|1
 +
|-
 +
|Ameye
 +
|Lieveke
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Belgium
 +
|1998
 +
|2015
 +
|BIG
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|17
 +
|17
 +
|1
 +
|-
 +
|Amiel
 +
|Jean Louis
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1969
 +
|1969
 +
|
 +
|
 +
|B-cell acute lymphoblastic leukemia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|7
 +
|7
 +
|1
 +
|-
 +
|Amillano
 +
|Kepa
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Spain
 +
|2015
 +
|2021
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|39
 +
|39
 +
|1
 +
|-
 +
|Amin
 +
|Amanda L
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2010
 +
|2016
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|33
 +
|33
 +
|1
 +
|-
 +
|Amin
 +
|Asim
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2013
 +
|2020
 +
|
 +
|
 +
|Renal cell carcinoma; Small cell lung cancer
 +
|4
 +
|0
 +
|1
 +
|2
 +
|107
 +
|74
 +
|1
 +
|-
 +
|Amin
 +
|Bipinkumar
 +
|UNMATCHED
 +
|
 +
|
 +
|
 +
|
 +
|2008
 +
|2011
 +
|
 +
|
 +
|Follicular lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Amin
 +
|Himal
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2014
 +
|2021
 +
|
 +
|
 +
|Multiple myeloma
 +
|4
 +
|0
 +
|2
 +
|2
 +
|92
 +
|61
 +
|1
 +
|-
 +
|Amin
 +
|Mahul B
 +
|MALE
 +
|
 +
|
 +
|
 +
|Canada; USA
 +
|1994
 +
|2020
 +
|RTOG
 +
|
 +
|Prostate cancer; Upper tract urothelial carcinoma
 +
|3
 +
|0
 +
|2
 +
|0
 +
|61
 +
|57
 +
|1
 +
|-
 +
|Aminossadati
 +
|Behnaz
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2001
 +
|2009
 +
|
 +
|
 +
|Neuroendocrine tumor; Pancreatic NET
 +
|1
 +
|0
 +
|1
 +
|0
 +
|13
 +
|13
 +
|1
 +
|-
 +
|Amiot
 +
|Martine
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|France
 +
|2012
 +
|2017
 +
|
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Amista
 +
|P
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|2004
 +
|2004
 +
|
 +
|
 +
|Glioblastoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|6
 +
|6
 +
|1
 +
|-
 +
|Amler
 +
|Susanne
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Germany
 +
|2000
 +
|2018
 +
|AML-CG
 +
|
 +
|Acute myeloid leukemia; Autologous HSCT; Ewing sarcoma
 +
|2
 +
|0
 +
|2
 +
|0
 +
|84
 +
|84
 +
|1
 +
|-
 +
|Ammassari
 +
|Adriana
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2002
 +
|2002
 +
|
 +
|
 +
|HIV-associated lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|12
 +
|12
 +
|1
 +
|-
 +
|Amonkar
 +
|Mayur
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2006
 +
|2021
 +
|
 +
|
 +
|Colorectal cancer; Head and neck cancer
 +
|2
 +
|0
 +
|2
 +
|1
 +
|43
 +
|43
 +
|1
 +
|-
 +
|Amorim
 +
|Gilberto
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2006
 +
|2019
 +
|CIBOMA; GEICAM; LACOG (Latin American Cooperative Oncology Group)
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|37
 +
|37
 +
|1
 +
|-
 +
|Amoroso
 +
|Domenico
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2007
 +
|2018
 +
|GOIRC
 +
|
 +
|Breast cancer; Colorectal cancer; Non-small cell lung cancer
 +
|5
 +
|0
 +
|3
 +
|0
 +
|105
 +
|85
 +
|1
 +
|-
 +
|Amoroso
 +
|Mariangela
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1990
 +
|2002
 +
|
 +
|
 +
|Cervical cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|10
 +
|10
 +
|1
 +
|-
 +
|Amoroso
 +
|Vito
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2014
 +
|2021
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|25
 +
|25
 +
|1
 +
|-
 +
|Amos
 +
|Claire L
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2005
 +
|2019
 +
|
 +
|
 +
|Prostate cancer
 +
|3
 +
|0
 +
|1
 +
|0
 +
|141
 +
|83
 +
|1
 +
|-
 +
|Amott
 +
|S J
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|
 +
|1984
 +
|1996
 +
|MRC
 +
|
 +
|Rectal cancer
 +
|1
 +
|1
 +
|1
 +
|0
 +
|2
 +
|2
 +
|1
 +
|-
 +
|Amoura
 +
|Zahir
 +
|MALE
 +
|
 +
|
 +
|
 +
|France
 +
|2014
 +
|2014
 +
|
 +
|
 +
|Erdheim-Chester disease
 +
|1
 +
|1
 +
|0
 +
|0
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Amrein
 +
|Philip C
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1990
 +
|2004
 +
|CALGB
 +
|
 +
|Acute myeloid leukemia
 +
|2
 +
|0
 +
|1
 +
|0
 +
|16
 +
|16
 +
|1
 +
|-
 +
|Amthauer
 +
|Holger
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2003
 +
|2012
 +
|Arbeitsgemeinschaft Medikamentoese Tumortherapie; GHSG; SAKK
 +
|
 +
|Hodgkin lymphoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|30
 +
|30
 +
|1
 +
|-
 +
|Amundsen
 +
|Tore
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2005
 +
|2012
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|21
 +
|15
 +
|1
 +
|-
 +
|Amunni
 +
|Gianni
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1990
 +
|2002
 +
|
 +
|
 +
|Cervical cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|10
 +
|10
 +
|1
 +
|-
 +
|Amutio
 +
|Elena
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1996
 +
|2003
 +
|Programa de Estudio y Traitmiento de las Hemopatias Malignas
 +
|
 +
|Acute promyelocytic leukemia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Amylon
 +
|Michael D
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1987
 +
|1999
 +
|POG
 +
|
 +
|B-cell acute lymphoblastic leukemia; B-cell acute lymphoblastic leukemia pediatric; Graft versus host disease; T-cell acute lymphoblastic leukemia pediatric
 +
|3
 +
|1
 +
|2
 +
|0
 +
|36
 +
|35
 +
|1
 +
|-
 +
|Amzal
 +
|Billy
 +
|MALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2011
 +
|2016
 +
|
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|21
 +
|21
 +
|1
 +
|-
 +
|An
 +
|Gang
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|China
 +
|2017
 +
|2021
 +
|
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|19
 +
|19
 +
|1
 +
|-
 +
|An
 +
|J Y
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|South Korea
 +
|2013
 +
|2020
 +
|
 +
|
 +
|Gastric cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|22
 +
|22
 +
|1
 +
|-
 +
|An
 +
|Ruifang
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|China
 +
|2017
 +
|2022
 +
|
 +
|
 +
|Ovarian cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|70
 +
|60
 +
|1
 +
|-
 +
|An
 +
|Xin
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|China
 +
|2010
 +
|2022
 +
|South China Breast Cancer Group (SCBCG)
 +
|
 +
|Breast cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|58
 +
|40
 +
|1
 +
|-
 +
|An
 +
|Xuebei
 +
|CBD
 +
|
 +
|
 +
|
 +
|USA
 +
|2016
 +
|2020
 +
|
 +
|
 +
|Breast cancer; CNS carcinoma
 +
|1
 +
|0
 +
|1
 +
|1
 +
|28
 +
|28
 +
|1
 +
|-
 +
|Anagnostopoulos
 +
|Achilles
 +
|MALE
 +
|
 +
|
 +
|
 +
|Greece
 +
|2007
 +
|2022
 +
|HORG
 +
|
 +
|Acute myeloid leukemia; Chronic myelomonocytic leukemia; Colon cancer; Myelodysplastic syndrome
 +
|5
 +
|0
 +
|4
 +
|1
 +
|104
 +
|80
 +
|1
 +
|-
 +
|Anagnostopoulos
 +
|Athanasios
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1999
 +
|2007
 +
|
 +
|
 +
|Multiple myeloma; Waldenstroem macroglobulinemia
 +
|5
 +
|2
 +
|1
 +
|0
 +
|58
 +
|40
 +
|1
 +
|-
 +
|Anagnostopoulos
 +
|Ioannis
 +
|MALE
 +
|
 +
|
 +
|
 +
|Germany
 +
|1999
 +
|2016
 +
|European PTLD Network; German PTLD Study Group.
 +
|
 +
|Post-transplant lymphoproliferative disorder
 +
|3
 +
|0
 +
|0
 +
|0
 +
|51
 +
|38
 +
|1
 +
|-
 +
|Anagnostopoulos
 +
|Nikolaos
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1999
 +
|2007
 +
|
 +
|
 +
|Multiple myeloma; Waldenstroem macroglobulinemia
 +
|5
 +
|1
 +
|1
 +
|0
 +
|59
 +
|35
 +
|1
 +
|-
 +
|Anagnostopoulou
 +
|Ourania
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1999
 +
|2005
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|16
 +
|16
 +
|1
 +
|-
 +
|Anaissie
 +
|Elias
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1990
 +
|2010
 +
|
 +
|
 +
|Multiple myeloma
 +
|9
 +
|0
 +
|0
 +
|0
 +
|122
 +
|54
 +
|1
 +
|-
 +
|Anak
 +
|Oezlem
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Switzerland; USA
 +
|1999
 +
|2021
 +
|EORTC
 +
|
 +
|Autologous HSCT; Colorectal cancer; Diffuse large B-cell lymphoma; Follicular lymphoma; Hepatocellular carcinoma; Renal cell carcinoma; Subependymal giant cell astrocytoma; Transformed lymphoma
 +
|7
 +
|0
 +
|3
 +
|3
 +
|147
 +
|139
 +
|1
 +
|-
 +
|Anand
 +
|Aseem
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2007
 +
|2010
 +
|Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Anand
 +
|Palka
 +
|UNMATCHED
 +
|
 +
|
 +
|
 +
|USA
 +
|2012
 +
|2016
 +
|
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|8
 +
|8
 +
|1
 +
|-
 +
|Ananthakrishnan
 +
|Revathi
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2016
 +
|2016
 +
|
 +
|
 +
|Follicular lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|9
 +
|9
 +
|1
 +
|-
 +
|Anasetti
 +
|Claudio
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1985
 +
|2003
 +
|
 +
|
 +
|Allogeneic HSCT; Chronic myeloid leukemia
 +
|2
 +
|1
 +
|0
 +
|0
 +
|28
 +
|25
 +
|1
 +
|-
 +
|Anastasi
 +
|John
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1998
 +
|2008
 +
|CALGB
 +
|
 +
|Acute myeloid leukemia
 +
|2
 +
|0
 +
|1
 +
|0
 +
|23
 +
|16
 +
|1
 +
|-
 +
|Anastasia
 +
|Antonella
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2008
 +
|2021
 +
|FIL; Rete Ematologica Lombarda–CLL Workgroup
 +
|
 +
|Chronic lymphocytic leukemia; Follicular lymphoma; Hairy cell leukemia; Hodgkin lymphoma
 +
|5
 +
|0
 +
|1
 +
|0
 +
|136
 +
|121
 +
|1
 +
|-
 +
|Anastasopoulou
 +
|Anastasia
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2001
 +
|2001
 +
|EORTC
 +
|
 +
|Cervical cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|12
 +
|12
 +
|1
 +
|-
 +
|Ancell
 +
|Kristin
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2010
 +
|2014
 +
|
 +
|
 +
|Uveal melanoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|27
 +
|27
 +
|1
 +
|-
 +
|Anchisi
 +
|Sandro
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Switzerland
 +
|2007
 +
|2016
 +
|SAKK
 +
|
 +
|Breast cancer; Colorectal cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|39
 +
|36
 +
|1
 +
|-
 +
|Anciaux
 +
|Nicole
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1998
 +
|2006
 +
|EORTC
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Ancliff
 +
|Philip
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2003
 +
|2010
 +
|
 +
|
 +
|B-cell acute lymphoblastic leukemia pediatric; T-cell acute lymphoblastic leukemia pediatric
 +
|1
 +
|0
 +
|1
 +
|0
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Ancona
 +
|Ermanno
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|1992
 +
|2001
 +
|
 +
|
 +
|Esophageal cancer
 +
|1
 +
|1
 +
|1
 +
|0
 +
|8
 +
|8
 +
|1
 +
|-
 +
|Ancukiewicz
 +
|Marek
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2006
 +
|2009
 +
|
 +
|
 +
|Hepatocellular carcinoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Andel
 +
|Johannes
 +
|MALE
 +
|
 +
|
 +
|
 +
|Austria
 +
|2007
 +
|2016
 +
|AGMT
 +
|
 +
|Chronic lymphocytic leukemia; Diffuse large B-cell lymphoma
 +
|2
 +
|0
 +
|2
 +
|0
 +
|45
 +
|40
 +
|1
 +
|-
 +
|Andergassen
 +
|Ulrich
 +
|MALE
 +
|
 +
|
 +
|
 +
|Germany
 +
|2005
 +
|2020
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|24
 +
|24
 +
|1
 +
|-
 +
|Anderl
 +
|Janet
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2012
 +
|2016
 +
|
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|16
 +
|16
 +
|1
 +
|-
 +
|Anderlini
 +
|Paolo
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2009
 +
|2014
 +
|
 +
|
 +
|Allogeneic HSCT; Diffuse large B-cell lymphoma; Follicular lymphoma; Hodgkin lymphoma; Mantle cell lymphoma; Transformed lymphoma
 +
|6
 +
|1
 +
|0
 +
|0
 +
|101
 +
|55
 +
|1
 +
|-
 +
|Anders
 +
|Carey K
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2008
 +
|2022
 +
|CALGB
 +
|
 +
|Breast cancer; CNS carcinoma
 +
|4
 +
|0
 +
|3
 +
|1
 +
|90
 +
|68
 +
|1
 +
|-
 +
|Anders
 +
|Robert A
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2013
 +
|2017
 +
|
 +
|
 +
|Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; MSI-H or dMMR
 +
|2
 +
|0
 +
|0
 +
|1
 +
|79
 +
|57
 +
|1
 +
|-
 +
|Andersen
 +
|Barbara L
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2015
 +
|2020
 +
|
 +
|
 +
|Chronic lymphocytic leukemia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Andersen
 +
|E
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|1983
 +
|1990
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|6
 +
|6
 +
|1
 +
|-
 +
|Andersen
 +
|J C
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|USA
 +
|1994
 +
|1994
 +
|
 +
|
 +
|Immune thrombocytopenia
 +
|1
 +
|1
 +
|0
 +
|0
 +
|0
 +
|0
 +
|1
 +
|-
 +
|Andersen
 +
|James S
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1992
 +
|1996
 +
|
 +
|
 +
|Pancreatic cancer
 +
|1
 +
|0
 +
|0
 +
|1
 +
|11
 +
|11
 +
|1
 +
|-
 +
|Andersen
 +
|Janet W
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1977
 +
|2002
 +
|ECOG
 +
|
 +
|Acute promyelocytic leukemia; Breast cancer; Chronic lymphocytic leukemia; Diffuse large B-cell lymphoma; Follicular lymphoma
 +
|6
 +
|0
 +
|5
 +
|0
 +
|56
 +
|43
 +
|1
 +
|-
 +
|Andersen
 +
|Jay C
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2017
 +
|2022
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|1
 +
|29
 +
|29
 +
|1
 +
|-
 +
|Andersen
 +
|Joern Erik
 +
|MALE
 +
|
 +
|
 +
|
 +
|Denmark
 +
|1994
 +
|2000
 +
|
 +
|
 +
|Ovarian cancer
 +
|1
 +
|0
 +
|1
 +
|1
 +
|27
 +
|27
 +
|1
 +
|-
 +
|Andersen
 +
|John
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1992
 +
|1997
 +
|
 +
|
 +
|Pancreatic cancer
 +
|1
 +
|0
 +
|1
 +
|1
 +
|13
 +
|13
 +
|1
 +
|-
 +
|Andersen
 +
|Jorn
 +
|MALE
 +
|
 +
|
 +
|
 +
|Denmark
 +
|1977
 +
|2013
 +
|DBCG; Intergroup Exemestane Study; Scandinavian Breast Group
 +
|
 +
|Breast cancer; Diffuse large B-cell lymphoma
 +
|10
 +
|2
 +
|8
 +
|1
 +
|126
 +
|76
 +
|1
 +
|-
 +
|Andersen
 +
|Knud West
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1977
 +
|1983
 +
|DBCG
 +
|
 +
|Breast cancer
 +
|2
 +
|1
 +
|2
 +
|0
 +
|12
 +
|10
 +
|1
 +
|-
 +
|Andersen
 +
|Niels Frost
 +
|MALE
 +
|
 +
|
 +
|
 +
|Denmark
 +
|2005
 +
|2020
 +
|
 +
|
 +
|Multiple myeloma
 +
|3
 +
|0
 +
|3
 +
|0
 +
|101
 +
|92
 +
|1
 +
|-
 +
|Andersen
 +
|Niels S
 +
|MALE
 +
|
 +
|
 +
|
 +
|Denmark
 +
|2000
 +
|2016
 +
|Nordic Lymphoma Group
 +
|
 +
|Autologous HSCT; Mantle cell lymphoma
 +
|3
 +
|0
 +
|0
 +
|0
 +
|67
 +
|30
 +
|1
 +
|-
 +
|Andersen
 +
|Willie A
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1993
 +
|2004
 +
|GOG
 +
|
 +
|Cervical cancer; Endometrial cancer
 +
|4
 +
|4
 +
|1
 +
|0
 +
|22
 +
|18
 +
|1
 +
|-
 +
|Anderson
 +
|Abraham
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2009
 +
|2021
 +
|
 +
|
 +
|Esophageal adenocarcinoma; Non-small cell lung cancer
 +
|2
 +
|0
 +
|0
 +
|1
 +
|40
 +
|40
 +
|1
 +
|-
 +
|Anderson
 +
|Barrie
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|
 +
|1990
 +
|1997
 +
|GOG
 +
|
 +
|Cervical cancer
 +
|1
 +
|1
 +
|1
 +
|0
 +
|6
 +
|6
 +
|1
 +
|-
 +
|Anderson
 +
|Barry
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2001
 +
|2010
 +
|CCG; COG
 +
|
 +
|Ewing sarcoma; Neuroblastoma; Osteosarcoma
 +
|2
 +
|0
 +
|1
 +
|1
 +
|26
 +
|26
 +
|1
 +
|-
 +
|Anderson
 +
|Cathy
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1980
 +
|1987
 +
|
 +
|
 +
|Autologous HSCT; Diffuse large B-cell lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Anderson
 +
|Charles K
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2016
 +
|2021
 +
|
 +
|
 +
|Ovarian cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|47
 +
|47
 +
|1
 +
|-
 +
|Anderson
 +
|Clay M
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1995
 +
|2022
 +
|RTOG
 +
|
 +
|Esophageal cancer; Melanoma
 +
|2
 +
|0
 +
|2
 +
|0
 +
|41
 +
|41
 +
|1
 +
|-
 +
|Anderson
 +
|Daniel M
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2011
 +
|2021
 +
|ECOG
 +
|
 +
|Breast cancer; Follicular lymphoma; Multiple myeloma
 +
|3
 +
|0
 +
|2
 +
|0
 +
|74
 +
|74
 +
|1
 +
|-
 +
|Anderson
 +
|David R
 +
|MALE
 +
|
 +
|
 +
|
 +
|Canada
 +
|2003
 +
|2018
 +
|
 +
|
 +
|Antiphospholipid antibody syndrome; Venous thromboembolism
 +
|3
 +
|2
 +
|3
 +
|0
 +
|65
 +
|44
 +
|1
 +
|-
 +
|Anderson
 +
|Harald
 +
|MALE
 +
|
 +
|
 +
|
 +
|Sweden
 +
|1978
 +
|2016
 +
|Nordic Lymphoma Group; Scandinavian Breast Group
 +
|
 +
|Autologous HSCT; Breast cancer; CNS lymphoma; Diffuse large B-cell lymphoma; Peripheral T-cell lymphoma
 +
|7
 +
|0
 +
|5
 +
|0
 +
|92
 +
|76
 +
|1
 +
|-
 +
|Anderson
 +
|Heather A
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1995
 +
|2006
 +
|BTOG
 +
|
 +
|Esophageal cancer; Gastric cancer; Non-small cell lung cancer
 +
|4
 +
|0
 +
|4
 +
|0
 +
|47
 +
|40
 +
|1
 +
|-
 +
|Anderson
 +
|J
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|USA
 +
|2008
 +
|2008
 +
|
 +
|
 +
|Anaplastic glioma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|9
 +
|9
 +
|1
 +
|-
 +
|Anderson
 +
|James R
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1972
 +
|2019
 +
|CALGB; CCG; COG; ECOG
 +
|
 +
|Acute myeloid leukemia; B-cell acute lymphoblastic leukemia; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Melanoma; Rhabdomyosarcoma; Soft tissue sarcoma
 +
|14
 +
|2
 +
|11
 +
|1
 +
|164
 +
|124
 +
|1
 +
|-
 +
|Anderson
 +
|Jeanne E
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1995
 +
|2002
 +
|SWOG
 +
|
 +
|Acute myeloid leukemia
 +
|1
 +
|1
 +
|1
 +
|0
 +
|10
 +
|10
 +
|1
 +
|-
 +
|Anderson
 +
|Jeffrey
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2012
 +
|2020
 +
|
 +
|
 +
|Hepatocellular carcinoma
 +
|2
 +
|0
 +
|0
 +
|1
 +
|40
 +
|31
 +
|1
 +
|-
 +
|Anderson
 +
|Jennifer J
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1976
 +
|2004
 +
|
 +
|
 +
|Autologous HSCT; Light-chain (AL) amyloidosis
 +
|2
 +
|0
 +
|0
 +
|0
 +
|19
 +
|17
 +
|1
 +
|-
 +
|Anderson
 +
|John B
 +
|MALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|1995
 +
|2012
 +
|MRC; NCIC
 +
|
 +
|Prostate cancer
 +
|4
 +
|0
 +
|3
 +
|0
 +
|52
 +
|43
 +
|1
 +
|-
 +
|Anderson
 +
|Karen S
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2013
 +
|2017
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|33
 +
|33
 +
|1
 +
|-
 +
|Anderson
 +
|Kenneth C
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1982
 +
|2022
 +
|CALGB; FIRST Trial Team; IFM; SWOG; Waldenstroem's Macroglobulinemia Clinical Trials Group
 +
|
 +
|Autologous HSCT; Diffuse large B-cell lymphoma; Multiple myeloma; Waldenstroem macroglobulinemia
 +
|38
 +
|18
 +
|13
 +
|9
 +
|818
 +
|389
 +
|1
 +
|-
 +
|Anderson
 +
|Larry D
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2010
 +
|2022
 +
|
 +
|
 +
|Multiple myeloma
 +
|4
 +
|1
 +
|2
 +
|2
 +
|167
 +
|151
 +
|1
 +
|-
 +
|Anderson
 +
|Lisa
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2017
 +
|2019
 +
|
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|1
 +
|1
 +
|34
 +
|34
 +
|1
 +
|-
 +
|Anderson
 +
|Lxxx
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|
 +
|1983
 +
|1994
 +
|BNLI
 +
|
 +
|Hodgkin lymphoma
 +
|2
 +
|0
 +
|2
 +
|0
 +
|12
 +
|7
 +
|1
 +
|-
 +
|Anderson
 +
|Mary Ann
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Australia
 +
|2011
 +
|2018
 +
|
 +
|
 +
|Chronic lymphocytic leukemia; Mantle cell lymphoma
 +
|2
 +
|0
 +
|0
 +
|1
 +
|34
 +
|32
 +
|1
 +
|-
 +
|Anderson
 +
|Michael J
 +
|MALE
 +
|
 +
|
 +
|
 +
|Denmark; USA
 +
|1979
 +
|2015
 +
|BIG
 +
|
 +
|Breast cancer; Cutaneous T-cell lymphoma
 +
|2
 +
|0
 +
|2
 +
|0
 +
|29
 +
|29
 +
|1
 +
|-
 +
|Anderson
 +
|Nancy
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|USA
 +
|2012
 +
|2020
 +
|GOG
 +
|
 +
|Gestational trophoblastic neoplasia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|12
 +
|12
 +
|1
 +
|-
 +
|Anderson
 +
|Nicole D
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2003
 +
|2003
 +
|
 +
|
 +
|Autologous HSCT; CNS lymphoma; Stem cell mobilization
 +
|1
 +
|0
 +
|0
 +
|0
 +
|12
 +
|12
 +
|1
 +
|-
 +
|Anderson
 +
|Patricia
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1985
 +
|1992
 +
|SWOG
 +
|
 +
|Ovarian cancer
 +
|1
 +
|0
 +
|1
 +
|1
 +
|9
 +
|9
 +
|1
 +
|-
 +
|Anderson
 +
|Peter M
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2002
 +
|2002
 +
|
 +
|
 +
|Osteosarcoma
 +
|1
 +
|1
 +
|0
 +
|0
 +
|7
 +
|7
 +
|1
 +
|-
 +
|Anderson
 +
|Richard T
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1979
 +
|1991
 +
|NCCTG
 +
|
 +
|Non-small cell lung cancer; Small cell lung cancer
 +
|2
 +
|2
 +
|2
 +
|0
 +
|24
 +
|19
 +
|1
 +
|-
 +
|Anderson
 +
|Russell D
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2009
 +
|2009
 +
|
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|15
 +
|15
 +
|1
 +
|-
 +
|Anderson
 +
|Sibyl
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2003
 +
|2010
 +
|Sorafenib TARGET Clinical Trial Group
 +
|
 +
|Clear cell renal cell carcinoma; Renal cell carcinoma
 +
|2
 +
|0
 +
|1
 +
|1
 +
|27
 +
|21
 +
|1
 +
|-
 +
|Anderson
 +
|Stewart J
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1982
 +
|2018
 +
|BOOG Dutch Breast Cancer Trialists' Group; Breast International Group; GEICAM Spanish Breast Cancer Group; International Breast Cancer Study Group; NRG Oncology; NSABP
 +
|
 +
|Breast cancer
 +
|11
 +
|0
 +
|11
 +
|2
 +
|153
 +
|81
 +
|1
 +
|-
 +
|Anderson
 +
|Sxxx
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|1996
 +
|2004
 +
|
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|7
 +
|7
 +
|1
 +
|-
 +
|Anderson
 +
|Tara
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2009
 +
|2012
 +
|
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Anderson
 +
|Thomas
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1972
 +
|2008
 +
|ECOG; Hoosier Oncology Group; US Oncology
 +
|
 +
|Colorectal cancer; Non-small cell lung cancer; Ovarian cancer
 +
|3
 +
|0
 +
|3
 +
|0
 +
|34
 +
|34
 +
|1
 +
|-
 +
|Andersson
 +
|Borje S
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1990
 +
|2019
 +
|
 +
|
 +
|Acute myeloid leukemia; Allogeneic HSCT; Breast cancer; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Multiple myeloma
 +
|8
 +
|3
 +
|2
 +
|0
 +
|125
 +
|99
 +
|1
 +
|-
 +
|Andersson
 +
|Haakan
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|
 +
|1995
 +
|2010
 +
|EORTC
 +
|
 +
|Endometrial cancer; Ovarian cancer
 +
|3
 +
|0
 +
|3
 +
|0
 +
|29
 +
|23
 +
|1
 +
|-
 +
|Andersson
 +
|Michael
 +
|MALE
 +
|
 +
|
 +
|
 +
|Denmark
 +
|1977
 +
|2021
 +
|BIG; DBCG; EORTC; GBG; Herceptin Adjuvant (HERA) Trial Study Team; monarchE Committee Members
 +
|
 +
|Breast cancer
 +
|17
 +
|2
 +
|13
 +
|3
 +
|299
 +
|203
 +
|1
 +
|-
 +
|Andersson
 +
|Per-Ola
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Sweden
 +
|2011
 +
|2016
 +
|
 +
|
 +
|Chronic lymphocytic leukemia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Andersson
 +
|Ronny
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1998
 +
|1998
 +
|
 +
|
 +
|Melanoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|12
 +
|12
 +
|1
 +
|-
 +
|Andersson
 +
|Swen Olof
 +
|MALE
 +
|
 +
|
 +
|
 +
|Sweden
 +
|1989
 +
|2018
 +
|SPCG
 +
|
 +
|Prostate cancer
 +
|6
 +
|0
 +
|1
 +
|0
 +
|78
 +
|22
 +
|1
 +
|-
 +
|Ando
 +
|Jiro
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1994
 +
|2014
 +
|JCOG
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|10
 +
|10
 +
|1
 +
|-
 +
|Ando
 +
|Kiyoshi
 +
|MALE
 +
|
 +
|
 +
|
 +
|Japan
 +
|2002
 +
|2021
 +
|JCOG
 +
|
 +
|Acute myeloid leukemia; Cutaneous T-cell lymphoma; Diffuse large B-cell lymphoma; Follicular lymphoma; Multiple myeloma; Peripheral T-cell lymphoma
 +
|12
 +
|1
 +
|5
 +
|1
 +
|229
 +
|166
 +
|1
 +
|-
 +
|Ando
 +
|Masahiko
 +
|MALE
 +
|
 +
|
 +
|
 +
|Japan
 +
|2000
 +
|2021
 +
|JCOG; WJOG; WJTOG
 +
|
 +
|Cholangiocarcinoma; Colorectal cancer; Non-small cell lung cancer; Non-small cell lung cancer squamous; Small cell lung cancer
 +
|14
 +
|0
 +
|13
 +
|0
 +
|260
 +
|168
 +
|1
 +
|-
 +
|Ando
 +
|Masahiro
 +
|MALE
 +
|
 +
|
 +
|
 +
|Japan
 +
|2006
 +
|2010
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|22
 +
|22
 +
|1
 +
|-
 +
|Ando
 +
|Masashi
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2004
 +
|2009
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|15
 +
|15
 +
|1
 +
|-
 +
|Ando
 +
|Nobutoshi
 +
|MALE
 +
|
 +
|
 +
|
 +
|Japan
 +
|1988
 +
|2011
 +
|JCOG
 +
|
 +
|Esophageal cancer
 +
|3
 +
|3
 +
|3
 +
|0
 +
|43
 +
|32
 +
|1
 +
|-
 +
|Ando
 +
|Yuichi
 +
|MALE
 +
|
 +
|
 +
|
 +
|Japan
 +
|2012
 +
|2018
 +
|
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|23
 +
|23
 +
|1
 +
|-
 +
|Andoh
 +
|J
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|1999
 +
|2009
 +
|JCOG
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|10
 +
|10
 +
|1
 +
|-
 +
|Andorsky
 +
|David
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2011
 +
|2019
 +
|
 +
|
 +
|Chronic myeloid leukemia; Diffuse large B-cell lymphoma
 +
|2
 +
|0
 +
|2
 +
|0
 +
|35
 +
|35
 +
|1
 +
|-
 +
|Andrade
 +
|Luciana
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Brazil
 +
|2017
 +
|2021
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Andre
 +
|Fabrice
 +
|MALE
 +
|
 +
|
 +
|
 +
|France
 +
|2006
 +
|2022
 +
|
 +
|
 +
|Breast cancer
 +
|16
 +
|4
 +
|9
 +
|4
 +
|336
 +
|223
 +
|1
 +
|-
 +
|Andre
 +
|Marc P E
 +
|MALE
 +
|
 +
|
 +
|
 +
|Belgium
 +
|1996
 +
|2021
 +
|EORTC; European Mantle Cell Lymphoma Network; FIL; GELA; Lymphoma Study Association; LYSA; SFGM
 +
|
 +
|Autologous HSCT; Diffuse large B-cell lymphoma; Follicular lymphoma; Hodgkin lymphoma; Mantle cell lymphoma; Peripheral T-cell lymphoma; Transformed lymphoma
 +
|14
 +
|1
 +
|14
 +
|1
 +
|340
 +
|212
 +
|1
 +
|-
 +
|Andre
 +
|Niko
 +
|MALE
 +
|
 +
|
 +
|
 +
|Switzerland
 +
|2007
 +
|2013
 +
|
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|10
 +
|10
 +
|1
 +
|-
 +
|Andre
 +
|Thierry
 +
|MALE
 +
|
 +
|
 +
|
 +
|France
 +
|1996
 +
|2022
 +
|AERO; FFCD; FNCLCC; GERCOR; GISCAD; Group Cooperateur Multidisciplinaire en Oncologie; HORG; PRODIGE investigators, GERCOR, Federation Francaise de Cancerologie Digestive, UNICANCER
 +
|
 +
|Anal cancer; Colon cancer; Colorectal cancer; Desmoid tumor; Esophageal adenocarcinoma; Gastric cancer; MSI-H or dMMR; Pancreatic cancer; Rectal cancer
 +
|35
 +
|16
 +
|20
 +
|5
 +
|612
 +
|348
 +
|1
 +
|-
 +
|Andre
 +
|Valerie A M
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2017
 +
|2021
 +
|monarchE Committee Members
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|1
 +
|34
 +
|34
 +
|1
 +
|-
 +
|Andreadis
 +
|Charalambos
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1998
 +
|2021
 +
|
 +
|
 +
|Autologous HSCT; Diffuse large B-cell lymphoma; Follicular lymphoma; Ovarian cancer; Primary mediastinal B-cell lymphoma; Transformed lymphoma
 +
|5
 +
|0
 +
|2
 +
|3
 +
|124
 +
|101
 +
|1
 +
|-
 +
|Andreas
 +
|Stefan
 +
|MALE
 +
|
 +
|
 +
|
 +
|Germany
 +
|2005
 +
|2016
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|10
 +
|10
 +
|1
 +
|-
 +
|Andreasson
 +
|Bjoern
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2007
 +
|2012
 +
|
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Andreeff
 +
|Michael
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1984
 +
|2020
 +
|
 +
|
 +
|Acute myeloid leukemia; Acute promyelocytic leukemia; B-cell acute lymphoblastic leukemia; Chronic lymphocytic leukemia; CNS leukemia; Hypereosinophilic syndrome
 +
|15
 +
|1
 +
|2
 +
|1
 +
|273
 +
|130
 +
|1
 +
|-
 +
|Andreescu
 +
|Astrid C
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2010
 +
|2022
 +
|
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|55
 +
|55
 +
|1
 +
|-
 +
|Andreesen
 +
|Reinhard
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1992
 +
|2012
 +
|Arbeitsgemeinschaft Medikamentoese Tumortherapie; GHSG; SAKK
 +
|
 +
|Breast cancer; Hodgkin lymphoma
 +
|2
 +
|0
 +
|2
 +
|0
 +
|44
 +
|44
 +
|1
 +
|-
 +
|Andreetta
 +
|Claudia
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2014
 +
|2021
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|25
 +
|25
 +
|1
 +
|-
 +
|Andren
 +
|Ove
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Sweden
 +
|1989
 +
|2018
 +
|SPCG
 +
|
 +
|Prostate cancer
 +
|2
 +
|0
 +
|1
 +
|0
 +
|25
 +
|14
 +
|1
 +
|-
 +
|Andreola
 +
|Giovanna
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Switzerland
 +
|2019
 +
|2021
 +
|
 +
|
 +
|Diffuse large B-cell lymphoma; Waldenstroem macroglobulinemia
 +
|2
 +
|0
 +
|1
 +
|0
 +
|53
 +
|53
 +
|1
 +
|-
 +
|Andreoli
 +
|Laura
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2018
 +
|2018
 +
|
 +
|
 +
|Antiphospholipid antibody syndrome
 +
|1
 +
|0
 +
|1
 +
|0
 +
|21
 +
|21
 +
|1
 +
|-
 +
|Andreopoulos
 +
|Demetrios
 +
|MALE
 +
|
 +
|
 +
|
 +
|Cyprus
 +
|2001
 +
|2021
 +
|EORTC
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|21
 +
|21
 +
|1
 +
|-
 +
|Andreou
 +
|Cal
 +
|MALE
 +
|
 +
|
 +
|
 +
|Canada
 +
|2006
 +
|2008
 +
|
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|1
 +
|1
 +
|8
 +
|8
 +
|1
 +
|-
 +
|Andreou
 +
|Pantelis
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Canada
 +
|2013
 +
|2018
 +
|
 +
|
 +
|Venous thromboembolism
 +
|2
 +
|0
 +
|2
 +
|0
 +
|47
 +
|28
 +
|1
 +
|-
 +
|Andresen Daniil
 +
|Corina
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2013
 +
|2018
 +
|PLATO collaborators
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|7
 +
|7
 +
|1
 +
|-
 +
|Andreuccetti
 +
|Michele
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2001
 +
|2010
 +
|GONO
 +
|
 +
|Colorectal cancer
 +
|2
 +
|0
 +
|1
 +
|0
 +
|34
 +
|30
 +
|1
 +
|-
 +
|Andrews
 +
|Chris
 +
|MALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2012
 +
|2015
 +
|
 +
|
 +
|Myelofibrosis
 +
|1
 +
|0
 +
|0
 +
|0
 +
|11
 +
|11
 +
|1
 +
|-
 +
|Andrews
 +
|Glen I
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2010
 +
|2016
 +
|
 +
|
 +
|Renal cell carcinoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|8
 +
|8
 +
|1
 +
|-
 +
|Andrews
 +
|Michael B
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2000
 +
|2005
 +
|
 +
|
 +
|Follicular lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|6
 +
|6
 +
|1
 +
|-
 +
|Andrews
 +
|Stephen
 +
|MALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2007
 +
|2018
 +
|
 +
|
 +
|Bladder cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|17
 +
|17
 +
|1
 +
|-
 +
|Andrews
 +
|Vivienne E
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2008
 +
|2019
 +
|National Cancer Research Institute Haemato-oncology Clinical Studies Group
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|2
 +
|0
 +
|21
 +
|21
 +
|1
 +
|-
 +
|Andric
 +
|Zoran
 +
|MALE
 +
|
 +
|
 +
|
 +
|Serbia
 +
|2015
 +
|2021
 +
|
 +
|
 +
|Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous
 +
|2
 +
|0
 +
|1
 +
|1
 +
|39
 +
|25
 +
|1
 +
|-
 +
|Andrien
 +
|J M
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|1985
 +
|1993
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|9
 +
|9
 +
|1
 +
|-
 +
|Andrieu
 +
|Jean Marie
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1990
 +
|2003
 +
|
 +
|
 +
|Hodgkin lymphoma
 +
|1
 +
|1
 +
|1
 +
|0
 +
|15
 +
|15
 +
|1
 +
|-
 +
|Andriole
 +
|Gerald L
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1994
 +
|2017
 +
|
 +
|
 +
|Prostate cancer
 +
|2
 +
|0
 +
|1
 +
|0
 +
|27
 +
|20
 +
|1
 +
|-
 +
|Andritsos
 +
|Leslie A
 +
|UNMATCHED
 +
|
 +
|
 +
|
 +
|USA
 +
|2011
 +
|2015
 +
|
 +
|
 +
|Chronic lymphocytic leukemia
 +
|1
 +
|0
 +
|0
 +
|0
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Androulakis
 +
|Ioannis
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1993
 +
|2002
 +
|HeCOG
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|13
 +
|13
 +
|1
 +
|-
 +
|Androulakis
 +
|Nikolaos
 +
|MALE
 +
|
 +
|
 +
|
 +
|Greece
 +
|1999
 +
|2019
 +
|HORG
 +
|
 +
|Colon cancer; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Small cell lung cancer
 +
|7
 +
|0
 +
|6
 +
|0
 +
|108
 +
|59
 +
|1
 +
|-
 +
|Andrulis
 +
|Irene L
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Canada
 +
|1989
 +
|2006
 +
|NCIC-CTG
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|1
 +
|6
 +
|6
 +
|1
 +
|-
 +
|Andtbacka
 +
|Robert H I
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2009
 +
|2019
 +
|
 +
|
 +
|Melanoma
 +
|2
 +
|2
 +
|1
 +
|1
 +
|34
 +
|30
 +
|1
 +
|-
 +
|Ang
 +
|Agnes
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2012
 +
|2021
 +
|
 +
|
 +
|Gastric cancer; Non-small cell lung cancer
 +
|2
 +
|0
 +
|0
 +
|1
 +
|45
 +
|45
 +
|1
 +
|-
 +
|Ang
 +
|Kie Kian
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1994
 +
|2015
 +
|EORTC; RTOG
 +
|
 +
|Head and neck cancer
 +
|9
 +
|5
 +
|5
 +
|1
 +
|120
 +
|73
 +
|0
 +
|-
 +
|Ang
 +
|Mei Kim
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Singapore
 +
|2004
 +
|2015
 +
|
 +
|
 +
|Nasopharyngeal carcinoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|13
 +
|13
 +
|1
 +
|-
 +
|Ang
 +
|Peng Tiam
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1990
 +
|1994
 +
|
 +
|
 +
|Nasopharyngeal carcinoma
 +
|1
 +
|1
 +
|0
 +
|0
 +
|1
 +
|1
 +
|1
 +
|-
 +
|Angchaisuksiri
 +
|Pantep
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Thailand
 +
|2016
 +
|2016
 +
|
 +
|
 +
|Venous thromboembolism
 +
|1
 +
|0
 +
|1
 +
|0
 +
|13
 +
|13
 +
|1
 +
|-
 +
|Angele
 +
|Martin
 +
|MALE
 +
|
 +
|
 +
|
 +
|Germany
 +
|1997
 +
|2018
 +
|EORTC; European Society for Hyperthermic Oncology
 +
|
 +
|Soft tissue sarcoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|21
 +
|21
 +
|1
 +
|-
 +
|Angeli
 +
|Alberto
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1993
 +
|2005
 +
|Italian Group for the Study of Adrenal Cancer
 +
|
 +
|Adrenocortical carcinoma
 +
|2
 +
|0
 +
|0
 +
|0
 +
|16
 +
|12
 +
|1
 +
|-
 +
|Angelopoulou
 +
|Maria K
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2010
 +
|2010
 +
|
 +
|
 +
|Mantle cell lymphoma
 +
|1
 +
|1
 +
|0
 +
|0
 +
|16
 +
|16
 +
|1
 +
|-
 +
|Angelot Delettre
 +
|Fanny
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|France
 +
|2013
 +
|2014
 +
|
 +
|
 +
|Blastic plasmacytoid dendritic cell neoplasm
 +
|1
 +
|0
 +
|0
 +
|0
 +
|14
 +
|14
 +
|1
 +
|-
 +
|Angelsen
 +
|Anders
 +
|MALE
 +
|
 +
|
 +
|
 +
|Norway
 +
|1995
 +
|2018
 +
|Scandinavian Prostate Cancer Group; SPCG; Swedish Association for Urological Oncology
 +
|
 +
|Prostate cancer
 +
|3
 +
|0
 +
|3
 +
|0
 +
|25
 +
|24
 +
|1
 +
|-
 +
|Angelucci
 +
|Emanuele
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|1995
 +
|2022
 +
|CYTO-PV Collaborative Group; FIL; GIMEMA; Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation
 +
|
 +
|Aplastic anemia; Chronic lymphocytic leukemia; Chronic myelomonocytic leukemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Hodgkin lymphoma; Polycythemia vera
 +
|9
 +
|0
 +
|6
 +
|0
 +
|221
 +
|188
 +
|1
 +
|-
 +
|Angermund
 +
|Ralf
 +
|MALE
 +
|
 +
|
 +
|
 +
|Germany
 +
|2006
 +
|2013
 +
|
 +
|
 +
|Multiple myeloma
 +
|2
 +
|0
 +
|0
 +
|1
 +
|20
 +
|17
 +
|1
 +
|-
 +
|Anghel
 +
|Rodica
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Romania
 +
|2008
 +
|2016
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Angiolillo
 +
|Anne L
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2000
 +
|2021
 +
|CCG; COG
 +
|
 +
|B-cell acute lymphoblastic leukemia pediatric; Ewing sarcoma; Osteosarcoma
 +
|4
 +
|2
 +
|3
 +
|1
 +
|63
 +
|43
 +
|1
 +
|-
 +
|Anglaret
 +
|Bruno
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1995
 +
|2012
 +
|GELA; IFM
 +
|
 +
|Diffuse large B-cell lymphoma; Multiple myeloma
 +
|3
 +
|0
 +
|3
 +
|0
 +
|78
 +
|61
 +
|1
 +
|-
 +
|Anglin
 +
|Peter
 +
|MALE
 +
|
 +
|
 +
|
 +
|Canada
 +
|2003
 +
|2015
 +
|NCIC-CTG
 +
|
 +
|Multiple myeloma; Transformed lymphoma
 +
|2
 +
|0
 +
|1
 +
|0
 +
|26
 +
|26
 +
|1
 +
|-
 +
|Angra
 +
|Natasha
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2015
 +
|2020
 +
|
 +
|
 +
|Bladder cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|28
 +
|28
 +
|1
 +
|-
 +
|Angrilli
 +
|Francesco
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2000
 +
|2017
 +
|FIL; IELSG
 +
|
 +
|CNS lymphoma; Follicular lymphoma; Hodgkin lymphoma; Mantle cell lymphoma
 +
|6
 +
|0
 +
|2
 +
|0
 +
|132
 +
|92
 +
|1
 +
|-
 +
|Angyalfi
 +
|Steve J
 +
|MALE
 +
|
 +
|
 +
|
 +
|Canada
 +
|1999
 +
|2022
 +
|NCIC-CTG
 +
|
 +
|Prostate cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|41
 +
|41
 +
|1
 +
|-
 +
|Anichini
 +
|Andrea
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Italy
 +
|2017
 +
|2018
 +
|
 +
|
 +
|Bladder cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|22
 +
|22
 +
|1
 +
|-
 +
|Anker
 +
|Christopher J
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2008
 +
|2017
 +
|RTOG
 +
|
 +
|Esophageal cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Anker
 +
|Gun
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1994
 +
|2000
 +
|Scandinavian Breast Group
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|17
 +
|17
 +
|1
 +
|-
 +
|Annamalai
 +
|Lakshmanan
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2015
 +
|2016
 +
|
 +
|
 +
|Merkel cell carcinoma
 +
|1
 +
|0
 +
|0
 +
|1
 +
|30
 +
|30
 +
|1
 +
|-
 +
|Anne
 +
|P Rani
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1999
 +
|2006
 +
|RTOG
 +
|
 +
|Esophageal adenocarcinoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|10
 +
|10
 +
|1
 +
|-
 +
|Annechini
 +
|Giorgia
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2016
 +
|2016
 +
|
 +
|
 +
|Hodgkin lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|17
 +
|17
 +
|1
 +
|-
 +
|Annecke
 +
|K
 +
|CBD
 +
|
 +
|
 +
|
 +
|Germany
 +
|2001
 +
|2016
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|11
 +
|11
 +
|1
 +
|-
 +
|Annett
 +
|Robert D
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2014
 +
|2022
 +
|COG
 +
|
 +
|T-cell acute lymphoblastic leukemia pediatric
 +
|1
 +
|0
 +
|1
 +
|0
 +
|35
 +
|35
 +
|1
 +
|-
 +
|Annibali
 +
|Ombretta
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2007
 +
|2019
 +
|
 +
|
 +
|Acute promyelocytic leukemia
 +
|1
 +
|0
 +
|2
 +
|1
 +
|45
 +
|45
 +
|1
 +
|-
 +
|Annino
 +
|Luciana
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|1988
 +
|2016
 +
|EORTC; GIMEMA
 +
|
 +
|Acute myeloid leukemia; B-cell acute lymphoblastic leukemia; Multiple myeloma
 +
|3
 +
|1
 +
|3
 +
|1
 +
|67
 +
|66
 +
|1
 +
|-
 +
|Annunziata
 +
|Annalisa
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2003
 +
|2006
 +
|MITO
 +
|
 +
|Ovarian cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Annunziata
 +
|Mario
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2017
 +
|2021
 +
|
 +
|
 +
|Chronic myeloid leukemia; Thrombotic thrombocytopenic purpura
 +
|2
 +
|0
 +
|1
 +
|1
 +
|32
 +
|32
 +
|1
 +
|-
 +
|Anota
 +
|Amelie
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|France
 +
|2014
 +
|2018
 +
|
 +
|
 +
|Anal cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|26
 +
|26
 +
|1
 +
|-
 +
|Ansari
 +
|Hassan
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1983
 +
|1994
 +
|
 +
|
 +
|Chronic myeloid leukemia
 +
|1
 +
|1
 +
|1
 +
|0
 +
|43
 +
|42
 +
|1
 +
|-
 +
|Ansari
 +
|Marc
 +
|MALE
 +
|
 +
|
 +
|
 +
|Switzerland
 +
|2007
 +
|2020
 +
|EBMT Paediatric Diseases Working Party; I-BFM SCT Study Group; IBFM Study Group; IntReALL Study Group; SIOPEL
 +
|
 +
|Allogeneic HSCT; Hepatoblastoma
 +
|2
 +
|0
 +
|2
 +
|0
 +
|53
 +
|53
 +
|1
 +
|-
 +
|Ansari
 +
|Rafat H
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1984
 +
|2013
 +
|Alpha Oncology Research Network; CALGB; Fox Chase Network; Hoosier Oncology Group; NCIC-CTG; US Oncology
 +
|
 +
|Breast cancer; Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer
 +
|16
 +
|0
 +
|15
 +
|1
 +
|186
 +
|151
 +
|1
 +
|-
 +
|Ansell
 +
|Peter J
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2012
 +
|2021
 +
|
 +
|
 +
|Non-small cell lung cancer; Non-small cell lung cancer squamous; Ovarian cancer
 +
|3
 +
|0
 +
|2
 +
|0
 +
|70
 +
|67
 +
|1
 +
|-
 +
|Ansell
 +
|Stephen M
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2002
 +
|2022
 +
|NCCTG
 +
|
 +
|Diffuse large B-cell lymphoma; Follicular lymphoma; Hodgkin lymphoma; Mantle cell lymphoma; Transformed lymphoma; Waldenstroem macroglobulinemia
 +
|26
 +
|7
 +
|1
 +
|4
 +
|410
 +
|217
 +
|1
 +
|-
 +
|Anselmo
 +
|Anna Paola
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1988
 +
|2004
 +
|FIL; GHSG
 +
|
 +
|Diffuse large B-cell lymphoma; Hodgkin lymphoma
 +
|4
 +
|0
 +
|1
 +
|0
 +
|57
 +
|50
 +
|1
 +
|-
 +
|Ansfield
 +
|Fred J
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1961
 +
|1985
 +
|Cooperative Breast Cancer Group
 +
|
 +
|Breast cancer; Head and neck cancer
 +
|4
 +
|0
 +
|3
 +
|0
 +
|23
 +
|17
 +
|1
 +
|-
 +
|Ansstas
 +
|George
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2016
 +
|2022
 +
|
 +
|
 +
|Glioblastoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|23
 +
|23
 +
|1
 +
|-
 +
|Antal
 +
|Joyce
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2014
 +
|2017
 +
|
 +
|
 +
|Bladder cancer
 +
|1
 +
|0
 +
|0
 +
|1
 +
|18
 +
|18
 +
|1
 +
|-
 +
|Anter
 +
|A H
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|2006
 +
|2013
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|3
 +
|3
 +
|1
 +
|-
 +
|Anthes
 +
|M
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|
 +
|1996
 +
|2004
 +
|
 +
|
 +
|Glioblastoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|17
 +
|17
 +
|1
 +
|-
 +
|Anthoney
 +
|Alan
 +
|MALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2000
 +
|2021
 +
|Advanced Biliary Cancer Working Group; European Study Group for Pancreatic Cancer
 +
|
 +
|Cholangiocarcinoma; Gallbladder cancer; Pancreatic cancer; Periampullary adenocarcinoma
 +
|5
 +
|0
 +
|5
 +
|0
 +
|119
 +
|84
 +
|1
 +
|-
 +
|Anthony
 +
|Alan
 +
|MALE
 +
|
 +
|
 +
|
 +
|United Kingdom
 +
|2006
 +
|2022
 +
|
 +
|
 +
|Cholangiocarcinoma; Gallbladder cancer
 +
|2
 +
|0
 +
|1
 +
|0
 +
|52
 +
|29
 +
|1
 +
|-
 +
|Anthony
 +
|Stephen P
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1997
 +
|2006
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Antimi
 +
|Mauro
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1991
 +
|2003
 +
|Italian Co-operative Group on Bladder Cancer
 +
|
 +
|Bladder cancer; Breast cancer
 +
|2
 +
|0
 +
|1
 +
|0
 +
|27
 +
|27
 +
|1
 +
|-
 +
|Antin
 +
|Joseph H
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2003
 +
|2016
 +
|BMT CTN
 +
|
 +
|Allogeneic HSCT; Chronic myeloid leukemia; Graft versus host disease; Multiple myeloma
 +
|4
 +
|1
 +
|3
 +
|0
 +
|79
 +
|76
 +
|1
 +
|-
 +
|Antinori
 +
|Andrea
 +
|UNMATCHED
 +
|
 +
|
 +
|
 +
|
 +
|2002
 +
|2002
 +
|
 +
|
 +
|HIV-associated lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|12
 +
|12
 +
|1
 +
|-
 +
|Antman
 +
|Karen
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|1987
 +
|1993
 +
|
 +
|
 +
|Autologous HSCT; Breast cancer; Soft tissue sarcoma
 +
|2
 +
|2
 +
|1
 +
|0
 +
|26
 +
|25
 +
|1
 +
|-
 +
|Antolin Novoa
 +
|Silvia
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|2008
 +
|2021
 +
|GEICAM
 +
|
 +
|Breast cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|63
 +
|61
 +
|1
 +
|-
 +
|Anton Torres
 +
|A
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|1994
 +
|1998
 +
|TTD
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|12
 +
|12
 +
|1
 +
|-
 +
|Anton
 +
|Antonio
 +
|MALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|1990
 +
|2020
 +
|CIBOMA; GEICAM; LACOG (Latin American Cooperative Oncology Group); Spanish Lung Cancer Group; TTD
 +
|
 +
|Breast cancer; Colorectal cancer; Esophageal adenocarcinoma; Head and neck cancer; Non-small cell lung cancer; Small cell lung cancer
 +
|17
 +
|0
 +
|17
 +
|2
 +
|380
 +
|273
 +
|1
 +
|-
 +
|Antonarakis
 +
|Emmanuel S
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2011
 +
|2021
 +
|
 +
|
 +
|Prostate cancer
 +
|2
 +
|1
 +
|0
 +
|0
 +
|39
 +
|38
 +
|1
 +
|-
 +
|Antonelli
 +
|G
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|1998
 +
|2002
 +
|
 +
|
 +
|Bladder cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|9
 +
|9
 +
|1
 +
|-
 +
|Antonescu
 +
|Cristina R
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2002
 +
|2011
 +
|ACOSOG
 +
|
 +
|Gastrointestinal stromal tumor; Melanoma
 +
|2
 +
|0
 +
|1
 +
|1
 +
|31
 +
|31
 +
|1
 +
|-
 +
|Antonia
 +
|Scott J
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2007
 +
|2022
 +
|
 +
|
 +
|Malignant pleural mesothelioma; Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous; Small cell lung cancer
 +
|17
 +
|6
 +
|7
 +
|5
 +
|408
 +
|222
 +
|1
 +
|-
 +
|Antonini
 +
|Ninja F
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Netherlands
 +
|2003
 +
|2009
 +
|Dutch Colorectal Cancer Group
 +
|
 +
|Colorectal cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|36
 +
|28
 +
|1
 +
|-
 +
|Antonioli
 +
|Elisabetta
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2014
 +
|2021
 +
|
 +
|
 +
|Multiple myeloma; Paroxysmal nocturnal hemoglobinuria
 +
|2
 +
|0
 +
|1
 +
|1
 +
|37
 +
|37
 +
|1
 +
|-
 +
|Antoniotti
 +
|Carlotta
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2008
 +
|2022
 +
|
 +
|
 +
|Colorectal cancer
 +
|3
 +
|0
 +
|2
 +
|0
 +
|70
 +
|54
 +
|1
 +
|-
 +
|Antoniou
 +
|Dimosthenis
 +
|MALE
 +
|
 +
|
 +
|
 +
|Greece
 +
|2000
 +
|2010
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|33
 +
|27
 +
|1
 +
|-
 +
|Antoniou
 +
|Nicos
 +
|MALE
 +
|
 +
|
 +
|
 +
|Greece
 +
|2000
 +
|2013
 +
|SEUG
 +
|
 +
|Prostate cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|10
 +
|9
 +
|1
 +
|-
 +
|Antonuzzo
 +
|Lorenzo
 +
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2008
 +
|2022
 +
|
 +
|
 +
|Colorectal cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|45
 +
|42
 +
|1
 +
|-
 +
|Antonyan
 +
|Igor
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Ukraine
 +
|2017
 +
|2022
 +
|
 +
|
 +
|Renal cell carcinoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Anttila
 +
|Pekka
 +
|MALE
 +
|
 +
|
 +
|
 +
|Finland
 +
|2012
 +
|2016
 +
|
 +
|
 +
|Multiple myeloma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|30
 +
|30
 +
|1
 +
|-
 +
|Antunes
 +
|Luis
 +
|MALE
 +
|
 +
|
 +
|
 +
|Brazil
 +
|2017
 +
|2021
 +
|
 +
|
 +
|Esophageal cancer
 +
|1
 +
|0
 +
|1
 +
|1
 +
|24
 +
|24
 +
|1
 +
|-
 +
|Antunovic
 +
|Petar
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2004
 +
|2010
 +
|
 +
|
 +
|Acute myeloid leukemia; Chronic myelomonocytic leukemia; Myelodysplastic syndrome
 +
|1
 +
|0
 +
|0
 +
|0
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Anz
 +
|Bertrand
 +
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2014
 +
|2018
 +
|
 +
|
 +
|Chronic lymphocytic leukemia
 +
|1
 +
|0
 +
|1
 +
|1
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Aogi
 +
|Kenjiro
 +
|MALE
 +
|
 +
|
 +
|
 +
|Japan
 +
|1994
 +
|2021
 +
|JCOG; NSAS
 +
|
 +
|Breast cancer
 +
|9
 +
|0
 +
|8
 +
|1
 +
|140
 +
|103
 +
|1
 +
|-
 +
|Aokage
 +
|Keiju
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Japan
 +
|2013
 +
|2020
 +
|JCOG
 +
|
 +
|Small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|19
 +
|19
 +
|1
 +
|-
 +
|Aoki
 +
|Daisuke
 +
|MALE
 +
|
 +
|
 +
|
 +
|Japan
 +
|2003
 +
|2021
 +
|JGOG
 +
|
 +
|Cervical cancer; Endometrial cancer; Ovarian cancer
 +
|6
 +
|1
 +
|5
 +
|0
 +
|121
 +
|89
 +
|1
 +
|-
 +
|Aoki
 +
|Hiroshi
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2005
 +
|2013
 +
|
 +
|
 +
|Bladder cancer; Upper tract urothelial carcinoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|22
 +
|22
 +
|1
 +
|-
 +
|Aoki
 +
|Takuya
 +
|Not yet determined
 +
|
 +
|
 +
|
 +
|Japan
 +
|2001
 +
|2021
 +
|WJTOG
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|20
 +
|20
 +
|1
 +
|-
 +
|Aoki
 +
|Yoichi
 +
|MALE
 +
|
 +
|
 +
|
 +
|Japan
 +
|2008
 +
|2021
 +
|
 +
|
 +
|Cervical cancer; Ovarian cancer
 +
|2
 +
|1
 +
|2
 +
|0
 +
|60
 +
|57
 +
|1
 +
|-
 +
|Aondio
 +
|Gian Marco
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2004
 +
|2009
 +
|IELSG
 +
|
 +
|CNS lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|31
 +
|31
 +
|1
 +
|-
 +
|Aotani
 +
|Eriko
 +
|FEMALE
 +
|
 +
|
 +
|
 +
|Japan
 +
|2006
 +
|2016
 +
|JGOG
 +
|
 +
|Ovarian cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|23
 +
|23
 +
|1
 +
|-
 +
|Aoudjhane
 +
|A
 +
|CBD
 +
|
 +
|
 +
|
 +
|France
 +
|2003
 +
|2014
 +
|Lymphoma Study Association
 +
|
 +
|Hodgkin lymphoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|17
 +
|17
 +
|1
 +
|-
 +
|Aoudjhane
 +
|Malek
 +
|MALE
 +
|
 +
|
 +
|
 +
|France
 +
|1989
 +
|2003
 +
|EORTC
 +
|
 +
|Hodgkin lymphoma
 +
|1
 +
|0
 +
|2
 +
|0
 +
|28
 +
|28
 +
|1
 +
|-
 +
|Aoyama
 +
|H
 +
|CBD
 +
|
 +
|
 +
|
 +
|
 +
|1993
 +
|1996
 +
|
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|6
 +
|6
 +
|1
 +
|-
 +
|Aoyama
 +
|Norio
 +
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1992
 +
|2011
 +
|JCOG
 +
|
 +
|Esophageal cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|32
 +
|29
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1093/annonc/11.suppl_1.S87 Linch et al. 2000]
+
|Aoyama
−
|1987-1991
+
|Toru
−
| style="background-color:#1a9851" |Phase 3 (E-esc)
+
|Not yet determined
−
|[[#CHOP|CHOP]]
+
|
−
| style="background-color:#d9ef8b" |Might have superior cause-specific survival
+
|
 +
|
 +
|Japan; USA
 +
|2011
 +
|2017
 +
|
 +
|
 +
|Gastric cancer; Rectal cancer
 +
|2
 +
|1
 +
|2
 +
|0
 +
|30
 +
|30
 +
|1
 
|-
 
|-
−
|}
+
|Aozasa
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Katsuyuki
−
====Glucocorticoid therapy====
+
|Not yet determined
−
*[[Prednisolone (Millipred)]]
+
|
−
====Chemotherapy====
+
|
−
*[[Doxorubicin (Adriamycin)]]
+
|
−
*[[Cyclophosphamide (Cytoxan)]]
+
|
−
*[[Etoposide (Vepesid)]]
+
|2005
−
*[[Bleomycin (Blenoxane)]]
+
|2005
−
*[[Vincristine (Oncovin)]]
+
|
−
*[[Methotrexate (MTX)]]
+
|
−
</div></div>
+
|Castleman disease
−
===References===
+
|1
−
# Linch DC, Smith P, Hancock BW, Hoskin PJ, Cunningham DC, Newland AC, Milligan D, Stevenson PA, Wood JK, Maclennan KA, Vaughan B, Vaughan G, Gregory WM; British National Lymphoma Investigation. A randomized British National Lymphoma Investigation trial of CHOP vs a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma. Ann Oncol. 2000;11 Suppl 1:87-90. [https://doi.org/10.1093/annonc/11.suppl_1.S87 link to original article] [https://pubmed.ncbi.nlm.nih.gov/10707786 PubMed]
+
|0
−
==PEN {{#subobject:d26134|Regimen=1}}==
+
|0
−
PEN: '''<u>P</u>'''rednisone, '''<u>E</u>'''toposide, '''<u>N</u>'''ovantrone (Mitoxantrone)
+
|0
−
<div class="toccolours" style="background-color:#eeeeee">
+
|20
−
===Regimen {{#subobject:a5253e|Variant=1}}===
+
|20
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
+
|1
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[https://doi.org/10.3109/10428199509064935 Goss et al. 1995]
+
|Apanovitch
−
|1991-1993
+
|Anne Marie
−
|style="background-color:#91cf61"|Phase 2
+
|FEMALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2005
 +
|2007
 +
|
 +
|
 +
|B-cell acute lymphoblastic leukemia
 +
|1
 +
|0
 +
|0
 +
|1
 +
|11
 +
|11
 +
|1
 
|-
 
|-
−
|}
+
|Aparicio
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Jorge
−
====Glucocorticoid therapy====
+
|MALE
−
*[[Prednisone (Sterapred)]]
+
|
−
====Chemotherapy====
+
|
−
*[[Etoposide (Vepesid)]]
+
|
−
*[[Mitoxantrone (Novantrone)]]
+
|Spain
−
</div></div>
+
|1994
−
===References===
+
|2011
−
# Goss P, Burkes R, Rudinskas L, King M, Chow W, Myers R, Davidson M, Poldre P, Crump M, Sutton D, Scott G. A phase II trial of prednisone, oral etoposide, and novantrone (PEN) as initial treatment of non-Hodgkin's lymphoma in elderly patients. Leuk Lymphoma. 1995 Jun;18(1-2):145-52. [https://doi.org/10.3109/10428199509064935 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8580817 PubMed]
+
|Spanish Germ Cell Cancer Cooperative Group; TTD
−
==PMitCEBO {{#subobject:6b10e7|Regimen=1}}==
+
|
−
PMitCEBO: '''<u>P</u>'''rednisolone, '''<u>Mit</u>'''oxantrone, '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''toposide, '''<u>B</u>'''leomycin, '''<u>O</u>'''ncovin (Vincristine)
+
|Colorectal cancer; Hodgkin lymphoma; Testicular cancer
−
<div class="toccolours" style="background-color:#eeeeee">
+
|6
−
===Regimen {{#subobject:8b4d2d|Variant=1}}===
+
|3
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|2
−
!style="width: 20%"|Study
+
|0
−
!style="width: 20%"|Years of enrollment
+
|81
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
|68
−
!style="width: 20%"|Comparator
+
|1
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[http://www.bloodjournal.org/content/97/10/2991.long Mainwaring et al. 2001]
+
|Aparicio
−
|1993-1997
+
|Samuel
−
|style="background-color:#1a9851"|Phase 3 (E-switch-ic)
+
|MALE
−
|[[#PAdriaCEBO_88|PAdriaCEBO]]
+
|
−
| style="background-color:#1a9850" |Superior OS
+
|
 +
|
 +
|Canada
 +
|2008
 +
|2015
 +
|NCIC-CTG
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|26
 +
|26
 +
|1
 
|-
 
|-
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3216418/ Burton et al. 2006 (BNLI CHOPVPMITCEBO-GOODRISK)]
+
|Aparicio
−
|1997-1999
+
|Thomas
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
+
|MALE
−
|[[#CHOP|CHOP]]
+
|
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of FFS
+
|
 +
|
 +
|France
 +
|2000
 +
|2018
 +
|FFCD; SFRO; UNICANCER
 +
|
 +
|Colorectal cancer; Esophageal adenocarcinoma; Gastric cancer; Hepatocellular carcinoma; Pancreatic cancer
 +
|5
 +
|2
 +
|5
 +
|0
 +
|89
 +
|71
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1016/S1470-2045%2806%2970664-7 Pfreundschuh et al. 2006 (NCIC-CTG LY.9)]
+
|Apfelbeck
−
|2000-2003
+
|Ute
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|FEMALE
−
|1. [[Diffuse_large_B-cell_lymphoma#R-CHOP|R-CHOP]]<br>2. [[#R-CHOEP_88|R-CHOEP]]<br>3. [[#R-MACOP-B_88|R-MACOP-B]]<br>4. [[#R-PMitCEBO_88|R-PMitCEBO]]
+
|
−
|style="background-color:#d73027"|Inferior EFS<sup>1</sup>
+
|
 +
|
 +
|Austria
 +
|1994
 +
|2003
 +
|
 +
|
 +
|Chronic myeloid leukemia
 +
|1
 +
|0
 +
|1
 +
|0
 +
|25
 +
|25
 +
|1
 
|-
 
|-
−
|}
+
|Apffelstaedt
−
''<sup>1</sup>Reported efficacy is based on the 2011 update.''
+
|Justus
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|MALE
−
====Glucocorticoid therapy====
+
|
−
*[[Prednisolone (Millipred)]]
+
|
−
====Chemotherapy====
+
|
−
*[[Mitoxantrone (Novantrone)]]
+
|South Africa
−
*[[Cyclophosphamide (Cytoxan)]]
+
|1996
−
*[[Etoposide (Vepesid)]]
+
|2003
−
*[[Bleomycin (Blenoxane)]]
+
|
−
*[[Vincristine (Oncovin)]]
+
|
−
</div></div>
+
|Breast cancer
−
===References===
+
|3
−
# Mainwaring PN, Cunningham D, Gregory W, Hoskin P, Hancock B, Norton AJ, MacLennan K, Smith P, Vaughan Hudson G, Linch D. Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO. Blood. 2001 May 15;97(10):2991-7. [http://www.bloodjournal.org/content/97/10/2991.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/11342422 PubMed]
+
|0
−
# '''BNLI CHOPVPMITCEBO-GOODRISK:''' Burton C, Linch D, Hoskin P, Milligan D, Dyer MJ, Hancock B, Mouncey P, Smith P, Qian W, MacLennan K, Jack A, Webb A, Cunningham D. A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma. Br J Cancer. 2006 Mar 27;94(6):806-13. [https://doi.org/10.1038/sj.bjc.6602975 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3216418/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/16508640 PubMed] NCT00005867
+
|2
−
#'''NCIC-CTG LY.9:''' Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 May;7(5):379-91. [https://doi.org/10.1016/S1470-2045%2806%2970664-7 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16648042 PubMed] NCT00064116
+
|1
−
## '''Update:''' Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; MabThera International Trial Group. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011 Oct;12(11):1013-22. [https://doi.org/10.1016/S1470-2045%2811%2970235-2 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/21940214 PubMed]
+
|51
−
==ProMACE-CytaBOM {{#subobject:5285e6|Regimen=1}}==
+
|32
−
ProMACE-CytaBOM: '''<u>Pro</u>'''lix (Prednisone), '''<u>M</u>'''ethotrexate, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''toposide, '''<u>Cyta</u>'''rabine, '''<u>B</u>'''leomycin, '''<u>O</u>'''ncovin (Vincristine), '''<u>M</u>'''ethotrexate
+
|1
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:37d27b|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.1991.9.1.25 Longo et al. 1991]
+
|Aplenc
−
|1981-1988
+
|Richard
−
|style="background-color:#1a9851"|Phase 3 (E-switch-ic)
+
|MALE
−
|[[#ProMACE-MOPP|ProMACE-MOPP]]
+
|
−
| style="background-color:#91cf60" |Seems to have superior OS
+
|
 +
|
 +
|USA
 +
|2011
 +
|2014
 +
|COG
 +
|
 +
|Acute myeloid leukemia pediatric; B-cell acute lymphoblastic leukemia; B-cell acute lymphoblastic leukemia pediatric
 +
|3
 +
|1
 +
|0
 +
|0
 +
|44
 +
|36
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1056/NEJM199304083281404 Fisher et al. 1993 (SWOG-8516/Intergroup 0067)]
+
|Apolo
−
|1986-1991
+
|Andrea B
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
+
|MALE
−
|1. [[#CHOP|CHOP]]<br>2. [[#MACOP-B|MACOP-B]]<br> 3. [[#m-BACOD|m-BACOD]]
+
|
−
| style="background-color:#ffffbf" |Did not meet endpoint of OS
+
|
 +
|
 +
|USA
 +
|2014
 +
|2022
 +
|
 +
|
 +
|Bladder cancer; Renal cell carcinoma
 +
|4
 +
|2
 +
|1
 +
|2
 +
|81
 +
|59
 +
|1
 
|-
 
|-
−
|}
+
|Apolone
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Giovanni
−
====Glucocorticoid therapy====
+
|MALE
−
*[[Prednisone (Sterapred)|Prednisone (Prolix)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 14
+
|
−
====Chemotherapy====
+
|
−
*[[Methotrexate (MTX)]] 120 mg/m<sup>2</sup> IV once on day 8
+
|
−
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Cyclophosphamide (Cytoxan)]] 650 mg/m<sup>2</sup> IV once on day 1
+
|1987
−
*[[Etoposide (Vepesid)]] 120 mg/m<sup>2</sup> IV once on day 1
+
|1998
−
*[[Cytarabine (Ara-C)]] 300 mg/m<sup>2</sup> IV once on day 8
+
|EORTC; Gruppo Interdisciplinare Valutazione Interventi in Oncologia; Japanese Foundation for Cancer Research
−
*[[Bleomycin (Blenoxane)]] 5 units/m<sup>2</sup> IV once on day 8
+
|
−
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once on day 8
+
|Colon cancer
−
====Supportive therapy====
+
|1
−
*[[Folinic acid (Leucovorin)]] 25 mg/m<sup>2</sup> PO every 6 hours on day 9, starting 24 hours after [[Methotrexate (MTX)]]
+
|0
−
*[[Trimethoprim-Sulfamethoxazole (Bactrim DS)]] 160/800 mg PO twice per day throughout the course of treatment
+
|1
−
====Dose modifications====
+
|0
−
*"If WBC count is at least 4 x 10<sup>9</sup>/L, use 100% doses of all drugs
+
|14
−
*If WBC count is 3 to 3.999 x 10<sup>9</sup>/L, 100% prednisone, bleomycin, vincristine, cytarabine, and methotrexate; 75% cyclophosphamide, doxorubicin, and etoposide
+
|14
−
*If WBC count is 2 to 2.999 x 10<sup>9</sup>/L, 100% prednisone, bleomycin, vincristine, and methotrexate; 75% etoposide, cytarabine; 50% cyclophosphamide, doxorubicin
+
|1
−
*If WBC count is 1 to 1.999 x 10<sup>9</sup>/L, 100% prednisone, bleomycin, vincristine and methotrexate; 25% cyclophosphamide, doxorubicin, etoposide, and cytarabine
 
−
*If WBC count is 0 to 0.999 x 10<sup>9</sup>/L, 100% prednisone, vincristine, and bleomycin; 50% methotrexate, no other drugs
 
−
*If platelet count is at least 100 x 10<sup>9</sup>/L, use 100% doses of all drugs
 
−
*If platelet count is 50 to 99 x 10<sup>9</sup>/L, 100% prednisone, bleomycin, vincristine, and methotrexate; 50% etoposide and cytarabine; 25% cyclophosphamide and doxorubicin
 
−
*If platelet count is 0 to 49 x 10<sup>9</sup>/L, 100% prednisone, bleomycin, and vincristine; 50% methotrexate, no other drugs"
 
−
====CNS therapy, prophylaxis====
 
−
*Patients with initial bone or bone marrow involvement who achieved a CR were treated with 2400 cGy prophylactic cranial irradiation.
 
−
'''21-day cycle for 6 cycles or 2 cycles after maximum clinical response'''
 
−
</div></div>
 
−
===References===
 
−
# Longo DL, DeVita VT Jr, Duffey PL, Wesley MN, Ihde DC, Hubbard SM, Gilliom M, Jaffe ES, Cossman J, Fisher RI, Young RC. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol. 1991 Jan;9(1):25-38. Erratum in: J Clin Oncol 1991 Apr;9(4):710. [https://doi.org/10.1200/jco.1991.9.1.25 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/1702144 PubMed]
 
−
# '''SWOG-8516:''' Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993 Apr 8;328(14):1002-6. [https://doi.org/10.1056/NEJM199304083281404 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7680764 PubMed]
 
−
<!-- ## '''Update:''' Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. A phase III comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol. 1994;5 Suppl 2:91-5. [https://pubmed.ncbi.nlm.nih.gov/7515652 PubMed] -->
 
−
## '''Update:''' Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. J Clin Oncol. 2009 Jan 1;27(1):114-9. Epub 2008 Dec 1. [https://doi.org/10.1200/jco.2008.16.8021 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4879698/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19047289 PubMed]
 
−
==ProMACE-MOPP {{#subobject:0aa31b|Regimen=1}}==
 
−
ProMACE-MOPP: '''<u>Pro</u>'''lix (Prednisone), '''<u>M</u>'''ethotrexate, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''toposide, '''<u>M</u>'''ustargen (Mechlorethamine), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:cf90b9|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.7326/0003-4819-98-3-304 Fisher et al. 1983]
+
|Aponte
−
|1977-1981
+
|John
−
| style="background-color:#91cf61" |Non-randomized
+
|MALE
−
| style="background-color:#d3d3d3" |
+
|
−
| style="background-color:#d3d3d3" |
+
|
 +
|
 +
|
 +
|1996
 +
|2002
 +
|Barcelona Liver Cancer Group
 +
|
 +
|Hepatocellular carcinoma
 +
|1
 +
|0
 +
|1
 +
|0
 +
|11
 +
|11
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.1991.9.1.25 Longo et al. 1991]
+
|Apostolou
−
|1981-1988
+
|Theofanis
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|MALE
−
|[[#ProMACE-CytaBOM|ProMACE-CytaBOM]]
+
|
−
| style="background-color:#fc8d59" |Seems to have inferior OS
+
|
 +
|
 +
|
 +
|2008
 +
|2012
 +
|
 +
|
 +
|Light-chain (AL) amyloidosis
 +
|1
 +
|0
 +
|0
 +
|0
 +
|12
 +
|12
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1093/annonc/5.suppl_2.s85 Somers et al. 1994a]
+
|Appel
−
|1986-1991
+
|Tabea
−
|style="background-color:#1a9851"|Phase 3 (E-switch-ic)
+
|FEMALE
−
|[[#CHVmP-VB|CHVmP-VB]]
+
|
−
| style="background-color:#1a9850" |Superior ORR
+
|
 +
|
 +
|
 +
|2006
 +
|2006
 +
|
 +
|
 +
|Non-small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|10
 +
|10
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.1994.12.7.1366 Sertoli et al. 1994]
+
|Appel
−
|1987-1991
+
|Wiebke
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|FEMALE
−
|[[#MACOP-B|MACOP-B]]
+
|
−
| style="background-color:#ffffbf" |Did not meet endpoint of OS36
+
|
 +
|
 +
|United Kingdom
 +
|2008
 +
|2017
 +
|CONVERT Study Team
 +
|
 +
|Small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|19
 +
|19
 +
|1
 
|-
 
|-
−
|}
+
|Appelbaum
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Frederick R
−
====Chemotherapy====
+
|MALE
−
*[[Methotrexate (MTX)]]
+
|
−
*[[Doxorubicin (Adriamycin)]]
+
|
−
*[[Cyclophosphamide (Cytoxan)]]
+
|
−
*[[Etoposide (Vepesid)]]
+
|USA
−
*[[Mechlorethamine (Mustargen)]]
+
|1971
−
*[[Vincristine (Oncovin)]]
+
|2021
−
*[[Procarbazine (Matulane)]]
+
|CALGB; ECOG; SWOG
−
====Glucocorticoid therapy====
+
|
−
*[[Prednisone (Sterapred)]]
+
|Acute myeloid leukemia; Acute promyelocytic leukemia; Allogeneic HSCT; B-cell acute lymphoblastic leukemia; Chronic lymphocytic leukemia; Chronic myeloid leukemia; Chronic myelomonocytic leukemia; Follicular lymphoma; Graft versus host disease; Hairy cell leukemia; Myelodysplastic syndrome; T-cell acute lymphoblastic leukemia
−
</div></div>
+
|36
−
===References===
+
|11
−
# Fisher RI, DeVita VT Jr, Hubbard SM, Longo DL, Wesley R, Chabner BA, Young RC. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Ann Intern Med. 1983 Mar;98(3):304-9. [https://doi.org/10.7326/0003-4819-98-3-304 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6600902 PubMed]
+
|16
−
# Longo DL, DeVita VT Jr, Duffey PL, Wesley MN, Ihde DC, Hubbard SM, Gilliom M, Jaffe ES, Cossman J, Fisher RI, Young RC. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol. 1991 Jan;9(1):25-38. Erratum in: J Clin Oncol 1991 Apr;9(4):710. [https://doi.org/10.1200/jco.1991.9.1.25 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1702144 PubMed]
+
|4
−
# Somers R, Carde P, Thomas J, Tirelli U, Keuning JJ, Bron D, Delmer A, de Bock R, De Wolf-Peeters C, van Glabbeke M, Duez N. EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma. Ann Oncol. 1994;5 Suppl 2:85-9. Erratum in: Ann Oncol 1994 May;5(5):475. [https://doi.org/10.1093/annonc/5.suppl_2.s85 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7515651 PubMed]
+
|477
−
# Sertoli MR, Santini G, Chisesi T, Congiu AM, Rubagotti A, Contu A, Salvagno L, Coser P, Porcellini A, Vespignani M, Capnist G, Rossi E, Mangoni L, Fabris P, Vinante O, Tedeschi L, Endrizzi L, Miglio LP, Perrotta A, Rosso R, Damasio E, Rizzoli V. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol. 1994 Jul;12(7):1366-74. [https://doi.org/10.1200/jco.1994.12.7.1366 link to original article] '''does not contain dosing details''' [https://pubmed.ncbi.nlm.nih.gov/7517442 PubMed]
+
|273
−
==R-CHMP {{#subobject:5510fa|Regimen=1}}==
+
|1
−
R-CHMP: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>M</u>'''arqibo (Vincristine liposomal), '''<u>P</u>'''rednisone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #1, 3 cycles {{#subobject:e77893|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[https://doi.org/10.1111/bjh.12446 Hagemeister et al. 2013]
+
|Appenzeller
−
|2001-2002
+
|Christina
−
| style="background-color:#91cf61" |Phase 2
+
|Not yet determined
 +
|
 +
|
 +
|
 +
|Switzerland
 +
|2017
 +
|2021
 +
|
 +
|
 +
|Small cell lung cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|21
 +
|21
 +
|1
 
|-
 
|-
−
|}
+
|Apperley
−
''Note: This regimen was intended for stage I patients with no LN greater than 5 cm.''
+
|Jane F
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|FEMALE
−
====Targeted therapy====
+
|
−
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
+
|
−
====Chemotherapy====
+
|
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
+
|United Kingdom
−
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
+
|1981
−
*[[Vincristine liposomal (Marqibo)]] 2 mg/m<sup>2</sup> IV once on day 1
+
|2021
−
====Glucocorticoid therapy====
+
|
−
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5
+
|
−
'''21-day cycle for 3 cycles'''
+
|B-cell acute lymphoblastic leukemia; Chronic myeloid leukemia; Hypereosinophilic syndrome
−
</div>
+
|12
−
<div class="toccolours" style="background-color:#cbd5e7">
+
|1
−
====Subsequent treatment====
+
|1
−
*[[#Radiation_therapy|RT]]
+
|4
−
</div></div><br>
+
|227
−
<div class="toccolours" style="background-color:#eeeeee">
+
|140
−
===Regimen variant #2, 6 cycles {{#subobject:a8501b|Variant=1}}===
+
|1
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[https://doi.org/10.1111/bjh.12446 Hagemeister et al. 2013]
+
|Appiani
−
|2001-2002
+
|Carlos
−
| style="background-color:#91cf61" |Phase 2
+
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2008
 +
|2018
 +
|
 +
|
 +
|Mantle cell lymphoma
 +
|1
 +
|0
 +
|1
 +
|1
 +
|15
 +
|15
 +
|1
 
|-
 
|-
−
|}
+
|Appleman
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Leonard J
−
====Targeted therapy====
+
|MALE
−
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
+
|
−
====Chemotherapy====
+
|
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
+
|USA
−
*[[Vincristine liposomal (Marqibo)]] 2 mg/m<sup>2</sup> IV once on day 1
+
|2008
−
====Glucocorticoid therapy====
+
|2014
−
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5
+
|
−
'''21-day cycle for 6 cycles'''
+
|
−
</div></div>
+
|Bladder cancer
−
===References===
+
|1
−
#Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A, Dang NH, Forman A, McLaughlin P, Medeiros LJ, Pro B, Romaguera J, Samaniego F, Silverman JA, Sarris A, Cabanillas F. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Br J Haematol. 2013 Sep;162(5):631-8. Epub 2013 Jun 27. [https://doi.org/10.1111/bjh.12446 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23802738 PubMed]
+
|0
−
 
+
|0
−
==VABE {{#subobject:583b52|Regimen=1}}==
+
|0
−
VABE: '''<u>V</u>'''incristine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, Prednisone
+
|18
−
<div class="toccolours" style="background-color:#eeeeee">
+
|18
−
===Regimen {{#subobject:a1b549|Variant=1}}===
+
|1
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.1991.9.5.741 O'Reilly et al. 1991]
+
|Aprea
−
|1983-1985
+
|Pasquale
−
|style="background-color:#91cf61"|Non-randomized
+
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|2002
 +
|2013
 +
|SICOG
 
|
 
|
−
|}
+
|Melanoma
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|1
−
====Chemotherapy====
+
|0
−
*[[Vincristine (Oncovin)]]
+
|1
−
*[[Doxorubicin (Adriamycin)]]
+
|0
−
*[[Bleomycin (Blenoxane)]]
+
|17
−
*[[Etoposide (Vepesid)]]
+
|17
−
====Glucocorticoid therapy====
+
|1
−
*[[Prednisone (Sterapred)]]
 
−
</div></div>
 
−
===References===
 
−
# O'Reilly SE, Klimo P, Connors JM. Low-dose ACOP-B and VABE: weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma. J Clin Oncol. 1991 May;9(5):741-7. [https://doi.org/10.1200/jco.1991.9.5.741 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1707954 PubMed]
 
−
==VACOP-B {{#subobject:b78c96|Regimen=1}}==
 
−
VACOP-B: '''<u>V</u>'''epesid (Etoposide), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone, '''<u>B</u>'''leomycin
 
−
<br>P-VABEC: '''<u>P</u>'''rednisone, '''<u>V</u>'''incristine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>C</u>'''yclophosphamide 
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:5b3956|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[https://doi.org/10.1093/oxfordjournals.annonc.a058295 Pichert et al. 1992]
+
|Aprile
 +
|Giuseppe
 +
|MALE
 
|
 
|
−
|style="background-color:#ffffbe"|Retrospective
+
|
 +
|
 +
|Italy
 +
|2005
 +
|2022
 +
|
 +
|
 +
|Colorectal cancer; Esophageal adenocarcinoma; Esophageal cancer; Gastric cancer
 +
|4
 +
|0
 +
|3
 +
|2
 +
|89
 +
|81
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.1993.11.12.2362 Martelli et al. 1993]
+
|Apte
−
|1988-1990
+
|Ron N
−
|style="background-color:#91cf61"|Phase 2
+
|MALE
 +
|
 +
|
 +
|
 +
|Israel
 +
|2014
 +
|2017
 +
|
 +
|
 +
|Colorectal cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|14
 +
|14
 +
|1
 
|-
 
|-
−
|}
+
|Aqui
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Nicole A
−
====Chemotherapy====
+
|FEMALE
−
*[[Etoposide (Vepesid)]]
+
|
−
*[[Doxorubicin (Adriamycin)]]
+
|
−
*[[Cyclophosphamide (Cytoxan)]]
+
|
−
*[[Vincristine (Oncovin)]]
+
|USA
−
*[[Bleomycin (Blenoxane)]]
+
|2008
−
====Glucocorticoid therapy====
+
|2015
−
*[[Prednisone (Sterapred)]]
+
|
−
</div></div>
+
|
−
===References===
+
|Follicular lymphoma; Mantle cell lymphoma
−
# '''Retrospective:''' Pichert G, Peters J, Stahel RA, Dommann C, Joss R, Gebbers JO, Kroner T, Sulser H, Honegger HP, Maurer R, Pampallona S. Chemotherapy with MACOP-B and VACOP-B for intermediate- and high-grade non-Hodgkin's lymphoma: clinical results and analysis of prognostic factors. Ann Oncol. 1992 Sep;3(8):645-9. [https://doi.org/10.1093/oxfordjournals.annonc.a058295 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1280460 PubMed]
+
|2
−
# Martelli M, Guglielmi C, Coluzzi S, Avvisati G, Amadori S, Giovannini M, Torromeo C, Mandelli F. P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1993 Dec;11(12):2362-9. [https://doi.org/10.1200/jco.1993.11.12.2362 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7504091 PubMed]
+
|0
−
==VCAP {{#subobject:31e6b7|Regimen=1}}==
+
|0
−
VCAP: '''<u>V</u>'''indesine, '''<u>C</u>'''yclophosphamide,  '''<u>A</u>'''driamycin (Doxorubicin), '''<u>P</u>'''rednisone
+
|0
−
<div class="toccolours" style="background-color:#eeeeee">
+
|14
−
===Regimen {{#subobject:0aaaf3|Variant=1}}===
+
|8
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
+
|1
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[http://www.haematologica.org/content/90/6/802.long Bernard et al. 2005]
+
|Aquino
−
|1984-1996
+
|Sara
−
|style="background-color:#91cf61"|Phase 2
+
|Not yet determined
 +
|
 +
|
 +
|
 +
|Italy
 +
|2011
 +
|2021
 +
|
 +
|
 +
|Multiple myeloma
 +
|3
 +
|0
 +
|1
 +
|0
 +
|123
 +
|78
 +
|1
 
|-
 
|-
−
|}
+
|Arachchillage
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Deepa R J
−
====Chemotherapy====
+
|Not yet determined
−
*[[Vindesine (Eldisine)]]
+
|
−
*[[Cyclophosphamide (Cytoxan)]]
+
|
−
*[[Doxorubicin (Adriamycin)]]
+
|
−
====Glucocorticoid therapy====
+
|United Kingdom
−
*[[Prednisone (Sterapred)]]
+
|2016
−
</div></div>
+
|2016
−
===References===
+
|
−
# Bernard M, Cartron G, Rachieru P, LeMevel A, Branger B, Le Maignan C, Berthou C, Ghandour C, Delwail V, Milpied N, Cassasus P, Celigny PS, Guyotat D, Lamy T, Desablens B; GOELAMS. Long-term outcome of localized high-grade non-Hodgkin's lymphoma treated with high dose CHOP regimen and involved field radiotherapy: results of a GOELAMS study. Haematologica. 2005 Jun;90(6):802-9.  [http://www.haematologica.org/content/90/6/802.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/15951293 PubMed]
+
|
−
==VEPA {{#subobject:4ca994|Regimen=1}}==
+
|Antiphospholipid antibody syndrome
−
VEPA: '''<u>V</u>'''incristine, '''<u>E</u>'''ndoxan (Cyclophosphamide), '''<u>P</u>'''rednisolone, '''<u>A</u>'''driamycin (Doxorubicin)
+
|1
−
<div class="toccolours" style="background-color:#eeeeee">
+
|0
−
===Regimen {{#subobject:7285da|Variant=1}}===
+
|0
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|0
−
!style="width: 20%"|Study
+
|13
−
!style="width: 20%"|Years of enrollment
+
|13
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
|1
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1200/JCO.1988.6.1.128 Shimoyama et al. 1988 (JCOG8101)]
+
|Aracil
−
|1981-1983
+
|Miguel
−
| style="background-color:#1a9851" |Phase 3 (C)
+
|Not yet determined
−
|[[#VEPA-M_99|VEPA-M]]
+
|
−
| style="background-color:#ffffbf" |Did not meet efficacy endpoints
+
|
 +
|
 +
|Spain
 +
|2015
 +
|2021
 +
|
 +
|
 +
|Ovarian cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|19
 +
|19
 +
|1
 
|-
 
|-
−
|}
+
|Aragon Ching
−
''Note: while the drugs are the same as those used in CHOP, administration details vary significantly; see paper for details.''
+
|Jeanny B
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|FEMALE
−
====Chemotherapy====
+
|
−
*[[Vincristine (Oncovin)]]
+
|
−
*[[Cyclophosphamide (Cytoxan)]]
+
|
−
*[[Doxorubicin (Adriamycin)]]
+
|USA
−
====Glucocorticoid therapy====
+
|2011
−
*[[Prednisolone (Millipred)]]
+
|2020
−
</div></div>
+
|
−
===References===
+
|
−
# '''JCOG8101:''' Shimoyama M, Ota K, Kikuchi M, Yunoki K, Konda S, Takatsuki K, Ichimaru M, Ogawa M, Kimura I, Tominaga S, Tsugane S, Taguchi H, Minato K, Takenaka T, Tobinai K, Kurita S, Oyama A, Hisano S, Kozuru M, Matsumoto M, Nomura K, Takiguchi T, Sugai S, Yamaguchi K, Hattori T, Kinoshita K, Tajima K, Suemasu K. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. J Clin Oncol. 1988 Jan;6(1):128-41. [https://doi.org/10.1200/JCO.1988.6.1.128 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2891797 PubMed]
+
|Bladder cancer
−
==VNCOP-B {{#subobject:e53c96|Regimen=1}}==
+
|3
−
VNCOP-B: '''<u>V</u>'''epesid (Etoposide), '''<u>N</u>'''ovantrone (Mitoxantrone), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone, '''<u>B</u>'''leomycin
+
|0
−
<div class="toccolours" style="background-color:#eeeeee">
+
|2
−
===Regimen {{#subobject:5b7296|Variant=1}}===
+
|1
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|91
−
!style="width: 20%"|Study
+
|82
−
!style="width: 20%"|Years of enrollment
+
|1
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[http://www.bloodjournal.org/content/89/11/3974.long Zinzani et al. 1997]
+
|Arahmani
−
|1993-1995
+
|Amal
−
| style="background-color:#1a9851" |Phase 3 (C)
+
|FEMALE
−
|[[#VNCOP-B_.26_G-CSF_99|VNCOP-B & G-CSF]]
+
|
−
| style="background-color:#ffffbf" |Did not meet endpoint of RFS
+
|
 +
|
 +
|Belgium
 +
|2011
 +
|2021
 +
|
 +
|
 +
|Breast cancer
 +
|2
 +
|0
 +
|2
 +
|2
 +
|55
 +
|51
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1093/annonc/mdf208 Zinzani et al. 2002]
+
|Arai
−
|1996-2001
+
|Gaku
−
| style="background-color:#1a9851" |Phase 3 (C)
+
|Not yet determined
−
|[[#VNCOP-B_.26_G-CSF_99|VNCOP-B & G-CSF]] x 12 wk
+
|
−
| style="background-color:#ffffbf" |Did not meet endpoint of RFS60
+
|
 +
|
 +
|Japan
 +
|2001
 +
|2020
 +
|
 +
|
 +
|Prostate cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|48
 +
|45
 +
|1
 
|-
 
|-
−
|}
+
|Arai
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Kuniyoshi
−
====Chemotherapy====
+
|MALE
−
*[[Etoposide (Vepesid)]]
+
|
−
*[[Mitoxantrone (Novantrone)]]
+
|
−
*[[Cyclophosphamide (Cytoxan)]]
+
|
−
*[[Vincristine (Oncovin)]]
+
|Japan
−
*[[Bleomycin (Blenoxane)]]
+
|1993
−
====Glucocorticoid therapy====
+
|2011
−
*[[Prednisone (Sterapred)]]
+
|ACTS-GC Group; JCOG
−
</div></div>
+
|
−
===References===
+
|Gastric cancer
−
# Zinzani PL, Pavone E, Storti S, Moretti L, Fattori PP, Guardigni L, Falini B, Gobbi M, Gentilini P, Lauta VM, Bendandi M, Gherlinzoni F, Magagnoli M, Venturi S, Aitini E, Tabanelli M, Leone G, Liso V, Tura S. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood. 1997 Jun 1;89(11):3974-9. [http://www.bloodjournal.org/content/89/11/3974.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/9166835 PubMed]
+
|2
−
# Zinzani PL, Gherlinzoni F, Storti S, Zaccaria A, Pavone E, Moretti L, Gentilini P, Guardigni L, De Renzo A, Fattori PP, Falini B, Lauta VM, Mannina D, Zaja F, Mazza P, Volpe E, Lauria F, Aitini E, Ciccone F, Tani M, Stefoni V, Alinari L, Baccarani M, Tura S. Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. Ann Oncol. 2002 Sep;13(9):1364-9. [https://doi.org/10.1093/annonc/mdf208 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12196361 PubMed]
+
|2
−
==VR-CHOP {{#subobject:477a16|Regimen=1}}==
+
|2
−
VR-CHOP: '''<u>V</u>'''elcade (Bortezomib), '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''redniso(lo)ne
+
|0
−
<br>RB-CHOP: '''<u>R</u>'''ituximab, '''<u>B</u>'''ortezomib, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''redniso(lo)ne
+
|21
−
<div class="toccolours" style="background-color:#eeeeee">
+
|16
−
===Regimen {{#subobject:f22c05|Variant=1}}===
+
|1
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.2010.31.1142 Ruan et al. 2010 (Cornell 0309006313)]
+
|Arai
−
|2004-2007
+
|Makoto
−
|style="background-color:#91cf61"|Phase 2
+
|Not yet determined
−
|style="background-color:#d3d3d3"|
+
|
−
|style="background-color:#d3d3d3"|
+
|
 +
|
 +
|Japan
 +
|2019
 +
|2019
 +
|
 +
|
 +
|Carcinoma of unknown primary
 +
|1
 +
|0
 +
|0
 +
|0
 +
|20
 +
|20
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1200/JCO.2017.73.2784 Leonard et al. 2017 (C05013)]
+
|Arai
−
|2009-2013
+
|Masahide
−
|style="background-color:#1a9851"|Randomized Phase 2 (E-esc)
+
|Not yet determined
−
|[[Diffuse_large_B-cell_lymphoma#R-CHOP_.28Prednisolone.29|R-CHOP]]
+
|
−
|style="background-color:#ffffbf"|Did not meet primary endpoint of PFS
+
|
 +
|
 +
|Japan
 +
|2006
 +
|2019
 +
|JGOG
 +
|
 +
|Endometrial cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|16
 +
|16
 +
|1
 
|-
 
|-
−
|}
+
|Arai
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Sally
−
====Targeted therapy====
+
|FEMALE
−
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1 & 4
+
|
−
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
+
|
−
====Chemotherapy====
+
|
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
+
|USA
−
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
+
|2006
−
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
+
|2016
−
====Glucocorticoid therapy====
+
|
−
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5
+
|
−
====Supportive therapy====
+
|Allogeneic HSCT
−
*'''Cornell 0309006313:''' "Standard" [[Acetaminophen (Tylenol)]] and [[Diphenhydramine (Benadryl)]] prior to [[Rituximab (Rituxan)]]
+
|2
−
*'''C05013:''' Prophylaxis against VZV and PJP were recommended
+
|0
−
'''21-day cycle for 6 cycles'''
+
|1
−
</div></div>
+
|0
−
===References===
+
|45
−
# '''Cornell 0309006313:''' Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM, Lacasce A, Morrison J, Elstrom R, Ely S, Chadburn A, Cesarman E, Coleman M, Leonard JP. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol. 2011 Feb 20;29(6):690-7. Epub 2010 Dec 28. [https://doi.org/10.1200/jco.2010.31.1142 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21189393 PubMed] NCT00151320
+
|45
−
# '''C05013:''' Leonard JP, Kolibaba KS, Reeves JA, Tulpule A, Flinn IW, Kolevska T, Robles R, Flowers CR, Collins R, DiBella NJ, Papish SW, Venugopal P, Horodner A, Tabatabai A, Hajdenberg J, Park J, Neuwirth R, Mulligan G, Suryanarayan K, Esseltine DL, de Vos S. Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2017 Nov 1;35(31):3538-3546. Epub 2017 Sep 1. [https://doi.org/10.1200/JCO.2017.73.2784 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28862883 PubMed] NCT00931918
+
|1
−
# '''REMoDL-B:''' Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, Caddy J, Stanton L, Kazmi-Stokes S, McMillan A, Fields P, Pocock C, Collins GP, Stephens R, Cucco F, Clipson A, Sha C, Tooze R, Care MA, Griffiths G, Du MQ, Westhead DR, Burton C, Johnson PWM. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019 May;20(5):649-662. Epub 2019 Apr 1. [https://doi.org/10.1016/S1470-2045(18)30935-5 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494978/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30948276 PubMed] NCT01324596
 
−
=Consolidation after upfront therapy=
 
−
==Cyclophosphamide & TBI {{#subobject:0a4915|Regimen=1}}==
 
−
Cy/TBI: '''<u>Cy</u>'''clophosphamide & '''<u>T</u>'''otal '''<u>B</u>'''ody '''<u>I</u>'''rradiation
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:a2b2d3|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[https://doi.org/10.1056/NEJM198706113162402 Takvorian et al. 1987]
+
|Arai
−
|1982-1987
+
|Yasuaki
−
| style="background-color:#91cf61" |Non-randomized
+
|MALE
 +
|
 +
|
 +
|
 +
|Japan
 +
|2010
 +
|2018
 +
|
 +
|
 +
|Hepatocellular carcinoma
 +
|2
 +
|2
 +
|2
 +
|0
 +
|34
 +
|32
 +
|1
 
|-
 
|-
−
|}
+
|Arai
−
<section begin=a2b2d3 />
+
|Yoichi
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|MALE
−
====Chemotherapy====
+
|
−
*[[Cyclophosphamide (Cytoxan)]] 60 mg/kg IV once per day on days -3 & -2
+
|
−
====Radiotherapy====
+
|
−
*[[External_beam_radiotherapy|Total body irradiation (TBI)]]  1200 cGy in fractions on days –6 to –4 (pulmonary dosage was limited to 800 cGy)
+
|
−
</div>
+
|2000
−
<section end=a2b2d3 />
+
|2013
−
</div>
+
|Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer
−
===References===
+
|
−
# Takvorian T, Canellos GP, Ritz J, Freedman AS, Anderson KC, Mauch P, Tarbell N, Coral F, Daley H, Yeap B, Schlossman SF, Nadler LM. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med. 1987 Jun 11;316(24):1499-505. [https://doi.org/10.1056/NEJM198706113162402 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3295542 PubMed]
+
|Bladder cancer; Prostate cancer; Upper tract urothelial carcinoma
−
=Relapsed or refractory, salvage therapy=
+
|3
−
==DHAP {{#subobject:cd4f8f|Regimen=1}}==
+
|1
−
DHAP: '''<u>D</u>'''examethasone, '''<u>H</u>'''igh-dose '''<u>A</u>'''ra-C (Cytarabine), '''<u>P</u>'''latinol (Cisplatin)
+
|1
−
<div class="toccolours" style="background-color:#eeeeee">
+
|0
−
===Regimen {{#subobject:ebcb68|Variant=1}}===
+
|38
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
|34
−
!style="width: 20%"|Study
+
|1
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[http://www.bloodjournal.org/content/71/1/117 Velasquez et al. 1988]
+
|Arakelyan
−
|1984-1986
+
|Nina
−
|style="background-color:#91cf61"|Phase 2
+
|FEMALE
−
|style="background-color:#d3d3d3"|
+
|
−
|style="background-color:#d3d3d3"|
+
|
 +
|
 +
|
 +
|1994
 +
|2013
 +
|GOELAMS
 +
|
 +
|Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma
 +
|3
 +
|0
 +
|1
 +
|0
 +
|57
 +
|46
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1056/NEJM199512073332305 Philip et al. 1995 (PARMA)]
+
|Araki
−
|1987-1994
+
|K
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|CBD
−
|[[#DHAP|DHAP]] x 2, then [[Transplant_conditioning_regimens#BEAC|BEAC]]
+
|
−
|style="background-color:#fc8d59"|Seems to have inferior OS
+
|
 +
|
 +
|
 +
|1994
 +
|2001
 +
|JCOG
 +
|
 +
|Adult T-cell leukemia-lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|15
 +
|15
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1093/annonc/mdi248 Josting et al. 2005]
+
|Araki
−
|NR
+
|Nobuhito
−
|style="background-color:#91cf61"|Phase 2
+
|MALE
−
|style="background-color:#d3d3d3"|
+
|
−
|style="background-color:#d3d3d3"|
+
|
 +
|
 +
|Japan
 +
|2008
 +
|2016
 +
|
 +
|
 +
|Soft tissue sarcoma
 +
|3
 +
|0
 +
|1
 +
|1
 +
|45
 +
|40
 +
|1
 
|-
 
|-
−
|}
+
|Arana Yi
−
''Note: Velasquez et al. 1988 report giving 6 to 10 courses, usually 4 courses beyond maximum response. To our knowledge, this regimen was not tested as an experimental arm in a RCT prior to becoming a standard comparator arm.''
+
|C
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|CBD
−
====Glucocorticoid therapy====
+
|
−
*[[Dexamethasone (Decadron)]] 40 mg IV over 15 minutes once per day on days 1 to 4
+
|
−
====Chemotherapy====
+
|
−
*[[Cytarabine (Ara-C)]] by the following age-based criteria:
+
|USA
−
**Patients younger than 70: 2000 mg/m<sup>2</sup> IV over 3 hours every 12 hours on day 2 (total dose per cycle: 4000 mg/m<sup>2</sup>)
+
|2007
−
**Patients older than 70: 1000 mg/m<sup>2</sup> IV over 3 hours every 12 hours on day 2 (total dose per cycle: 2000 mg/m<sup>2</sup>)
+
|2014
−
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1
+
|
−
====Supportive therapy====
+
|
−
*[[Metoclopramide (Reglan)]] 1 mg/kg (route and frequency not indicated)
+
|Acute myeloid leukemia
−
*[[Diphenhydramine (Benadryl)]] 25 mg IV (frequency not indicated)
+
|1
−
'''3- to 4-week cycle for 2 cycles (PARMA & Josting et al. 2005) or up to 10 cycles (see note)'''
+
|0
−
</div>
+
|0
−
<div class="toccolours" style="background-color:#cbd5e7">
+
|0
−
====Subsequent treatment====
+
|17
−
*PARMA, responders (PR/CR) after cycle 2: [[#DHAP|DHAP]] x 4 versus [[Diffuse_large_B-cell_lymphoma#BEAC.2C_then_auto_HSCT|BEAC, then autologous HSCT]]
+
|17
−
*Josting et al. 2005, responders (PR/CR) after cycle 2: [[#Methotrexate_monotherapy_88|HD-MTX with stem cell mobilization]], then [[Regimen_classes#High-dose_chemotherapy_with_auto_HSCT|HDT, then autologous HSCT]]
+
|1
−
</div></div>
 
−
===References===
 
−
# Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F, Barlogie B. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988 Jan;71(1):117-22. [http://www.bloodjournal.org/content/71/1/117 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/3334893 PubMed]
 
−
# '''PARMA:''' Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, Coiffier B, Biron P, Mandelli F, Chauvin F. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995 Dec 7;333(23):1540-5. [https://doi.org/10.1056/NEJM199512073332305 link to original article] '''does not contain dosing details''' [https://pubmed.ncbi.nlm.nih.gov/7477169 PubMed]
 
−
# Josting A, Sieniawski M, Glossmann JP, Staak O, Nogova L, Peters N, Mapara M, Dörken B, Ko Y, Metzner B, Kisro J, Diehl V, Engert A. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol. 2005 Aug;16(8):1359-65. Epub 2005 Jun 6. [https://doi.org/10.1093/annonc/mdi248 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/15939712 PubMed]
 
−
==EPIC regimen {{#subobject:9f53f1|Regimen=1}}==
 
−
EPIC: '''<u>E</u>'''toposide, '''<u>P</u>'''rednisolone, '''<u>I</u>'''fosfamide,  '''<u>C</u>'''arboplatin
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:c450a9|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968387/ Hickish et al. 1993]
+
|Arance
−
|1989-1991
+
|Ana M
−
|style="background-color:#91cf61"|Phase 2
+
|FEMALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|2009
 +
|2022
 +
|CheckMate 238 Collaborators
 +
|
 +
|CNS melanoma; Melanoma
 +
|24
 +
|1
 +
|11
 +
|8
 +
|562
 +
|205
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1002/hon.2900120304 Richardson et al. 1994]
+
|Aranda
−
|1991-1993
+
|Enrique
−
|style="background-color:#ffffbe"|Phase 2, <20 patients
+
|MALE
 +
|
 +
|
 +
|
 +
|Spain
 +
|1994
 +
|2020
 +
|GEICAM; TTD
 +
|
 +
|Breast cancer; Colon cancer; Colorectal cancer; Esophageal adenocarcinoma
 +
|9
 +
|7
 +
|7
 +
|0
 +
|179
 +
|127
 +
|1
 
|-
 
|-
−
|}
+
|Aranda
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Ignacio
−
====Chemotherapy====
+
|MALE
−
*[[Etoposide (Vepesid)]]
+
|
−
*[[Ifosfamide (Ifex)]]
+
|
−
*[[Carboplatin (Paraplatin)]]
+
|
−
====Glucocorticoid therapy====
+
|Spain
−
*[[Prednisolone (Millipred)]]
+
|1999
−
</div></div>
+
|2010
−
===References===
+
|GEICAM
−
# Hickish T, Roldan A, Cunningham D, Mansi J, Ashley S, Nicolson V, Gore ME, Catovsky D, Smith IE. EPIC: an effective low toxicity regimen for relapsing lymphoma. Br J Cancer. 1993 Sep;68(3):599-604. [https://doi.org/10.1038/bjc.1993.393 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968387/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/8353050 PubMed]
+
|
−
# Richardson DS, Tighe M, Cull G, Johnson SA, Phillips MJ. Salvage chemotherapy for relapsed and resistant lymphoma with a carboplatin containing schedule--EPIC. Hematol Oncol. 1994 May-Jun;12(3):125-8. [https://doi.org/10.1002/hon.2900120304 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7959640 PubMed]
+
|Breast cancer
−
==HAM {{#subobject:c6c400|Regimen=1}}==
+
|1
−
HAM: '''<u>H</u>'''igh-dose '''<u>A</u>'''ra-C (Cytarabine) & '''<u>M</u>'''itoxantrone
+
|0
−
<br>NOAC: '''<u>NO</u>'''vantrone (Mitoxantrone) & '''<u>A</u>'''ra-'''<u>C</u>''' (Cytarabine)
+
|1
−
<div class="toccolours" style="background-color:#eeeeee">
+
|0
−
===Regimen {{#subobject:e86c0b|Variant=1}}===
+
|30
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
+
|30
−
!style="width: 33%"|Study
+
|1
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[https://doi.org/10.1002/1097-0142%2819891001)64%3A7%3C1388%3A%3AAID-CNCR2820640703%3E3.0.CO%3B2-0 Ho et al. 1989]
+
|Aranda
−
|1986-1987
+
|J
−
|style="background-color:#91cf61"|Phase 2
+
|CBD
 +
|
 +
|
 +
|
 +
|Spain
 +
|1987
 +
|2003
 +
|GEICAM
 +
|
 +
|Breast cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|14
 +
|14
 +
|1
 
|-
 
|-
−
|}
+
|Arango Hisijara
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Israel
−
====Chemotherapy====
+
|MALE
−
*[[Cytarabine (Ara-C)]]
+
|
−
*[[Mitoxantrone (Novantrone)]]
+
|
−
</div></div>
+
|
−
===References===
+
|USA
−
# Ho AD, del Valle F, Rückle H, Schwammborn J, Schlimok G, Hiddemann W, Meusers P, Thiel E, Dörken B, Hunstein W. Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma. Cancer. 1989 Oct 1;64(7):1388-92. [https://doi.org/10.1002/1097-0142%2819891001)64%3A7%3C1388%3A%3AAID-CNCR2820640703%3E3.0.CO%3B2-0 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2776103 PubMed]
+
|2013
−
==MINE {{#subobject:aff118|Regimen=1}}==
+
|2021
−
MINE: '''<u>M</u>'''esna, '''<u>I</u>'''fosfamide, '''<u>N</u>'''ovantrone (Mitoxantrone), '''<u>E</u>'''toposide
+
|
−
<div class="toccolours" style="background-color:#eeeeee">
+
|
−
===Regimen {{#subobject:3a1597|Variant=1}}===
+
|Marginal zone lymphoma; Waldenstroem macroglobulinemia
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
+
|2
−
!style="width: 33%"|Study
+
|0
−
!style="width: 33%"|Years of enrollment
+
|1
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
|2
 +
|37
 +
|36
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.1995.13.7.1734 Rodriguez et al. 1995]
+
|Arango Ossa
−
|NR
+
|Juan E
−
|style="background-color:#91cf61"|Phase 2
+
|Not yet determined
 +
|
 +
|
 +
|
 +
|USA
 +
|2011
 +
|2022
 +
|
 +
|
 +
|Polycythemia vera
 +
|1
 +
|0
 +
|1
 +
|0
 +
|42
 +
|42
 +
|1
 
|-
 
|-
−
|}
+
|Arasteh
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Keikawus
−
====Chemotherapy====
+
|MALE
−
*[[Ifosfamide (Ifex)]] 1333 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 3
+
|
−
*[[Mitoxantrone (Novantrone)]] 8 mg/m<sup>2</sup> IV once on day 1
+
|
−
*[[Etoposide (Vepesid)]] 65 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 3
+
|
−
====Supportive therapy====
+
|
−
*[[Mesna (Mesnex)]] 1333 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 3
+
|1993
−
*[[Mesna (Mesnex)]] 500 mg PO once, diluted in water or juice, 4 hours following ifosfamide administration
+
|1998
−
'''21-day cycles (see below)'''
+
|
−
</div>
+
|
−
<div class="toccolours" style="background-color:#cbd5e7">
+
|Kaposi sarcoma
−
====Subsequent treatment====
+
|1
−
*Rodriguez et al. 1995, CR: A total of 6 cycles of MINE, then [[#ESHAP|ESHAP]] consolidation x 3.
+
|0
−
*Rodriguez et al. 1995, PR: MINE was given to the point of maximal response, and then patients were crossed over to ESHAP.
+
|1
−
</div></div>
+
|0
−
===References===
+
|8
−
# Rodriguez MA, Cabanillas FC, Velasquez W, Hagemeister FB, McLaughlin P, Swan F, Romaguera JE. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol. 1995 Jul;13(7):1734-41. [https://doi.org/10.1200/jco.1995.13.7.1734 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/7602363 PubMed]
+
|8
−
==VIM {{#subobject:d58124|Regimen=1}}==
+
|1
−
VIM: '''<u>V</u>'''epesid (Etoposide), '''<u>I</u>'''fosfamide, '''<u>M</u>'''itoxantrone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:9817aa|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[https://doi.org/10.1111/j.1600-0609.1995.tb00261.x Hopfinger et al. 1995]
+
|Araujo
−
|1986-1992
+
|Carla
−
|style="background-color:#91cf61"|Phase 2
+
|FEMALE
 +
|
 +
|
 +
|
 +
|France
 +
|2008
 +
|2022
 +
|IFM
 +
|
 +
|Autologous HSCT; Multiple myeloma
 +
|6
 +
|0
 +
|4
 +
|1
 +
|217
 +
|121
 +
|1
 
|-
 
|-
−
|}
+
|Araujo
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|John C
−
====Chemotherapy====
+
|MALE
−
*[[Etoposide (Vepesid)]]
+
|
−
*[[Ifosfamide (Ifex)]]
+
|
−
*[[Mitoxantrone (Novantrone)]]
+
|
−
</div></div>
+
|USA
−
===References===
+
|2008
−
# Hopfinger G, Heinz R, Koller E, Schneider B, Pittermann E. Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma. Eur J Haematol. 1995 Oct;55(4):223-7. [https://doi.org/10.1111/j.1600-0609.1995.tb00261.x link to original article] [https://pubmed.ncbi.nlm.nih.gov/7589338 PubMed]
+
|2013
−
==VIPD {{#subobject:bf2293|Regimen=1}}==
+
|
−
VIPD: '''<u>V</u>'''P-16 (Etoposide), '''<u>I</u>'''fosfamide,  '''<u>P</u>'''latinol (Cisplatin), '''<u>D</u>'''examethasone
+
|
−
<br>DVIP: '''<u>D</u>'''examethasone, '''<u>V</u>'''P-16 (Etoposide), '''<u>I</u>'''fosfamide,  '''<u>P</u>'''latinol (Cisplatin)
+
|Prostate cancer
−
<div class="toccolours" style="background-color:#eeeeee">
+
|1
−
===Regimen {{#subobject:463c54|Variant=1}}===
+
|1
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
+
|1
−
!style="width: 33%"|Study
+
|0
−
!style="width: 33%"|Years of enrollment
+
|24
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
|24
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1007/BF00686323 Haim et al. 1992]
+
|Aravantinos
−
|1989-1991
+
|Gerasimos
−
|style="background-color:#91cf61"|Phase 2
+
|MALE
 +
|
 +
|
 +
|
 +
|Greece
 +
|1989
 +
|2012
 +
|HCOG; HeCOG
 +
|
 +
|Bladder cancer; Breast cancer; Colon cancer; Colorectal cancer; Endometrial cancer; Ovarian cancer; Pancreatic cancer; Testicular cancer
 +
|13
 +
|2
 +
|11
 +
|0
 +
|212
 +
|101
 +
|1
 
|-
 
|-
−
|}
+
|Arazy
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Melina
−
====Glucocorticoid therapy====
+
|FEMALE
−
*[[Dexamethasone (Decadron)]]
+
|
−
====Chemotherapy====
+
|
−
*[[Etoposide (Vepesid)]]
+
|
−
*[[Ifosfamide (Ifex)]]
+
|USA
−
*[[Cisplatin (Platinol)]]
+
|2017
−
</div></div>
+
|2020
−
===References===
+
|
−
# Haim N, Rosenblatt E, Wollner M, Ben-Shahar M, Epelbaum R, Robinson E. Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide, and cisplatin. Cancer Chemother Pharmacol. 1992;30(3):243-4. [https://doi.org/10.1007/BF00686323 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1628376 PubMed]
+
|
−
=Consolidation after salvage therapy=
+
|Multiple myeloma
−
==ESHAP {{#subobject:ff76de|Regimen=1}}==
+
|1
−
ESHAP: '''<u>E</u>'''toposide, '''<u>S</u>'''olumedrol (Methylprednisolone), '''<u>H</u>'''igh dose '''<u>A</u>'''ra-C (Cytarabine), '''<u>P</u>'''latinol (Cisplatin)
+
|0
−
<div class="toccolours" style="background-color:#eeeeee">
+
|1
−
===Regimen {{#subobject:562c75|Variant=1}}===
+
|1
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
+
|57
−
!style="width: 33%"|Study
+
|57
−
!style="width: 33%"|Years of enrollment
+
|1
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.1995.13.7.1734 Rodriguez et al. 1995]
+
|Arbogast
−
|NR
+
|Daria
−
|style="background-color:#91cf61"|Phase 2
+
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2010
 +
|2010
 +
|
 +
|
 +
|Thyroid cancer medullary
 +
|1
 +
|0
 +
|0
 +
|0
 +
|18
 +
|18
 +
|1
 
|-
 
|-
−
|}
+
|Arbuck
−
<div class="toccolours" style="background-color:#cbd5e8">
+
|Susan G
−
====Preceding treatment====
+
|FEMALE
−
*[[#MINE|MINE]] salvage
+
|
−
</div>
+
|
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|
−
====Chemotherapy====
+
|
−
*[[Etoposide (Vepesid)]] 60 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 4
+
|1992
−
*[[Cytarabine (Ara-C)]] 2000 mg/m<sup>2</sup> IV over 2 hours once on day 5
+
|2003
−
*[[Cisplatin (Platinol)]] 25 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 100 mg/m<sup>2</sup>)
+
|
−
====Glucocorticoid therapy====
+
|
−
*[[Methylprednisolone (Solumedrol)]] 500 mg IV as a short infusion once per day on days 1 to 4
+
|Cervical cancer; Ovarian cancer
−
'''21-day cycle for 3 cycles'''
+
|2
−
</div></div>
+
|1
−
===References===
+
|1
−
# Rodriguez MA, Cabanillas FC, Velasquez W, Hagemeister FB, McLaughlin P, Swan F, Romaguera JE. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol. 1995 Jul;13(7):1734-41. [https://doi.org/10.1200/jco.1995.13.7.1734 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/7602363 PubMed]
+
|0
−
=Relapsed or refractory, further lines of therapy=
+
|22
−
==CEPP(B) {{#subobject:bec105|Regimen=1}}==
+
|21
−
CEPP(B): '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''toposide, '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone, (optional) '''<u>B</u>'''leomycin
+
|1
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:696b13|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[http://www.bloodjournal.org/content/76/7/1293.long Chao et al. 1990]
+
|Arbushites
−
|1982-1989
+
|Michael C
−
|style="background-color:#91cf61"|Phase 2
+
|MALE
 +
|
 +
|
 +
|
 +
|USA
 +
|2004
 +
|2020
 +
|
 +
|
 +
|Breast cancer; Graft versus host disease
 +
|2
 +
|0
 +
|1
 +
|1
 +
|25
 +
|25
 +
|1
 
|-
 
|-
−
|}
+
|Arcaini
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Luca
−
====Chemotherapy====
+
|MALE
−
*[[Cyclophosphamide (Cytoxan)]]
+
|
−
*[[Etoposide (Vepesid)]]
+
|
−
*[[Procarbazine (Matulane)]]
+
|
−
*[[Bleomycin (Blenoxane)]]
+
|Italy
−
====Glucocorticoid therapy====
+
|2006
−
*[[Prednisone (Sterapred)]]
+
|2021
−
</div></div>
+
|FIL; SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network
−
===References===
+
|
−
# Chao NJ, Rosenberg SA, Horning SJ. CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. Blood. 1990 Oct 1;76(7):1293-8. [http://www.bloodjournal.org/content/76/7/1293.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/2207307 PubMed]
+
|Follicular lymphoma; Mantle cell lymphoma
−
==DICE {{#subobject:deaf96|Regimen=1}}==
+
|7
−
DICE: '''<u>D</u>'''examethasone, '''<u>I</u>'''fosfamide, '''<u>C</u>'''arboplatin, '''<u>E</u>'''toposide
+
|1
−
<div class="toccolours" style="background-color:#eeeeee">
+
|3
−
===Regimen {{#subobject:e35f1a|Variant=1}}===
+
|0
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
+
|164
−
!style="width: 33%"|Study
+
|132
−
!style="width: 33%"|Years of enrollment
+
|1
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[https://doi.org/10.1093/annonc/2.suppl_1.43 Goss et al. 1991]
+
|Arcamone
−
|NR
+
|Manuela
−
|style="background-color:#91cf61"|Phase 2
+
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2012
 +
|2012
 +
|
 +
|
 +
|Follicular lymphoma
 +
|1
 +
|0
 +
|0
 +
|0
 +
|14
 +
|14
 +
|1
 
|-
 
|-
−
|[https://pubmed.ncbi.nlm.nih.gov/11486401 Coleman et al. 2001]
+
|Arcangeli
−
|NR in abstract
+
|Annarosa
−
|style="background-color:#91cf61"|Phase 2
+
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|1995
 +
|2008
 +
|Italian Oncology Group for Cancer Research
 +
|
 +
|Gastric cancer
 +
|1
 +
|0
 +
|1
 +
|0
 +
|15
 +
|15
 +
|1
 
|-
 
|-
−
|}
+
|Arcangeli
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Giuseppina
−
====Glucocorticoid therapy====
+
|FEMALE
−
*[[Dexamethasone (Decadron)]]
+
|
−
====Chemotherapy====
+
|
−
*[[Ifosfamide (Ifex)]]
+
|
−
*[[Carboplatin (Paraplatin)]]
+
|
−
*[[Etoposide (Vepesid)]]
+
|1995
−
</div></div>
+
|1995
−
===References===
+
|
−
# Goss PE, Shepherd FA, Scott JG, Warner E, Baker MA, Sutton D, Farquharson HA, Buick S, Sutcliffe S. Dexamethasone/ifosfamide/cisplatin/etoposide (DICE) as therapy for patients with advanced refractory non-Hodgkin's lymphoma: preliminary report of a phase II study. Ann Oncol. 1991 Jan;2 Suppl 1:43-6. [https://doi.org/10.1093/annonc/2.suppl_1.43 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2043497 PubMed]
+
|
−
#  Coleman M, Leonard J, Shuster MW, Kaufman TP. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL). Eur J Haematol. 2001 Jul;64:41-5. [https://pubmed.ncbi.nlm.nih.gov/11486401 PubMed]
+
|Hepatocellular carcinoma
−
==DICEP {{#subobject:9eab06|Regimen=1}}==
+
|1
−
DICEP: '''<u>D</u>'''ose '''<u>I</u>'''ntensive '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''toposide, '''<u>P</u>'''latinol (Cisplatin)
+
|1
−
<div class="toccolours" style="background-color:#eeeeee">
+
|0
−
===Regimen {{#subobject:49a4cd|Variant=1}}===
+
|0
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
+
|3
−
!style="width: 33%"|Study
+
|3
−
!style="width: 33%"|Years of enrollment
+
|1
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[https://doi.org/10.3109/07357909409021387 Neidhart et al. 1994]
+
|Arcangeli
−
|1987-1991
+
|Valentina
−
|style="background-color:#91cf61"|Phase 2
+
|FEMALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|2010
 +
|2015
 +
|MITO
 +
|
 +
|Ovarian cancer
 +
|1
 +
|0
 +
|0
 +
|0
 +
|22
 +
|22
 +
|1
 
|-
 
|-
−
|}
+
|Arcari
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Annalisa
−
====Chemotherapy====
+
|FEMALE
−
*[[Cyclophosphamide (Cytoxan)]]
+
|
−
*[[Etoposide (Vepesid)]]
+
|
−
*[[Cisplatin (Platinol)]]
+
|
−
</div></div>
+
|Italy
−
===References===
+
|2003
−
# Neidhart JA, Kubica R, Stidley C, Pfile J, Clark D, Rinehart J. Multiple cycles of dose-intensive cyclophosphamide, etoposide, and cisplatinum (DICEP) produce durable responses in refractory non-Hodgkin's lymphoma. Cancer Invest. 1994;12(1):1-11. [https://doi.org/10.3109/07357909409021387 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8281458 PubMed]
+
|2021
−
==EPOCH {{#subobject:eca645|Regimen=1}}==
+
|ANZ BCTG; FIL
−
EPOCH: '''<u>E</u>'''toposide, '''<u>P</u>'''rednisone, '''<u>O</u>'''ncovin (Vincristine), '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin)
+
|
−
<br>CHEOP: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>E</u>'''toposide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
+
|Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma
−
<div class="toccolours" style="background-color:#eeeeee">
+
|4
−
===Regimen {{#subobject:492bdc|Variant=1}}===
+
|0
−
{| class="wikitable sortable" style="width: 80%; text-align:center;"
+
|2
−
!style="width: 25%"|Study
+
|0
−
!style="width: 25%"|Years of enrollment
+
|93
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
|78
−
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+
|1
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.1993.11.8.1573 Wilson et al. 1993]
+
|Arcasoy
−
|1990-1992
+
|Murat O
−
|style="background-color:#91cf61"|Phase 2
+
|MALE
−
| style="background-color:#e0ecf4" |ORR: 87%
+
|
 +
|
 +
|
 +
|USA
 +
|2009
 +
|2022
 +
|
 +
|
 +
|Myelofibrosis; Polycythemia vera
 +
|6
 +
|0
 +
|2
 +
|1
 +
|161
 +
|74
 +
|1
 
|-
 
|-
−
|}
+
|Arce Lara
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Carlos
−
====Chemotherapy====
+
|MALE
−
*[[Etoposide (Vepesid)]] 50 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 200 mg/m<sup>2</sup>)
+
|
−
*[[Vincristine (Oncovin)]] 0.4 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 1.6 mg/m<sup>2</sup>)
+
|
−
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV over 15 minutes once on day 6
+
|
−
*[[Doxorubicin (Adriamycin)]] 10 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 40 mg/m<sup>2</sup>)
+
|USA
−
====Glucocorticoid therapy====
+
|2015
−
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO on days 1 to 6
+
|2019
−
====Supportive therapy====
+
|
−
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting on day 6 and continuing until ANC >5000/uL past nadir
+
|
−
*PCP prophylaxis with any one of the following:
+
|Multiple myeloma
−
**[[Trimethoprim-Sulfamethoxazole (Bactrim DS)]] 160/800 mg PO twice per day 3 days per week
+
|1
−
**[[Atovaquone (Mepron)]] 1500 mg PO once per day
+
|0
−
**[[Pentamidine (Nebupent)]] 300 mg nebulized every 28 days
+
|0
−
'''21-day cycle for 6 to 8 cycles'''
+
|0
−
</div></div>
+
|10
−
===References===
+
|10
−
# Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe ES, Herdt J, Cheson BD, Chabner BA. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol. 1993 Aug;11(8):1573-82 [https://doi.org/10.1200/jco.1993.11.8.1573 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/7687667 PubMed]
+
|1
−
## '''Update:''' Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, Fojo A, Wilson WH. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol. 2000 Nov 1;18(21):3633-42. [https://doi.org/10.1200/JCO.2000.18.21.3633 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11054436 PubMed]
 
−
==ESHAP {{#subobject:4c0082|Regimen=1}}==
 
−
ESHAP: '''<u>E</u>'''toposide, '''<u>S</u>'''olumedrol (Methylprednisolone) '''<u>H</u>'''igh-dose '''<u>A</u>'''ra-C (Cytarabine), '''<u>P</u>'''latinol (Cisplatin)
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:ae8823|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.1994.12.6.1169 Velasquez et al. 1994]
+
|Arce Salinas
−
|1986-1988
+
|Claudia H
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
+
|FEMALE
−
|[[#ESHA_88|ESHA]]
+
|
−
|style="background-color:#1a9850"|Superior RR
+
|
 +
|
 +
|Mexico
 +
|2011
 +
|2021
 +
|
 +
|
 +
|Breast cancer
 +
|2
 +
|0
 +
|2
 +
|1
 +
|61
 +
|60
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.3816/CLML.2010.n.017 Avilés et al. 2010]
+
|Arceci
−
|NR
+
|Robert J
−
|style="background-color:#1a9851"|Phase 3 (C)
+
|MALE
−
|[[Diffuse_large_B-cell_lymphoma#R-ESHAP|R-ESHAP]]
+
|
−
|style="background-color:#ffffbf"|Did not meet efficacy endpoints
+
|
 +
|
 +
|USA
 +
|1979
 +
|2011
 +
|CCG; COG
 +
|
 +
|Acute myeloid leukemia; B-cell acute lymphoblastic leukemia pediatric; Chronic myeloid leukemia pediatric; Langerhans cell histiocytosis
 +
|5
 +
|2
 +
|4
 +
|2
 +
|60
 +
|53
 +
|1
 
|-
 
|-
−
|}
+
|Arcenas
−
''Note: timing of cycle was variable and dependent on "recovery of the toxic effects"
+
|Anthony
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|MALE
−
====Chemotherapy====
+
|
−
*[[Etoposide (Vepesid)]] 40 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 4
+
|
−
*[[Cytarabine (Ara-C)]] 2000 mg/m<sup>2</sup> IV over 2 hours once on day 5
+
|
−
*[[Cisplatin (Platinol)]] 25 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 100 mg/m<sup>2</sup>)
+
|
−
====Glucocorticoid therapy====
+
|2000
−
*[[Methylprednisolone (Solumedrol)]] 250 to 500 mg IV over 15 minutes once per day on days 1 to 5
+
|2000
−
====Supportive therapy====
+
|
−
*At least 1 liter normal saline with 25 to 50 g [[Mannitol]] once per day throughout chemotherapy
+
|
−
*[[Metoclopramide (Reglan)]] 0.5 to 1 mg/kg (route not specified) "given regularly"
+
|Non-small cell lung cancer
−
'''21- to 28-day cycle for 6 to 8 cycles'''
+
|1
−
</div></div>
+
|0
−
===References===
+
|1
−
# Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994 Jun;12(6):1169-76. [https://doi.org/10.1200/jco.1994.12.6.1169 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/8201379 PubMed]
+
|0
−
# Avilés A, Neri N, Huerta-Guzmán J, de Jesús Nambo M. ESHAP versus rituximab-ESHAP in frail patients with refractory diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2010 Apr;10(2):125-8. [https://doi.org/10.3816/CLML.2010.n.017 link to original article] [https://pubmed.ncbi.nlm.nih.gov/20371445 PubMed]
+
|18
−
==Etoposide, Ifosfamide, Methotrexate {{#subobject:d49400|Regimen=1}}==
+
|18
−
IMVP-16: '''<u>I</u>'''fosfamide, '''<u>M</u>'''ethotrexate, '''<u>VP-16</u>''' (Etoposide)
+
|1
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:9f78e9|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[http://www.bloodjournal.org/content/60/3/693.long Cabanillas et al. 1982]
+
|Arcese
−
|NR
+
|William
−
|style="background-color:#91cf61"|Phase 2
+
|MALE
 +
|
 +
|
 +
|
 +
|Italy
 +
|1988
 +
|2015
 +
|
 +
|
 +
|Acute myeloid leukemia; Allogeneic HSCT
 +
|2
 +
|0
 +
|1
 +
|0
 +
|40
 +
|40
 +
|1
 
|-
 
|-
−
|}
+
|Archambaud
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Baptiste
−
====Chemotherapy====
+
|Not yet determined
−
*[[Ifosfamide (Ifex)]]
+
|
−
*[[Methotrexate (MTX)]]
+
|
−
*[[Etoposide (Vepesid)]]
+
|
−
</div></div>
+
|France
−
===References===
+
|2017
−
# Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood. 1982 Sep;60(3):693-7. [http://www.bloodjournal.org/content/60/3/693.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/7104493 PubMed]
+
|2022
−
==GDP {{#subobject:20e899|Regimen=1}}==
+
|French Sarcoma Group
−
GDP: '''<u>G</u>'''emcitabine, '''<u>D</u>'''examethasone, '''<u>P</u>'''latinol (Cisplatin)
+
|
−
<div class="toccolours" style="background-color:#eeeeee">
+
|Leiomyosarcoma
−
===Regimen {{#subobject:325d38|Variant=1}}===
+
|1
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
+
|0
−
!style="width: 33%"|Study
+
|1
−
!style="width: 33%"|Years of enrollment
+
|0
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
|19
 +
|19
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1002/cncr.20587 Crump et al. 2004]
+
|Archambault
−
|2001-2002
+
|Robert
−
|style="background-color:#91cf61"|Phase 2
+
|MALE
 +
|
 +
|
 +
|
 +
|Canada
 +
|2000
 +
|2020
 +
|
 +
|
 +
|Prostate cancer
 +
|2
 +
|0
 +
|2
 +
|0
 +
|23
 +
|17
 +
|1
 
|-
 
|-
−
|}
+
|Archer
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|Caroline
−
====Chemotherapy====
+
|FEMALE
−
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8
+
|
−
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1
+
|
−
====Glucocorticoid therapy====
+
|
−
*[[Dexamethasone (Decadron)]] 40 mg IV or PO once per day on days 1 to 4
+
|United Kingdom
−
'''21-day cycle for up to 6 cycles'''
+
|2007
−
</div></div>
+
|2014
−
===References===
+
|
−
# Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, Imrie K, Myers R, Adams G, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R; National Cancer Institute of Canada Clinical Trials Group. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer. 2004 Oct 15;101(8):1835-42. [https://doi.org/10.1002/cncr.20587 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15386331 PubMed]
+
|
−
==ICE {{#subobject:f535c2|Regimen=1}}==
+
|Pancreatic cancer
−
ICE: '''<u>I</u>'''fosfamide, '''<u>C</u>'''arboplatin, '''<u>E</u>'''toposide
+
|1
−
<div class="toccolours" style="background-color:#eeeeee">
+
|0
−
===Regimen variant #1, inpatient {{#subobject:d573d9|Variant=1}}===
+
|1
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
+
|0
−
!style="width: 33%"|Study
+
|32
−
!style="width: 33%"|Years of enrollment
+
|32
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
|1
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.1999.17.12.3776 Moskowitz et al. 1999]
+
|Archer
−
|1993-1997
+
|J Hunter
−
|style="background-color:#91cf61"|Phase 2
+
|Not yet determined
 +
|
 +
|
 +
|
 +
|USA
 +
|2014
 +
|2022
 +
|COG
 +
|
 +
|T-cell acute lymphoblastic leukemia pediatric
 +
|1
 +
|0
 +
|1
 +
|0
 +
|35
 +
|35
 +
|1
 
|-
 
|-
−
|[https://doi.org/10.1093/annonc/mdg702 Zelenetz et al. 2003]
+
|Archer
−
|1993-2000
+
|Laura
−
|style="background-color:#91cf61"|Phase 2
+
|FEMALE
 +
|
 +
|
 +
|
 +
|
 +
|2003
 +
|2010
 +
|CALGB
 +
|
 +
|Renal cell carcinoma
 +
|2
 +
|0
 +
|1
 +
|0
 +
|21
 +
|11
 +
|1
 
|-
 
|-
−
|}
+
|Archer
−
''Note: Third cycle intended to be followed by peripheral blood hematopoietic cell collection''
+
|Venice
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|FEMALE
−
====Chemotherapy====
+
|
−
*[[Ifosfamide (Ifex)]] 5000 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 2, '''mixed with mesna'''
+
|
−
*[[Carboplatin (Paraplatin)]] AUC 5 (maximum dose of 800 mg) IV bolus once on day 2
+
|
−
**Carboplatin AUC calculated based on a 12-hour creatinine clearance
+
|United Kingdom
−
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV bolus once per day on days 1 to 3
+
|2005
−
====Supportive therapy====
+
|2019
−
*[[Mesna (Mesnex)]] 5000 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 2, '''mixed with [[Ifosfamide (Ifex)]]'''
+
|
−
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 5 to 12 (10 mcg/kg with cycle 3, given until collection of peripheral blood hematopoietic cells)
+
|
−
'''14-day cycle for 3 cycles; treatment can be delayed until ANC is greater than 1000/uL and platelet count greater than 50 x 10<sup>9</sup>/L'''
+
|Non-small cell lung cancer; Non-small cell lung cancer nonsquamous
−
</div></div><br>
+
|4
−
<div class="toccolours" style="background-color:#eeeeee">
+
|0
−
===Regimen variant #2, outpatient {{#subobject:b30a1b|Variant=1}}===
+
|3
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
+
|2
−
!style="width: 33%"|Study
+
|49
−
!style="width: 33%"|Years of enrollment
+
|38
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
|1
 
|-
 
|-
−
|[https://doi.org/10.1093/annonc/mdg703 Hertzberg et al. 2003]
+
|Archimbaud
−
|NR
+
|Eric
−
| style="background-color:#ffffbe" |Phase 2, <20 pts in this subgroup
+
|MALE
 +
|
 +
|
 +
|
 +
|
 +
|1980
 +
|2004
 +
|ALFA; EAPLG; EORTC; European APL Group; GELA; HOVON
 +
|
 +
|Acute myeloid leukemia; Acute promyelocytic leukemia; Diffuse large B-cell lymphoma
 +
|6
 +
|0
 +
|5
 +
|0
 +
|110
 +
|83
 +
|1
 
|-
 
|-
−
|}
+
|Arcila
−
''Note: Third cycle intended to be followed by peripheral blood hematopoietic cell collection''
+
|Maria E
−
<div class="toccolours" style="background-color:#b3e2cd">
+
|FEMALE
−
====Chemotherapy====
+
|
−
*[[Ifosfamide (Ifex)]] 1667 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 3, '''mixed with mesna'''
+
|
−
*[[Carboplatin (Paraplatin)]] AUC 5 (maximum dose of 800 mg) IV over 60 minutes once on day 1
+
|
−
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 3
+
|USA
−
====Supportive therapy====
+
|2012
−
*[[Mesna (Mesnex)]] 1667 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 3, '''mixed with [[Ifosfamide (Ifex)]]'''
+
|2021
−
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, started on day 5
+
|
−
'''21-day cycle for 3 cycles'''
+
|
−
</div></div>
+
|ERBB2 (HER2); Erdheim-Chester disease; Multiple myeloma
−
===References===
+
|3
−
# Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A, O'Brien J, Portlock CS, Straus DS, Childs B, Frank R, Yahalom J, Filippa D, Louie D, Nimer SD, Zelenetz AD. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999 Dec;17(12):3776-85. [https://doi.org/10.1200/jco.1999.17.12.3776 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/10577849 PubMed]
+
|1
−
# Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2003;14 Suppl 1:i5-10. [https://doi.org/10.1093/annonc/mdg702 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/12736224 PubMed]
+
|0
−
# Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease. Ann Oncol. 2003;14 Suppl 1:i11-6. [https://doi.org/10.1093/annonc/mdg703 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/12736225 PubMed]
+
|1
−
 
+
|88
−
==R-INO {{#subobject:429f9a|Regimen=1}}==
+
|85
−
R-INO: '''<u>R</u>'''ituximab, '''<u>INO</u>'''tuzumab ozogamicin
+
|1
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:9a3b4b|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
 
|-
 
|-
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878046/ Fayad et al. 2013 (B1931004)]
+
|Arcusa
−
|2006-NR
+
|Angels
−
|style="background-color:#91cf61"|Phase 1/2
+
|FEMALE
−
| style="background-color:#d3d3d3" |
+
|
−
| style="background-color:#d3d3d3" |
+
|
 +
|
 +
|Spain
 +
|1988
 +
|2010
 +
|GEICAM
 +
|
 +
|Breast cancer; Gastric cancer
 +
|3
 +
|0
 +
|3
 +
|0
 +
|59
 +
|52
 +
|1
 
|-
 
|-
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200343/ Dang et al. 2017 (B1931008)]
 
−
|2011-2013
 
−
| style="background-color:#1a9851" |Phase 3 (E-switch-ooc)
 
−
|Investigator's choice of:<br>1a. [[Diffuse_large_B-cell_lymphoma#Bendamustine_.26_Rituximab_.28BR.29_2|BR]]<br>1b. [[Diffuse_large_B-cell_lymphoma#Gemcitabine_.26_Rituximab|Gemcitabine & Rituximab]]
 
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS<br>Median OS: 9.5 vs 9.5 mo<br>(HR 1.1, 95% CI 0.8-1.4)
 
 
|-
 
|-
−
|}
+
}
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Targeted therapy====
 
−
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
 
−
====Antibody-drug conjugate therapy====
 
−
*[[Inotuzumab ozogamicin (Besponsa)]] 1.8 mg/m<sup>2</sup> IV once on day 2
 
−
'''28-day cycle for up to 8 cycles'''
 
−
</div></div>
 
−
===References===
 
−
# '''B1931004:''' Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, Rohatiner A, Advani A, Foran J, Hess G, Coiffier B, Czuczman M, Giné E, Durrant S, Kneissl M, Luu KT, Hua SY, Boni J, Vandendries E, Dang NH. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013 Feb 10;31(5):573-83. Epub 2013 Jan 7. [https://doi.org/10.1200/jco.2012.42.7211 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878046/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23295790 PubMed] NCT00299494
 
−
# '''B1931008:''' Dang NH, Ogura M, Castaigne S, Fayad LE, Jerkeman M, Radford J, Pezzutto A, Bondarenko I, Stewart DA, Shnaidman M, Sullivan S, Vandendries E, Tobinai K, Ramchandren R, Hamlin PA, Giné E, Ando K. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2018 Aug;182(4):583-586. Epub 2017 Jul 5. [https://doi.org/10.1111/bjh.14820 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200343/ link to PMC article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/28677896 PubMed] NCT01232556
 
−
[[Category:Diffuse large B-cell lymphoma regimens]]
 
−
[[Category:Historical regimens]]
 
−
[[Category:Disease-specific pages]]
 
−
[[Category:Aggressive lymphomas]]
 
−
[[Category:Non-Hodgkin lymphomas]]
 

Revision as of 14:39, 14 January 2023

}
Surname Forename Gender Site City Region Country First active year Last active year Study group(s) Sponsor(s) Conditions Total publications Senior publications Phase 3 RCTs FDA pivotal studies Co-authorships Co-authors Vital status
A'Hern Roger P MALE United Kingdom 1987 2015 London Gynaecological Oncology Group; TOPIC Trial Group Breast cancer; Ovarian cancer; Prostate cancer 5 0 4 0 100 83 1
Aamdal Steinar MALE Norway 1989 2015 EORTC; Nordic Melanoma Cooperative Group Melanoma; Small cell lung cancer 7 2 6 0 87 84 1
Aanur Praveen MALE USA 2016 2021 Malignant pleural mesothelioma 1 0 1 1 20 20 1
Aapro Matti S FEMALE Belgium; Switzerland 1984 2018 EORTC; International Collaborative Cancer Group Breast cancer; Endometrial cancer 5 3 5 1 109 108 1
Aaron Lorne MALE 2006 2012 Prostate cancer 1 0 1 0 7 7 1
Aaronson Neil K MALE 1992 2001 EORTC Melanoma; Prostate cancer 2 0 2 0 26 26 1
Aarts Maureen J B FEMALE Netherlands 2006 2017 BOOG; Dutch WIN-O Consortium Breast cancer; Renal cell carcinoma 3 0 2 0 38 30 1
Aasebo Ulf MALE Norway 1989 2013 Non-small cell lung cancer; Small cell lung cancer 7 1 7 0 65 44 1
Aass Nina FEMALE Norway 1996 2012 EORTC; MRC Renal cell carcinoma; Testicular cancer 5 1 4 0 48 34 1
Aastroem Lennart MALE Sweden 2014 2022 SPCG Prostate cancer 2 0 2 0 21 21 1
Aavall Lundqvist Elisabeth FEMALE Sweden 1999 2017 AGO; Gynecologic Cancer Intergroup Ovarian cancer 4 0 4 0 64 52 1
Abacioglu Ufuk MALE 2000 2012 Glioblastoma 1 0 1 0 11 11 1
Abad Alberto MALE Spain 1989 2012 TTD Colorectal cancer; Non-small cell lung cancer 3 1 3 0 53 44 1
Abada Paolo B MALE USA 2010 2019 Hepatocellular carcinoma 2 0 2 1 42 38 1
Abadie Lacourtoisie Sophie FEMALE France 2006 2019 GINECO Breast cancer 3 0 1 0 55 36 1
Abaskharoun Mena FEMALE USA 2018 2022 Melanoma 1 0 0 1 21 21 1
Abaza Yasmin FEMALE USA 2002 2017 Acute promyelocytic leukemia 1 1 0 0 26 26 1
Abbadessa A CBD 2007 2007 CNS lymphoma 1 0 0 0 17 17 1
Abbadessa Giovanni MALE USA 2012 2018 Hepatocellular carcinoma 1 0 1 0 29 29 1
Abbal Claire FEMALE Switzerland 2006 2015 GRAALL B-cell acute lymphoblastic leukemia 1 0 1 0 19 19 1
Abbas Abbas MALE 2002 2010 Esophageal adenocarcinoma 1 0 0 0 8 8 1
Abbas Haider MALE United Kingdom 2009 2014 COG Esophageal cancer 1 0 1 0 20 20 1
Abbas Mohammad MALE 2008 2012 Multiple myeloma 1 0 0 0 14 14 1
Abbas Moncef MALE 2002 2011 FFCD Colorectal cancer 1 0 1 0 18 18 1
Abbas Richat MALE USA 2006 2011 B-cell acute lymphoblastic leukemia; Chronic myeloid leukemia 1 0 0 1 14 14 1
Abbas Tahir Not yet determined Canada 2016 2020 NCIC-CTG Colorectal cancer 1 0 0 0 20 20 1
Abbattista Antonello MALE Italy 2014 2019 Non-small cell lung cancer 3 0 0 1 50 28 1
Abbink Floor FEMALE Netherlands 2011 2019 Chronic myeloid leukemia pediatric 1 0 0 1 15 15 1
Abbott Amanda FEMALE USA 2012 2019 Gastrointestinal stromal tumor 1 0 0 0 15 15 1
Abbott R L CBD 1982 1989 Bladder cancer 1 0 1 0 14 14 1
Abbott Thomas M MALE 1979 1989 SWOG Ovarian cancer 1 0 1 0 8 8 1
Abbou Clement Claude MALE France 1986 1993 Prostate cancer 1 0 1 1 14 14 1
Abboud Camille N FEMALE USA 1993 2016 ECOG Acute myeloid leukemia 2 0 1 0 49 49 1
Abboud Miguel R MALE Lebanon 2017 2019 Sickle cell anemia 1 0 1 0 21 21 1
Abbrederis Klaus MALE 1994 2003 Chronic myeloid leukemia 1 0 1 0 25 25 1
Abbruzzese Alberto MALE 2003 2009 Bladder cancer 1 0 1 0 11 11 1
Abbruzzese James L MALE 1988 2010 SWOG Colorectal cancer; Esophageal adenocarcinoma; Hepatocellular carcinoma; Pancreatic cancer 5 3 2 0 47 44 1
Abdalla K CBD Brazil 2011 2017 Gastric cancer 1 0 1 0 18 18 1
Abdallah Al Ola MALE USA 2018 2021 Multiple myeloma 2 0 0 1 55 38 1
Abdallah Rehab Not yet determined USA 2015 2021 Prostate cancer 1 0 0 0 27 27 1
Abdeddaim Cyril MALE France 2017 2020 Endometrial cancer 1 0 0 1 14 14 1
Abdel Hamid Abdel MALE United Kingdom 2007 2012 Thyroid cancer differentiated 1 0 1 0 27 27 1
Abdel Rahman Omar MALE Egypt 2010 2013 Hepatocellular carcinoma 1 1 0 0 5 5 1
Abdel Rahman Sultan MALE Germany 1997 2018 EORTC; European Society for Hyperthermic Oncology Soft tissue sarcoma 2 0 1 0 40 26 1
Abdel Wahab Manal FEMALE 2010 2013 Hepatocellular carcinoma 1 0 0 0 5 5 1
Abdel Wahab Omar MALE USA 2002 2019 ECOG Acute myeloid leukemia; Chronic myelomonocytic leukemia; Erdheim-Chester disease; Essential thrombocythemia; Hairy cell leukemia; Langerhans cell histiocytosis; Polycythemia vera; Rosai-Dorfman-Destombes disease 6 1 1 1 124 114 1
Abdel Wahab Sherif MALE 2010 2013 Hepatocellular carcinoma 1 0 0 0 5 5 1
Abdelfattah Murad MALE 2001 2009 Colorectal cancer 1 0 0 0 12 12 1
Abdelghany Osama MALE USA 2011 2020 Endometrial cancer 2 0 0 0 46 24 1
Abdi Ehtesham A MALE Australia 1994 2021 ALLG; IBCSG Breast cancer; Diffuse large B-cell lymphoma 4 0 3 0 95 72 1
Abdiche Menouar Samir Not yet determined France 2008 2020 GETUG Prostate cancer 1 0 1 0 17 17 1
Abdo Andre MALE Brazil 2017 2021 Chronic myeloid leukemia 1 0 1 1 25 25 1
Abdul Razak Albiruni R MALE Canada 2015 2020 Soft tissue sarcoma 1 0 1 0 20 20 1
Abdulkadyrov Kudrat M FEMALE Russian Federation 2004 2019 Chronic lymphocytic leukemia; Chronic myeloid leukemia; Essential thrombocythemia; Multiple myeloma 6 0 4 2 117 76 1
Abdullaev S Not yet determined USA 2014 2022 Colorectal cancer 1 0 0 1 18 18 1
Abdullah Shaad E MALE United Kingdom 2017 2021 Uveal melanoma 1 0 1 1 27 27 1
Abe Hajime MALE 2002 2010 Breast cancer 1 0 1 0 20 20 1
Abe Osahiko UNMATCHED 1981 1994 Breast cancer 2 0 2 0 23 17 1
Abe Rikiya FEMALE 1996 2009 Adjuvant CEF Research Group for Breast Cancer Breast cancer 2 0 2 0 27 24 1
Abe Tetsuya MALE Japan 2008 2015 JCOG Non-small cell lung cancer 1 1 1 0 19 19 1
Abe Yasunobu MALE Japan 2012 2016 Adult T-cell leukemia-lymphoma 1 0 0 0 17 17 1
Abedi Mehrdad MALE USA 2010 2021 B-cell acute lymphoblastic leukemia; Follicular lymphoma 2 0 0 1 37 37 1
Abel Edvard MALE Sweden 2013 2020 Head and neck cancer 1 0 1 0 14 14 1
Abel Ulrich MALE 1990 2012 Diffuse large B-cell lymphoma; Pancreatic cancer 2 0 2 0 40 40 1
Abella Eugenia FEMALE 2001 2013 GELCAB; GELTAMO; GESIDA; PETHEMA Chronic lymphocytic leukemia; HIV-associated lymphoma 4 0 0 0 68 42 1
Abellan Pascual Fernandez MALE 1999 2008 GEM; PETHEMA Multiple myeloma 1 0 1 0 16 16 1
Abeloff Martin D MALE USA 1979 2009 Breast Cancer Intergroup of North America; CALGB; ECOG; SWOG Breast cancer; Small cell lung cancer 10 4 10 0 89 59 1
Abels J CBD 1983 1989 EORTC Acute myeloid leukemia 2 0 2 0 22 15 1
Abelson Herbert T MALE 1982 1986 Osteosarcoma 1 0 1 0 14 14 1
Abenhardt Wolfgang MALE Germany 1997 2017 GCLLSG Breast cancer; Chronic lymphocytic leukemia 4 0 4 0 52 37 1
Abergel Armand MALE France 1995 2019 FFCD Hepatocellular carcinoma 3 0 3 0 48 42 1
Abernethy Amy FEMALE USA 2013 2017 Melanoma 1 0 1 1 22 22 1
Abeyakoon Sarath UNMATCHED 1996 2003 Head and neck cancer 1 0 1 0 10 10 1
Abgrall Jean Francois MALE France 1991 1997 Intergroupe Francais des Leucemies Myeloides Chroniques Chronic myeloid leukemia 1 0 1 0 11 11 1
Abhyankar Sunil MALE USA 2018 2018 BMT CTN Graft versus host disease 1 0 0 0 21 21 1
Abi Gerges Dany MALE Lebanon 2008 2014 Breast cancer 1 0 1 0 19 19 1
Abianui Abongnwen Not yet determined Canada 2018 2018 Venous thromboembolism 1 0 1 0 26 26 1
Abidi Muneer H MALE USA 2004 2020 SWOG Hodgkin lymphoma; Multiple myeloma 6 0 3 1 82 48 1
Abidoye Oyewale O MALE USA 2014 2016 Bladder cancer 2 0 0 2 64 43 1
Abildgaard Niels MALE 2002 2013 Multiple myeloma 2 0 2 0 48 37 1
Abir Esshagh Not yet determined 1965 1965 B-cell acute lymphoblastic leukemia 1 0 0 0 19 19 1
Ablin Arthur R MALE 1988 1988 CCG T-cell acute lymphoblastic leukemia pediatric 1 0 0 0 11 11 1
Aboelhassan Rasha Not yet determined Egypt 2013 2019 Malignant pleural mesothelioma 1 0 0 0 25 25 1
Abonour Rafat MALE USA 2004 2018 ECOG Multiple myeloma 3 0 1 1 53 50 1
Abou Alfa Ghassan K MALE USA 2001 2021 CALGB Cholangiocarcinoma; Hepatocellular carcinoma; Pancreatic cancer 13 11 7 4 267 191 1
Abou Nassar Karim MALE Canada 2013 2019 Follicular lymphoma; Venous thromboembolism 2 0 1 1 44 44 1
Abou Rached Antoine MALE France 1990 1995 Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire Hepatocellular carcinoma 1 0 1 0 5 5 1
Aboulafia David MALE 1993 2009 AIDS Malignancy Consortium HIV-associated lymphoma; Kaposi sarcoma 3 0 2 0 33 29 1
Abraham Aby FEMALE 1998 2010 Acute promyelocytic leukemia 1 0 0 0 11 11 1
Abraham Christine FEMALE France 2003 2019 Prostate cancer 1 0 1 0 27 27 1
Abraham George MALE India 2012 2019 Head and neck cancer 1 0 1 0 50 50 1
Abraham Jacinta FEMALE United Kingdom 2008 2018 Breast cancer 1 0 1 0 37 37 1
Abraham Jean E FEMALE United Kingdom 2001 2019 tAnGo trial collaborators Breast cancer 4 0 4 0 102 66 1
Abraham Julie FEMALE France 2014 2021 Diffuse large B-cell lymphoma 1 0 1 0 24 24 1
Abraham Mirta FEMALE 1996 2013 Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group Breast cancer 1 0 1 0 37 37 1
Abrahamse Testroote Martine C J FEMALE Netherlands 2006 2014 HOVON Chronic lymphocytic leukemia 1 0 1 0 14 14 1
Abrahamsson Jonas MALE Sweden 2004 2019 Nordic Society of Paediatric Haematology and Oncology (NOPHO) Acute myeloid leukemia; B-cell acute lymphoblastic leukemia pediatric 2 0 2 0 18 17 1
Abrahamsson Per Anders MALE 2001 2007 Atrasentan Phase III Study Group Institutions Prostate cancer 1 0 1 0 8 8 1
Abram Paul MALE 1998 2004 Breast cancer 1 0 1 0 10 10 1
Abram Steven R MALE USA 2007 2018 Glioblastoma 1 0 1 0 68 68 1
Abramov M CBD Russian Federation 2011 2017 Gastric cancer 1 0 1 0 18 18 1
Abrams Jeffrey S MALE USA 1982 2018 CALGB; NCIC-CTG Breast cancer; Melanoma 9 1 6 2 145 85 1
Abrams K Not yet determined 1988 1994 Colorectal cancer 1 0 1 0 4 4 1
Abrams Paul G MALE 1984 1984 Follicular lymphoma 1 0 0 0 11 11 1
Abrams Ross A MALE USA 1987 2011 Radiation Therapy Oncology Group; RTOG Cholangiocarcinoma; Pancreatic cancer; Prostate cancer 3 0 2 1 36 27 1
Abrams Thomas A MALE USA 2006 2018 Cholangiocarcinoma; Gallbladder cancer; Hepatocellular carcinoma 3 0 0 0 59 40 1
Abramson David H MALE USA 2010 2014 Uveal melanoma 1 0 0 0 27 27 1
Abramson Jeremy S MALE USA 2005 2022 Alliance; Blood Cancer Research Partnership of the Leukemia and Lymphoma Society; CALGB Chronic lymphocytic leukemia; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Primary mediastinal B-cell lymphoma; Transformed lymphoma 8 3 5 3 156 140 1
Abramson Neil MALE USA 1979 2001 ECOG; NSABP Breast cancer; Multiple myeloma 5 0 6 0 63 40 1
Abramson Vandana G FEMALE USA 2010 2022 NCIC-CTG Breast cancer; CNS carcinoma; Thyroid cancer 6 1 2 2 131 98 1
Abrao Miziara Jose Elias MALE Brazil 2006 2015 Non-small cell lung cancer; Non-small cell lung cancer nonsquamous 3 0 3 0 62 52 1
Abratt Raymond Pierre MALE South Africa 1995 2011 GLOB 2 group Non-small cell lung cancer; Prostate cancer 6 3 6 0 58 53 1
Abrey Lauren E FEMALE Switzerland; USA 1992 2018 Autologous HSCT; CNS lymphoma; Glioblastoma; High-grade glioma pediatric; Stem cell mobilization 9 4 1 1 101 76 1
Abrisqueta Pau MALE Spain 2005 2021 Chronic lymphocytic leukemia; Diffuse large B-cell lymphoma 5 1 2 1 111 87 1
Abromowitch Minnie FEMALE 1979 2012 COG B-cell acute lymphoblastic leukemia; B-cell acute lymphoblastic leukemia pediatric 3 1 3 0 30 27 1
Abruzzese Elisabetta FEMALE Italy 2004 2018 EORTC; FIL; GIMEMA; LYSA B-cell acute lymphoblastic leukemia; Chronic myeloid leukemia; Hodgkin lymphoma 7 0 5 1 174 122 1
Abruzzo Lynne V FEMALE USA 2015 2020 Chronic lymphocytic leukemia; Hodgkin lymphoma 2 0 0 0 29 29 1
Abshire T C Not yet determined USA 2000 2000 POG B-cell acute lymphoblastic leukemia pediatric 1 1 0 0 4 4 1
Abt Markus MALE Switzerland 1998 2005 Colon cancer 1 0 1 1 25 25 1
Abu Samra Maisun Not yet determined Germany 2010 2019 Acute myeloid leukemia 1 0 1 0 32 32 1
Abu Zahra Hakam MALE Canada 1984 1998 NCIC-CTG Breast cancer 2 0 2 2 38 31 1
Abuav Rachel FEMALE USA 2009 2009 Cutaneous T-cell lymphoma 1 0 0 1 13 13 1
Abubakr Yousif A MALE 2002 2008 Colorectal cancer 2 0 3 0 30 29 1
Abulizi G Not yet determined China 2017 2021 Ovarian cancer 1 0 1 0 33 33 1
Accario Winslow Chrisann FEMALE 2001 2009 Gynecologic Cancer Intergroup Ovarian cancer 1 0 1 0 15 15 1
Accomando Emilio MALE Italy 1987 1992 Head and neck cancer 1 0 1 0 24 24 1
Accortanzo Valeria FEMALE Italy 1996 2016 GONO Breast cancer 1 0 1 0 18 18 1
Acha Tomas MALE Spain 2001 2015 Wilms tumor 1 0 1 0 13 13 1
Acharya Sandip MALE India 2009 2018 Chronic myeloid leukemia 2 0 1 1 36 32 1
Acharyya Suddhasatta Not yet determined USA 2018 2021 Non-small cell lung cancer 1 0 0 0 20 20 1
Achebe Maureen M FEMALE USA 2017 2021 Sickle cell anemia 2 0 1 0 32 23 1
Achille Emmanuel MALE 1996 2007 GERCOR Colon cancer; Colorectal cancer 3 0 2 0 41 22 1
Acholonu Sandra FEMALE 2008 2008 Allogeneic HSCT; Hodgkin lymphoma 1 0 0 0 17 17 1
Achour Eddine UNMATCHED 2001 2001 CNS lymphoma; Stem cell mobilization 1 0 0 0 11 11 1
Achtelik W CBD 1994 2001 DeCOG Melanoma 1 0 1 0 15 15 1
Achtnicht U CBD 1985 1992 Renal cell carcinoma 1 0 1 0 8 8 1
Acin Yolene FEMALE France 2009 2015 Gastrointestinal stromal tumor; Pancreatic cancer 2 0 1 0 33 29 1
Acker Thomas MALE 2002 2012 “Aktion Bronchialkarzinom” (ABC Study Group) Small cell lung cancer 1 0 1 0 15 15 1
Ackerman Charlotte FEMALE United Kingdom 2007 2016 Bladder cancer 1 0 1 0 18 18 1
Ackerman Ilana Not yet determined Australia 2022 2022 Venous thromboembolism 1 0 1 0 45 45 1
Ackerman Judie FEMALE 2001 2006 Pancreatic cancer 1 0 1 0 10 10 1
Ackerstaff Annemiek H FEMALE 2000 2010 Head and neck cancer 1 0 1 0 12 12 1
Ackerstein Aliza FEMALE 1998 1998 Allogeneic HSCT; Chronic lymphocytic leukemia 1 0 0 0 14 14 1
Ackland Stephen P MALE Australia 1990 2012 AGITG; ANZ BCTG; Australasian Gastro-Intestinal Trials Group; Trans-Tasman Radiation Oncology Group; TROG Breast cancer; Colorectal cancer; Esophageal cancer; Rectal cancer 8 1 8 1 109 97 1
Acosta Rivera Mirelis FEMALE USA 2012 2020 Hepatocellular carcinoma 1 0 0 1 20 20 1
Acosta Mark MALE USA 2010 2010 Cutaneous T-cell lymphoma 1 0 1 1 8 8 1
Acosta Soraida C Not yet determined Cuba 2006 2016 Non-small cell lung cancer 1 0 1 0 33 33 1
Acquino Parsons C CBD 1995 2001 Endometrial cancer 1 0 0 0 6 6 1
Acs Peter I MALE 2008 2013 Diffuse large B-cell lymphoma 1 0 0 0 5 5 1
Acton Gary MALE USA 2010 2015 Acute myeloid leukemia 1 0 1 0 35 35 1
Adab Fawzi MALE United Kingdom 2002 2017 CRUK Pancreatic cancer; Prostate cancer 2 0 2 0 65 65 1
Adachi Hisanobu Not yet determined 2005 2013 Bladder cancer; Upper tract urothelial carcinoma 1 0 0 0 22 22 1
Adachi Isamu MALE Japan 1993 1996 Breast cancer 1 1 0 0 6 6 1
Adachi Susumu MALE 2001 2008 Malignant pleural mesothelioma 2 0 1 0 23 21 1
Adak Sudeshna FEMALE USA 1991 2001 ECOG Non-small cell lung cancer; Small cell lung cancer 2 0 2 0 12 11 1
Adam H CBD 1982 1994 SAKK Breast cancer 1 0 1 0 17 17 1
Adam Rene MALE France 1994 2017 SARAH Trial Group Colorectal cancer; Hepatocellular carcinoma 2 0 2 0 52 52 1
Adam Zdenek MALE 2001 2013 Multiple myeloma 4 1 1 0 45 24 1
Adamchuk Hryhoriy Not yet determined Ukraine 2008 2019 Breast cancer 1 0 1 0 24 24 1
Adami Bernd MALE 2001 2009 Colorectal cancer 1 0 0 0 12 12 1
Adami Fausto MALE Italy 1999 2017 Light-chain (AL) amyloidosis; POEMS syndrome 2 0 0 0 17 16 1
Adami Francesca FEMALE Italy 1996 2016 GONO Breast cancer 1 0 1 0 18 18 1
Adami Hans Olov MALE Sweden; USA 1989 2018 SPCG Prostate cancer 6 0 1 0 78 22 1
Adamkewicz Joanne I FEMALE USA 2018 2018 Inherited coagulopathy 1 0 1 0 16 16 1
Adamo Francesco MALE 1995 2006 EORTC; FIL; GIMEMA Acute myeloid leukemia; Hodgkin lymphoma 2 0 1 0 37 36 1
Adamo Vincenzo MALE 1983 2005 Italian Lung Cancer Project; Italian Multicentre Breast Study with Epirubicin Breast cancer; Colon cancer; Non-small cell lung cancer; Ovarian cancer 5 0 4 0 138 121 1
Adamou Adamos MALE 1992 2009 HeCOG; HORG Breast cancer 2 0 2 0 35 34 1
Adams Bonne Not yet determined USA 2017 2022 Vascular sarcoma 1 0 1 0 15 15 1
Adams George L MALE 1989 2003 Head and neck cancer; Nasopharyngeal carcinoma 2 0 3 0 17 14 1
Adams Grenfell MALE 1984 2004 NCIC-CTG Diffuse large B-cell lymphoma; Hodgkin lymphoma 2 0 1 0 28 27 1
Adams Hans Peter MALE 1995 2003 AGO Ovarian cancer 1 0 1 0 16 16 1
Adams Julian MALE USA 2001 2004 Follicular lymphoma; Mantle cell lymphoma; Multiple myeloma 3 0 0 1 49 34 1
Adams M CBD 1995 2002 ICON Ovarian cancer 1 0 1 0 20 20 1
Adams Paul T MALE USA 2007 2015 NSABP Breast cancer 2 0 1 0 39 21 1
Adams Richard A MALE United Kingdom 2005 2021 MRC Anal cancer; Colorectal cancer 5 2 5 0 99 79 1
Adams Sylvia FEMALE USA 2015 2021 Breast cancer 3 0 1 1 47 22 1
Adamska Krystyna FEMALE Poland 2008 2014 Canadian Brain Tumor Consortium; CENTRIC study team; EORTC Glioblastoma 1 0 1 0 36 36 1
Adamski Henri MALE 2011 2011 Cutaneous squamous cell carcinoma 1 0 0 0 19 19 1
Adamson Peter C MALE USA 2008 2020 Children's Oncology Group; COG; European Intergroup for Childhood Non-Hodgkin Lymphoma Anaplastic large cell lymphoma pediatric; B-cell acute lymphoblastic leukemia pediatric; Non-Hodgkin lymphoma pediatric 3 0 2 3 50 50 1
Adamus Jerzy MALE 1974 1982 Melanoma 1 0 1 0 25 25 1
Addamo B CBD 1998 2004 AML Study Group Ulm Acute myeloid leukemia 1 0 1 0 24 24 1
Adde Magdalena FEMALE Sweden 2001 2006 Burkitt lymphoma; Diffuse large B-cell lymphoma; HIV-associated lymphoma 2 1 0 0 15 15 1
Addeo Raffaele MALE Italy 2003 2009 Bladder cancer 1 1 1 0 11 11 1
Addison Alicia FEMALE USA 2013 2015 Mantle cell lymphoma 1 0 0 0 24 24 1
Adebamowo Clement MALE Nigeria 2004 2016 Breast cancer 1 0 1 0 29 29 1
Adelman Carrie A FEMALE United Kingdom 2020 2020 Prostate cancer 2 0 0 0 38 23 1
Adelson Mark D MALE USA 1985 1999 GOG Endometrial cancer; Ovarian cancer 2 0 2 0 18 18 1
Adelstein David J MALE USA 1988 2018 RTOG; SWOG Diffuse large B-cell lymphoma; Head and neck cancer; Oropharyngeal cancer 6 4 4 0 62 56 1
Ademokun Debo Not yet determined United Kingdom 2008 2019 National Cancer Research Institute Haemato-oncology Clinical Studies Group Multiple myeloma 1 0 2 0 21 21 1
Ademuyiwa Foluso Not yet determined USA 2013 2017 Breast cancer 1 0 0 0 33 33 1
Adeniran Adebowale Not yet determined USA 2016 2021 SWOG Papillary renal cell carcinoma 1 0 0 0 19 19 1
Adenis Antoine MALE France 1992 2022 EORTC; FFCD; FNCLCC; French Sarcoma Group; GI Group of the French Anti-Cancer Centers; PAZOGIST study group of the French Sarcoma Groupe-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO); UNICANCER Anal cancer; Colorectal cancer; Esophageal cancer; Esophageal squamous cell carcinoma; Gastrointestinal stromal tumor; Pancreatic cancer 18 2 12 5 322 225 1
Ades Lionel MALE France 1993 2022 EAPLG; European APL Group; French Belgian Swiss APL group; Groupe Francophone des Myelodysplasies; PETHEMA Acute myeloid leukemia; Acute promyelocytic leukemia; Chronic myelomonocytic leukemia; Myelodysplastic syndrome 8 7 6 1 182 121 1
Adeva Jorge MALE Spain 2017 2021 Cholangiocarcinoma 2 0 1 1 51 28 1
Adewoye Adeboye H MALE USA 2012 2017 Chronic lymphocytic leukemia 1 0 1 0 22 22 1
Adhoute X CBD France 2003 2015 FFCD Colorectal cancer 1 0 1 0 23 23 1
Adib Deyaa MALE USA 2015 2020 Follicular lymphoma 1 0 0 1 20 20 1
Adibi Mehrad Not yet determined USA 2017 2020 Upper tract urothelial carcinoma 1 0 0 0 35 35 1
Adie Sam MALE Australia 2022 2022 Venous thromboembolism 1 0 1 0 45 45 1
Adiguzel Ibrahim MALE 2007 2011 Small cell lung cancer 1 0 0 0 9 9 1
Adinin Rosnie B UNMATCHED 2001 2008 Breast cancer 1 0 1 0 10 10 1
Adjei Alex A MALE USA 1999 2017 ECOG-ACRIN; NCCTG Non-small cell lung cancer 2 0 2 0 38 38 1
Adkins Douglas MALE USA 2004 2021 Head and neck cancer; Soft tissue sarcoma; Thyroid cancer 3 0 1 2 54 54 1
Adler Reichel S Not yet determined Germany 2001 2016 Multiple myeloma 1 0 1 0 34 34 1
Adler Brian MALE 1992 2003 Sickle cell anemia 1 0 1 0 26 26 1
Adler Mathias MALE Germany 1991 2011 CONKO; GHSG Hodgkin lymphoma; Pancreatic cancer 3 0 2 0 66 59 1
Adotevi Olivier MALE France 2014 2018 Anal cancer 1 0 0 0 26 26 1
Adrian Nicole FEMALE Germany 2012 2016 Diffuse large B-cell lymphoma 1 0 0 0 12 12 1
Adrover Encarna FEMALE Spain 1999 2015 GEICAM Breast cancer 5 0 5 0 122 74 1
Advani Anjali S FEMALE USA 2006 2019 CALGB; SWOG Acute myeloid leukemia; B-cell acute lymphoblastic leukemia; B-cell acute lymphoblastic leukemia pediatric; Diffuse large B-cell lymphoma; Follicular lymphoma; Myelodysplastic syndrome 7 3 1 1 112 91 1
Advani Ranjana H FEMALE USA 1995 2022 ECOG; WMCTG Acute myeloid leukemia; Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Hodgkin lymphoma nodular lymphocyte-predominant; Mantle cell lymphoma; Mediastinal gray-zone lymphoma; Peripheral T-cell lymphoma; Primary mediastinal B-cell lymphoma; Waldenstroem macroglobulinemia 38 6 5 5 607 314 1
Advani Suresh H MALE 1996 2005 Breast cancer 1 0 1 0 10 10 1
Aeberhard Peter MALE 1981 2008 SAKK Colon cancer 2 0 2 0 12 9 1
Aebersold Daniel M MALE 1994 2011 SAKK Head and neck cancer 1 1 1 0 10 10 1
Aebi Stefan MALE Switzerland 1993 2021 BOOG Dutch Breast Cancer Trialists' Group; Breast International Group; GEICAM Spanish Breast Cancer Group; International Breast Cancer Study Group; NRG Oncology; SAKK Breast cancer 9 2 5 0 179 83 1
Aerts Joachim G J V MALE Netherlands 2007 2021 Malignant pleural mesothelioma; Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous; Small cell lung cancer 9 1 6 1 152 125 1
Afable Manuel MALE 2012 2012 Myelodysplastic syndrome 1 0 0 0 16 16 1
Afanasyev Boris V MALE Russian Federation 2003 2020 SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network Acute myeloid leukemia; Chronic lymphocytic leukemia; Mantle cell lymphoma; Myelodysplastic syndrome 4 0 3 2 95 95 1
Afchain Pauline FEMALE 2004 2009 Colorectal cancer 1 0 1 0 16 16 1
Afenjar Karen FEMALE France 2008 2019 Breast cancer; Gastric cancer 3 0 2 0 62 47 1
Afflitto Anthony J MALE USA 2013 2018 Hepatocellular carcinoma 1 0 0 0 20 20 1
Affronti M L Not yet determined 1992 2006 Breast cancer 1 0 1 0 11 11 1
Afra Denes MALE 1988 2008 EORTC Anaplastic glioma 1 0 1 0 9 9 1
Afrin Lawrence B MALE USA 2009 2017 Systemic mastocytosis 1 0 1 0 25 25 1
Aft Rebecca FEMALE USA 2013 2017 Breast cancer 1 0 0 0 33 33 1
Aftab Dana T FEMALE USA 2013 2016 Renal cell carcinoma 1 0 1 1 22 22 1
Aftimos Philippe MALE Belgium 2017 2022 Breast cancer 2 0 2 1 57 54 1
Agajanian Richy MALE USA 2012 2016 Multiple myeloma 1 0 0 0 16 16 1
Agaram Narasimhan P MALE USA 2014 2018 Alliance Desmoid tumor 1 0 1 0 24 24 1
Agarwal Archi Not yet determined India 2012 2019 Head and neck cancer 1 0 1 0 50 50 1
Agarwal Jaiprakash MALE India 2000 2019 Head and neck cancer 3 1 3 0 87 54 1
Agarwal Mohan B MALE India 2007 2011 Chronic myeloid leukemia 1 0 1 1 19 19 1
Agarwal Neeraj MALE USA 2006 2022 SWOG Bladder cancer; Prostate cancer; Renal cell carcinoma 15 2 8 3 299 211 1
Agarwal Prasheen MALE USA 2004 2007 Chronic myeloid leukemia 2 0 0 0 32 25 1
Agarwal Rishu FEMALE Australia 2015 2018 Mantle cell lymphoma 1 0 0 0 16 16 1
Agarwal Shefali FEMALE USA 2013 2020 Epithelioid sarcoma; Follicular lymphoma; Ovarian cancer 3 0 1 3 71 71 1
Agarwal Suresh K MALE USA 2012 2019 Acute myeloid leukemia; Chronic lymphocytic leukemia; Multiple myeloma 4 0 0 3 71 60 1
Agarwala A Not yet determined 2002 2011 Non-small cell lung cancer 1 0 1 0 14 14 1
Agarwala Sanjiv S MALE USA 1974 2017 ECOG; EORTC Head and neck cancer; Melanoma 16 5 13 3 268 198 1
Agate Laura FEMALE 2014 2014 Thyroid cancer differentiated; Thyroid cancer medullary 1 0 0 0 14 14 1
Agathocleous Agathoclis MALE United Kingdom 2010 2010 Follicular lymphoma 1 1 0 0 11 11 1
Agbalika Felix MALE 2007 2007 Castleman disease 1 0 0 0 12 12 1
Agelaki Sophia FEMALE Greece 2001 2017 HORG Breast cancer; Colorectal cancer; Non-small cell lung cancer; Small cell lung cancer 5 0 4 0 65 39 1
Agelidou Athina FEMALE Greece 1999 2011 HORG Non-small cell lung cancer; Small cell lung cancer 8 0 7 0 99 47 1
Agelidou Maria FEMALE Greece 2000 2013 HORG Non-small cell lung cancer; Small cell lung cancer 6 0 5 0 79 42 1
Ageno Walter MALE Italy 2008 2018 Venous thromboembolism 3 0 3 0 30 30 1
Ager Phyllis Joyce FEMALE 1984 1990 NSABP Breast cancer 1 0 1 1 19 19 1
Agerbaek Mads MALE Denmark 2002 2021 EORTC; German Association of Urologic Oncology; Groupe d'Etude des Tumeurs Urogenitales; National Cancer Institute of Canada Clinical Trials Group; National Cancer Research Institute Bladder Cancer Study Group Bladder cancer 2 0 2 1 56 55 1
Aggarwal Charu FEMALE USA 2011 2015 Non-small cell lung cancer 1 0 0 0 26 26 1
Aggarwal Sanjay MALE USA 2012 2016 Multiple myeloma 2 0 1 1 37 37 1
Aggerholm Anni FEMALE 2004 2010 Acute myeloid leukemia; Chronic myelomonocytic leukemia; Myelodysplastic syndrome 1 0 0 0 19 19 1
Agha Mounzer E UNMATCHED USA 2008 2022 Multiple myeloma 3 0 1 1 104 100 1
Aghajanian Carol A FEMALE USA 2005 2021 GOG Endometrial cancer; Leiomyosarcoma; Low-grade serous ovarian cancer; Ovarian cancer 19 3 11 6 375 215 1
Aghemo E CBD Italy 2010 2016 Multiple myeloma 1 0 0 0 29 29 1
Agis Hermine FEMALE Austria 2000 2006 Chronic myeloid leukemia 1 0 1 1 31 31 1
Aglietta Massimo MALE Italy 1998 2022 Italian Group for the Study of Gastrointestinal Cancer Colorectal cancer; Multiple myeloma; Osteosarcoma; Soft tissue sarcoma 8 1 4 2 138 119 1
Agnelli Giancarlo MALE Italy 2010 2020 Venous thromboembolism 6 3 6 0 81 51 1
Agnelli L CBD Italy 2013 2013 Plasma cell leukemia 1 0 0 0 29 29 1
Agodoa Irene FEMALE USA 2017 2021 Sickle cell anemia 1 0 1 0 11 11 1
Agopian Julie FEMALE France 2009 2017 Systemic mastocytosis 1 0 1 0 25 25 1
Agostara Biagio MALE 1997 2010 GOIM; Gruppo Oncologico Italia Meridionale Breast cancer; Colorectal cancer; Non-small cell lung cancer 3 0 3 0 53 46 1
Agostinelli Claudio MALE Italy 2006 2017 Diffuse large B-cell lymphoma 1 0 1 0 25 25 1
Agostini Cecile FEMALE 2000 2007 Breast cancer 1 0 1 0 13 13 1
Agrawal Manish MALE USA 2014 2017 Bladder cancer 1 0 0 1 17 17 1
Agrawal Rajiv K MALE United Kingdom 1996 2019 NEAT Investigators and the SCTBG; tAnGo trial collaborators Breast cancer 5 0 5 0 120 71 1
Agrawal Samir MALE 2006 2012 NCRI Chronic lymphocytic leukemia; Multiple myeloma; Stem cell mobilization 2 0 0 0 34 34 1
Agrawal Shruti FEMALE USA 2006 2021 Chronic myeloid leukemia pediatric; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous 2 0 1 2 42 42 1
Agresta Samuel V MALE USA 2013 2019 Acute myeloid leukemia 4 0 0 2 109 54 1
Agricola Karen FEMALE USA 2007 2015 Subependymal giant cell astrocytoma 3 0 0 1 23 14 1
Aguado Fraile Elia FEMALE USA 2017 2021 Cholangiocarcinoma 1 0 1 1 26 26 1
Aguado M Jose MALE 1999 1999 Hodgkin lymphoma 1 0 0 0 5 5 1
Aguggini S CBD 1997 2005 Breast cancer 1 0 1 0 13 13 1
Aguiar Melanie Not yet determined United Kingdom 2012 2022 B-cell acute lymphoblastic leukemia 1 0 1 0 25 25 1
Aguiar Ricardo C T MALE USA 2014 2014 Hypereosinophilic syndrome 1 0 0 0 18 18 1
Aguilera Nadia FEMALE Cuba 2006 2016 Non-small cell lung cancer 1 0 1 0 33 33 1
Aguilo Rafael MALE 2000 2010 Spanish Lung Cancer Group Non-small cell lung cancer 1 0 1 0 19 19 1
Agulnik Jason MALE Canada 2008 2016 Non-small cell lung cancer nonsquamous 1 0 1 0 14 14 1
Agulnik Mark B MALE USA 2004 2020 Epithelioid sarcoma; Head and neck cancer; Osteosarcoma; Soft tissue sarcoma; Vascular sarcoma 7 1 3 2 132 100 1
Agunwamba Blessing U FEMALE USA 2009 2013 Melanoma 1 0 0 0 23 23 1
Agura Edward MALE USA 1997 2018 Acute myeloid leukemia; Allogeneic HSCT; Chronic lymphocytic leukemia; Hodgkin lymphoma 8 1 1 1 131 83 1
Agus David B MALE USA 1993 2015 Diffuse large B-cell lymphoma; Prostate cancer 2 0 1 0 38 38 1
Aguzzi Rasha Not yet determined USA 2018 2018 Paroxysmal nocturnal hemoglobinuria 1 0 1 1 13 13 1
Ah See Antoinne K MALE 2002 2002 Breast cancer 1 0 1 0 11 11 1
Ah See Mei Lin Not yet determined United Kingdom 2007 2019 Breast cancer 1 0 1 0 31 31 1
Ahern Charlotte FEMALE USA 2009 2013 COG Anaplastic large cell lymphoma pediatric 1 0 0 1 13 13 1
Ahlberg Lucia FEMALE 2002 2013 Multiple myeloma 2 0 2 0 48 37 1
Ahlborn Miriam FEMALE Germany 2012 2021 GHSG Hodgkin lymphoma 1 0 2 0 35 35 1
Ahlgren Goeran M MALE Sweden 2005 2018 SPCG Prostate cancer 2 1 2 0 30 29 1
Ahlgren James D MALE 1984 1989 MAOP Colorectal cancer 1 0 1 0 4 4 1
Ahlgren Johan MALE Sweden 2004 2022 Breast cancer 3 0 1 0 57 27 1
Ahlgren Tomas MALE Sweden 2002 2015 Nordic Lymphoma Group Follicular lymphoma 1 0 1 0 12 12 1
Ahlman Hakan MALE 1979 2010 Adrenocortical carcinoma 1 1 0 0 8 8 1
Ahlmann Martina FEMALE Germany 2020 2020 Hemophagocytic lymphohistiocytosis 1 0 0 1 19 19 1
Ahluwalia Manmeet S MALE USA 2009 2020 Glioblastoma 2 0 2 0 47 46 1
Ahmad Chaudhary E Not yet determined Canada 2016 2020 NCIC-CTG Colorectal cancer 1 0 0 0 20 20 1
Ahmad Rizvana FEMALE United Kingdom 2009 2015 Breast cancer 1 0 1 0 20 20 1
Ahmad Shaharyar UNMATCHED 2013 2013 Hodgkin lymphoma 1 0 0 0 3 3 1
Ahmadi Jamshid MALE USA 1992 2015 SWOG Meningioma 1 0 1 0 12 12 1
Ahmadi Tahamtan MALE USA 2008 2021 Follicular lymphoma; Light-chain (AL) amyloidosis; Mantle cell lymphoma; Multiple myeloma 16 1 6 9 409 214 1
Ahmann David L MALE USA 1977 1995 Breast cancer; Melanoma 7 2 7 1 54 30 1
Ahmann Frederick R MALE 2002 2007 Prostate cancer 1 0 1 0 18 18 1
Ahmann Gregory J MALE USA 2004 2018 ECOG Multiple myeloma 2 0 1 1 42 39 1
Ahmed Asra FEMALE 2005 2012 Multiple myeloma 2 0 0 0 28 25 1
Ahmed Atif A Not yet determined USA 2010 2021 COG Ewing sarcoma 1 0 1 0 23 23 1
Ahmed Ikhlaaq Not yet determined United Kingdom 1998 2019 Breast cancer 1 0 1 0 19 19 1
Ahmed Nazma FEMALE Switzerland 2006 2015 Head and neck cancer 1 0 1 0 24 24 1
Ahmed Sairah FEMALE USA 2009 2014 Allogeneic HSCT; Mantle cell lymphoma; Transformed lymphoma 1 0 0 0 13 13 1
Ahn Chul MALE USA 2013 2014 Blastic plasmacytoid dendritic cell neoplasm 1 0 0 0 14 14 1
Ahn Daniel H MALE USA 2015 2019 Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer 2 0 0 0 31 30 1
Ahn Hanjong Not yet determined South Korea 2014 2022 Prostate cancer 1 0 1 0 8 8 1
Ahn Inhye E Not yet determined USA 2015 2020 Chronic lymphocytic leukemia 1 1 0 0 16 16 1
Ahn Jae Sook MALE South Korea 2009 2015 Adult Acute Lymphoblastic Leukemia Working Party of the Korean Society of Hematology B-cell acute lymphoblastic leukemia; CNS leukemia 1 0 0 0 36 36 1
Ahn Jin Hee FEMALE South Korea 2007 2022 KCSG Breast cancer 4 0 4 1 79 66 1
Ahn Jin Seok MALE South Korea 2002 2020 KCSG Breast cancer; CNS carcinoma; Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Small cell lung cancer 15 1 10 4 230 152 1
Ahn Joong Bae MALE South Korea 2008 2019 Colorectal cancer; Rectal cancer 6 0 3 1 103 65 1
Ahn Myung Ju FEMALE South Korea 2002 2021 KCSG CNS carcinoma; Esophageal squamous cell carcinoma; Head and neck cancer; Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous; NTRK; Small cell lung cancer 41 4 20 11 735 423 1
Ahn Sei Hyun Not yet determined South Korea 2012 2020 Breast cancer 1 1 1 0 9 8 1
Ahn Sung Ja Not yet determined 2005 2013 Non-small cell lung cancer 1 1 1 0 11 11 1
Ahn Yeon S Not yet determined 1983 1983 Immune thrombocytopenia 1 1 0 0 5 5 1
Ahn Yong Chan MALE South Korea 2003 2015 Consortium for Improving Survival of Lymphoma; KCSG Extranodal NK- and T-cell lymphoma nasal type; Gastric cancer; Non-small cell lung cancer; Small cell lung cancer 4 1 3 0 69 60 1
Ahren Bo MALE 1991 2003 Neuroendocrine tumor 1 1 0 0 3 3 1
Ahrens S CBD 2001 2001 Ewing sarcoma 1 0 0 0 18 18 1
Ahsan S Not yet determined USA 2011 2019 Melanoma 1 0 0 0 19 19 1
Ahsan Sama FEMALE United Kingdom; USA 2015 2022 SWOG Melanoma 2 0 2 1 57 54 1
Ahuja Harish MALE 2005 2005 Esophageal cancer 1 0 0 0 10 10 1
Ai Ping FEMALE China 2011 2019 Nasopharyngeal carcinoma 2 0 2 0 67 34 1
Ai Weiyun FEMALE USA 2018 2021 Diffuse large B-cell lymphoma; Transformed lymphoma 1 0 0 1 17 17 1
Ai Xinghao Not yet determined China 2018 2021 Non-small cell lung cancer nonsquamous; Small cell lung cancer 2 1 2 0 57 51 1
Aiba Keisuke Not yet determined Japan 2010 2021 Colon cancer 2 0 1 0 41 30 1
Aiello Maria FEMALE USA 2012 2014 Chronic lymphocytic leukemia 1 0 1 1 26 26 1
Aieta Michele MALE Italy 2007 2018 Reader study level-I and level-II Groups Breast cancer; Testicular cancer 2 0 1 0 40 40 1
Aihara Satomi Not yet determined Japan 2015 2021 Ovarian cancer 1 0 1 0 41 41 1
Aihara Tomohiko MALE Japan 2002 2010 Breast cancer 1 1 1 0 20 20 1
Aikata Hiroshi MALE Japan 2008 2018 Hepatocellular carcinoma 2 0 2 0 35 32 1
Aikawa Keiko Not yet determined Japan 1995 2010 JCOG Adult T-cell leukemia-lymphoma; Diffuse large B-cell lymphoma 2 0 1 0 32 25 1
Aiken Robert Not yet determined USA 2007 2018 Glioblastoma 1 0 1 0 68 68 1
Ailawadhi Sikander MALE USA 2012 2018 Chronic myeloid leukemia; Multiple myeloma 3 0 0 1 70 51 1
Aimone Paola FEMALE Switzerland 2007 2021 Chronic myeloid leukemia; Chronic myeloid leukemia pediatric; Head and neck cancer; Renal cell carcinoma 7 0 3 4 146 116 1
Airatovich Gafanov Rustem MALE Russian Federation 2016 2021 Clear cell renal cell carcinoma; Non-clear cell renal cell carcinoma; Prostate cancer; Renal cell carcinoma 5 0 2 1 107 78 1
Aird William MALE 1990 2000 Acute myeloid leukemia 1 0 0 0 6 6 1
Airewele Gladstone Not yet determined USA 2004 2014 Acute myeloid leukemia pediatric; Sickle cell anemia 2 0 1 0 56 56 1
Airoma G CBD 1990 1996 GOSCI Non-small cell lung cancer 1 0 1 0 18 18 1
Aisa Yoshinobu MALE 2015 2015 Follicular lymphoma 1 0 0 0 18 18 1
Aisner D L CBD USA 2011 2015 Pancreatic cancer 1 0 0 0 30 30 1
Aisner Joseph A MALE USA 1976 2003 CALGB Breast cancer; Head and neck cancer; Soft tissue sarcoma; Thymoma 9 3 6 0 93 65 1
Aisner Seena C FEMALE USA 1982 2017 ECOG; ECOG-ACRIN; SECSG; SWOG Non-small cell lung cancer; Small cell lung cancer; Thymoma 8 0 3 0 72 56 1
Aitchison Michael A MALE United Kingdom 1998 2018 EORTC; MRC Renal cell carcinoma 3 1 3 0 48 47 1
Aitini Enrico MALE Italy 1987 2014 GERCOR; GISCAD; Italian Group for the Study of Digestive Tract Cancer; Mammella InterGruppo Breast cancer; Colorectal cancer; Diffuse large B-cell lymphoma; Gastric cancer; Malignant pleural mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer 13 0 10 0 216 176 1
Aitken Casey N UNMATCHED USA 2017 2017 Transformed lymphoma 1 0 0 0 34 34 1
Aivado Manuel MALE 2010 2010 Immune thrombocytopenia 1 0 1 0 8 8 1
Aix Santiago Ponce Not yet determined Spain 2014 2020 Non-small cell lung cancer 1 0 1 0 19 19 1
Aizawa Masataka Not yet determined 2005 2013 Bladder cancer; Upper tract urothelial carcinoma 1 0 0 0 22 22 1
Ajani Jaffer A MALE USA 1990 2022 RTOG; USA Intergroup Anal cancer; Esophageal adenocarcinoma; Esophageal cancer; Esophageal squamous cell carcinoma; Gastric cancer 21 11 13 5 316 237 1
Ajaz Mazhar Not yet determined United Kingdom 2016 2019 Melanoma 1 0 0 0 18 18 1
Akabane Hiromitsu MALE Japan 2006 2021 Breast cancer 2 0 2 0 21 19 1
Akaike Makoto MALE Japan 2003 2014 JCOG Colorectal cancer 1 0 1 0 17 17 1
Akaike Tomoko FEMALE USA 2015 2021 Merkel cell carcinoma 1 0 0 1 28 28 1
Akamaru Yusuke MALE Japan 2007 2015 Gastric cancer 1 0 1 0 16 16 1
Akamatsu Hiroaki MALE Japan 2014 2021 CNS carcinoma; Non-small cell lung cancer; Non-small cell lung cancer nonsquamous 3 0 2 1 53 42 1
Akamatsu Hiroki Not yet determined Japan 2011 2017 Rectal cancer 1 0 1 0 12 12 1
Akapame Sydney MALE USA 2015 2022 Bladder cancer 1 0 0 1 18 18 1
Akard Luke MALE USA 2006 2015 Chronic myeloid leukemia; Testicular cancer 3 0 0 2 40 34 1
Akaza Hideyuki MALE Japan 2000 2020 Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer Prostate cancer 6 3 5 1 66 57 1
Akazawa Kohei MALE Japan 2010 2018 Hepatocellular carcinoma 1 0 1 0 21 21 1
Akazawa Rio FEMALE Japan 2013 2018 Prostate cancer 1 0 1 0 11 11 1
Akbulut Hakan MALE 1992 2005 Turkish Oncology Group Breast cancer 2 0 2 0 25 21 1
Akdas Atif MALE Turkey 1997 2009 EORTC Prostate cancer 1 0 1 0 15 15 1
Aker Memet MALE 1998 1998 Allogeneic HSCT; Chronic lymphocytic leukemia 1 0 0 0 14 14 1
Akerley Wallace MALE USA 1998 2016 CALGB Melanoma; Non-small cell lung cancer; Small cell lung cancer 4 0 4 1 74 72 1
Akerman Maans MALE 1989 2008 Nordic Lymphoma Group Autologous HSCT; Diffuse large B-cell lymphoma; Mantle cell lymphoma 2 1 1 0 30 28 1
Akewanlop Charuwan FEMALE Thailand 2015 2020 Non-small cell lung cancer 1 0 1 1 23 23 1
Akhter Chameli Not yet determined Bangladesh 2004 2016 Breast cancer 1 0 1 0 29 29 1
Akilov Oleg E MALE USA 2012 2021 Cutaneous T-cell lymphoma 2 0 1 1 57 37 1
Akimasa Nakao UNMATCHED 2003 2007 Chubu Clinical Cancer Group Gastric cancer 1 1 0 0 12 12 1
Akimov Mikhail MALE Switzerland 2020 2020 Non-small cell lung cancer 1 0 0 1 31 31 1
Akin Cem MALE USA 2003 2016 Hypereosinophilic syndrome; Systemic mastocytosis 3 0 0 1 34 34 1
Akinaga Shiro MALE Japan 2010 2015 Adult T-cell leukemia-lymphoma; CNS leukemia; Cutaneous T-cell lymphoma; Non-small cell lung cancer; Peripheral T-cell lymphoma 3 0 1 0 54 47 1
Akita Hirotoshi MALE 1992 1992 Small cell lung cancer 1 0 1 0 10 10 1
Akiya Toshikazu MALE 2002 2008 Gastric cancer 1 0 1 0 16 16 1
Akiyama Hideki MALE 1993 2013 JALSG B-cell acute lymphoblastic leukemia; Chronic myeloid leukemia 2 0 1 1 35 35 1
Akiyoshi Kohei Not yet determined Japan 2019 2019 Carcinoma of unknown primary 1 0 0 0 20 20 1
Akkermans Vogelaar Janine M FEMALE Netherlands 2013 2022 Dutch Pancreatic Cancer Group Pancreatic cancer 2 0 1 0 60 31 1
Akopov Audrey FEMALE Russian Federation 2015 2021 Non-small cell lung cancer 1 0 1 1 20 20 1
Akpek Gorgun UNMATCHED USA 2016 2016 BMT CTN Autologous HSCT; HIV-associated lymphoma 1 0 0 0 21 21 1
Akram Hussain Syed Md Not yet determined Bangladesh 2004 2016 Breast cancer 1 0 1 0 29 29 1
Akram Muhammed MALE USA 2018 2021 Multiple myeloma 1 0 0 1 35 35 1
Aksnes Anne Kirsti FEMALE Norway 2008 2014 Prostate cancer 1 0 1 1 12 12 1
Aktan Gursel MALE USA 2005 2022 NeoALTTO Study Team Breast cancer 6 0 5 2 123 95 1
Aktan Melih MALE Turkey 2010 2018 Chronic lymphocytic leukemia 1 0 1 0 16 16 1
Aktas Bahriye FEMALE Germany 2000 2019 GBG Breast cancer 7 0 5 0 144 87 1
Akusawa Hiroshi MALE 1987 1996 Non-small cell lung cancer 1 0 1 0 7 7 1
Al Akash Samhar I Not yet determined USA 2016 2016 Atypical hemolytic uremic syndrome 1 0 0 0 14 14 1
Al Ali Haifa Kathrin FEMALE Germany 1997 2017 OSHO Acute myeloid leukemia; Allogeneic HSCT; Autologous HSCT; Chronic lymphocytic leukemia; CNS lymphoma; Follicular lymphoma; Myelofibrosis 10 1 5 1 165 117 1
Al Batran Salah Eddin MALE Germany 2000 2020 AIO Breast cancer; Colorectal cancer; Esophageal adenocarcinoma; Esophageal squamous cell carcinoma; Follicular lymphoma; Gastric cancer; Gastrointestinal stromal tumor; Mantle cell lymphoma; Marginal zone lymphoma; MSI-H or dMMR; Waldenstroem macroglobulinemia 19 6 10 2 415 280 1
Al Booz Hoda FEMALE United Kingdom 2012 2018 De-ESCALaTE HPV Trial Group Oropharyngeal cancer 1 0 1 0 30 30 1
Al Dewik Nader MALE Qatar 2015 2015 Essential thrombocythemia 1 0 0 0 13 13 1
Al Fayoumi Suliman MALE USA 2014 2018 Myelofibrosis 1 0 1 1 18 18 1
Al Ghuzlan Abir Not yet determined France 2013 2022 Thyroid cancer differentiated 1 0 1 0 33 33 1
Al Kali Aref MALE USA 2010 2016 Myelodysplastic syndrome 1 0 1 0 20 20 1
Al Kateb Hussam Not yet determined USA 2013 2017 Breast cancer 1 0 0 0 33 33 1
Al Rajabi Raed MALE USA 2015 2020 Cholangiocarcinoma; Esophageal cancer; Esophageal squamous cell carcinoma 2 0 1 2 44 44 1
Al Sakaff Nedal MALE Switzerland 2001 2019 Herceptin Adjuvant (HERA) Trial Study Team Breast cancer 2 0 2 2 26 25 1
al Sarraf Muhyi MALE USA 1977 1999 Radiation Therapy Oncology Group; RTOG; SWOG Esophageal cancer; Glioblastoma; Melanoma; Nasopharyngeal carcinoma; Prostate cancer 7 2 6 1 70 53 1
Al Sawaf Othman MALE Germany 2005 2022 GCLLSG Chronic lymphocytic leukemia 6 2 4 1 148 80 1
Al Shukri Salman MALE Russian Federation 2010 2016 Renal cell carcinoma 2 0 1 0 17 11 1
Al Toubah Taymeyah E Not yet determined USA 2016 2020 Cholangiocarcinoma 1 0 0 0 10 10 1
Al Tweigeri Taher MALE Canada 1997 2005 BCIRG Breast cancer 1 0 1 1 31 31 1
Al Zoubi Ammar MALE 2005 2012 Multiple myeloma 2 0 0 0 28 25 1
Alabiso O CBD 2007 2007 Malignant pleural mesothelioma 1 0 0 0 14 14 1
Alakel N CBD Germany 2012 2015 Acute myeloid leukemia; Allogeneic HSCT 1 0 0 0 25 25 1
Alakl May FEMALE France 1994 2010 EORTC Breast cancer; Colorectal cancer; Light-chain (AL) amyloidosis 5 0 3 3 82 81 1
Alam A CBD 2005 2005 Follicular lymphoma 1 0 0 0 18 18 1
Alam Rafeul MALE USA 2001 2003 Hypereosinophilic syndrome 1 0 0 0 25 25 1
Alam Yasmin FEMALE Italy 2006 2012 Non-small cell lung cancer 3 0 1 0 70 47 1
Alama A CBD 1983 1987 Breast cancer 1 0 1 0 15 15 1
Alamoudi Sameer MALE Canada 2003 2015 NCIC-CTG Transformed lymphoma 1 0 1 0 18 18 1
Alamouti Sepideh FEMALE Canada 2010 2016 Diffuse large B-cell lymphoma 1 0 0 0 23 23 1
Alanko Tuomo MALE Finland 2000 2009 Breast cancer 3 0 2 0 56 34 1
Alao Hawwa Not yet determined USA 2014 2019 Hypereosinophilic syndrome 1 0 0 0 24 24 1
Alapi Krisztina Zuborne Not yet determined United Kingdom 2012 2022 B-cell acute lymphoblastic leukemia 1 0 1 0 25 25 1
Alarcon Jesus MALE 2007 2007 Diffuse large B-cell lymphoma 1 0 0 0 9 9 1
Alashkar Ferras Not yet determined Germany 2021 2021 Paroxysmal nocturnal hemoglobinuria 1 0 0 0 14 14 1
Alatorre Alexander Jorge MALE Mexico 2016 2021 Small cell lung cancer 1 0 1 1 19 19 1
Alattar Mona Lisa FEMALE 2011 2013 Acute myeloid leukemia 1 0 0 0 19 19 1
Alavi Jane FEMALE 2003 2003 CNS lymphoma 1 0 0 0 7 7 1
Alba Emilio MALE Spain 1995 2021 GEICAM Breast cancer 13 3 12 1 280 186 1
Albain Kathy S FEMALE USA 1989 2021 Breast Cancer Intergroup of North America; NCIC-CTG; NSABP; RTOG; SWOG Breast cancer; Non-small cell lung cancer 19 4 12 3 361 250 1
Albala Maurice M MALE 1968 1968 Head and neck cancer 1 0 0 0 2 2 1
Albanell Juan MALE Spain 1987 2014 GEICAM Breast cancer 3 0 2 0 38 38 1
Albano Edythe FEMALE USA 2002 2006 B-cell acute lymphoblastic leukemia pediatric 1 0 0 1 19 19 1
Albano Francesco MALE Italy 2004 2019 GIMEMA Acute promyelocytic leukemia; Chronic myeloid leukemia 3 0 3 1 113 69 1
Alberici Federico MALE Italy 1994 2015 GOIRC; POLAR-01 Trial Investigators Erdheim-Chester disease; Renal cell carcinoma 2 0 1 0 34 32 1
Alberola Vincente MALE Spain 1989 2012 Spanish Lung Cancer Group Non-small cell lung cancer; Non-small cell lung cancer nonsquamous 6 1 6 2 109 85 1
Albers Gregory W MALE USA 2018 2018 Venous thromboembolism 1 0 1 0 12 12 1
Albers Mary E FEMALE USA 1990 1998 Head and neck cancer 1 0 1 0 8 8 1
Albers Peter MALE Germany 1994 2021 AUO; EORTC; German Association of Urologic Oncology; Groupe d'Etude des Tumeurs Urogenitales; National Cancer Institute of Canada Clinical Trials Group; National Cancer Research Institute Bladder Cancer Study Group Bladder cancer; Prostate cancer; Testicular cancer 9 3 8 0 156 127 1
Albert Catherine M FEMALE USA 2015 2020 NTRK 1 0 0 3 28 28 1
Albert Donald MALE 2002 2008 Non-small cell lung cancer 1 0 1 0 7 7 1
Albert Istvan MALE Hungary 2006 2019 Non-small cell lung cancer 4 0 4 1 74 64 1
Albert Michael H MALE Germany 2003 2015 Allogeneic HSCT; B-cell acute lymphoblastic leukemia pediatric; T-cell acute lymphoblastic leukemia pediatric 1 0 0 0 22 22 1
Albert Paul S MALE USA 2006 2008 Glioblastoma 1 0 0 1 12 12 1
Albert Ute Susann FEMALE 1998 2009 Breast cancer 1 0 1 0 19 19 1
Alberti Daniele UNMATCHED 1996 2002 Breast cancer 1 0 1 0 9 9 1
Albertini Mark R MALE USA 1998 2019 ECOG Melanoma; Uveal melanoma 3 0 2 0 67 58 1
Alberto Pierre MALE 1979 1994 SAKK Breast cancer 2 1 2 0 22 19 1
Alberts David S MALE USA 1974 2019 GOG; GRACES Clinical Trial Consortium; Gynecologic Cancer Intergroup; SWOG Cervical cancer; Multiple myeloma; Ovarian cancer 16 13 11 1 144 105 1
Alberts Steven R MALE USA 1997 2017 CALGB; ECOG; NCCTG; SWOG Cholangiocarcinoma; Colon cancer; Colorectal cancer; Gallbladder cancer; Gastric cancer; Pancreatic cancer 10 2 8 2 121 97 1
Albertsen Birgitte Klug FEMALE Denmark 2008 2019 B-cell acute lymphoblastic leukemia pediatric 1 1 1 0 9 9 1
Albertson Tina M FEMALE USA 2016 2020 Diffuse large B-cell lymphoma; Primary mediastinal B-cell lymphoma; Transformed lymphoma 1 0 0 1 21 21 1
Albertsson Maria FEMALE Sweden 1991 2015 Nordic Gastrointestinal Tumour Adjuvant Therapy Group Colon cancer; Colorectal cancer; Esophageal cancer; Esophageal squamous cell carcinoma 4 1 3 0 34 30 1
Albiges Laurence MALE France; USA 2004 2022 GETUG Non-clear cell renal cell carcinoma; Papillary renal cell carcinoma; Prostate cancer; Renal cell carcinoma 9 3 7 2 187 143 1
Albitar Maher MALE USA 1998 2009 Acute myeloid leukemia; B-cell acute lymphoblastic leukemia; Chronic lymphocytic leukemia; Chronic myeloid leukemia; CNS leukemia; Hypereosinophilic syndrome; Myelodysplastic syndrome; Systemic mastocytosis 7 0 2 3 98 74 1
Albo Vincent C MALE 1988 1988 CCG T-cell acute lymphoblastic leukemia pediatric 1 0 0 0 11 11 1
Albright A L Not yet determined 1999 1999 CCG Medulloblastoma 1 0 0 0 15 15 1
Albright Robert E MALE USA 1999 2000 Temodal Brain Tumor Group Anaplastic glioma; Glioblastoma 2 0 0 1 36 27 1
Albritton Karen FEMALE 2004 2004 Ewing sarcoma 1 0 0 0 9 9 1
Albuquerque Marco MALE Canada 2010 2016 Diffuse large B-cell lymphoma 1 0 0 0 23 23 1
Alcaide Julia FEMALE Spain 2010 2018 TTD Colorectal cancer 1 0 0 0 26 26 1
Alcaide Miguel MALE Canada 2010 2016 Diffuse large B-cell lymphoma 1 0 0 0 23 23 1
Alcaraz Antonio MALE Spain 2011 2022 Prostate cancer 3 0 2 1 50 38 1
Alcedo Juan Carlos MALE Panama 2002 2016 Breast cancer; Cervical cancer 2 0 3 0 26 26 1
Alcindor Thierry MALE Canada 2003 2019 EORTC Gastric cancer; Liposarcoma; Soft tissue sarcoma; Tenosynovial giant cell tumor 7 0 6 2 138 107 1
Aldaoud Ali MALE Germany 1996 2017 European Mantle Cell Lymphoma Network; GCLLSG; GLSG Autologous HSCT; Chronic lymphocytic leukemia; Follicular lymphoma; Mantle cell lymphoma; Stem cell mobilization 6 0 6 1 111 75 1
Aldape Kenneth D MALE Canada; USA 2002 2017 Canadian Brain Tumor Consortium; CENTRIC study team; EORTC; RTOG Anaplastic glioma; Glioblastoma 5 0 6 0 137 102 1
Alderdice M CBD 1995 2002 Breast cancer 1 0 1 0 16 16 1
Alderete Daniel MALE 1987 1997 Hodgkin lymphoma 1 0 1 0 9 9 1
Alderson Derek MALE United Kingdom 1989 2017 MRC Colorectal cancer; Esophageal adenocarcinoma 3 1 4 0 42 33 1
Alderuccio Juan Pablo MALE USA 2018 2021 Diffuse large B-cell lymphoma; Transformed lymphoma 1 0 0 1 17 17 1
Aldrighetti Daniela FEMALE 1996 2004 GONO Breast cancer 1 0 1 0 14 14 1
Aldrighetti Luca MALE 2000 2005 Pancreatic cancer 1 0 1 0 16 16 1
Aledo Alexander MALE USA 2002 2014 COG B-cell acute lymphoblastic leukemia pediatric 2 0 0 1 37 20 1
Aledort Louis M MALE 1991 2008 Immune thrombocytopenia 2 1 2 0 35 34 1
Alegakis Athanasios MALE 2004 2004 Non-small cell lung cancer 1 1 1 0 14 14 1
Alegre Adrian MALE Spain 2004 2021 GEM; PETHEMA Multiple myeloma 8 0 3 2 199 112 1
Aleinikova Olga FEMALE Belarus 2001 2020 EBMT Paediatric Diseases Working Party; I-BFM SCT Study Group; IBFM Study Group; IntReALL Study Group Acute myeloid leukemia; Acute myeloid leukemia pediatric; Allogeneic HSCT 2 0 3 0 49 49 1
Alekar Shilpa FEMALE USA 2014 2014 B-cell acute lymphoblastic leukemia 1 0 0 0 19 19 1
Aleksandrovic Jasna FEMALE 1991 2000 Head and neck cancer 1 0 1 0 7 7 1
Alekseev Boris Yakovlevich MALE Russian Federation 2010 2022 Bladder cancer; Non-clear cell renal cell carcinoma; Prostate cancer; Renal cell carcinoma 22 0 15 8 482 310 1
Alekseev Sergey MALE Russian Federation 2012 2021 Hodgkin lymphoma 3 0 1 1 79 38 1
Alekseeva Yulia FEMALE Russian Federation 2017 2022 Multiple myeloma 1 0 1 0 27 27 1
Aleman Berthe M P FEMALE Netherlands 1988 2017 EORTC; GELA Hodgkin lymphoma 3 1 5 0 75 56 1
Aleman Karen FEMALE USA 2012 2016 Kaposi sarcoma 2 0 0 1 27 20 1
Alencar Alvaro Not yet determined USA 2014 2019 Blood Cancer Research Partnership of the Leukemia and Lymphoma Society Chronic lymphocytic leukemia 1 0 0 0 22 22 1
Alese Olatunji B Not yet determined USA 2016 2020 Cholangiocarcinoma 1 0 0 0 10 10 1
Alessandri S CBD 1982 1986 Ovarian cancer 1 0 1 0 33 33 1
Alessandrino Emilio Paolo MALE Italy 1996 2015 Acute myeloid leukemia; Allogeneic HSCT; Multiple myeloma; Stem cell mobilization 3 0 1 0 77 60 1
Alessandroni Paolo MALE 2006 2012 Colorectal cancer 1 0 1 0 10 10 1
Alexander Eben MALE USA 1969 1980 BTSG Glioblastoma 2 0 2 0 27 18 1
Alexander Sarah FEMALE Canada 2011 2021 Children's Oncology Group; COG; European Intergroup for Childhood Non-Hodgkin Lymphoma Anaplastic large cell lymphoma pediatric; Non-Hodgkin lymphoma pediatric 3 1 1 1 38 33 1
Alexandre Jerome MALE Canada 2006 2016 JGOG Ovarian cancer 1 0 1 0 23 23 1
Alexandris Ekaterine FEMALE USA 2010 2014 Non-small cell lung cancer 1 0 1 1 25 25 1
Alexandru Aurelia FEMALE Romania 2015 2021 Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous 3 0 2 2 77 52 1
Alexanian Raymond MALE USA 1965 2008 SWOG Multiple myeloma 14 10 3 2 90 48 1
Alexeeva Julia A FEMALE Russian Federation 2004 2016 SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network Acute myeloid leukemia; Mantle cell lymphoma 3 0 2 1 65 63 1
Alexis Vigier Magda FEMALE France 1990 2021 France Intergroupe des Leucemies Myeloides Chroniques; GOELAMS Chronic myeloid leukemia; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Mantle cell lymphoma 4 0 2 0 106 96 1
Alexopoulos Athanasios MALE 1997 2003 Greek Oncology Cooperative Group (GOCG) for Lung Cancer; HORG Non-small cell lung cancer 2 0 2 0 19 18 1
Alexopoulos Constantinos G MALE 1990 2007 ELCWP Non-small cell lung cancer 4 0 4 0 51 23 1
Alfaro Elizabeth FEMALE 1987 1997 Hodgkin lymphoma 1 0 1 0 9 9 1
Alfaro Vicente MALE Spain 2008 2021 Multiple myeloma; Ovarian cancer; Small cell lung cancer; Soft tissue sarcoma 4 0 3 1 84 76 1
Alfieri Sergio MALE Italy 2005 2019 Rectal cancer 1 0 1 0 27 27 1
Alfonsi Marc MALE France 1994 2020 GORTEC Head and neck cancer 9 0 8 0 162 84 1
Algarra Lorenzo MALE Spain 2014 2021 PETHEMA Group Acute myeloid leukemia 1 0 1 0 32 32 1
Algazi Alain P MALE USA 2010 2021 CNS melanoma; Melanoma 7 0 0 1 166 91 1
Algeri Renato MALE 1991 2000 Breast cancer 1 0 1 0 9 9 1
Algul Hana FEMALE Germany 2015 2019 Pancreatic cancer 1 0 1 1 18 18 1
Ali Adnan Not yet determined United Kingdom 2005 2019 Prostate cancer 1 0 1 0 49 49 1
Ali Arif N MALE USA 1990 2018 RTOG Glioblastoma 1 1 1 0 17 17 1
Ali Haris MALE USA 2016 2020 Graft versus host disease 1 0 0 1 12 12 1
Ali Haythem MALE USA 2008 2017 Thyroid cancer medullary 2 0 1 1 36 21 1
Ali Kulsam MALE 2003 2009 Small cell lung cancer 1 0 1 0 10 10 1
Ali Marco MALE Italy 2017 2017 Thymoma 1 0 0 0 23 23 1
Ali Nasim MALE United Kingdom 2010 2020 Gastrointestinal stromal tumor; Leiomyosarcoma; Soft tissue sarcoma 2 0 1 0 38 37 1
Ali Ridvan MALE 2006 2010 Multiple myeloma 1 0 1 0 14 14 1
Ali Saad MALE United Kingdom 2015 2018 Endometrial cancer 1 0 1 0 13 13 1
Ali Sahra FEMALE United Kingdom 2006 2017 MRC; UK NCRI Acute myeloid leukemia; Essential thrombocythemia; Myelofibrosis 4 0 1 0 53 42 1
Ali Shamshad MALE USA 1992 2014 GOG Cervical cancer; Vulvar cancer 3 0 2 0 24 24 1
Ali Shyanne FEMALE USA 2009 2014 Breast cancer 1 0 1 0 22 22 1
Ali Siraj M MALE USA 2017 2022 Bladder cancer; Non-small cell lung cancer 4 0 1 0 121 106 1
Aliberti Camillo MALE 2006 2012 Colorectal cancer 1 0 1 0 10 10 1
Aliberti Sandra FEMALE 2009 2009 Osteosarcoma 1 0 0 0 8 8 1
Alietti Alessandra FEMALE 2008 2014 Chronic lymphocytic leukemia 1 0 0 0 39 39 1
Alimam Samah FEMALE United Kingdom 2012 2017 Essential thrombocythemia 1 0 0 0 20 20 1
Alimena Giuliana FEMALE Italy 2001 2016 EORTC; GIMEMA; GIMEMA CML Working Party Acute myeloid leukemia; Chronic myeloid leukemia 8 0 3 2 171 108 1
Alinari Lapo MALE 1996 2010 Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma 3 0 2 0 51 39 1
Aljijakli Ahmad MALE France 2008 2012 ALFA Acute myeloid leukemia 1 0 1 1 21 21 1
Aljitawi Omar S MALE 2011 2011 BMT CTN Allogeneic HSCT 1 0 0 0 13 13 1
Aljumaily Raid MALE USA 2014 2017 Bladder cancer 1 0 0 1 17 17 1
Alkan Serhan MALE 2008 2008 Acute myeloid leukemia 1 0 0 0 9 9 1
Alkhouri Naim Not yet determined USA 2013 2020 Thrombocytopenia in liver disease 1 1 2 0 7 7 1
Alkindi Salam Not yet determined Oman 2017 2019 Sickle cell anemia 1 0 1 0 21 21 1
Alkuzweny Baha MALE 2004 2004 Follicular lymphoma 1 0 0 0 4 4 1
Allaham Wassim MALE France 2011 2017 SARAH Trial Group Hepatocellular carcinoma 1 0 1 0 36 36 1
Allal Abdelkarim S MALE 1994 2011 SAKK Head and neck cancer 2 0 1 0 28 24 1
Allan John N MALE USA 2021 2021 Waldenstroem macroglobulinemia 1 0 0 0 22 22 1
Allan Karen FEMALE United Kingdom 2008 2018 Colorectal cancer 1 0 1 0 35 35 1
Allan Norman C MALE United Kingdom 1986 1995 MRC Chronic myeloid leukemia 1 1 1 0 2 2 1
Alland Leila FEMALE USA 1998 2006 B-cell acute lymphoblastic leukemia; Breast cancer; Chronic myeloid leukemia; Hypereosinophilic syndrome; Systemic mastocytosis 3 0 2 1 43 41 1
Allangba Olivier MALE France 2013 2018 IFM Multiple myeloma 2 0 1 0 77 54 1
Allard Christian MALE France 2003 2010 Intergroupe Francais des Leucemies Myeloides Chroniques; SPIRIT Investigators Chronic myeloid leukemia 1 0 1 0 22 22 1
Allegra Carmen J MALE USA 1991 2020 NSABP; SWOG Colon cancer; Colorectal cancer; Rectal cancer 11 6 6 1 153 82 1
Allegrini Giacomo MALE Italy 2001 2015 GONO Colorectal cancer 4 0 3 0 75 48 1
Allen Mersh T G Not yet determined United Kingdom 1988 1994 Colorectal cancer 1 1 1 0 4 4 1
Allen Aaron M MALE Israel 2008 2022 Prostate cancer 1 0 1 0 21 21 1
Allen Andrew R MALE USA 2013 2016 Ovarian cancer 1 0 0 1 30 30 1
Allen Carl MALE USA 2020 2020 Hemophagocytic lymphohistiocytosis 1 0 0 1 19 19 1
Allen Jeffrey C MALE 1985 1999 CCG High-grade glioma pediatric; Low-grade glioma; Medulloblastoma 3 0 1 0 47 36 1
Allen Jennifer L FEMALE United Kingdom 2015 2018 Endometrial cancer 1 0 1 0 13 13 1
Allen Jill N FEMALE USA 2006 2018 Cholangiocarcinoma; Gallbladder cancer; Hepatocellular carcinoma; Pancreatic cancer 3 0 0 0 56 44 1
Allen John MALE USA 1995 2014 Hodgkin lymphoma; Hodgkin lymphoma nodular lymphocyte-predominant 2 0 0 0 14 10 1
Allen L CBD United Kingdom 1984 1985 Prostate cancer 1 0 1 0 5 5 1
Allen Lee F MALE USA 2006 2018 Cutaneous T-cell lymphoma; Immune thrombocytopenia; Peripheral T-cell lymphoma; Thrombocytopenia in liver disease 4 1 3 1 47 42 1
Allen Mary S FEMALE USA 2014 2014 Autologous HSCT 1 0 0 0 6 6 1
Allen Peter J MALE USA 2007 2016 Hepatocellular carcinoma 1 0 0 0 19 19 1
Allen Roberta S FEMALE USA 1998 2002 Follicular lymphoma 1 0 0 1 11 11 1
Allen Steven L MALE USA 1977 2015 CALGB Acute myeloid leukemia; Acute promyelocytic leukemia; Adult T-cell leukemia-lymphoma; Breast cancer; Cutaneous T-cell lymphoma; Diffuse large B-cell lymphoma; Peripheral T-cell lymphoma 9 0 3 1 128 100 1
Allepuz Alex MALE Switzerland 2013 2021 Chronic myeloid leukemia; Chronic myeloid leukemia pediatric 3 0 1 2 63 45 1
Allerton Rozenn FEMALE United Kingdom 2009 2015 Breast cancer; CNS carcinoma 1 0 1 0 20 20 1
Allevi G CBD 1997 2005 Breast cancer 1 0 1 0 13 13 1
Allewelt Heather FEMALE USA 2014 2022 Marginal zone lymphoma 1 0 0 1 13 13 1
Allgeier Anouk FEMALE Belgium 1988 2012 EORTC; NCIC-CTG Anaplastic glioma; Glioblastoma 5 0 3 1 84 43 1
Allietta Nathalie FEMALE France 2006 2013 Multiple myeloma 2 0 0 1 20 17 1
Allione Bernardino MALE Italy 1993 2020 EORTC Acute myeloid leukemia; Chronic myelomonocytic leukemia; HIV-associated lymphoma; Multiple myeloma 4 0 2 0 81 80 1
Allis Simona FEMALE 1992 2010 Head and neck cancer 1 0 1 0 13 13 1
Allison James MALE USA 2015 2017 Anal cancer 1 0 0 0 28 28 1
Allison Mary Ann K FEMALE USA 2007 2013 Breast cancer 1 0 0 0 18 18 1
Allman David MALE France 1996 2001 Colorectal cancer 1 0 1 1 20 20 1
Allmark Christine FEMALE 2014 2021 Gastric cancer 1 0 1 0 33 33 1
Allmer Christine FEMALE 2004 2008 NCCTG Mantle cell lymphoma 1 0 0 0 11 11 1
Alloisio M CBD 1998 2002 Bladder cancer 1 0 0 0 9 9 1
Allolio Bruno MALE Germany 2004 2012 Adrenocortical carcinoma 1 0 1 0 36 36 1
Allotey David MALE United Kingdom 2011 2021 UK NCRI Multiple myeloma 1 0 1 0 22 22 1
Allouache Djelila FEMALE France 1999 2022 GINECO; Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01) Breast cancer; Carcinoma of unknown primary 3 0 1 0 58 55 1
Allouache Nedla Not yet determined France 2006 2019 GETUG Prostate cancer 1 0 1 0 21 21 1
Allred Alicia J FEMALE USA 2010 2021 Melanoma; Multiple myeloma 2 0 0 1 60 59 1
Allred D Craig MALE USA 1989 2011 ACOSOG Breast cancer 3 0 1 0 38 38 1
Allred Jacob B MALE USA 2004 2012 Light-chain (AL) amyloidosis; Multiple myeloma; Myelofibrosis 7 0 0 0 126 40 1
Allsup David J MALE United Kingdom 2006 2017 NCRI Chronic lymphocytic leukemia 2 0 0 0 38 35 1
Allum William H MALE United Kingdom 1976 2017 British Stomach Cancer Group; MAGIC Trial Participants; MRC Esophageal adenocarcinoma; Esophageal cancer; Gastric cancer 5 3 5 0 40 33 1
Ally Mina S FEMALE USA 2009 2016 Cutaneous basal cell carcinoma 1 0 0 0 12 12 1
Alm Gunnar MALE Sweden 1983 1983 Neuroendocrine tumor 1 1 0 0 2 2 1
Almeida Antonio MALE Portugal 2010 2021 Myelodysplastic syndrome 2 0 2 0 48 39 1
Almeida M S S Not yet determined Brazil 2006 2015 Multiple myeloma 1 0 1 0 11 11 1
Almenar Daniel MALE 2000 2005 Spanish Germ Cell Cancer Cooperative Group; Spanish Lung Cancer Group Non-small cell lung cancer; Testicular cancer 2 0 1 0 38 38 1
Almenar Sergio MALE Spain 1999 2010 GEICAM Breast cancer 2 0 2 0 64 49 1
Almond Jennifer P FEMALE 1994 2001 European Study Group for Pancreatic Cancer Pancreatic cancer 1 0 1 0 16 16 1
Aloe Alessandra Not yet determined 1996 2009 Breast cancer 1 0 1 0 10 10 1
Aloj Luigi MALE 2014 2014 Hodgkin lymphoma 1 0 0 0 16 16 1
Alonso Carrion Lorenzo MALE Spain 2021 2021 Uveal melanoma 1 0 0 0 13 13 1
Alonso Garcia Miriam MALE Spain 1995 2021 Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous 2 0 3 3 44 44 1
Alonso Gordoa Teresa FEMALE Spain 2016 2021 Clear cell renal cell carcinoma; Renal cell carcinoma 2 0 1 1 56 55 1
Alonso Orduna Vicente MALE Spain 2006 2012 TTD Colorectal cancer; Esophageal adenocarcinoma 2 0 1 1 33 33 1
Alonso Carmen FEMALE Spain 1994 2004 Small cell lung cancer 1 0 1 0 16 16 1
Alonso Guillermo MALE 2000 2010 Spanish Lung Cancer Group Non-small cell lung cancer 1 0 1 0 19 19 1
Alonso Liuba FEMALE Cuba 2006 2016 Non-small cell lung cancer 1 0 1 0 33 33 1
Alonso Maria Carmen FEMALE Spain 1978 1995 Breast cancer 2 1 2 0 13 12 1
Alonso Mirta Garcia FEMALE Spain 2009 2020 Breast cancer 1 0 1 1 30 30 1
Alonso Natalia FEMALE 2013 2013 Burkitt lymphoma; HIV-associated lymphoma 1 0 0 0 19 19 1
Alonso Silvia FEMALE 2003 2009 Bladder cancer 1 0 0 0 8 8 1
Alonzo Todd A MALE USA 1979 2014 CCG; COG Acute myeloid leukemia; Acute myeloid leukemia pediatric; Chronic myeloid leukemia pediatric 4 1 4 1 46 37 1
Alousi Amin M MALE USA 2009 2020 BMT CTN Acute myeloid leukemia; Allogeneic HSCT; Follicular lymphoma; Graft versus host disease; Mantle cell lymphoma; Transformed lymphoma 5 0 1 0 84 60 1
Alpen B Not yet determined 1997 1997 MALT lymphoma 1 0 0 0 9 9 1
Alquati Palmiro MALE 1991 2005 Epirubicin-Lonidamine Group Breast cancer 3 0 3 0 46 37 1
Alsayed Yazan MALE 1998 2010 Multiple myeloma 4 0 0 0 59 28 1
Alsina Maqueda Maria FEMALE Spain 2011 2021 Colorectal cancer; Esophageal cancer; Esophageal squamous cell carcinoma; Gastric cancer 8 0 8 2 161 129 1
Alsina Melissa FEMALE USA 2001 2022 Multiple myeloma 14 0 2 4 279 159 1
Altavilla Giuseppe MALE Italy 1983 2012 Associazione Italiana Oncologia Toracica; Groupe Francais de Pneumo-Cancerologie; Italian Lung Cancer Project; Italian Lung Cancer Task Force; Italian Multicentre Breast Study with Epirubicin; Spanish Lung Cancer Group Breast cancer; Non-small cell lung cancer 4 0 4 1 157 151 1
Altenhofer Petra FEMALE Austria 2010 2016 AGMT Chronic lymphocytic leukemia 1 0 1 0 34 34 1
Alter Robert S MALE USA 2015 2020 Bladder cancer 1 0 0 0 20 20 1
Alterio D CBD Italy 2008 2017 GSTTC Head and neck cancer 1 0 0 0 36 36 1
Altermatt Hans J MALE 1998 2007 BIG Breast cancer 1 0 1 1 18 18 1
Altes Albert MALE 2001 2008 Chronic lymphocytic leukemia 1 0 0 0 19 19 1
Althaus Betsy L FEMALE USA 2009 2020 Breast cancer; Gastric cancer 3 0 1 0 42 42 1
Althausen Alex F MALE USA 1993 1993 Bladder cancer 1 0 0 0 5 5 1
Altieri Vincenzo MALE 2011 2011 Penile cancer 1 0 0 0 15 15 1
Altinbas M CBD 1997 2005 Turkish Oncology Group Breast cancer 1 0 1 0 16 16 1
Altinmakas Emre MALE USA 2010 2015 Non-clear cell renal cell carcinoma 1 0 0 0 15 15 1
Altintas Sevilay FEMALE Belgium 2011 2016 Ovarian cancer 1 0 1 0 23 23 1
Altman Arnold MALE USA 2002 2006 B-cell acute lymphoblastic leukemia pediatric 1 0 0 1 19 19 1
Altman Jessica K FEMALE USA 2007 2022 ECOG Acute myeloid leukemia; Acute promyelocytic leukemia; Hairy cell leukemia; Myelodysplastic syndrome 10 0 4 2 248 176 1
Altman Stanley J MALE USA 1979 1993 COG; SWOG Breast cancer; Soft tissue sarcoma; Testicular cancer 3 0 3 0 26 26 1
Altmann Bettina FEMALE Germany 2003 2021 DSHNHL; FLYER Trial Investigators; German Lymphoma Alliance Autologous HSCT; Diffuse large B-cell lymphoma; Peripheral T-cell lymphoma 4 1 4 0 130 90 1
Altorjai Gabriela FEMALE 2004 2007 Breast cancer 1 0 0 0 8 8 1
Altorki Nasser K MALE USA 2007 2021 Non-small cell lung cancer 2 0 2 1 35 35 1
Altug Sedat MALE Turkey 2009 2014 Non-small cell lung cancer nonsquamous 1 0 1 0 11 11 1
Altwein Jens Erik MALE 1986 1991 Prostate cancer 2 0 2 0 12 12 1
Alu Massimiliano MALE 1996 2002 Breast cancer 1 0 1 0 9 9 1
Alumkal Joshi J MALE USA 2007 2017 Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium Prostate cancer 3 0 0 0 40 35 1
Alva Ajjai S MALE USA 2012 2021 SWOG Bladder cancer; Clear cell renal cell carcinoma; Papillary renal cell carcinoma; Renal cell carcinoma 4 1 3 2 100 92 1
Alvarado Gladys FEMALE 1995 2009 Melanoma 1 0 1 0 20 20 1
Alvarado Yesid MALE USA 2011 2020 Acute myeloid leukemia; B-cell acute lymphoblastic leukemia; Chronic lymphocytic leukemia; Myelodysplastic syndrome 4 0 0 0 115 66 1
Alvarez Cabellos Ruth FEMALE 2013 2013 GOTEL Follicular lymphoma 1 0 0 0 11 11 1
Alvarez de Celis Isabel FEMALE Italy 2004 2013 Follicular lymphoma 1 0 2 0 20 20 1
Alvarez Larran Alberto MALE 2005 2005 Myelofibrosis 1 0 0 0 4 4 1
Alvarez Secord Angeles FEMALE USA 1999 2022 GOG Endometrial cancer; Gestational trophoblastic neoplasia; Low-grade serous ovarian cancer; Ovarian cancer 8 1 7 2 149 122 1
Alvarez Twose Ivan MALE Spain 2018 2021 Systemic mastocytosis 1 0 0 1 23 23 1
Alvarez Vicent J J CBD 1996 2002 Head and neck cancer 1 0 0 0 10 10 1
Alvarez Ana FEMALE Spain 2005 2015 Prostate cancer 1 0 1 0 14 14 1
Alvarez Axxx CBD Argentina 1991 1999 Breast cancer 1 0 1 0 9 9 1
Alvarez Elena FEMALE 1987 1999 Breast cancer 1 1 1 0 9 9 1
Alvarez Isabel FEMALE Spain 1995 2020 ANZ BCTG; GEICAM; Intergroup Exemestane Study Breast cancer; Diffuse large B-cell lymphoma 9 0 9 1 230 159 1
Alvarez Ivan MALE Spain 2006 2006 Allogeneic HSCT; Hodgkin lymphoma 1 1 0 0 17 17 1
Alvarez Jose Valero MALE 1999 2008 GEICAM Breast cancer 1 0 1 0 34 34 1
Alvarez Ofelia A FEMALE USA 2013 2016 Sickle cell anemia 1 0 0 1 15 15 1
Alvarez Pablo MALE United Kingdom 2007 2012 Thyroid cancer differentiated 1 0 1 0 27 27 1
Alvarez Ronald D MALE 1985 2008 GOG; GRACES Clinical Trial Consortium; SWOG Cervical cancer; Endometrial cancer; Ovarian cancer 5 1 4 0 39 36 1
Alvarnas Joseph C MALE USA 2016 2016 BMT CTN Autologous HSCT; HIV-associated lymphoma 1 1 0 0 21 21 1
Alvegaard Thor MALE Sweden 2004 2020 Gastrointestinal stromal tumor 3 0 1 1 58 29 1
Aly Abdalla MALE USA 2009 2018 Pancreatic cancer 1 0 1 1 11 11 1
Alyasova Anna FEMALE Russian Federation 2010 2021 Head and neck cancer; Renal cell carcinoma 4 0 2 1 95 89 1
Alyea Edwin P MALE USA 2003 2017 BMT CTN; CALGB Acute myeloid leukemia; Allogeneic HSCT; Multiple myeloma 3 1 2 0 60 51 1
Alzate Stefanie FEMALE USA 2012 2017 Multiple myeloma 1 0 0 0 20 20 1
Alzieu Claude MALE 1984 2006 FNCLCC Head and neck cancer 2 0 2 0 25 25 1
Alzouebi Mymoona FEMALE United Kingdom 2005 2015 Prostate cancer 1 0 1 0 46 46 1
Amabile Marilina FEMALE 1994 2009 GIMEMA; GIMEMA CML Working Party; Italian Cooperative Study Group on Myeloid Leukemia Chronic myeloid leukemia 3 0 1 0 51 32 1
Amado Rafael G MALE USA 2004 2008 Colorectal cancer 2 2 2 1 23 23 1
Amador Barciela Maria L FEMALE Spain 2014 2021 PETHEMA Group Acute myeloid leukemia 1 0 1 0 32 32 1
Amador Rosa M FEMALE Cuba 2006 2016 Non-small cell lung cancer 1 0 1 0 33 33 1
Amadori Dino MALE Italy 1981 2017 GONO; International Collaborative Cancer Group Bladder cancer; Breast cancer; Colorectal cancer; Gastric cancer; Hepatocellular carcinoma 14 4 11 0 196 155 1
Amadori Sergio MALE Italy 1984 2020 AIEOP; EORTC; German-Austrian Acute Myeloid Leukemia Study Group; GIMEMA; Study Alliance Leukemia Acute myeloid leukemia; Acute promyelocytic leukemia; B-cell acute lymphoblastic leukemia; Chronic myeloid leukemia; CNS leukemia; Diffuse large B-cell lymphoma; Multiple myeloma; Myelodysplastic syndrome 30 7 21 3 594 249 1
Amaducci Laura FEMALE Italy 1997 2021 GIM; Reader study level-I and level-II Groups Breast cancer 3 0 3 0 77 71 1
Amagai Kenji MALE Japan 2008 2018 Tokyo Cooperative Oncology Group Gastric cancer 4 0 4 0 70 61 1
Amam Josif MALE Germany 2005 2019 FLYER Trial Investigators; German Lymphoma Alliance Diffuse large B-cell lymphoma 1 0 1 0 43 43 1
Amann G CBD 2001 2001 Ewing sarcoma 1 0 0 0 18 18 1
Amano Hodaka UNMATCHED 1986 2002 Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract Periampullary adenocarcinoma 1 0 1 0 7 7 1
Amant Frederic MALE Belgium 1998 2010 EORTC; NCIC-CTG Breast cancer; Ovarian cancer 2 0 2 0 32 32 1
Amar Avraham MALE 1998 1998 Allogeneic HSCT; Chronic lymphocytic leukemia 1 0 0 0 14 14 1
Amaravadi Ravi K MALE USA 2009 2012 Melanoma 1 0 0 1 24 24 1
Amare Mammo Not yet determined 1977 1983 SWOG Multiple myeloma 1 0 1 0 0 0 1
Amato Giovanni MALE Italy 2013 2021 CNS melanoma 1 0 1 0 16 16 1
Amato Robert J MALE USA 1985 2010 Bladder cancer; Penile cancer; Prostate cancer; Renal cell carcinoma; Testicular cancer 5 2 3 0 39 35 1
Amato S CBD Argentina 1995 1999 Breast cancer 1 0 0 0 14 14 1
Amatruda Thomas T MALE USA 2006 2015 NCCTG Melanoma 3 0 1 1 48 43 1
Amatu Alessio MALE Italy 2012 2017 Colorectal cancer; Non-small cell lung cancer; NTRK 2 0 0 2 63 57 1
Ambarkhane Sumeet MALE Germany 2016 2021 Diffuse large B-cell lymphoma; Transformed lymphoma 2 0 0 1 36 21 1
Ambinder Richard F MALE USA 1998 2018 A5264/AMC-067 REACT-KS Team; AIDS Malignancy Consortium; BMT CTN Autologous HSCT; Burkitt lymphoma; Diffuse large B-cell lymphoma; Graft versus host disease; HIV-associated lymphoma; Hodgkin lymphoma; Kaposi sarcoma 9 2 4 0 136 109 1
Ambo Y CBD Japan 2007 2018 Cholangiocarcinoma 1 0 1 0 14 14 1
Ambros Peter F MALE Austria 2002 2018 SIOP Europe Neuroblastoma Group (SIOPEN) Neuroblastoma 2 0 1 0 50 32 1
Ambrose David MALE USA 2015 2015 Chronic lymphocytic leukemia 1 0 0 0 17 17 1
Ambrosetti Achille MALE Italy 1995 2017 FIL; IELSG Chronic lymphocytic leukemia; CNS lymphoma; Hairy cell leukemia; Hodgkin lymphoma; MALT lymphoma; Mantle cell lymphoma 7 0 1 0 211 166 1
Ambrosini Giovanni MALE Italy 1983 2011 Italian Multicentre Breast Study with Epirubicin Breast cancer; Rectal cancer 3 2 2 0 97 96 1
Ambrosini Grazia FEMALE USA 2010 2014 Uveal melanoma 1 0 0 0 27 27 1
Ambrosini Maria Teresa FEMALE 2002 2007 GIMEMA--Italian Multiple Myeloma Network; Gruppo Italiano Malattie Ematologicche dell'Adulto; Italian Multiple Myeloma Network Multiple myeloma 3 0 1 0 52 36 1
Ambrosio Francesca FEMALE Italy 2009 2017 GOIRC Small cell lung cancer 1 0 1 0 18 18 1
Ambrun Alexis Not yet determined France 2016 2016 Hereditary hemorrhagic telangiectasia 1 0 0 0 18 18 1
Amellal Nadia FEMALE Germany; USA 1999 2008 Head and neck cancer 4 0 2 3 53 40 1
Amendola Angela FEMALE 2006 2006 GIMEMA Immune thrombocytopenia 1 0 0 0 15 15 1
Amenedo Gancedo Margarita FEMALE Spain 1999 2020 GEICAM Breast cancer; Ovarian cancer 4 0 2 1 93 48 1
Ames Frederick C MALE USA 1977 2004 Breast cancer 5 0 5 0 65 36 1
Ames Patricia FEMALE 1998 2002 Melanoma 1 0 0 0 11 11 1
Ameye Lieveke FEMALE Belgium 1998 2015 BIG Breast cancer 1 0 1 0 17 17 1
Amiel Jean Louis MALE 1969 1969 B-cell acute lymphoblastic leukemia 1 0 0 0 7 7 1
Amillano Kepa Not yet determined Spain 2015 2021 Breast cancer 1 0 1 0 39 39 1
Amin Amanda L FEMALE USA 2010 2016 Breast cancer 1 0 0 0 33 33 1
Amin Asim MALE USA 2013 2020 Renal cell carcinoma; Small cell lung cancer 4 0 1 2 107 74 1
Amin Bipinkumar UNMATCHED 2008 2011 Follicular lymphoma 1 0 0 0 14 14 1
Amin Himal MALE USA 2014 2021 Multiple myeloma 4 0 2 2 92 61 1
Amin Mahul B MALE Canada; USA 1994 2020 RTOG Prostate cancer; Upper tract urothelial carcinoma 3 0 2 0 61 57 1
Aminossadati Behnaz FEMALE 2001 2009 Neuroendocrine tumor; Pancreatic NET 1 0 1 0 13 13 1
Amiot Martine Not yet determined France 2012 2017 Multiple myeloma 1 0 0 0 20 20 1
Amista P CBD 2004 2004 Glioblastoma 1 0 0 0 6 6 1
Amler Susanne FEMALE Germany 2000 2018 AML-CG Acute myeloid leukemia; Autologous HSCT; Ewing sarcoma 2 0 2 0 84 84 1
Ammassari Adriana FEMALE 2002 2002 HIV-associated lymphoma 1 0 0 0 12 12 1
Amonkar Mayur MALE USA 2006 2021 Colorectal cancer; Head and neck cancer 2 0 2 1 43 43 1
Amorim Gilberto MALE 2006 2019 CIBOMA; GEICAM; LACOG (Latin American Cooperative Oncology Group) Breast cancer 1 0 1 0 37 37 1
Amoroso Domenico MALE Italy 2007 2018 GOIRC Breast cancer; Colorectal cancer; Non-small cell lung cancer 5 0 3 0 105 85 1
Amoroso Mariangela FEMALE 1990 2002 Cervical cancer 1 0 1 0 10 10 1
Amoroso Vito MALE Italy 2014 2021 Breast cancer 1 0 1 0 25 25 1
Amos Claire L FEMALE United Kingdom 2005 2019 Prostate cancer 3 0 1 0 141 83 1
Amott S J Not yet determined 1984 1996 MRC Rectal cancer 1 1 1 0 2 2 1
Amoura Zahir MALE France 2014 2014 Erdheim-Chester disease 1 1 0 0 20 20 1
Amrein Philip C MALE 1990 2004 CALGB Acute myeloid leukemia 2 0 1 0 16 16 1
Amthauer Holger MALE 2003 2012 Arbeitsgemeinschaft Medikamentoese Tumortherapie; GHSG; SAKK Hodgkin lymphoma 1 0 1 0 30 30 1
Amundsen Tore MALE 2005 2012 Non-small cell lung cancer 2 0 2 0 21 15 1
Amunni Gianni MALE 1990 2002 Cervical cancer 1 0 1 0 10 10 1
Amutio Elena FEMALE 1996 2003 Programa de Estudio y Traitmiento de las Hemopatias Malignas Acute promyelocytic leukemia 1 0 0 0 18 18 1
Amylon Michael D MALE USA 1987 1999 POG B-cell acute lymphoblastic leukemia; B-cell acute lymphoblastic leukemia pediatric; Graft versus host disease; T-cell acute lymphoblastic leukemia pediatric 3 1 2 0 36 35 1
Amzal Billy MALE United Kingdom 2011 2016 Prostate cancer 1 0 1 0 21 21 1
An Gang Not yet determined China 2017 2021 Multiple myeloma 1 0 1 0 19 19 1
An J Y Not yet determined South Korea 2013 2020 Gastric cancer 1 0 1 0 22 22 1
An Ruifang Not yet determined China 2017 2022 Ovarian cancer 2 0 2 0 70 60 1
An Xin Not yet determined China 2010 2022 South China Breast Cancer Group (SCBCG) Breast cancer 2 0 2 0 58 40 1
An Xuebei CBD USA 2016 2020 Breast cancer; CNS carcinoma 1 0 1 1 28 28 1
Anagnostopoulos Achilles MALE Greece 2007 2022 HORG Acute myeloid leukemia; Chronic myelomonocytic leukemia; Colon cancer; Myelodysplastic syndrome 5 0 4 1 104 80 1
Anagnostopoulos Athanasios MALE 1999 2007 Multiple myeloma; Waldenstroem macroglobulinemia 5 2 1 0 58 40 1
Anagnostopoulos Ioannis MALE Germany 1999 2016 European PTLD Network; German PTLD Study Group. Post-transplant lymphoproliferative disorder 3 0 0 0 51 38 1
Anagnostopoulos Nikolaos MALE 1999 2007 Multiple myeloma; Waldenstroem macroglobulinemia 5 1 1 0 59 35 1
Anagnostopoulou Ourania FEMALE 1999 2005 Non-small cell lung cancer 1 0 1 0 16 16 1
Anaissie Elias MALE USA 1990 2010 Multiple myeloma 9 0 0 0 122 54 1
Anak Oezlem FEMALE Switzerland; USA 1999 2021 EORTC Autologous HSCT; Colorectal cancer; Diffuse large B-cell lymphoma; Follicular lymphoma; Hepatocellular carcinoma; Renal cell carcinoma; Subependymal giant cell astrocytoma; Transformed lymphoma 7 0 3 3 147 139 1
Anand Aseem MALE 2007 2010 Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium Prostate cancer 1 0 0 0 18 18 1
Anand Palka UNMATCHED USA 2012 2016 Multiple myeloma 1 0 0 0 8 8 1
Ananthakrishnan Revathi FEMALE USA 2016 2016 Follicular lymphoma 1 0 0 0 9 9 1
Anasetti Claudio MALE USA 1985 2003 Allogeneic HSCT; Chronic myeloid leukemia 2 1 0 0 28 25 1
Anastasi John MALE 1998 2008 CALGB Acute myeloid leukemia 2 0 1 0 23 16 1
Anastasia Antonella FEMALE Italy 2008 2021 FIL; Rete Ematologica Lombarda–CLL Workgroup Chronic lymphocytic leukemia; Follicular lymphoma; Hairy cell leukemia; Hodgkin lymphoma 5 0 1 0 136 121 1
Anastasopoulou Anastasia FEMALE 2001 2001 EORTC Cervical cancer 1 0 0 0 12 12 1
Ancell Kristin FEMALE USA 2010 2014 Uveal melanoma 1 0 0 0 27 27 1
Anchisi Sandro Not yet determined Switzerland 2007 2016 SAKK Breast cancer; Colorectal cancer 2 0 2 0 39 36 1
Anciaux Nicole FEMALE 1998 2006 EORTC Colorectal cancer 1 0 1 0 19 19 1
Ancliff Philip MALE 2003 2010 B-cell acute lymphoblastic leukemia pediatric; T-cell acute lymphoblastic leukemia pediatric 1 0 1 0 14 14 1
Ancona Ermanno MALE Italy 1992 2001 Esophageal cancer 1 1 1 0 8 8 1
Ancukiewicz Marek MALE 2006 2009 Hepatocellular carcinoma 1 0 0 0 20 20 1
Andel Johannes MALE Austria 2007 2016 AGMT Chronic lymphocytic leukemia; Diffuse large B-cell lymphoma 2 0 2 0 45 40 1
Andergassen Ulrich MALE Germany 2005 2020 Breast cancer 1 0 1 0 24 24 1
Anderl Janet FEMALE USA 2012 2016 Multiple myeloma 1 0 0 0 16 16 1
Anderlini Paolo MALE USA 2009 2014 Allogeneic HSCT; Diffuse large B-cell lymphoma; Follicular lymphoma; Hodgkin lymphoma; Mantle cell lymphoma; Transformed lymphoma 6 1 0 0 101 55 1
Anders Carey K FEMALE USA 2008 2022 CALGB Breast cancer; CNS carcinoma 4 0 3 1 90 68 1
Anders Robert A MALE USA 2013 2017 Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; MSI-H or dMMR 2 0 0 1 79 57 1
Andersen Barbara L FEMALE USA 2015 2020 Chronic lymphocytic leukemia 1 0 0 0 18 18 1
Andersen E CBD 1983 1990 Breast cancer 1 0 1 0 6 6 1
Andersen J C Not yet determined USA 1994 1994 Immune thrombocytopenia 1 1 0 0 0 0 1
Andersen James S MALE USA 1992 1996 Pancreatic cancer 1 0 0 1 11 11 1
Andersen Janet W FEMALE USA 1977 2002 ECOG Acute promyelocytic leukemia; Breast cancer; Chronic lymphocytic leukemia; Diffuse large B-cell lymphoma; Follicular lymphoma 6 0 5 0 56 43 1
Andersen Jay C MALE USA 2017 2022 Breast cancer 1 0 1 1 29 29 1
Andersen Joern Erik MALE Denmark 1994 2000 Ovarian cancer 1 0 1 1 27 27 1
Andersen John MALE USA 1992 1997 Pancreatic cancer 1 0 1 1 13 13 1
Andersen Jorn MALE Denmark 1977 2013 DBCG; Intergroup Exemestane Study; Scandinavian Breast Group Breast cancer; Diffuse large B-cell lymphoma 10 2 8 1 126 76 1
Andersen Knud West MALE 1977 1983 DBCG Breast cancer 2 1 2 0 12 10 1
Andersen Niels Frost MALE Denmark 2005 2020 Multiple myeloma 3 0 3 0 101 92 1
Andersen Niels S MALE Denmark 2000 2016 Nordic Lymphoma Group Autologous HSCT; Mantle cell lymphoma 3 0 0 0 67 30 1
Andersen Willie A MALE 1993 2004 GOG Cervical cancer; Endometrial cancer 4 4 1 0 22 18 1
Anderson Abraham MALE USA 2009 2021 Esophageal adenocarcinoma; Non-small cell lung cancer 2 0 0 1 40 40 1
Anderson Barrie Not yet determined 1990 1997 GOG Cervical cancer 1 1 1 0 6 6 1
Anderson Barry MALE USA 2001 2010 CCG; COG Ewing sarcoma; Neuroblastoma; Osteosarcoma 2 0 1 1 26 26 1
Anderson Cathy FEMALE 1980 1987 Autologous HSCT; Diffuse large B-cell lymphoma 1 0 0 0 18 18 1
Anderson Charles K MALE USA 2016 2021 Ovarian cancer 2 0 2 0 47 47 1
Anderson Clay M MALE USA 1995 2022 RTOG Esophageal cancer; Melanoma 2 0 2 0 41 41 1
Anderson Daniel M MALE USA 2011 2021 ECOG Breast cancer; Follicular lymphoma; Multiple myeloma 3 0 2 0 74 74 1
Anderson David R MALE Canada 2003 2018 Antiphospholipid antibody syndrome; Venous thromboembolism 3 2 3 0 65 44 1
Anderson Harald MALE Sweden 1978 2016 Nordic Lymphoma Group; Scandinavian Breast Group Autologous HSCT; Breast cancer; CNS lymphoma; Diffuse large B-cell lymphoma; Peripheral T-cell lymphoma 7 0 5 0 92 76 1
Anderson Heather A FEMALE 1995 2006 BTOG Esophageal cancer; Gastric cancer; Non-small cell lung cancer 4 0 4 0 47 40 1
Anderson J Not yet determined USA 2008 2008 Anaplastic glioma 1 0 0 0 9 9 1
Anderson James R MALE USA 1972 2019 CALGB; CCG; COG; ECOG Acute myeloid leukemia; B-cell acute lymphoblastic leukemia; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Melanoma; Rhabdomyosarcoma; Soft tissue sarcoma 14 2 11 1 164 124 1
Anderson Jeanne E FEMALE USA 1995 2002 SWOG Acute myeloid leukemia 1 1 1 0 10 10 1
Anderson Jeffrey MALE USA 2012 2020 Hepatocellular carcinoma 2 0 0 1 40 31 1
Anderson Jennifer J FEMALE 1976 2004 Autologous HSCT; Light-chain (AL) amyloidosis 2 0 0 0 19 17 1
Anderson John B MALE United Kingdom 1995 2012 MRC; NCIC Prostate cancer 4 0 3 0 52 43 1
Anderson Karen S FEMALE USA 2013 2017 Breast cancer 1 0 0 0 33 33 1
Anderson Kenneth C MALE USA 1982 2022 CALGB; FIRST Trial Team; IFM; SWOG; Waldenstroem's Macroglobulinemia Clinical Trials Group Autologous HSCT; Diffuse large B-cell lymphoma; Multiple myeloma; Waldenstroem macroglobulinemia 38 18 13 9 818 389 1
Anderson Larry D MALE USA 2010 2022 Multiple myeloma 4 1 2 2 167 151 1
Anderson Lisa FEMALE USA 2017 2019 Colorectal cancer 1 0 1 1 34 34 1
Anderson Lxxx Not yet determined 1983 1994 BNLI Hodgkin lymphoma 2 0 2 0 12 7 1
Anderson Mary Ann FEMALE Australia 2011 2018 Chronic lymphocytic leukemia; Mantle cell lymphoma 2 0 0 1 34 32 1
Anderson Michael J MALE Denmark; USA 1979 2015 BIG Breast cancer; Cutaneous T-cell lymphoma 2 0 2 0 29 29 1
Anderson Nancy Not yet determined USA 2012 2020 GOG Gestational trophoblastic neoplasia 1 0 1 0 12 12 1
Anderson Nicole D FEMALE 2003 2003 Autologous HSCT; CNS lymphoma; Stem cell mobilization 1 0 0 0 12 12 1
Anderson Patricia FEMALE USA 1985 1992 SWOG Ovarian cancer 1 0 1 1 9 9 1
Anderson Peter M MALE USA 2002 2002 Osteosarcoma 1 1 0 0 7 7 1
Anderson Richard T MALE 1979 1991 NCCTG Non-small cell lung cancer; Small cell lung cancer 2 2 2 0 24 19 1
Anderson Russell D MALE 2009 2009 Multiple myeloma 1 0 0 0 15 15 1
Anderson Sibyl FEMALE USA 2003 2010 Sorafenib TARGET Clinical Trial Group Clear cell renal cell carcinoma; Renal cell carcinoma 2 0 1 1 27 21 1
Anderson Stewart J MALE USA 1982 2018 BOOG Dutch Breast Cancer Trialists' Group; Breast International Group; GEICAM Spanish Breast Cancer Group; International Breast Cancer Study Group; NRG Oncology; NSABP Breast cancer 11 0 11 2 153 81 1
Anderson Sxxx Not yet determined United Kingdom 1996 2004 Multiple myeloma 1 0 1 0 7 7 1
Anderson Tara FEMALE 2009 2012 Multiple myeloma 1 0 0 0 18 18 1
Anderson Thomas MALE USA 1972 2008 ECOG; Hoosier Oncology Group; US Oncology Colorectal cancer; Non-small cell lung cancer; Ovarian cancer 3 0 3 0 34 34 1
Andersson Borje S MALE USA 1990 2019 Acute myeloid leukemia; Allogeneic HSCT; Breast cancer; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Multiple myeloma 8 3 2 0 125 99 1
Andersson Haakan Not yet determined 1995 2010 EORTC Endometrial cancer; Ovarian cancer 3 0 3 0 29 23 1
Andersson Michael MALE Denmark 1977 2021 BIG; DBCG; EORTC; GBG; Herceptin Adjuvant (HERA) Trial Study Team; monarchE Committee Members Breast cancer 17 2 13 3 299 203 1
Andersson Per-Ola Not yet determined Sweden 2011 2016 Chronic lymphocytic leukemia 1 0 1 0 18 18 1
Andersson Ronny MALE 1998 1998 Melanoma 1 0 1 0 12 12 1
Andersson Swen Olof MALE Sweden 1989 2018 SPCG Prostate cancer 6 0 1 0 78 22 1
Ando Jiro MALE 1994 2014 JCOG Breast cancer 1 0 1 0 10 10 1
Ando Kiyoshi MALE Japan 2002 2021 JCOG Acute myeloid leukemia; Cutaneous T-cell lymphoma; Diffuse large B-cell lymphoma; Follicular lymphoma; Multiple myeloma; Peripheral T-cell lymphoma 12 1 5 1 229 166 1
Ando Masahiko MALE Japan 2000 2021 JCOG; WJOG; WJTOG Cholangiocarcinoma; Colorectal cancer; Non-small cell lung cancer; Non-small cell lung cancer squamous; Small cell lung cancer 14 0 13 0 260 168 1
Ando Masahiro MALE Japan 2006 2010 Non-small cell lung cancer 1 0 1 0 22 22 1
Ando Masashi MALE 2004 2009 Breast cancer 1 0 1 0 15 15 1
Ando Nobutoshi MALE Japan 1988 2011 JCOG Esophageal cancer 3 3 3 0 43 32 1
Ando Yuichi MALE Japan 2012 2018 Colorectal cancer 1 0 0 0 23 23 1
Andoh J CBD 1999 2009 JCOG Breast cancer 1 0 1 0 10 10 1
Andorsky David MALE USA 2011 2019 Chronic myeloid leukemia; Diffuse large B-cell lymphoma 2 0 2 0 35 35 1
Andrade Luciana FEMALE Brazil 2017 2021 Breast cancer 1 0 1 0 18 18 1
Andre Fabrice MALE France 2006 2022 Breast cancer 16 4 9 4 336 223 1
Andre Marc P E MALE Belgium 1996 2021 EORTC; European Mantle Cell Lymphoma Network; FIL; GELA; Lymphoma Study Association; LYSA; SFGM Autologous HSCT; Diffuse large B-cell lymphoma; Follicular lymphoma; Hodgkin lymphoma; Mantle cell lymphoma; Peripheral T-cell lymphoma; Transformed lymphoma 14 1 14 1 340 212 1
Andre Niko MALE Switzerland 2007 2013 Colorectal cancer 1 0 1 0 10 10 1
Andre Thierry MALE France 1996 2022 AERO; FFCD; FNCLCC; GERCOR; GISCAD; Group Cooperateur Multidisciplinaire en Oncologie; HORG; PRODIGE investigators, GERCOR, Federation Francaise de Cancerologie Digestive, UNICANCER Anal cancer; Colon cancer; Colorectal cancer; Desmoid tumor; Esophageal adenocarcinoma; Gastric cancer; MSI-H or dMMR; Pancreatic cancer; Rectal cancer 35 16 20 5 612 348 1
Andre Valerie A M FEMALE USA 2017 2021 monarchE Committee Members Breast cancer 1 0 1 1 34 34 1
Andreadis Charalambos MALE USA 1998 2021 Autologous HSCT; Diffuse large B-cell lymphoma; Follicular lymphoma; Ovarian cancer; Primary mediastinal B-cell lymphoma; Transformed lymphoma 5 0 2 3 124 101 1
Andreas Stefan MALE Germany 2005 2016 Non-small cell lung cancer 1 0 1 0 10 10 1
Andreasson Bjoern MALE 2007 2012 Multiple myeloma 1 0 1 0 18 18 1
Andreeff Michael MALE USA 1984 2020 Acute myeloid leukemia; Acute promyelocytic leukemia; B-cell acute lymphoblastic leukemia; Chronic lymphocytic leukemia; CNS leukemia; Hypereosinophilic syndrome 15 1 2 1 273 130 1
Andreescu Astrid C FEMALE USA 2010 2022 Multiple myeloma 1 0 1 0 55 55 1
Andreesen Reinhard MALE 1992 2012 Arbeitsgemeinschaft Medikamentoese Tumortherapie; GHSG; SAKK Breast cancer; Hodgkin lymphoma 2 0 2 0 44 44 1
Andreetta Claudia FEMALE Italy 2014 2021 Breast cancer 1 0 1 0 25 25 1
Andren Ove Not yet determined Sweden 1989 2018 SPCG Prostate cancer 2 0 1 0 25 14 1
Andreola Giovanna FEMALE Switzerland 2019 2021 Diffuse large B-cell lymphoma; Waldenstroem macroglobulinemia 2 0 1 0 53 53 1
Andreoli Laura FEMALE Italy 2018 2018 Antiphospholipid antibody syndrome 1 0 1 0 21 21 1
Andreopoulos Demetrios MALE Cyprus 2001 2021 EORTC Prostate cancer 1 0 1 0 21 21 1
Andreou Cal MALE Canada 2006 2008 Prostate cancer 1 0 1 1 8 8 1
Andreou Pantelis Not yet determined Canada 2013 2018 Venous thromboembolism 2 0 2 0 47 28 1
Andresen Daniil Corina FEMALE USA 2013 2018 PLATO collaborators Prostate cancer 1 0 1 0 7 7 1
Andreuccetti Michele MALE 2001 2010 GONO Colorectal cancer 2 0 1 0 34 30 1
Andrews Chris MALE United Kingdom 2012 2015 Myelofibrosis 1 0 0 0 11 11 1
Andrews Glen I MALE USA 2010 2016 Renal cell carcinoma 1 0 1 0 8 8 1
Andrews Michael B MALE 2000 2005 Follicular lymphoma 1 0 0 0 6 6 1
Andrews Stephen MALE United Kingdom 2007 2018 Bladder cancer 1 0 1 0 17 17 1
Andrews Vivienne E FEMALE United Kingdom 2008 2019 National Cancer Research Institute Haemato-oncology Clinical Studies Group Multiple myeloma 1 0 2 0 21 21 1
Andric Zoran MALE Serbia 2015 2021 Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous 2 0 1 1 39 25 1
Andrien J M CBD 1985 1993 Breast cancer 1 0 1 0 9 9 1
Andrieu Jean Marie MALE 1990 2003 Hodgkin lymphoma 1 1 1 0 15 15 1
Andriole Gerald L MALE USA 1994 2017 Prostate cancer 2 0 1 0 27 20 1
Andritsos Leslie A UNMATCHED USA 2011 2015 Chronic lymphocytic leukemia 1 0 0 0 20 20 1
Androulakis Ioannis MALE 1993 2002 HeCOG Colorectal cancer 1 0 1 0 13 13 1
Androulakis Nikolaos MALE Greece 1999 2019 HORG Colon cancer; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Small cell lung cancer 7 0 6 0 108 59 1
Andrulis Irene L FEMALE Canada 1989 2006 NCIC-CTG Breast cancer 1 0 1 1 6 6 1
Andtbacka Robert H I MALE USA 2009 2019 Melanoma 2 2 1 1 34 30 1
Ang Agnes FEMALE USA 2012 2021 Gastric cancer; Non-small cell lung cancer 2 0 0 1 45 45 1
Ang Kie Kian MALE USA 1994 2015 EORTC; RTOG Head and neck cancer 9 5 5 1 120 73 0
Ang Mei Kim FEMALE Singapore 2004 2015 Nasopharyngeal carcinoma 1 0 0 0 13 13 1
Ang Peng Tiam MALE 1990 1994 Nasopharyngeal carcinoma 1 1 0 0 1 1 1
Angchaisuksiri Pantep Not yet determined Thailand 2016 2016 Venous thromboembolism 1 0 1 0 13 13 1
Angele Martin MALE Germany 1997 2018 EORTC; European Society for Hyperthermic Oncology Soft tissue sarcoma 1 0 1 0 21 21 1
Angeli Alberto MALE 1993 2005 Italian Group for the Study of Adrenal Cancer Adrenocortical carcinoma 2 0 0 0 16 12 1
Angelopoulou Maria K FEMALE 2010 2010 Mantle cell lymphoma 1 1 0 0 16 16 1
Angelot Delettre Fanny FEMALE France 2013 2014 Blastic plasmacytoid dendritic cell neoplasm 1 0 0 0 14 14 1
Angelsen Anders MALE Norway 1995 2018 Scandinavian Prostate Cancer Group; SPCG; Swedish Association for Urological Oncology Prostate cancer 3 0 3 0 25 24 1
Angelucci Emanuele MALE Italy 1995 2022 CYTO-PV Collaborative Group; FIL; GIMEMA; Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation Aplastic anemia; Chronic lymphocytic leukemia; Chronic myelomonocytic leukemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Hodgkin lymphoma; Polycythemia vera 9 0 6 0 221 188 1
Angermund Ralf MALE Germany 2006 2013 Multiple myeloma 2 0 0 1 20 17 1
Anghel Rodica FEMALE Romania 2008 2016 Breast cancer 1 0 1 0 18 18 1
Angiolillo Anne L FEMALE USA 2000 2021 CCG; COG B-cell acute lymphoblastic leukemia pediatric; Ewing sarcoma; Osteosarcoma 4 2 3 1 63 43 1
Anglaret Bruno MALE 1995 2012 GELA; IFM Diffuse large B-cell lymphoma; Multiple myeloma 3 0 3 0 78 61 1
Anglin Peter MALE Canada 2003 2015 NCIC-CTG Multiple myeloma; Transformed lymphoma 2 0 1 0 26 26 1
Angra Natasha FEMALE USA 2015 2020 Bladder cancer 1 0 1 0 28 28 1
Angrilli Francesco MALE Italy 2000 2017 FIL; IELSG CNS lymphoma; Follicular lymphoma; Hodgkin lymphoma; Mantle cell lymphoma 6 0 2 0 132 92 1
Angyalfi Steve J MALE Canada 1999 2022 NCIC-CTG Prostate cancer 2 0 2 0 41 41 1
Anichini Andrea Not yet determined Italy 2017 2018 Bladder cancer 1 0 0 0 22 22 1
Anker Christopher J MALE USA 2008 2017 RTOG Esophageal cancer 1 0 1 0 18 18 1
Anker Gun FEMALE 1994 2000 Scandinavian Breast Group Breast cancer 1 0 1 0 17 17 1
Annamalai Lakshmanan MALE USA 2015 2016 Merkel cell carcinoma 1 0 0 1 30 30 1
Anne P Rani FEMALE 1999 2006 RTOG Esophageal adenocarcinoma 1 0 0 0 10 10 1
Annechini Giorgia FEMALE Italy 2016 2016 Hodgkin lymphoma 1 0 0 0 17 17 1
Annecke K CBD Germany 2001 2016 Breast cancer 1 0 1 0 11 11 1
Annett Robert D MALE USA 2014 2022 COG T-cell acute lymphoblastic leukemia pediatric 1 0 1 0 35 35 1
Annibali Ombretta FEMALE Italy 2007 2019 Acute promyelocytic leukemia 1 0 2 1 45 45 1
Annino Luciana FEMALE Italy 1988 2016 EORTC; GIMEMA Acute myeloid leukemia; B-cell acute lymphoblastic leukemia; Multiple myeloma 3 1 3 1 67 66 1
Annunziata Annalisa FEMALE 2003 2006 MITO Ovarian cancer 1 0 1 0 19 19 1
Annunziata Mario MALE Italy 2017 2021 Chronic myeloid leukemia; Thrombotic thrombocytopenic purpura 2 0 1 1 32 32 1
Anota Amelie FEMALE France 2014 2018 Anal cancer 1 0 0 0 26 26 1
Ansari Hassan MALE 1983 1994 Chronic myeloid leukemia 1 1 1 0 43 42 1
Ansari Marc MALE Switzerland 2007 2020 EBMT Paediatric Diseases Working Party; I-BFM SCT Study Group; IBFM Study Group; IntReALL Study Group; SIOPEL Allogeneic HSCT; Hepatoblastoma 2 0 2 0 53 53 1
Ansari Rafat H MALE USA 1984 2013 Alpha Oncology Research Network; CALGB; Fox Chase Network; Hoosier Oncology Group; NCIC-CTG; US Oncology Breast cancer; Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer 16 0 15 1 186 151 1
Ansell Peter J MALE USA 2012 2021 Non-small cell lung cancer; Non-small cell lung cancer squamous; Ovarian cancer 3 0 2 0 70 67 1
Ansell Stephen M MALE USA 2002 2022 NCCTG Diffuse large B-cell lymphoma; Follicular lymphoma; Hodgkin lymphoma; Mantle cell lymphoma; Transformed lymphoma; Waldenstroem macroglobulinemia 26 7 1 4 410 217 1
Anselmo Anna Paola FEMALE 1988 2004 FIL; GHSG Diffuse large B-cell lymphoma; Hodgkin lymphoma 4 0 1 0 57 50 1
Ansfield Fred J MALE 1961 1985 Cooperative Breast Cancer Group Breast cancer; Head and neck cancer 4 0 3 0 23 17 1
Ansstas George MALE USA 2016 2022 Glioblastoma 1 0 1 0 23 23 1
Antal Joyce FEMALE USA 2014 2017 Bladder cancer 1 0 0 1 18 18 1
Anter A H CBD 2006 2013 Breast cancer 1 0 1 0 3 3 1
Anthes M Not yet determined 1996 2004 Glioblastoma 1 0 0 0 17 17 1
Anthoney Alan MALE United Kingdom 2000 2021 Advanced Biliary Cancer Working Group; European Study Group for Pancreatic Cancer Cholangiocarcinoma; Gallbladder cancer; Pancreatic cancer; Periampullary adenocarcinoma 5 0 5 0 119 84 1
Anthony Alan MALE United Kingdom 2006 2022 Cholangiocarcinoma; Gallbladder cancer 2 0 1 0 52 29 1
Anthony Stephen P MALE 1997 2006 Breast cancer 1 0 1 0 19 19 1
Antimi Mauro MALE 1991 2003 Italian Co-operative Group on Bladder Cancer Bladder cancer; Breast cancer 2 0 1 0 27 27 1
Antin Joseph H MALE USA 2003 2016 BMT CTN Allogeneic HSCT; Chronic myeloid leukemia; Graft versus host disease; Multiple myeloma 4 1 3 0 79 76 1
Antinori Andrea UNMATCHED 2002 2002 HIV-associated lymphoma 1 0 0 0 12 12 1
Antman Karen FEMALE USA 1987 1993 Autologous HSCT; Breast cancer; Soft tissue sarcoma 2 2 1 0 26 25 1
Antolin Novoa Silvia FEMALE Spain 2008 2021 GEICAM Breast cancer 2 0 2 0 63 61 1
Anton Torres A CBD 1994 1998 TTD Colorectal cancer 1 0 1 0 12 12 1
Anton Antonio MALE Spain 1990 2020 CIBOMA; GEICAM; LACOG (Latin American Cooperative Oncology Group); Spanish Lung Cancer Group; TTD Breast cancer; Colorectal cancer; Esophageal adenocarcinoma; Head and neck cancer; Non-small cell lung cancer; Small cell lung cancer 17 0 17 2 380 273 1
Antonarakis Emmanuel S MALE USA 2011 2021 Prostate cancer 2 1 0 0 39 38 1
Antonelli G CBD 1998 2002 Bladder cancer 1 0 0 0 9 9 1
Antonescu Cristina R FEMALE USA 2002 2011 ACOSOG Gastrointestinal stromal tumor; Melanoma 2 0 1 1 31 31 1
Antonia Scott J MALE USA 2007 2022 Malignant pleural mesothelioma; Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous; Small cell lung cancer 17 6 7 5 408 222 1
Antonini Ninja F FEMALE Netherlands 2003 2009 Dutch Colorectal Cancer Group Colorectal cancer 2 0 2 0 36 28 1
Antonioli Elisabetta FEMALE Italy 2014 2021 Multiple myeloma; Paroxysmal nocturnal hemoglobinuria 2 0 1 1 37 37 1
Antoniotti Carlotta FEMALE Italy 2008 2022 Colorectal cancer 3 0 2 0 70 54 1
Antoniou Dimosthenis MALE Greece 2000 2010 Non-small cell lung cancer 2 0 2 0 33 27 1
Antoniou Nicos MALE Greece 2000 2013 SEUG Prostate cancer 1 0 1 0 10 9 1
Antonuzzo Lorenzo MALE Italy 2008 2022 Colorectal cancer 2 0 2 0 45 42 1
Antonyan Igor Not yet determined Ukraine 2017 2022 Renal cell carcinoma 1 0 1 0 20 20 1
Anttila Pekka MALE Finland 2012 2016 Multiple myeloma 1 0 0 0 30 30 1
Antunes Luis MALE Brazil 2017 2021 Esophageal cancer 1 0 1 1 24 24 1
Antunovic Petar MALE 2004 2010 Acute myeloid leukemia; Chronic myelomonocytic leukemia; Myelodysplastic syndrome 1 0 0 0 19 19 1
Anz Bertrand MALE USA 2014 2018 Chronic lymphocytic leukemia 1 0 1 1 19 19 1
Aogi Kenjiro MALE Japan 1994 2021 JCOG; NSAS Breast cancer 9 0 8 1 140 103 1
Aokage Keiju Not yet determined Japan 2013 2020 JCOG Small cell lung cancer 1 0 1 0 19 19 1
Aoki Daisuke MALE Japan 2003 2021 JGOG Cervical cancer; Endometrial cancer; Ovarian cancer 6 1 5 0 121 89 1
Aoki Hiroshi MALE 2005 2013 Bladder cancer; Upper tract urothelial carcinoma 1 0 0 0 22 22 1
Aoki Takuya Not yet determined Japan 2001 2021 WJTOG Non-small cell lung cancer 1 0 1 0 20 20 1
Aoki Yoichi MALE Japan 2008 2021 Cervical cancer; Ovarian cancer 2 1 2 0 60 57 1
Aondio Gian Marco MALE 2004 2009 IELSG CNS lymphoma 1 0 0 0 31 31 1
Aotani Eriko FEMALE Japan 2006 2016 JGOG Ovarian cancer 1 0 1 0 23 23 1
Aoudjhane A CBD France 2003 2014 Lymphoma Study Association Hodgkin lymphoma 1 0 1 0 17 17 1
Aoudjhane Malek MALE France 1989 2003 EORTC Hodgkin lymphoma 1 0 2 0 28 28 1
Aoyama H CBD 1993 1996 Breast cancer 1 0 0 0 6 6 1
Aoyama Norio MALE 1992 2011 JCOG Esophageal cancer 2 0 2 0 32 29 1
Aoyama Toru Not yet determined Japan; USA 2011 2017 Gastric cancer; Rectal cancer 2 1 2 0 30 30 1
Aozasa Katsuyuki Not yet determined 2005 2005 Castleman disease 1 0 0 0 20 20 1
Apanovitch Anne Marie FEMALE USA 2005 2007 B-cell acute lymphoblastic leukemia 1 0 0 1 11 11 1
Aparicio Jorge MALE Spain 1994 2011 Spanish Germ Cell Cancer Cooperative Group; TTD Colorectal cancer; Hodgkin lymphoma; Testicular cancer 6 3 2 0 81 68 1
Aparicio Samuel MALE Canada 2008 2015 NCIC-CTG Breast cancer 1 0 1 0 26 26 1
Aparicio Thomas MALE France 2000 2018 FFCD; SFRO; UNICANCER Colorectal cancer; Esophageal adenocarcinoma; Gastric cancer; Hepatocellular carcinoma; Pancreatic cancer 5 2 5 0 89 71 1
Apfelbeck Ute FEMALE Austria 1994 2003 Chronic myeloid leukemia 1 0 1 0 25 25 1
Apffelstaedt Justus MALE South Africa 1996 2003 Breast cancer 3 0 2 1 51 32 1
Aplenc Richard MALE USA 2011 2014 COG Acute myeloid leukemia pediatric; B-cell acute lymphoblastic leukemia; B-cell acute lymphoblastic leukemia pediatric 3 1 0 0 44 36 1
Apolo Andrea B MALE USA 2014 2022 Bladder cancer; Renal cell carcinoma 4 2 1 2 81 59 1
Apolone Giovanni MALE 1987 1998 EORTC; Gruppo Interdisciplinare Valutazione Interventi in Oncologia; Japanese Foundation for Cancer Research Colon cancer 1 0 1 0 14 14 1
Aponte John MALE 1996 2002 Barcelona Liver Cancer Group Hepatocellular carcinoma 1 0 1 0 11 11 1
Apostolou Theofanis MALE 2008 2012 Light-chain (AL) amyloidosis 1 0 0 0 12 12 1
Appel Tabea FEMALE 2006 2006 Non-small cell lung cancer 1 0 1 0 10 10 1
Appel Wiebke FEMALE United Kingdom 2008 2017 CONVERT Study Team Small cell lung cancer 1 0 1 0 19 19 1
Appelbaum Frederick R MALE USA 1971 2021 CALGB; ECOG; SWOG Acute myeloid leukemia; Acute promyelocytic leukemia; Allogeneic HSCT; B-cell acute lymphoblastic leukemia; Chronic lymphocytic leukemia; Chronic myeloid leukemia; Chronic myelomonocytic leukemia; Follicular lymphoma; Graft versus host disease; Hairy cell leukemia; Myelodysplastic syndrome; T-cell acute lymphoblastic leukemia 36 11 16 4 477 273 1
Appenzeller Christina Not yet determined Switzerland 2017 2021 Small cell lung cancer 1 0 1 0 21 21 1
Apperley Jane F FEMALE United Kingdom 1981 2021 B-cell acute lymphoblastic leukemia; Chronic myeloid leukemia; Hypereosinophilic syndrome 12 1 1 4 227 140 1
Appiani Carlos MALE USA 2008 2018 Mantle cell lymphoma 1 0 1 1 15 15 1
Appleman Leonard J MALE USA 2008 2014 Bladder cancer 1 0 0 0 18 18 1
Aprea Pasquale MALE 2002 2013 SICOG Melanoma 1 0 1 0 17 17 1
Aprile Giuseppe MALE Italy 2005 2022 Colorectal cancer; Esophageal adenocarcinoma; Esophageal cancer; Gastric cancer 4 0 3 2 89 81 1
Apte Ron N MALE Israel 2014 2017 Colorectal cancer 1 0 1 0 14 14 1
Aqui Nicole A FEMALE USA 2008 2015 Follicular lymphoma; Mantle cell lymphoma 2 0 0 0 14 8 1
Aquino Sara Not yet determined Italy 2011 2021 Multiple myeloma 3 0 1 0 123 78 1
Arachchillage Deepa R J Not yet determined United Kingdom 2016 2016 Antiphospholipid antibody syndrome 1 0 0 0 13 13 1
Aracil Miguel Not yet determined Spain 2015 2021 Ovarian cancer 1 0 1 0 19 19 1
Aragon Ching Jeanny B FEMALE USA 2011 2020 Bladder cancer 3 0 2 1 91 82 1
Arahmani Amal FEMALE Belgium 2011 2021 Breast cancer 2 0 2 2 55 51 1
Arai Gaku Not yet determined Japan 2001 2020 Prostate cancer 2 0 2 0 48 45 1
Arai Kuniyoshi MALE Japan 1993 2011 ACTS-GC Group; JCOG Gastric cancer 2 2 2 0 21 16 1
Arai Makoto Not yet determined Japan 2019 2019 Carcinoma of unknown primary 1 0 0 0 20 20 1
Arai Masahide Not yet determined Japan 2006 2019 JGOG Endometrial cancer 1 0 1 0 16 16 1
Arai Sally FEMALE USA 2006 2016 Allogeneic HSCT 2 0 1 0 45 45 1
Arai Yasuaki MALE Japan 2010 2018 Hepatocellular carcinoma 2 2 2 0 34 32 1
Arai Yoichi MALE 2000 2013 Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer Bladder cancer; Prostate cancer; Upper tract urothelial carcinoma 3 1 1 0 38 34 1
Arakelyan Nina FEMALE 1994 2013 GOELAMS Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma 3 0 1 0 57 46 1
Araki K CBD 1994 2001 JCOG Adult T-cell leukemia-lymphoma 1 0 0 0 15 15 1
Araki Nobuhito MALE Japan 2008 2016 Soft tissue sarcoma 3 0 1 1 45 40 1
Arana Yi C CBD USA 2007 2014 Acute myeloid leukemia 1 0 0 0 17 17 1
Arance Ana M FEMALE Spain 2009 2022 CheckMate 238 Collaborators CNS melanoma; Melanoma 24 1 11 8 562 205 1
Aranda Enrique MALE Spain 1994 2020 GEICAM; TTD Breast cancer; Colon cancer; Colorectal cancer; Esophageal adenocarcinoma 9 7 7 0 179 127 1
Aranda Ignacio MALE Spain 1999 2010 GEICAM Breast cancer 1 0 1 0 30 30 1
Aranda J CBD Spain 1987 2003 GEICAM Breast cancer 1 0 1 0 14 14 1
Arango Hisijara Israel MALE USA 2013 2021 Marginal zone lymphoma; Waldenstroem macroglobulinemia 2 0 1 2 37 36 1
Arango Ossa Juan E Not yet determined USA 2011 2022 Polycythemia vera 1 0 1 0 42 42 1
Arasteh Keikawus MALE 1993 1998 Kaposi sarcoma 1 0 1 0 8 8 1
Araujo Carla FEMALE France 2008 2022 IFM Autologous HSCT; Multiple myeloma 6 0 4 1 217 121 1
Araujo John C MALE USA 2008 2013 Prostate cancer 1 1 1 0 24 24 1
Aravantinos Gerasimos MALE Greece 1989 2012 HCOG; HeCOG Bladder cancer; Breast cancer; Colon cancer; Colorectal cancer; Endometrial cancer; Ovarian cancer; Pancreatic cancer; Testicular cancer 13 2 11 0 212 101 1
Arazy Melina FEMALE USA 2017 2020 Multiple myeloma 1 0 1 1 57 57 1
Arbogast Daria FEMALE 2010 2010 Thyroid cancer medullary 1 0 0 0 18 18 1
Arbuck Susan G FEMALE 1992 2003 Cervical cancer; Ovarian cancer 2 1 1 0 22 21 1
Arbushites Michael C MALE USA 2004 2020 Breast cancer; Graft versus host disease 2 0 1 1 25 25 1
Arcaini Luca MALE Italy 2006 2021 FIL; SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network Follicular lymphoma; Mantle cell lymphoma 7 1 3 0 164 132 1
Arcamone Manuela FEMALE 2012 2012 Follicular lymphoma 1 0 0 0 14 14 1
Arcangeli Annarosa FEMALE 1995 2008 Italian Oncology Group for Cancer Research Gastric cancer 1 0 1 0 15 15 1
Arcangeli Giuseppina FEMALE 1995 1995 Hepatocellular carcinoma 1 1 0 0 3 3 1
Arcangeli Valentina FEMALE Italy 2010 2015 MITO Ovarian cancer 1 0 0 0 22 22 1
Arcari Annalisa FEMALE Italy 2003 2021 ANZ BCTG; FIL Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma 4 0 2 0 93 78 1
Arcasoy Murat O MALE USA 2009 2022 Myelofibrosis; Polycythemia vera 6 0 2 1 161 74 1
Arce Lara Carlos MALE USA 2015 2019 Multiple myeloma 1 0 0 0 10 10 1
Arce Salinas Claudia H FEMALE Mexico 2011 2021 Breast cancer 2 0 2 1 61 60 1
Arceci Robert J MALE USA 1979 2011 CCG; COG Acute myeloid leukemia; B-cell acute lymphoblastic leukemia pediatric; Chronic myeloid leukemia pediatric; Langerhans cell histiocytosis 5 2 4 2 60 53 1
Arcenas Anthony MALE 2000 2000 Non-small cell lung cancer 1 0 1 0 18 18 1
Arcese William MALE Italy 1988 2015 Acute myeloid leukemia; Allogeneic HSCT 2 0 1 0 40 40 1
Archambaud Baptiste Not yet determined France 2017 2022 French Sarcoma Group Leiomyosarcoma 1 0 1 0 19 19 1
Archambault Robert MALE Canada 2000 2020 Prostate cancer 2 0 2 0 23 17 1
Archer Caroline FEMALE United Kingdom 2007 2014 Pancreatic cancer 1 0 1 0 32 32 1
Archer J Hunter Not yet determined USA 2014 2022 COG T-cell acute lymphoblastic leukemia pediatric 1 0 1 0 35 35 1
Archer Laura FEMALE 2003 2010 CALGB Renal cell carcinoma 2 0 1 0 21 11 1
Archer Venice FEMALE United Kingdom 2005 2019 Non-small cell lung cancer; Non-small cell lung cancer nonsquamous 4 0 3 2 49 38 1
Archimbaud Eric MALE 1980 2004 ALFA; EAPLG; EORTC; European APL Group; GELA; HOVON Acute myeloid leukemia; Acute promyelocytic leukemia; Diffuse large B-cell lymphoma 6 0 5 0 110 83 1
Arcila Maria E FEMALE USA 2012 2021 ERBB2 (HER2); Erdheim-Chester disease; Multiple myeloma 3 1 0 1 88 85 1
Arcusa Angels FEMALE Spain 1988 2010 GEICAM Breast cancer; Gastric cancer 3 0 3 0 59 52 1
Retrieved from "https://hemonc.org/w/index.php?title=Staging_page&oldid=65537"